0001628280-22-011291.txt : 20220429 0001628280-22-011291.hdr.sgml : 20220429 20220429074806 ACCESSION NUMBER: 0001628280-22-011291 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 91 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220429 DATE AS OF CHANGE: 20220429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lantheus Holdings, Inc. CENTRAL INDEX KEY: 0001521036 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 352318913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36569 FILM NUMBER: 22870245 BUSINESS ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 BUSINESS PHONE: 978 671-8001 MAIL ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 FORMER COMPANY: FORMER CONFORMED NAME: Lantheus MI Holdings, Inc. DATE OF NAME CHANGE: 20110517 10-Q 1 lnth-20220331.htm 10-Q lnth-20220331
false2022Q10001521036--12-31http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#LongTermDebtCurrenthttp://fasb.org/us-gaap/2021-01-31#LongTermDebtCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligations00015210362022-01-012022-03-3100015210362022-04-22xbrli:shares00015210362022-03-31iso4217:USD00015210362021-12-31iso4217:USDxbrli:shares00015210362021-01-012021-03-310001521036us-gaap:CommonStockMember2021-12-310001521036us-gaap:AdditionalPaidInCapitalMember2021-12-310001521036us-gaap:RetainedEarningsMember2021-12-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001521036us-gaap:RetainedEarningsMember2022-01-012022-03-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001521036us-gaap:CommonStockMember2022-01-012022-03-310001521036us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001521036us-gaap:CommonStockMember2022-03-310001521036us-gaap:AdditionalPaidInCapitalMember2022-03-310001521036us-gaap:RetainedEarningsMember2022-03-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001521036us-gaap:CommonStockMember2020-12-310001521036us-gaap:AdditionalPaidInCapitalMember2020-12-310001521036us-gaap:RetainedEarningsMember2020-12-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100015210362020-12-310001521036us-gaap:RetainedEarningsMember2021-01-012021-03-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001521036us-gaap:CommonStockMember2021-01-012021-03-310001521036us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001521036us-gaap:CommonStockMember2021-03-310001521036us-gaap:AdditionalPaidInCapitalMember2021-03-310001521036us-gaap:RetainedEarningsMember2021-03-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100015210362021-03-310001521036lnth:ProgenicsMember2020-02-200001521036lnth:ProgenicsMember2020-02-202020-02-200001521036lnth:ProgenicsMember2020-02-20lnth:contingent_value_rightxbrli:pure0001521036lnth:CashPayments2022Memberlnth:ProgenicsMember2020-02-200001521036lnth:CashPayments2023Memberlnth:ProgenicsMember2020-02-200001521036lnth:ProgenicsMember2020-06-1900015210362020-02-202020-02-200001521036us-gaap:ProductMember2022-01-012022-03-310001521036us-gaap:ProductMember2021-01-012021-03-310001521036lnth:LicenseandRoyaltyRevenuesMember2022-01-012022-03-310001521036lnth:LicenseandRoyaltyRevenuesMember2021-01-012021-03-310001521036lnth:DefinityMember2022-01-012022-03-310001521036lnth:DefinityMember2021-01-012021-03-310001521036lnth:TechneLiteMember2022-01-012022-03-310001521036lnth:TechneLiteMember2021-01-012021-03-310001521036lnth:OtherPrecisionDiagnosticsMember2022-01-012022-03-310001521036lnth:OtherPrecisionDiagnosticsMember2021-01-012021-03-310001521036lnth:TotalPrecisionDiagnosticsMember2022-01-012022-03-310001521036lnth:TotalPrecisionDiagnosticsMember2021-01-012021-03-310001521036lnth:PYLARIFYMember2022-01-012022-03-310001521036lnth:PYLARIFYMember2021-01-012021-03-310001521036lnth:OtherRadiopharmaceuticalOncologyMember2022-01-012022-03-310001521036lnth:OtherRadiopharmaceuticalOncologyMember2021-01-012021-03-310001521036lnth:RadiopharmaceuticalOncologyMember2022-01-012022-03-310001521036lnth:RadiopharmaceuticalOncologyMember2021-01-012021-03-310001521036lnth:StrategicPartnershipsAndOtherMember2022-01-012022-03-310001521036lnth:StrategicPartnershipsAndOtherMember2021-01-012021-03-310001521036us-gaap:MoneyMarketFundsMember2022-03-310001521036us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-03-310001521036us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2022-03-310001521036us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2022-03-310001521036us-gaap:InterestRateSwapMember2022-03-310001521036us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMember2022-03-310001521036us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMember2022-03-310001521036us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateSwapMember2022-03-310001521036us-gaap:FairValueInputsLevel1Member2022-03-310001521036us-gaap:FairValueInputsLevel2Member2022-03-310001521036us-gaap:FairValueInputsLevel3Member2022-03-310001521036us-gaap:MoneyMarketFundsMember2021-12-310001521036us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-12-310001521036us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-12-310001521036us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2021-12-310001521036us-gaap:InterestRateSwapMember2021-12-310001521036us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMember2021-12-310001521036us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMember2021-12-310001521036us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateSwapMember2021-12-310001521036us-gaap:FairValueInputsLevel1Member2021-12-310001521036us-gaap:FairValueInputsLevel2Member2021-12-310001521036us-gaap:FairValueInputsLevel3Member2021-12-310001521036us-gaap:RoyaltyMemberlnth:ProgenicsMember2022-01-012022-03-310001521036lnth:ProgenicsMember2022-01-012022-03-310001521036lnth:NetSalesTargetsForAzedraMemberlnth:ProgenicsMember2022-03-310001521036lnth:A1095CommercializationMemberlnth:ProgenicsMember2022-03-310001521036lnth:A1404CommercializationMilestoneMemberlnth:ProgenicsMember2022-03-310001521036lnth:ProgenicsMember2022-03-310001521036us-gaap:FairValueInputsLevel3Memberlnth:RegulatoryMilestoneMember2022-03-310001521036us-gaap:FairValueInputsLevel3Memberlnth:RegulatoryMilestoneMember2021-12-310001521036us-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMemberlnth:MeasurementInputProbabilityOfSuccessMemberlnth:RegulatoryMilestoneMember2022-03-310001521036us-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMemberlnth:MeasurementInputProbabilityOfSuccessMemberlnth:RegulatoryMilestoneMember2021-12-310001521036us-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMemberlnth:RegulatoryMilestoneMember2022-03-310001521036us-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMemberlnth:RegulatoryMilestoneMember2021-12-310001521036us-gaap:FairValueInputsLevel3Memberlnth:RoyaltiesMember2022-03-310001521036us-gaap:FairValueInputsLevel3Memberlnth:RoyaltiesMember2021-12-310001521036us-gaap:FairValueInputsLevel3Memberlnth:RoyaltiesMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberlnth:MeasurementInputProbabilityOfSuccessMembersrt:MinimumMember2022-03-310001521036us-gaap:FairValueInputsLevel3Memberlnth:RoyaltiesMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MaximumMemberlnth:MeasurementInputProbabilityOfSuccessMember2022-03-310001521036us-gaap:FairValueInputsLevel3Memberlnth:RoyaltiesMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberlnth:MeasurementInputProbabilityOfSuccessMembersrt:MinimumMember2021-12-310001521036us-gaap:FairValueInputsLevel3Memberlnth:RoyaltiesMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MaximumMemberlnth:MeasurementInputProbabilityOfSuccessMember2021-12-310001521036us-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberlnth:RoyaltiesMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2022-03-310001521036us-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberlnth:RoyaltiesMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2021-12-310001521036lnth:ContingentValueRightMemberus-gaap:FairValueInputsLevel3Member2022-03-310001521036lnth:ContingentValueRightMemberus-gaap:FairValueInputsLevel3Member2021-12-310001521036us-gaap:MeasurementInputDiscountRateMemberlnth:ContingentValueRightMemberus-gaap:FairValueInputsLevel3Memberlnth:MonteCarloSimulationMember2022-03-310001521036us-gaap:MeasurementInputDiscountRateMemberlnth:ContingentValueRightMemberus-gaap:FairValueInputsLevel3Memberlnth:MonteCarloSimulationMember2021-12-310001521036us-gaap:FairValueInputsLevel3Memberlnth:A1095CommercializationMember2022-03-310001521036us-gaap:FairValueInputsLevel3Memberlnth:A1095CommercializationMember2021-12-310001521036us-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMemberlnth:MeasurementInputProbabilityOfSuccessMemberlnth:A1095CommercializationMember2022-03-310001521036us-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMemberlnth:MeasurementInputProbabilityOfSuccessMemberlnth:A1095CommercializationMember2021-12-310001521036us-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMemberlnth:A1095CommercializationMember2022-03-310001521036us-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMemberlnth:A1095CommercializationMember2021-12-310001521036lnth:ContingentConsiderationNetSalesTargetsMemberus-gaap:FairValueInputsLevel3Member2022-03-310001521036lnth:ContingentConsiderationNetSalesTargetsMemberus-gaap:FairValueInputsLevel3Member2021-12-310001521036lnth:ContingentConsiderationNetSalesTargetsMemberus-gaap:FairValueInputsLevel3Memberlnth:MonteCarloSimulationMemberlnth:MeasurementInputProbabilityOfSuccessMembersrt:MinimumMember2022-03-310001521036lnth:ContingentConsiderationNetSalesTargetsMemberus-gaap:FairValueInputsLevel3Memberlnth:MonteCarloSimulationMembersrt:MaximumMemberlnth:MeasurementInputProbabilityOfSuccessMember2022-03-310001521036lnth:ContingentConsiderationNetSalesTargetsMemberus-gaap:FairValueInputsLevel3Memberlnth:MonteCarloSimulationMemberlnth:MeasurementInputProbabilityOfSuccessMembersrt:MinimumMember2021-12-310001521036lnth:ContingentConsiderationNetSalesTargetsMemberus-gaap:FairValueInputsLevel3Memberlnth:MonteCarloSimulationMembersrt:MaximumMemberlnth:MeasurementInputProbabilityOfSuccessMember2021-12-310001521036us-gaap:MeasurementInputDiscountRateMemberlnth:ContingentConsiderationNetSalesTargetsMemberus-gaap:FairValueInputsLevel3Memberlnth:MonteCarloSimulationMembersrt:MinimumMember2022-03-310001521036us-gaap:MeasurementInputDiscountRateMemberlnth:ContingentConsiderationNetSalesTargetsMemberus-gaap:FairValueInputsLevel3Memberlnth:MonteCarloSimulationMembersrt:MaximumMember2022-03-310001521036us-gaap:MeasurementInputDiscountRateMemberlnth:ContingentConsiderationNetSalesTargetsMemberus-gaap:FairValueInputsLevel3Memberlnth:MonteCarloSimulationMembersrt:MinimumMember2021-12-310001521036us-gaap:MeasurementInputDiscountRateMemberlnth:ContingentConsiderationNetSalesTargetsMemberus-gaap:FairValueInputsLevel3Memberlnth:MonteCarloSimulationMembersrt:MaximumMember2021-12-310001521036lnth:CurrentLiabilitiesMemberlnth:ProgenicsMember2022-03-310001521036lnth:ProgenicsMemberlnth:NoncurrentLiabilitiesMember2022-03-310001521036country:GB2022-03-310001521036country:SE2022-03-310001521036lnth:DefinityMember2021-12-310001521036us-gaap:LandMember2022-03-310001521036us-gaap:LandMember2021-12-310001521036us-gaap:BuildingMember2022-03-310001521036us-gaap:BuildingMember2021-12-310001521036lnth:MachineryEquipmentAndFixturesMember2022-03-310001521036lnth:MachineryEquipmentAndFixturesMember2021-12-310001521036us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-03-310001521036us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-12-310001521036us-gaap:ConstructionInProgressMember2022-03-310001521036us-gaap:ConstructionInProgressMember2021-12-310001521036lnth:PuertoRicanRadiopharmacyServicingSubsidiaryMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2021-01-290001521036lnth:PuertoRicanRadiopharmacyServicingSubsidiaryMember2021-01-012021-03-3100015210362021-01-012021-12-310001521036us-gaap:TrademarksMembersrt:MinimumMember2022-01-012022-03-310001521036us-gaap:TrademarksMembersrt:MaximumMember2022-01-012022-03-310001521036us-gaap:TrademarksMember2022-03-310001521036srt:MinimumMemberus-gaap:CustomerRelationshipsMember2022-01-012022-03-310001521036srt:MaximumMemberus-gaap:CustomerRelationshipsMember2022-01-012022-03-310001521036us-gaap:CustomerRelationshipsMember2022-03-310001521036lnth:CurrentlyMarketedProductMembersrt:MinimumMember2022-01-012022-03-310001521036srt:MaximumMemberlnth:CurrentlyMarketedProductMember2022-01-012022-03-310001521036lnth:CurrentlyMarketedProductMember2022-03-310001521036us-gaap:LicensingAgreementsMembersrt:MinimumMember2022-01-012022-03-310001521036us-gaap:LicensingAgreementsMembersrt:MaximumMember2022-01-012022-03-310001521036us-gaap:LicensingAgreementsMember2022-03-310001521036us-gaap:DevelopedTechnologyRightsMember2022-01-012022-03-310001521036us-gaap:DevelopedTechnologyRightsMember2022-03-310001521036us-gaap:TrademarksMembersrt:MinimumMember2021-01-012021-03-310001521036us-gaap:TrademarksMembersrt:MaximumMember2021-01-012021-03-310001521036us-gaap:TrademarksMember2021-12-310001521036srt:MinimumMemberus-gaap:CustomerRelationshipsMember2021-01-012021-03-310001521036srt:MaximumMemberus-gaap:CustomerRelationshipsMember2021-01-012021-03-310001521036us-gaap:CustomerRelationshipsMember2021-12-310001521036lnth:CurrentlyMarketedProductMembersrt:MinimumMember2021-01-012021-03-310001521036srt:MaximumMemberlnth:CurrentlyMarketedProductMember2021-01-012021-03-310001521036lnth:CurrentlyMarketedProductMember2021-12-310001521036us-gaap:LicensingAgreementsMembersrt:MinimumMember2021-01-012021-03-310001521036us-gaap:LicensingAgreementsMembersrt:MaximumMember2021-01-012021-03-310001521036us-gaap:LicensingAgreementsMember2021-12-310001521036us-gaap:DevelopedTechnologyRightsMember2021-01-012021-03-310001521036us-gaap:DevelopedTechnologyRightsMember2021-12-310001521036lnth:CurrentlyMarketedProductMember2022-01-012022-03-310001521036lnth:IPRDMember2022-01-012022-03-310001521036lnth:TwoThousandandNineteenTermFacilityMember2022-01-012022-03-310001521036lnth:TwoThousandandNineteenTermFacilityMember2022-03-310001521036lnth:RoyaltyBackedLoanMember2021-03-310001521036lnth:RoyaltyBackedLoanMember2021-03-312021-03-310001521036us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMember2020-03-310001521036us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentAssetsMember2022-03-310001521036us-gaap:CashFlowHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentAssetsMember2021-12-310001521036us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001521036us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310001521036us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-03-310001521036us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-03-310001521036us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310001521036us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-03-310001521036us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001521036us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310001521036us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-03-310001521036us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-03-310001521036us-gaap:AccumulatedTranslationAdjustmentMember2021-03-310001521036us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-03-310001521036us-gaap:CostOfSalesMember2022-01-012022-03-310001521036us-gaap:CostOfSalesMember2021-01-012021-03-310001521036us-gaap:SellingAndMarketingExpenseMember2022-01-012022-03-310001521036us-gaap:SellingAndMarketingExpenseMember2021-01-012021-03-310001521036us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001521036us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-310001521036us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001521036us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001521036lnth:MolecularInsightPharmaceuticalsIncMember2019-02-27iso4217:EUR0001521036lnth:EuropeanMember2015-10-012015-10-31lnth:patentlnth:segment
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2022
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number 001-36569
LANTHEUS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware 35-2318913
(State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.)
331 Treble Cove Road01862
North Billerica,MA 
(Address of principal executive offices) (Zip Code)
(978)671-8001
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.01 per shareLNTHThe Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   


Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act)    Yes      No  
The registrant had 68,634,063 shares of common stock, $0.01 par value, outstanding as of April 22, 2022.


LANTHEUS HOLDINGS, INC.
TABLE OF CONTENTS
Page


PART I. FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)
Lantheus Holdings, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands, except par value)
March 31,
2022
December 31,
2021
Assets
Current assets
Cash and cash equivalents$105,355 $98,508 
Accounts receivable, net172,283 89,336 
Inventory34,249 35,129 
Other current assets12,860 12,818 
Total current assets324,747 235,791 
Property, plant and equipment, net116,959 116,772 
Intangibles, net340,204 348,510 
Goodwill61,189 61,189 
Deferred tax assets, net47,868 62,764 
Other long-term assets42,199 38,758 
Total assets$933,166 $863,784 
Liabilities and stockholders’ equity
Current liabilities
Current portion of long-term debt and other borrowings$12,878 $11,642 
Accounts payable22,383 20,787 
Accrued expenses and other liabilities142,396 58,068 
Total current liabilities177,657 90,497 
Asset retirement obligations21,514 20,833 
Long-term debt, net and other borrowings159,369 163,121 
Other long-term liabilities58,776 124,894 
Total liabilities417,316 399,345 
Commitments and contingencies (See Note 19)
Stockholders’ equity
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)
  
Common stock ($0.01 par value, 250,000 shares authorized; 68,570 and 67,739 shares issued and outstanding, respectively)
686 677 
Additional paid-in capital691,516 685,472 
Accumulated deficit(178,263)(221,225)
Accumulated other comprehensive income (loss)1,911 (485)
Total stockholders’ equity515,850 464,439 
Total liabilities and stockholders’ equity$933,166 $863,784 
The accompanying notes are an integral part of these condensed consolidated financial statements.
1

Lantheus Holdings, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands, except per share data)
Three Months Ended
March 31,
20222021
Revenues$208,880 $92,509 
Cost of goods sold79,810 51,479 
Gross profit129,070 41,030 
Operating expenses
Sales and marketing20,354 14,173 
General and administrative37,588 16,138 
Research and development12,203 10,360 
Total operating expenses70,145 40,671 
Gain on sale of assets 15,263 
Operating income58,925 15,622 
Interest expense1,509 2,718 
Gain on extinguishment of debt (889)
Other income(485)(549)
 Income before income taxes57,901 14,342 
Income tax expense14,939 5,334 
Net income$42,962 $9,008 
Net income per common share:
Basic$0.63 $0.13 
Diluted$0.61 $0.13 
Weighted-average common shares outstanding:
Basic68,008 67,094 
Diluted70,051 67,714 
The accompanying notes are an integral part of these condensed consolidated financial statements.
2

Lantheus Holdings, Inc.
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
(in thousands)
Three Months Ended
March 31,
20222021
Net income$42,962 $9,008 
Other comprehensive income:
Foreign currency translation140 102 
Unrealized gain on cash flow hedges, net of tax2,256 706 
Total other comprehensive income2,396 808 
Comprehensive income$45,358 $9,816 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3

Lantheus Holdings, Inc.
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(Unaudited)
(in thousands)

Three Months Ended March 31, 2022
Common StockAdditional
Paid-In
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Income
Total
Stockholders’
Equity
SharesAmount
Balance, January 1, 202267,739 $677 $685,472 $(221,225)$(485)$464,439 
Net income— — — 42,962 — 42,962 
Other comprehensive income— — — — 2,396 2,396 
Stock option exercises and employee stock plan purchases296 3 5,931 — — 5,934 
Vesting of restricted stock awards and units645 7 (7)— —  
Shares withheld to cover taxes(110)(1)(5,503)— — (5,504)
Stock-based compensation— — 5,623 — — 5,623 
Balance, March 31, 202268,570 $686 $691,516 $(178,263)$1,911 $515,850 


Three Months Ended March 31, 2021
Common StockAdditional
Paid-In
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Loss
Total
Stockholders’
Equity
SharesAmount
Balance, January 1, 202166,875 $669 $665,530 $(149,946)$(2,048)$514,205 
Net income— — — 9,008 — 9,008 
Other comprehensive income— — — — 808 808 
Stock option exercises and employee stock plan purchases155 1 2,379 — — 2,380 
Vesting of restricted stock awards and units489 5 (5)— —  
Shares withheld to cover taxes(85)(1)(1,598)— — (1,599)
Stock-based compensation— — 3,317 — — 3,317 
Balance, March 31, 202167,434 $674 $669,623 $(140,938)$(1,240)$528,119 


The accompanying notes are an integral part of these condensed consolidated financial statements.
4

Lantheus Holdings, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)
Three Months Ended
March 31,
20222021
Operating activities
Net income$42,962 $9,008 
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation, amortization and accretion11,786 8,123 
ARO acceleration293  
Amortization of debt related costs246 (61)
Changes in fair value of contingent assets and liabilities18,400 300 
Gain on extinguishment of debt (889)
Provision for excess and obsolete inventory2,519 1,395 
Stock-based compensation5,623 3,317 
Gain on sale of assets (15,263)
Deferred taxes14,180 4,581 
Long-term income tax receivable(396)(573)
Long-term income tax payable and other long-term liabilities779 728 
Other829 655 
(Decreases) increases in cash from operating assets and liabilities:
Accounts receivable(85,155)(2,346)
Inventory(1,634)3,889 
Other current assets(104)(536)
Other long-term assets(533) 
Accounts payable1,506 4,110 
Accrued expenses and other liabilities(1,037)(6,620)
Net cash provided by operating activities10,264 9,818 
Investing activities
Capital expenditures(3,190)(2,520)
Proceeds from sale of assets, net1,800 15,823 
Net cash (used in) provided by investing activities(1,390)13,303 
Financing activities
Payments on long-term debt and other borrowings(2,609)(35,572)
Proceeds from stock option exercises5,357 2,043 
Proceeds from issuance of common stock577 337 
Payments for minimum statutory tax withholding related to net share settlement of equity awards(5,504)(1,599)
Net cash used in financing activities(2,179)(34,791)
Effect of foreign exchange rates on cash, cash equivalents and restricted cash151 (21)
Net increase (decrease) in cash, cash equivalents and restricted cash6,846 (11,691)
Cash, cash equivalents and restricted cash, beginning of period100,651 82,694 
Cash, cash equivalents and restricted cash, end of period$107,497 $71,003 





5


Lantheus Holdings, Inc.
Condensed Consolidated Statements of Cash Flows (Continued)
(Unaudited)
(in thousands)
Three Months Ended
March 31,
20222021
Reconciliation to amounts within the condensed consolidated balance sheets
  Cash and cash equivalents$105,355 $68,861 
  Restricted cash included in other long-term assets2,142 2,142 
      Cash, cash equivalents and restricted cash at end of period$107,497 $71,003 

The accompanying notes are an integral part of these condensed consolidated financial statements.
6

Lantheus Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note Regarding Company References and Trademarks
Unless the context otherwise requires, references to the “Company” and “Lantheus” refer to Lantheus Holdings, Inc. and its direct and indirect wholly-owned subsidiaries, references to “Holdings” refer to Lantheus Holdings, Inc. and not to any of its subsidiaries, references to “LMI” refer to Lantheus Medical Imaging, Inc., the direct subsidiary of Holdings, references to “Progenics” refer to Progenics Pharmaceuticals, Inc., a wholly-owned subsidiary of LMI, and references to “EXINI” refer to EXINI Diagnostics AB, a wholly-owned subsidiary of Progenics. Solely for convenience, the Company refers to trademarks, service marks and trade names without the TM, SM and ® symbols. Those references are not intended to indicate, in any way, that the Company will not assert, to the fullest extent permitted under applicable law, its rights to its trademarks, service marks and trade names.
1. Basis of Presentation
The accompanying unaudited condensed consolidated financial statements include the accounts of Holdings and its direct and indirect wholly-owned subsidiaries, including Progenics (as of the Closing Date, as defined below), and have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all of the information and notes required by generally accepted accounting principles in the United States of America (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement have been included. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ended December 31, 2022 or any future period.
The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities Exchange Commission (“SEC”) on February 24, 2022.
Progenics Acquisition
On June 19, 2020 (the “Closing Date”), pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the “Merger Agreement”), by and among Holdings, Plato Merger Sub, Inc., a wholly-owned subsidiary of Holdings (“Merger Sub”), and Progenics, Holdings completed the acquisition of Progenics by means of a merger of Merger Sub with and into Progenics, with Progenics surviving such merger as a wholly-owned subsidiary of Holdings (the “Progenics Acquisition”). Subsequently, on June 22, 2020, Holdings contributed all of the capital stock of Progenics to LMI, thereby making Progenics an indirect subsidiary of Holdings.
In accordance with the Merger Agreement, at the effective time of the Progenics Acquisition (the “Effective Time”), each share of Progenics common stock, par value $0.0013 per share, issued and outstanding immediately prior to the Effective Time (other than shares of Progenics common stock owned by Holdings, Progenics or any of their wholly-owned subsidiaries) was automatically cancelled and converted into the right to receive (i) 0.31 (the “Exchange Ratio”) of a share of Holdings common stock, par value $0.01 per share, and (ii) one contingent value right (a “CVR”) tied to the financial performance of PyL (18F-DCFPyL), Progenics’ prostate-specific membrane antigen (“PSMA”) targeted imaging agent designed to visualize prostate cancer. This agent was approved by the U.S. Food and Drug Administration (“FDA”) on May 26, 2021 under the name PYLARIFY (piflufolastat F 18), and the commercial launch of this agent began in June 2021. Each CVR entitles its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively. In no event will the Company’s aggregate payments in respect of the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Acquisition, exceed 19.9% of the total consideration the Company pays in the Progenics Acquisition (which the Company currently estimates could be approximately $100.0 million). The Company expects to issue any applicable cash payments related to the CVRs as early as the first quarter of 2023 and the first quarter of 2024. No fractional shares of Holdings common stock were issued in the Progenics Acquisition, and Progenics’ former stockholders have received cash in lieu of any fractional shares of Holdings common stock. In addition, in accordance with the Merger Agreement, at the Effective Time, each Progenics stock option with a per share exercise price less than or equal to $4.42 (an “in-the-money Progenics stock option”) received in exchange for each such in-the money Progenics stock option: (i) an option to purchase Holdings common stock (each, a “Replacement Stock Option”) converted based on the Exchange Ratio, and (ii) a vested or unvested CVR depending on whether the underlying in-the-money Progenics stock option was vested or unvested at the Effective Time. Each Progenics stock option with a per share exercise price greater than $4.42 (an “out-of-the-money Progenics stock option”) received in exchange for such out-of-the-money Progenics stock options a Replacement Stock Option converted at an exchange ratio determined based on the average of the
7

volume weighted average price per share of common stock of Progenics and Lantheus Holdings prior to the Effective Time, which exchange ratio was 0.31, the same as the Exchange Ratio. As a result of the acquisition, Holdings issued 26,844,877 shares of Holdings common stock and 86,630,633 CVRs to former Progenics stockholders and option holders.
2. Summary of Significant Accounting Policies
Recent Accounting Pronouncements

The Company has not adopted any new accounting standards during the three months ended March 31, 2022.
3. Revenue from Contracts with Customers
The following table summarizes revenue by revenue source as follows:
Three Months Ended
March 31,
Major Products/Service Lines (in thousands)20222021
    Product revenue, net(1)
$180,009 $87,319 
    License and royalty revenues(2)
28,871 5,190 
Total revenues$208,880 $92,509 
________________________________
(1)The Company’s principal products include PYLARIFY, DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the same revenue recognition policies and judgments for all its principal products.
(2)The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG. Please refer to Note 19, “Commitments and Contingencies” for further details on the license agreement.
The Company classifies its revenues into three product categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other revenue. Precision diagnostics includes DEFINITY, TechneLite and other imaging diagnostic products. Radiopharmaceutical oncology consists primarily of PYLARIFY and AZEDRA. Strategic partnerships and other revenue includes strategic partnerships and other arrangements related to other products of the Company, such as royalty revenue from our license of RELISTOR.
On January 31, 2022, the Company entered into a global settlement agreement with Novartis Pharma AG (“Novartis”), Advanced Accelerator Applications USA, Inc. (“AAA”), Endocyte, Inc. (“Endocyte”) and their affiliates (the “Novartis Agreement”) to settle certain disputes between the parties. Under the Novartis Agreement, Novartis agreed to make a lump sum payment to the Company, as well as to reimburse the Company for certain fees and expenses in connection with the German litigation (please refer to Note 19 “Commitments and Contingencies”) and the Company agreed to license certain intellectual property to Novartis. In addition, the Company agreed to supply PYLARIFY for clinical purposes at an arms-length value which will be recorded in the future as product is provided. In accordance with the Company's ASC 606, Revenue from Contracts with Customers, assessment, Novartis is considered to be a customer. The Company determined that the $24.0 million constituted a single element which was satisfied on the date of the execution of the Novartis Agreement. The Company determined that the license of intellectual property carried a fair value of $24.0 million. As such, the Company assigned the value to the fair value of the license, which constitutes the entire transaction price and does not require further allocation. The Company determined that the $24.0 million represented the point at which the licensee was able to use and benefit from the license and recognized revenue when the license was granted to Novartis upon execution of the Novartis Agreement. The Company recognized the $24.0 million fee as revenue on its consolidated statement of operations for the quarter ended March 31, 2022. The Company received the $24.0 million payment in April 2022.
Revenue by product category on a net basis is as follows:
8

Three Months Ended
March 31,
(in thousands)20222021
   DEFINITY$58,328 $55,971 
   TechneLite22,605 22,800 
   Other precision diagnostics5,265 6,984 
Total precision diagnostics86,198 85,755 
   PYLARIFY92,777  
   Other radiopharmaceutical oncology1,327 1,500 
Total radiopharmaceutical oncology94,104 1,500 
Strategic partnerships and other revenue28,578 5,254 
Total revenues$208,880 $92,509 
The Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.
4. Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability of fair value measurements, financial instruments are categorized based on a hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:
Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
Level 3 — Unobservable inputs that reflect a Company’s estimates about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.
The Company’s financial assets and liabilities measured at fair value on a recurring basis consist of money market funds, interest rate swaps, a contingent receivable and contingent consideration liabilities. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the condensed consolidated balance sheets at fair value using quoted prices in active markets for identical assets. The fair value of the interest rate swaps is determined based on observable market-based inputs, including interest rate curves and reflects the contractual terms of these instruments, including the period to maturity. Please refer to Note 13, “Derivative Instruments”, for further details on the interest rate swaps. The Company recorded a contingent receivable and the contingent consideration liabilities resulting from the Progenics Acquisition at fair value based on inputs that are not observable in the market.
9

The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:
March 31, 2022
(in thousands)Total Fair
Value
Level 1Level 2Level 3
Assets:
   Money market$38,986 $38,986 $ $ 
   Interest rate swaps3,387  3,387  
   Contingent receivable8,900   8,900 
Total assets$51,273 $38,986 $3,387 $8,900 
Liabilities:
   Contingent consideration liabilities$104,200 $ $ $104,200 
Total liabilities$104,200 $ $ $104,200 
December 31, 2021
(in thousands)Total Fair
Value
Level 1Level 2Level 3
Assets:
   Money market$40,140 $40,140 $ $ 
   Interest rate swaps357  357  
   Contingent receivable9,300   9,300 
Total assets$49,797 $40,140 $357 $9,300 
Liabilities:
   Contingent consideration liabilities$86,200 $ $ $86,200 
Total liabilities$86,200 $ $ $86,200 

During the three months ended March 31, 2022, there were no transfers into or out of Level 3.
As part of the Progenics Acquisition, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics from CytoDyn Inc. related to a prior sale of certain intellectual property. The Company has the right to receive $5.0 million upon regulatory approval and a 5% royalty on net sales of approved products. The Company considers the contingent receivable a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flows that included significant estimates and assumptions pertaining to regulatory events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success.
As part of the Progenics Acquisition, the Company issued CVRs and recorded the fair value as part of consideration transferred. Each CVR entitles its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively, subject to a maximum cap (which the Company currently estimates could be approximately $100.0 million). Refer to Note 1, “Basis of Presentation” for further details on the CVRs. Additionally, the Company assumed contingent consideration liabilities related to a previous acquisition completed by Progenics in 2013 (“2013 Acquisition”). These contingent consideration liabilities include potential payments of up to $70.0 million if the Company attains certain net sales targets primarily for AZEDRA and 1095 and a $5.0 million 1095 commercialization milestone. Additionally, there is a potential payment of up to $10.0 million related to a 1404 commercialization milestone. The Company’s total potential payments related to the 2013 Acquisition are approximately $85.0 million. The Company considers the contingent consideration liabilities relating to the CVRs and the 2013 Acquisition, each a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value of these was determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs with respect to 1095 and 1404 are the probabilities of achieving regulatory approval of those development projects and subsequent commercial success.
Significant changes in any of the probabilities of success, the probabilities as to the periods in which sales targets and milestones will be achieved, discount rates or underlying revenue forecasts would result in a significantly higher or lower fair value measurement. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in general and administrative expenses in the condensed consolidated statements of operations. The Company can give no assurance that the actual
10

amounts paid, if any, in connection with the contingent consideration liabilities, including the CVRs, will be consistent with any recurring fair value estimate of such contingent consideration liabilities.
The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of assets and liabilities using Level 3 inputs at March 31, 2022.

Fair Value atAssumptions
(in thousands)March 31, 2022December 31, 2021Valuation TechniqueUnobservable InputMarch 31, 2022December 31, 2021
Contingent receivable:
Regulatory milestone$2,500 $2,500 Probability adjusted discounted cash flow modelPeriod of expected milestone achievement20222022
Probability of success70 %70 %
Discount rate18 %17 %
Royalties6,400 6,800 Probability adjusted discounted cash flow model
Probability of success
10% - 60%
10% - 60%
Discount rate18 %17 %
Total$8,900 $9,300 

Fair Value atAssumptions
(in thousands)March 31, 2022December 31, 2021Valuation TechniqueUnobservable InputMarch 31, 2022December 31, 2021
Contingent consideration liability:
Net sales targets - PYLARIFY (CVRs)$91,700 $73,200 Monte Carlo simulationPeriod of expected milestone achievement and sales targets2022 - 20232022 - 2023
Discount rate18 %17 %
1095 commercialization milestone1,800 1,900 Probability adjusted discounted cash flow model
Period of expected milestone achievement20262026
Probability of success40 %40 %
Discount rate2.1 %1.3 %
Net sales targets - AZEDRA and 109510,700 11,100 Monte Carlo simulation
Probability of success and sales targets
40% - 100%
40% - 100%
Discount rate
17% - 18%
16% - 17%
Total$104,200 $86,200 
For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:

11

Financial AssetsFinancial Liabilities
(in thousands)Three Months Ended
March 31,
Three Months Ended
March 31,
2022202120222021
Fair value, beginning of period$9,300 $11,300 $86,200 $15,800 
Changes in fair value included in net income(400)900 18,000 1,200 
Fair value, end of period$8,900 $12,200 $104,200 $17,000 
The change in fair value of the contingent financial asset and contingent financial liabilities, including the CVRs, resulted in an expense of $18.4 million for the three months ended March 31, 2022 and was primarily due to changes in revenue forecasts, changes in market conditions, an increase in discount rates and the passage of time. The Company expects to issue any applicable cash payments related to the CVRs as early as the first quarter of 2023 and the first quarter of 2024. As of March 31, 2022, the Company has $83.3 million in current liabilities and $8.4 million in long term liabilities to account for the expected payments related to the CVRs.
5. Income Taxes
The Company calculates income taxes at the end of each reporting period based on the estimated effective tax rate for the full year, adjusted for any discrete events which are recorded in the period they occur. Cumulative adjustments to the tax provision are recorded in the reporting period in which a change in the estimated annual effective tax rate is determined. The Company’s income tax expense is presented below:            
Three Months Ended
March 31,
(in thousands)20222021
Income tax expense$14,939 $5,334 
The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realizability of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more-likely-than-not realizable, the Company evaluated all available positive and negative evidence, and weighed the objective evidence and expected impact. The Company assessed the need for a valuation allowance against certain state tax credit carryforwards added through the Progenics Acquisition. The Company continues to retain other valuation allowances of $1.2 million against the net deferred tax assets of its U.K. subsidiary, and $2.0 million against the net deferred tax assets of its Sweden subsidiary.
In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb (“BMS”) in 2008, the Company recorded a liability for uncertain tax positions related to the acquired business and simultaneously entered into a tax indemnification agreement with BMS under which BMS agreed to indemnify the Company for any payments made to settle those uncertain tax positions with the state taxing authorities. Accordingly, a long-term receivable is recorded to account for the expected value to the Company of future indemnification payments to be paid on behalf of the Company by BMS, net of actual tax benefits received by the Company. The tax indemnification receivable is recorded within other long-term assets.
In accordance with the Company’s accounting policy, the change in the tax liabilities, penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within income tax expense. As these reserves change adjustments are included in income tax expense while the offsetting adjustment is included in other income. Assuming that the remaining receivable from BMS continues to be considered recoverable by the Company, there will be no effect on net income and no net cash outflows related to these liabilities.
The Company finalized the accounting for the Progenics Acquisition for income taxes in the first quarter of 2021 resulting in a reduction of deferred tax assets, primarily related to state research credit carryforwards and an increase to goodwill of $2.6 million.
6. Inventory
Inventory consisted of the following:
        
12

(in thousands)March 31,
2022
December 31,
2021
Raw materials$13,861 $15,505 
Work in process13,071 13,042 
Finished goods7,317 6,582 
Total inventory$34,249 $35,129 
Inventory costs associated with products that have not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefit of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. As of December 31, 2021, the Company had $6.1 million of such product costs included in inventories related to DEFINITY that had been manufactured through the Company’s in-house manufacturing capabilities. The Company received regulatory approval for the manufacture of DEFINITY at its new in-house manufacturing facility during the first quarter of 2022 and has no inventory pending regulatory approval as of March 31, 2022.
7. Property, Plant and Equipment, Net
Property, plant and equipment, net, consisted of the following:
(in thousands)March 31,
2022
December 31,
2021
Land$13,450 $13,450 
Buildings73,560 73,559 
Machinery, equipment and fixtures84,983 83,608 
Computer software24,766 24,384 
Construction in progress12,186 10,686 
208,945 205,687 
Less: accumulated depreciation and amortization(91,986)(88,915)
Total property, plant and equipment, net$116,959 $116,772 
Depreciation and amortization expense related to property, plant and equipment, net, was $3.1 million and $3.0 million for the three months ended March 31, 2022 and 2021, respectively.
8. Accrued Expenses and Other Liabilities and Other Long-Term Liabilities
Accrued expenses and other liabilities and other long-term liabilities are comprised of the following:
(in thousands)March 31,
2022
December 31,
2021
Compensation and benefits$10,629 $22,730 
Freight, distribution and operations26,581 16,157 
Accrued rebates, discounts and chargebacks10,793 10,977 
Accrued professional fees3,596 2,850 
Short-term contingent liability (Note 4)83,300  
Other7,497 5,354 
Total accrued expenses and other liabilities$142,396 $58,068 
Operating lease liabilities (Note 16)$16,207 $16,546 
Long-term contingent liability (Note 4)20,900 86,200 
Other long-term liabilities21,669 22,148 
Total other long-term liabilities$58,776 $124,894 
9. Sale of Puerto Rico Subsidiary
During the fourth quarter of 2020, the Company entered into a stock purchase agreement (the “SPA”) with one of its existing radiopharmacy customers to sell all the stock of its Puerto Rico radiopharmacy subsidiary. The assets were classified as held for sale
13

and the Company determined that the fair value of the net assets being sold significantly exceeded the carrying value as of December 31, 2020. The transaction was consummated on January 29, 2021.
The purchase price for the stock sale was $18.0 million in cash, including a holdback amount of $1.8 million which the Company received during the first quarter of 2022; the purchase price also included a working capital adjustment. The SPA contains customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company’s representations, warranties and covenants in the SPA.
The Company determined that this sale of certain net assets did not constitute a strategic shift that had a major effect on the Company’s operations or financial results. As a result, this transaction was not classified as discontinued operations in the Company’s accompanying condensed consolidated financial statements.
The following table summarizes the major classes of assets and liabilities sold as of January 29, 2021 (date of sale):
(in thousands)
January 29, 2021
Current Assets:
Cash and cash equivalents
$540 
Accounts receivable, net
1,959 
Inventory
530 
Other current assets
65 
Total current assets
3,094 
Non-Current Assets:
Property, plant & equipment, net
780 
Intangibles, net
96 
Other long-term assets
774 
Total assets held for sale
$4,744 
Current Liabilities:
Accounts payable
$185 
Accrued expense and other liabilities
369 
Total current liabilities
554 
Non-Current Liabilities:
Asset retirement obligations
306 
Other long-term liabilities
588 
Total liabilities held for sale
$1,448 

The sale resulted in a pre-tax book gain of $15.3 million, which was recorded within operating income in the condensed consolidated statements of operations for the three months ended March 31, 2021.
10. Asset Retirement Obligations
The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts and Somerset, New Jersey sites. As of March 31, 2022, the liability is measured at the present value of the obligation expected to be incurred, of approximately $26.4 million.
The following table provides a summary of the changes in the Company’s asset retirement obligations:
14

(in thousands)Amount
Balance at January 1, 2022$20,833 
Accretion expense388 
Accelerated Costs293 
Balance at March 31, 2022$21,514 
In December 2021, the Company evaluated the accretion timeline of an asset group due to a revision in the planned period of use at the North Billerica site. As a result of the accelerated timeline, the Company determined the asset group’s present value exceeded the current value recorded as of December 31, 2021. Accordingly, the Company recorded a non-cash adjustment of $5.3 million to anticipate a revision in the end of useful life by the end of 2022.
The Company is required to provide the Massachusetts Department of Public Health and New Jersey Department of Environmental Protection financial assurance demonstrating the Company’s ability to fund the decommissioning of its North Billerica, Massachusetts and Somerset, New Jersey production facilities upon closure, although the Company has no current plans to close the facilities. The Company has provided this financial assurance in the form of a $28.2 million surety bond.
11. Intangibles, Net
Intangibles, net, consisted of the following:
March 31, 2022
(in thousands)Useful Lives
(in years)
Amortization MethodCostAccumulated AmortizationNet
Trademarks
15 - 25
Straight-Line$13,540 $(11,648)$1,892 
Customer relationships
15 - 25
Accelerated96,962 (94,856)2,106 
Currently marketed products
9 - 15
Straight-Line275,700 (29,416)246,284 
Licenses
11 - 16
Straight-Line85,800 (13,441)72,359 
Developed technology9Straight-Line2,400 (477)1,923 
IPR&DN/AN/A15,640 — 15,640 
   Total$490,042 $(149,838)$340,204 


December 31, 2021
(in thousands)Useful Lives
(in years)
Amortization MethodCostAccumulated AmortizationNet
Trademarks
15 - 25
Straight-Line$13,540 $(11,510)$2,030 
Customer relationships
15 - 25
Accelerated96,880 (94,630)2,250 
Currently marketed product
9 - 15
Straight-Line275,700 (23,345)252,355 
Licenses
11 - 16
Straight-Line85,800 (11,555)74,245 
Developed technology9Straight-Line2,400 (410)1,990 
IPR&DN/AN/A15,640 — 15,640 
   Total$489,960 $(141,450)$348,510 


The Company recorded amortization expense for its intangible assets of $8.3 million and $4.7 million for the three months ended March 31, 2022 and 2021, respectively.
In May 2021, PyL (18F-DCFPyL) was approved by the FDA under the name PYLARIFY. Accordingly, the Company reclassified the associated asset of $132.8 million from IPR&D to currently marketed products and commenced amortization of the asset.
15

The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:
(in thousands)Amount
Remainder of 2022$24,923 
202332,634 
202432,563 
202532,508 
202632,497 
2027 and thereafter169,439 
   Total$324,564 
12. Long-Term Debt, Net, and Other Borrowings
As of March 31, 2022, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows:
(in thousands)Amount
Remainder of 2022$8,750 
202315,000 
2024148,750 
Total principal outstanding172,500 
Unamortized debt discount(448)
Unamortized debt issuance costs(387)
Finance lease liabilities582 
Total172,247 
Less: current portion(12,878)
Total long-term debt, net and other borrowings$159,369 


At March 31, 2022, the Company’s interest rate under the five-year secured term loan facility, which matures on June 30, 2024 (the “2019 Term Facility” and the loans thereunder, the “2019 Term Loans”) was 2.2%.
On March 31, 2021, the Company voluntarily repaid in full the entire outstanding principal on the original $50.0 million loan agreement (the “Royalty-Backed Loan”) with a fund managed by HealthCare Royalty Partners III, L.P. in the amount of $30.9 million, which included a prepayment amount of $0.5 million, and terminated the agreement governing the Royalty-Backed Loan. The Company recorded a gain on extinguishment of debt of $0.9 million related to the write-off of an unamortized debt premium offset by the prepayment amount.
13. Derivative Instruments
The Company uses interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. In March 2020, the Company entered into interest rate swap contracts to fix the LIBOR rate on a notional amount of $100.0 million through May 31, 2024. The average fixed LIBOR rate on the interest rate swaps is approximately 0.82%. This agreement involves the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the agreement without an exchange of the underlying principal amount. The interest rate swaps were designated as cash flow hedges. In accordance with hedge accounting, the interest rate swaps are recorded on the Company’s condensed consolidated balance sheets at fair value, and changes in the fair value of the swap agreements are recorded to other comprehensive loss and reclassified to interest expense in the period during which the hedged transaction affected earnings or it will become probable that the forecasted transaction would not occur. At March 31, 2022, accumulated other comprehensive income included $1.0 million of pre-tax deferred gains that are expected to be reclassified to earnings during the next 12 months.
The following table presents the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheets:
16

(in thousands)March 31, 2022December 31, 2021
Derivatives typeClassification
Assets:
   Interest rate swapOther long-term assets$3,387 $357 
14. Accumulated Other Comprehensive Income (Loss)
The components of accumulated other comprehensive income (loss), net of tax of $0.9 million and $0.2 million for the three months ended March 31, 2022 and 2021, respectively, consisted of the following:
(in thousands)Foreign currency translationUnrealized loss on cash flow hedgesAccumulated other comprehensive loss
Balance at January 1, 2022$(754)$269 $(485)
Other comprehensive income before reclassifications140 2,086 2,226 
Amounts reclassified to earnings 170 170 
Balance at March 31, 2022$(614)$2,525 $1,911 
Balance at January 1, 2021$(630)$(1,418)$(2,048)
Other comprehensive loss before reclassifications102 533 635 
Amounts reclassified to earnings 173 173 
Balance at March 31, 2021$(528)$(712)$(1,240)
15. Stock-Based Compensation
The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations:
         
Three Months Ended
March 31,
(in thousands)20222021
Cost of goods sold$912 $622 
Sales and marketing1,013 350 
General and administrative3,002 1,920 
Research and development696 425 
Total stock-based compensation expense$5,623 $3,317 
17

16. Leases
Operating and finance lease assets and liabilities are as follows:
(in thousands)ClassificationMarch 31,
2022
December 31,
2021
Assets
OperatingOther long-term assets$8,675 $8,788 
FinanceProperty, plant and equipment, net602 556 
Total leased assets$9,277 $9,344 
Liabilities
Current                     
     OperatingAccrued expenses and other liabilities$1,619 $1,599 
     FinanceCurrent portion of long-term debt and other borrowings378 392 
Noncurrent
     OperatingOther long-term liabilities16,207 16,546 
     FinanceLong-term debt, net and other borrowings204 299 
Total leased liabilities$18,408 $18,836 
17. Net Income Per Common Share
A summary of net income per common share is presented below:
Three Months Ended
March 31,
(in thousands, except per share amounts)20222021
Net income$42,962 $9,008 
Basic weighted-average common shares outstanding68,008 67,094 
Effect of dilutive stock options406 82 
Effect of dilutive restricted stock1,637 538 
Diluted weighted-average common shares outstanding70,051 67,714 
Basic income per common share$0.63 $0.13 
Diluted income per common share$0.61 $0.13 
Antidilutive securities excluded from diluted net income per common share377 1,349 
18. Other Income
Other income consisted of the following:
Three Months Ended
March 31,
(in thousands)20222021
Foreign currency (gains) losses$(81)$42 
Tax indemnification income, net(396)(573)
Interest income(8)(17)
Other (1)
Total other income$(485)$(549)
18

19. Commitments and Contingencies
Legal Proceedings
From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The costs and outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements.
As of March 31, 2022, the Company did not have any material ongoing litigation in which the Company was a party. During the first quarter of 2022, the Company was able to resolve certain litigation matters as set forth below:
On January 31, 2022, the Company entered into a global settlement agreement with Novartis, AAA, Endocyte and certain of their affiliates to settle certain disputes between the parties, as further described below:
German PSMA-617 Litigation
On November 8, 2018, Molecular Insight Pharmaceuticals, Inc., a subsidiary of Progenics (“MIP”), filed a complaint against the University of Heidelberg (the “University”) in the District Court in Mannheim, Germany (the “German District Court” and, such litigation, the “German Litigation”). In this Complaint, MIP claimed that the discovery and development of PSMA-617 was related to work performed under a research collaboration sponsored by MIP. MIP alleged that the University breached certain contracts with MIP and that MIP is the co-owner of inventions embodied in certain worldwide patent filings related to PSMA-617 that were filed by the University. On February 27, 2019, Endocyte, a wholly owned subsidiary of Novartis, filed a motion to intervene in the German Litigation. Endocyte is the exclusive licensee of the patent rights that are the subject of the German proceedings.
In connection with this dispute, MIP filed a Confirmation of Ownership with the United States Patent and Trademark Office (“USPTO”) for certain U.S. patent applications filed by the University to support MIPs claim that it is the co-owner of these pending U.S. patent applications (the “Ownership Claim”).
On February 27, 2019, the German District Court set €0.4 million as the amount MIP must deposit with the German District Court as security in the event of an unfavorable final decision on the merits of the dispute. On August 24, 2020, the German District Court issued its decision dismissing MIP’s claims, stating that MIP failed to discharge its burden of proof in the matter.
MIP filed a Notice of Appeal of the German District Court’s decision on September 24, 2020 and filed its appeal brief on November 26, 2020. The University and Endocyte each filed oppositions to MIP’s Notice of Appeal on March 12, 2021 and an oral hearing for the appeal was scheduled for September 28, 2022, at the Higher Regional Court Karlsruhe.
Pursuant to the terms of the Novartis Agreement, the German Litigation was dismissed and the Ownership Claim withdrawn.
Post-Grant Review Proceeding
On February 4, 2021, AAA, a wholly-owned subsidiary of Novartis and parent of Endocyte, filed a petition for post-grant review of U.S. Patent No. 10,640,461 (the “’461 patent”) with the Patent Trial and Appeal Board (“PTAB”) of the USPTO. The ’461 patent is owned by MIP. In the petition, AAA challenged the patentability of certain claims of the ’461 patent. The PTAB instituted Post-Grant Review proceedings (the “PGR Proceeding”) on July 29, 2021. Pursuant to the terms of the Novartis Agreement, the PGR Proceeding was terminated.
Global Settlement Agreement
In addition to the dismissal of the German Litigation, the withdrawal of the Ownership Claim and the termination of the PGR Proceeding, under the Novartis Agreement, the parties, among other things, cross-licensed certain patent rights to one another, and Novartis made a $24.0 million lump sum payment to the Company and also reimbursed the Company for certain fees and expenses the Company is required to pay to the University in connection with the German Litigation. The Company received the $24.0 million payment in April 2022.
RELISTOR European Opposition Proceedings
19

In October 2015, Progenics received notices of opposition to three European patents relating to methylnaltrexone: EP1615646, EP2368553 and EP2368554. Notices of opposition were filed separately at the European Patent Office (the “EPO”) by each of Actavis Group PTC ehf and Fresenius Kabi Deutschland GmbH. Between May 11, 2017 and July 4, 2017, the Opposition Division of the EPO (the “Opposition Division”) provided notice that the three European patents would be revoked. Each of these matters was appealed to the Appeal Board of the EPO. On November 13, 2020, Progenics withdrew the appeal for EP2368553 and EP2368554. Notices of termination of the proceedings with revocation of the patent were issued on November 23, 2020 for both patents.
Progenics continued its appeal on the revocation of the third patent, EP1615646. Oral proceedings for EP1615646 were held at the Appeal Board of the EPO on September 22, 2020. The revocation decision under appeal was set aside and the case was remitted to the Opposition Division for further prosecution. An oral hearing was held before the Opposition Division on September 27, 2021. The Opposition Division issued its final written opinion on November 11, 2021, indicating that the patent will be maintained in amended form. The final written decision of the Opposition Division was appealable to the Appeal Board of the EPO by either party. Progenics appealed this decision on January 20, 2022 to hold open its option to file Grounds for Appeal. Given that neither opponent filed a Notice of Appeal, Progenics withdrew its Notice of Appeal on February 23, 2022. The Opposition Division communicated the Closure of Opposition Proceedings on March 7, 2022. The patent will proceed to issuance, in amended form, with the payment of publication fees and submission of translated claims by June 11, 2022.
20. Segment Information
In the first quarter of fiscal year 2021, the Company completed the evaluation of its operating and reporting structure, including the impact on the Company’s business of the acquisition of Progenics described in Note 1, and the sale of the Puerto Rico subsidiary in the first quarter, which resulted in a change in operating and reportable segments. The Company now operates as one business segment: the development, manufacture and sale of innovative imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to Find, Fight and Follow serious medical conditions. This conclusion reflects the Company’s focus on the performance of the business on a consolidated worldwide basis. The results of this operating segment are regularly reviewed by the Company’s chief operating decision maker, the President and Chief Executive Officer. The Company’s chief operating decision maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.
20

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Cautionary Note Regarding Forward-Looking Statements
Some of the statements contained in this Quarterly Report on Form 10-Q are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements, including, in particular, statements about our plans, strategies, prospects and industry estimates are subject to risks and uncertainties. These statements identify prospective information and can generally be identified by words such as “anticipates,” “believes,” “can,” “could,” “estimates,” “expects,” “hopes,” “intends,” “launch,” “may,” “pipeline,” “plans,” “predicts,” “seeks,” “should,” “target,” “will,” “would” and similar expressions, or by express or implied discussions regarding potential marketing approvals or new indications for the collaborations, products candidates or approved products described in this Quarterly Report on Form 10-Q, or regarding potential future revenues from such collaborations, product candidates and products. Examples of forward-looking statements include statements we make relating to our outlook and expectations including, without limitation, in connection with: (i) continued market expansion and penetration for our established commercial products, particularly DEFINITY, in the face of segment competition and potential generic competition, including as a result of patent and regulatory exclusivity expirations and challenges; (ii) our ability to continue to grow PYLARIFY as a commercial product, including (A) our ability to obtain FDA approval for additional positron emission tomography (“PET”) manufacturing facilities (“PMFs”) to manufacture PYLARIFY, (B) the ability of PMFs to manufacture PYLARIFY to meet product demand, (C) our ability to sell PYLARIFY to customers, (D) our ability to obtain and maintain adequate coding, coverage and payment for PYLARIFY, and (E) our ability to establish PYLARIFY as a leading PSMA PET imaging agent in a competitive environment in which other PSMA PET imaging agents have been approved and additional ones are in development; (iii) the global Molybdenum-99 (“Mo-99”) supply; (iv) our ability to have third party manufacturers manufacture our products and our ability to use our in-house manufacturing capacity; (v) our ability to successfully launch PYLARIFY AI as a commercial product; (vi) the continuing impact of the global COVID-19 pandemic on our business, financial condition and prospects; (vii) the efforts and timing for clinical development of our product candidates and new clinical applications for our products, in each case, that we may develop, including 1095 and LMI 1195, or that our strategic partners may develop, including flurpiridaz fluorine-18 (“F 18”); (viii) our ability to identify and acquire or in-license additional diagnostic and therapeutic product opportunities in oncology and other strategic areas; and (ix) the potential reclassification by the FDA of certain of our products and product candidates from drugs to devices with the expense, complexity and potentially more limited competitive protection such reclassification could cause. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, such statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. These statements are neither statements of historical fact nor guarantees or assurances of future performance. The matters referred to in the forward-looking statements contained in this Quarterly Report on Form 10-Q may not in fact occur. We caution you, therefore, against relying on any of these forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part I, Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021, and in Part II, Item 1A. “Risk Factors” in this Quarterly Report on Form 10-Q.
Any forward-looking statement made by us in this Quarterly Report on Form 10-Q speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Available Information
Our global Internet site is www.lantheus.com. We routinely make available important information, including copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after those reports are electronically filed with, or furnished to, the SEC, free of charge on our website at investor.lantheus.com. We recognize our website as a key channel of distribution to reach public investors and as a means of disclosing material non-public information to comply with our disclosure obligations under SEC Regulation FD. Information contained on our website shall not be deemed incorporated into, or to be part of this Quarterly Report on Form 10-Q, and any website references are not intended to be made through active hyperlinks.
Our reports filed with, or furnished to, the SEC are also available on the SEC’s website at www.sec.gov, and for Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, in an iXBRL (Inline Extensible Business Reporting Language) format. iXBRL is an electronic coding language used to create interactive financial statement data over the Internet. The information on our website is neither part of nor incorporated by reference into this Quarterly Report on Form 10-Q.
21

The following discussion and analysis of our financial condition and results of operations should be read together with the condensed consolidated financial statements and the related notes included in Item 1 of this Quarterly Report on Form 10-Q as well as the other factors described in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021, and in Part II, Item 1A. “Risk Factors” in this Quarterly Report on Form 10-Q.
Overview
Our Business
We are an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to Find, Fight and Follow serious medical conditions. We classify our products in three categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other revenue. Our leading precision diagnostic products assist healthcare professionals (“HCPs”) Find and Follow diseases in non-oncologic conditions. Our radiopharmaceutical oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Our strategic partnerships and other revenue category focuses on facilitating precision medicine through the use of biomarkers, digital solutions and radiotherapeutic platforms, and also includes royalty revenue from our license of RELISTOR.
Our commercial products are used by cardiologists, urologists, oncologists, internal medicine physicians, nuclear medicine physicians, radiologists, sonographers and technologists working in a variety of clinical settings. We believe that our diagnostic products provide improved diagnostic information that enables HCPs to better detect and characterize, or rule out, disease, with the potential to achieve better patient outcomes, reduce patient risk and limit overall costs for payors and throughout the healthcare system.
We produce and market our products throughout the United States (the “U.S.”), selling primarily to clinics, group practices, hospitals, integrated delivery networks, and radiopharmacies. We sell our products outside the U.S. through a combination of direct distribution in Canada and third party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Our headquarters are located in North Billerica, Massachusetts, with additional offices in Somerset, New Jersey; Montreal, Canada and Lund, Sweden.
In the first quarter of 2021, we completed the evaluation of our operating and reporting structure, including the impact on our business of the acquisition of Progenics and the sale of our Puerto Rico subsidiary, which resulted in a change in our operating segments to one reportable business segment.
Key Factors Affecting Our Results
Our business and financial performance have been, and continue to be, affected by the following:
PYLARIFY Approval, Commercial Launch and Revenue Growth
On May 27, 2021, we announced that the FDA had approved PYLARIFY, an F 18-labeled PET imaging agent targeting prostate-specific membrane antigen (“PSMA”). PYLARIFY is a product in our radiopharmaceutical oncology product category. We commercially launched PYLARIFY in the U.S. in June 2021.
PYLARIFY is a radioactive diagnostic agent indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy and with suspected recurrence based on elevated serum prostate-specific antigen (“PSA”) levels. PYLARIFY works by binding to PSMA, a protein that is overexpressed on the surface of more than 90% of primary and metastatic prostate cancer cells. PYLARIFY works with PET/CT technology to produce a combined PET/CT scan that enables the reader of the PET/CT scan to detect and locate the disease.
According to the American Cancer Society, prostate cancer is the second most common cancer in American men -- one in eight American men will be diagnosed with prostate cancer in their lifetimes and over 3.1 million American men are living with prostate cancer today. Based on estimates from third party sources regarding the incidence of prostate cancer in men in the U.S., we believe the market potential for all PSMA PET imaging agents in the U.S. could be up to 250,000 annual scans, comprised of 90,000 scans for patients with intermediate, unfavorable or high/very high risk of suspected metastases of prostate cancer; 130,000 scans for patients with suspected recurrence of prostate cancer; and 30,000 scans for patients with metastatic castration-resistant prostate cancer (“mCRPC”) who may be under consideration for PSMA-targeted therapy for the treatment of adult patients with PSMA-positive mCRPC who have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy). However, because we are still early in the commercialization of PYLARIFY, we can give no assurance as to how clinical practice may evolve or what our ultimate market penetration may be.
22

In March 2022, we announced a strategic collaboration with Novartis to include PYLARIFY in prostate cancer trials with Pluvicto, Novartis’ recently approved PSMA-targeted therapeutic. As part of the agreement with Novartis, we will supply PYLARIFY for the selection of patients with prostate cancer, and Novartis will provide all PYLARIFY-related clinical imaging data to us. In addition, the Society for Nuclear Medicine and Molecular Imaging, or SNMMI, recently updated their appropriate use criteria, noting that PSMA PET imaging agents, including PYLARIFY, can be used for patient selection for PSMA-targeted radioligand therapy.
The approval of PYLARIFY was based on data from two Company-sponsored pivotal studies (“OSPREY” and “CONDOR”) designed to establish the safety and diagnostic performance of PYLARIFY across the prostate cancer disease continuum. Results from OSPREY (Cohort A) demonstrated improvement in specificity and positive predictive value of PYLARIFY PET imaging over conventional imaging in men at risk for metastatic prostate cancer prior to initial definitive therapy. CONDOR studied men with biochemical recurrent prostate cancer. In patients with biochemical recurrent prostate cancer and non-informative baseline imaging, PYLARIFY demonstrated high correct localization and detection rates, including in patients with early recurrent disease with low, but rising, PSA blood levels (median PSA 0.8 ng/mL).
Upon commercial launch in June 2021, PYLARIFY was immediately available in select parts of the U.S. Over the course of the remainder of 2021, PYLARIFY availability expanded into additional regions and is now broadly available nationwide. We continue to expand our geographic coverage, customer contracting and market access coverage to serve our customers and the U.S. prostate cancer community.
The commercial launch of PYLARIFY has been complex and expensive. During 2021, we hired additional employees to assist us with the commercialization of PYLARIFY, including in sales, marketing, reimbursement, quality and medical affairs. To manufacture PYLARIFY, we assembled and qualified a nationwide network of PMFs with radioisotope-producing cyclotrons that make F 18, which has a 110-minute half-life, so PYLARIFY is manufactured and distributed rapidly to end-users. After being made on a cyclotron at a PMF, the F 18 is then combined with certain chemical ingredients in specially designed chemistry synthesis boxes to manufacture PYLARIFY. The finished PYLARIFY is then quality control tested and transferred to a radiopharmacist who prepares and dispenses patient-specific doses of the final product. Because each of the PMFs manufacturing these products is deemed by the FDA to be a separate manufacturing site, each has to be separately approved by the FDA. Although PYLARIFY is now broadly available nationwide and we continue to qualify additional PMFs, we can give no assurance that the FDA will continue to approve PMFs in accordance with our planned roll-out schedule. If FDA approval of manufacturing sites is delayed or withdrawn, our future business, results of operations, financial condition and cash flows could be adversely affected.
In addition to the network of PMFs, we have also been working with academic medical centers in the U.S. that have radioisotope-producing cyclotrons and which have expressed an interest in manufacturing PYLARIFY. Under this initiative, we enter into a fee-for-service arrangement under which the academic medical center’s PMF manufactures and supplies batches of PYLARIFY, and its radiopharmacy prepares patient-ready unit doses, in each case for and on behalf of us. We then sell those unit doses to the academic medical center’s hospitals and clinics, and in some instances, to additional customers in the academic medical center’s geographic area, in each case, under separate purchase agreements. The academic medical center’s PMF’s ability to manufacture and supply batches of PYLARIFY is subject to FDA approval, and we can give no assurance that the FDA will approve such PMFs in accordance with our planned roll-out schedule.
Our commercial launch also required obtaining adequate coding, coverage and payment for PYLARIFY, including not only coverage from Medicare, Medicaid and other government payors, as well as private payors, but also appropriate payment levels, to adequately cover our customers’ costs of using PYLARIFY in PSMA PET/CT imaging procedures. We received notification that our Healthcare Procedure Coding System (“HCPCS”) code, which enables streamlined billing, went into effect as of January 1, 2022. In addition, effective January 1, 2022, the Centers for Medicare and Medicaid Services (“CMS”) granted Transitional Pass-Through Payment Status in the hospital outpatient setting (“TPT Status”) for PYLARIFY, enabling traditional Medicare to provide an incremental payment for PET/CT scans performed with PYLARIFY in that setting. TPT Status for PYLARIFY is expected to expire December 31, 2024. After TPT Status expires, under current Medicare rules, PYLARIFY, similar to other diagnostic radiopharmaceuticals, would not be separately reimbursed in the hospital outpatient setting but rather would be included as part of the facility fee a hospital otherwise receives for a PET/CT imaging procedure, and the facility fee does not always adequately cover the total cost of the procedure. We can give no assurance that any CMS reimbursement in the hospital outpatient setting that follows the expiration of TPT Status will be adequate to cover the cost of a PYLARIFY PET/CT imaging procedure.
We actively pursue patents in connection with PYLARIFY, both in the U.S. and internationally. In the U.S. for PYLARIFY, we have four Orange Book-listed patents, including composition of matter patents, which expire in 2030 and 2037. Outside of the U.S., we are currently pursuing additional PYLARIFY patents to obtain similar patent protection as in the U.S.
PYLARIFY AI Clearance and Use
23

During 2021, we also announced that our subsidiary, EXINI, was granted 510(k) clearance by the FDA in the U.S. and received CE marking in Europe for aPROMISE. We commercially launched aPROMISE under the name PYLARIFY AI in the U.S. in November 2021.
PYLARIFY AI is artificial intelligence medical device software developed to assist with the reading and quantification of PYLARIFY scans. The technology automatically analyzes a PSMA PET/CT image to segment anatomical regions – 51 bones and 12 soft tissue organs. This image segmentation enables automated localization, detection and quantification of potential PSMA-avid lesions in a PSMA PET/CT image, which data is then incorporated into the reporting system used by physicians.
Anticipated Continued Growth of DEFINITY and Expansion of Our Ultrasound Microbubble Franchise
We believe the market opportunity for our ultrasound microbubble enhancing agent, DEFINITY, continues to be significant. Historically, DEFINITY has been our fastest growing and highest margin commercial product. We anticipate DEFINITY sales will continue to grow in the future. As we continue to educate the physician and healthcare provider community about the benefits and risks of DEFINITY, we believe we will be able to continue to grow the appropriate use of DEFINITY in suboptimal echocardiograms. In a U.S. market with three echocardiography ultrasound enhancing agents approved by the FDA, we estimate that DEFINITY had over 80% of the market as of December 31, 2021.
As we continue to pursue expanding our microbubble franchise, our activities include:
Patents - We continue to actively pursue additional patents in connection with DEFINITY and DEFINITY RT, both in the U.S. and internationally. In the U.S. for DEFINITY, we have five Orange Book-listed method of use patents, one of which expires in 2035 and four of which expire in 2037, as well as additional manufacturing patents that are not Orange Book-listed expiring in 2023 and 2037. In the U.S. for DEFINITY RT, we have six Orange Book-listed patents, including a composition of matter patent which expires in 2035. Outside of the U.S., we are currently pursuing additional DEFINITY and DEFINITY RT patents to obtain similar patent protection as in the U.S. The Orange Book-listed patents include a patent on the use of VIALMIX RFID which expires in 2037; we have submitted additional VIALMIX RFID patent applications in major markets throughout the world.
Hatch-Waxman Act - Even though our longest duration Orange Book-listed DEFINITY patent extends until March 2037, because our Orange Book-listed composition of matter patent expired in June 2019, we may face generic DEFINITY challengers in the near to intermediate term. Under the Hatch-Waxman Act, the FDA can approve Abbreviated New Drug Applications (“ANDAs”) for generic versions of drugs if the ANDA applicant demonstrates, among other things, that (i) its generic candidate is the same as the innovator product by establishing bioequivalence and providing relevant chemistry, manufacturing and product data, and (ii) either the marketing of that generic candidate does not infringe the Orange Book-listed patent(s) or the Orange Book-listed patent(s) is invalid. Similarly, the FDA can approve a Section 505(b)(2) New Drug Application (“505(b)(2)”) from an applicant that relies on some of the information required for marketing approval to come from studies which the applicant does not own or have a legal right of reference. With respect to the Orange Book-listed patent(s) covering an innovator product, the ANDA applicant or the Section 505(b)(2) applicant (if relying on studies related to the innovator product) (together, the “Applicant”) must give a notice (a “Notice”) to the innovator of its certification that its generic candidate will not infringe the innovator’s Orange Book-listed patent(s) or that the Orange Book-listed patent(s) is invalid. The innovator can then file suit against the Applicant within 45 days of receiving the Notice, and FDA approval to commercialize the generic candidate will be stayed (that is, delayed) for up to 30 months (measured from the date on which a Notice is received) while the patent dispute between the innovator and the Applicant is resolved in court. The 30-month stay could potentially expire sooner if the courts determine that no infringement had occurred or that the challenged Orange Book-listed patent is invalid or if the parties otherwise settle their dispute.
As of the date of filing of this Quarterly Report on Form 10-Q, we have not received any Notice from an Applicant. If we were to (i) receive any such Notice in the future, (ii) bring a patent infringement suit against the Applicant within 45 days of receiving that Notice, and (iii) successfully obtain the full 30-month stay, then the Applicant would be precluded from commercializing a generic version of DEFINITY prior to the expiration of that 30-month stay period and, potentially, thereafter, depending on how the patent dispute is resolved. Solely by way of example and not based on any knowledge we currently have, if we received a Notice from an Applicant in May 2022 and the full 30-month stay were obtained, then the Applicant would be precluded from commercialization until at least November 2024. If we received a Notice some number of months in the future and the full 30-month stay were obtained, the commercialization date would roll forward in the future by the same number of months. In the event a 505(b)(2) applicant does not rely on studies related to the innovator product, the 30-month stay would not apply, but additional clinical studies may be required.
DEFINITY RT - DEFINITY RT became commercially available in the fourth quarter of 2021. A modified formulation of DEFINITY that allows both storage and shipment at room temperature, DEFINITY RT provides clinicians an additional choice and allows for greater utility of this formulation in broader clinical settings. Given its physical characteristics, we
24

believe DEFINITY RT is also well-suited for inclusion in kits requiring microbubbles for other indications and applications (including in kits developed by third parties of the type described in the paragraph entitled Microbubble Franchise below).
VIALMIX RFID – VIALMIX RFID, our next-generation activation device designed specifically for both DEFINITY and DEFINITY RT, became commercially available in the fourth quarter of 2021. The activation rate and time are controlled by VIALMIX RFID through the use of radio-frequency identification technology (“RFID”) to ensure reproducible activation of DEFINITY and DEFINITY RT. The RFID tag, which is affixed to the vial label, enables the DEFINITY or DEFINITY RT vial to be appropriately activated with the VIALMIX RFID activation device.
Global Mo-99 Supply
We currently have Mo-99 supply agreements with Institute for Radioelements (“IRE”), running through December 31, 2022, with auto-renewal provisions that are terminable upon notice of non-renewal, and with NTP Radioisotopes (“NTP”), acting for itself and on behalf of its subcontractor, the Australian Nuclear Science and Technology Organisation (“ANSTO”), running through June 30, 2022, and for which we are currently negotiating an extension.
Although we have a globally diverse Mo-99 supply with IRE in Belgium, NTP in South Africa, and ANSTO in Australia, we still face supplier and logistical challenges in our Mo-99 supply chain. The NTP processing facility had periodic outages in 2017, 2018 and 2019. When NTP was not producing, we relied on Mo-99 supply from both IRE and ANSTO to limit the impact of the NTP outages. In 2019 and 2020, ANSTO experienced multiple facility issues that resulted in ANSTO outages and volume limitations, during which time we relied on IRE and NTP to limit the impact of those outages and limitations. Because of the COVID-19 pandemic, we experienced challenges receiving regularly scheduled orders of Mo-99 from our global suppliers, particularly in the second quarter of 2020. We continue to manage these various supply chain challenges, but depending on reactor and processor schedules and operations, at times we have not been able to fill some or all of the demand for our TechneLite generators on certain manufacturing days. A prolonged disruption of service from one of our three Mo-99 processing sites or one of their main Mo-99-producing reactors could have a substantial negative effect on our business, results of operations, financial condition and cash flows.
To augment our current supply of Mo-99, we have a strategic arrangement with SHINE Medical Technologies LLC (“SHINE”) for the future supply of Mo-99. Under the terms of the supply agreement, entered into in November 2014, SHINE will provide Mo-99 produced using its proprietary LEU-solution technology for use in our TechneLite generators once SHINE’s facility becomes operational and receives all necessary regulatory approvals, which SHINE now estimates will occur in 2023. The term of this arrangement provides for three years of supply of Mo-99. However, we cannot assure you that SHINE will be able to produce commercial quantities of Mo-99 for our business, or that SHINE, together with our current suppliers, will be able to deliver a sufficient quantity of Mo-99 to meet our needs.
Inventory Supply
We obtain a substantial portion of our imaging agents from a third party supplier. JHS is currently a significant supplier of DEFINITY and our sole source manufacturer of NEUROLITE, Cardiolite and evacuation vials, the latter being an ancillary component for our TechneLite generators. On February 23, 2022, our wholly-owned subsidiary, LMI, entered into a Manufacturing and Supply Agreement (the “MSA”) with JHS, effective as of February 23, 2022, pursuant to which JHS will manufacture, and LMI will purchase, our DEFINITY, NEUROLITE, Cardiolite and evacuation vial products. The new MSA supersedes all of the prior agreements of the parties. The initial term of the MSA runs through December 31, 2027 and can be further extended by mutual agreement of the parties. The MSA requires LMI to purchase from JHS specified percentages of its total requirements for DEFINITY, as well as specified quantities of NEUROLITE, Cardiolite and evacuation vial products, each year during the contract term. Either party can terminate the MSA upon the occurrence of certain events, including the material breach or bankruptcy of the other party. In addition to JHS, we rely on Samsung BioLogics as our sole source manufacturer of DEFINITY RT.
In 2021, we completed the construction of a specialized in-house manufacturing facility at our North Billerica campus for purposes of producing DEFINITY and, potentially, other sterile vial products. On February 22, 2022, we received FDA approval of our sNDA, authorizing commercial manufacturing of DEFINITY at our new facility, and inventory that we had previously manufactured at this facility became commercially saleable. We believe this facility will allow us to better manage DEFINITY manufacturing and inventory, reduce our costs in a potentially more price competitive environment, and provide us with supply chain redundancy.
Radiopharmaceuticals are decaying radioisotopes with half-lives ranging from a few hours to several days. These products cannot be kept in inventory because of their limited shelf lives and are subject to just-in-time manufacturing, processing and distribution, which takes place at our facilities in North Billerica, Massachusetts and Somerset, New Jersey.
COVID-19 Pandemic
25

The global COVID-19 pandemic has had, and may continue to have, a material impact on our business. Towards the end of the first quarter of 2020 we began to experience, and through the date of this filing we are continuing to experience, impacts to our business and operations related to the COVID-19 pandemic, including the impact of hospital staffing challenges, vaccination mandates, employee absences due to illness, and a decline in the volume of certain procedures and treatments using our products.
Although many of the restrictions, including stay-at-home mandates, imposed in response to the COVID-19 pandemic have been lifted in much of the U.S., and there has been a rapid rollout and development of multiple vaccines and boosters, the resurgence of COVID-19 infections continued to impact certain aspects of our business during the first quarter of 2022. For example, we believe sales of DEFINITY were impacted by elevated case counts and hospitalizations but improved over the course of the quarter, even amidst ongoing hospital nursing and sonographer shortages.
The pandemic could still have a future negative impact on our business, particularly if there are additional resurgences as a result of mutations or other variations to the virus that further increase its communicability or its impact on certain populations, geographic regions and the healthcare system, including elective procedures and hospital access.
Research and Development Expenses
To remain a leader in the marketplace, we have historically made and will continue to make substantial investments in new product development and lifecycle management for existing products.
For PYLARIFY, our development of PYLARIFY resulted in approval by the FDA in May 2021.
For PYLARIFY AI, our development of PYLARIFY AI resulted in a 510(k) clearance granted by the FDA in July 2021.
For 1095, we completed an interim analysis of the ARROW Phase 2 study in mCRPC patients in the fourth quarter of 2021 and are continuing that study without modifications. We currently expect to complete enrollment in the ARROW Phase 2 study later in 2022.
For LMI 1195, we plan to initiate a Phase 3 clinical trial for the use of LMI 1195 for the diagnosis and management of neuroblastoma tumors in pediatric and adult populations. We expect to initiate approximately 20 clinical sites in the U.S. to enroll approximately 100 patients with known or suspected neuroblastoma.
We are also exploring additional lifecycle management opportunities for some of our current products, including AZEDRA.
Our investments in these additional clinical activities and lifecycle management opportunities will increase our operating expenses and impact our results of operations and cash flow, and we can give no assurances as to whether any of our clinical development candidates or lifecycle management opportunities will be successful.
Strategic Initiatives
We continue to seek ways to further expand our portfolio of products and product candidates and to optimize the value of our current assets, evaluating a number of different opportunities to collaborate with others or to acquire or in-license additional products, product candidates, businesses and technologies to drive our future growth. In particular, we believe that diagnostic and therapeutic product opportunities in oncology and other strategic areas will be critical to our future success, and we are committed to further augmenting our commercial portfolio with revenue opportunities of a similar magnitude as DEFINITY and PYLARIFY, either through strategic transactions or internal development.
Oncology
As we continue to pursue expanding our strategic partnerships, our Pharma Services activities and strategic partnerships in oncology include:
Prostate Cancer - We collaborate with pharmaceutical companies developing therapies and diagnostics in prostate cancer.
In March 2022, we announced a collaboration with Novartis to include PYLARIFY in prostate cancer trials with Pluvicto. As part of the agreement with Novartis, the Company will provide PYLARIFY for the selection of patients with prostate cancer, and Novartis will provide all PYLARIFY related clinical imaging data to the Company.
In January 2022, we announced a collaboration with the Prostate Cancer Clinical Trial Consortium (“PCCTC”), a premier multicenter clinical research organization that specializes in prostate cancer research. The intent of the strategic collaboration is to integrate our AI platform into PCCTC studies to advance the development and validation of novel AI-enabled biomarkers.
In September 2021, we entered into a development and commercialization collaboration with RefleXion Medical, Inc. to evaluate the use of piflufolastat F 18 to enable real-time therapeutic guidance of biology-guided radiotherapy in prostate cancer using the RefleXion X1TM platform.
26

Prior to 2021, we also entered into several other separate agreements, including with POINT Biopharma and Regeneron, under which we supply piflufolastat F 18 in connection with their clinical studies, and Curium, under which we licensed exclusive rights to Curium to develop and commercialize piflufolastat F 18 in Europe.
Immuno-Oncology - In May 2019, we entered into a strategic collaboration and license agreement with NanoMab, a privately-held biopharmaceutical company focused on the development of next generation radiopharmaceuticals for cancer precision medicine.
Pan-Oncology - In March 2021, we acquired from Ratio Therapeutics LLC (previously Noria Therapeutics, Inc.) exclusive, worldwide rights to NTI-1309, an innovative imaging biomarker that targets fibroblast activation protein, an emerging target with broad potential imaging applicability and use in oncology. Upon further clinical development, we will assess options to bring NTI-1309 to market as a diagnostic or potentially a therapeutic product.
Microbubble Franchise
In addition, we continue to expand our microbubble franchise. In April 2021, we announced a strategic collaboration with Allegheny Health Network (“AHN”), which will use our microbubbles in combination with AHN’s ultrasound-assisted non-viral gene transfer technology for the development of a proposed treatment of xerostomia. Xerostomia is a lack of saliva production leading to dry mouth and has a variety of causes, including radiotherapy and chemotherapy, the chronic use of drugs and rheumatic and dysmetabolic diseases. Prior to 2021, we entered into microbubble collaborations with the following parties: (i) Cerevast Medical, Inc. (“Cerevast”), in which our microbubbles will be used in connection with Cerevast’s ocular ultrasound device to improve blood flow in occluded retinal veins in the eye; (ii) CarThera SAS, for the use of our microbubbles in combination with SonoCloud, a proprietary implantable device in development for the treatment of recurrent glioblastoma; and (iii) Insightec Ltd. (“Insightec”), which will use our microbubbles in connection with the development of Insightec’s transcranial guided focused ultrasound device for the treatment of glioblastoma as well as other neurodegenerative conditions.
Generally, our costs in connection with the strategic partnerships relate to the supply of drug and other ancillary expenses and the benefits can include possible supply, milestone and royalty payments, additional intellectual property rights and strategic relationships. We can give no assurance as to if or when or if any of these collaborations and other new initiatives will be successful or accretive to earnings.

27

Results of Operations
The following is a summary of our consolidated results of operations:
Three Months Ended
March 31,
(in thousands)20222021Change $Change %
Revenues$208,880 $92,509 $116,371 125.8 %
Cost of goods sold79,810 51,479 28,331 55.0 %
Gross profit129,070 41,030 88,040 214.6 %
Operating expenses
Sales and marketing20,354 14,173 6,181 43.6 %
General and administrative37,588 16,138 21,450 132.9 %
Research and development12,203 10,360 1,843 17.8 %
Total operating expenses70,145 40,671 29,474 72.5 %
Gain on sale of assets— 15,263 (15,263)N/A
Operating income58,925 15,622 43,303 277.2 %
Interest expense1,509 2,718 (1,209)(44.5)%
Gain on extinguishment of debt— (889)889 N/A
Other income(485)(549)64 (11.7)%
 Income before income taxes57,901 14,342 43,559 303.7 %
Income tax expense14,939 5,334 9,605 180.1 %
Net income$42,962 $9,008 $33,954 376.9 %

Comparison of the Periods Ended March 31, 2022 and 2021
Revenues
We classify our revenues into three product categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other revenue. Precision diagnostics includes DEFINITY, TechneLite and other imaging diagnostic products. Radiopharmaceutical oncology consists primarily of PYLARIFY and AZEDRA. Strategic partnerships and other revenue includes out-licensing arrangements, which includes $24.0 million of revenue recognized pursuant to the Novartis Agreement, partnerships that focus on facilitating precision medicine through the use of biomarkers, digital solutions and radiotherapeutic platforms, and on our other products, such as RELISTOR.
28

Revenues are summarized by product category on a net basis as follows:
Three Months Ended
March 31,
(in thousands)20222021Change $Change %
   DEFINITY$58,328 $55,971 $2,357 4.2 %
   TechneLite22,605 22,800 (195)(0.9)%
   Other precision diagnostics5,265 6,984 (1,719)(24.6)%
Total precision diagnostics86,198 85,755 443 0.5 %
   PYLARIFY92,777 — 92,777 N/A
   Other radiopharmaceutical oncology1,327 1,500 (173)(11.5)%
Total radiopharmaceutical oncology94,104 1,500 92,604 6,173.6 %
Strategic partnerships and other revenue28,578 5,254 23,324 443.9 %
Total revenues$208,880 $92,509 $116,371 125.8 %
The increase in revenues for the three months ended March 31, 2022, as compared to the prior year period, is primarily driven by the commercial launch of PYLARIFY and $24.0 million of revenue recognized pursuant to the Novartis Agreement, and an increase in DEFINITY sales volume period over period due to improving conditions relative to the COVID-19 pandemic in the prior year. The increase is offset, in part, by lower sales volumes from other precision diagnostic products.
Rebates and Allowances
Estimates for rebates and allowances represent our estimated obligations under contractual arrangements with third parties. Rebate accruals and allowances are recorded in the same period the related revenue is recognized, resulting in a reduction to revenue and the establishment of a liability which is included in accrued expenses. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and growth, Medicaid rebate programs for our products, administrative fees of group purchasing organizations and certain distributor related commissions. The calculation of the accrual for these rebates and allowances is based on an estimate of the third-party’s expected purchases and the resulting applicable contractual rebate to be earned over a contractual period.
An analysis of the amount of, and change in, reserves is summarized as follows:
(in thousands)Rebates and
Allowances
Balance, January 1, 2022$10,977 
Provision related to current period revenues6,411 
Adjustments relating to prior period revenues62 
Payments or credits made during the period(6,657)
Balance, March 31, 2022$10,793 

Gross Profit
The increase in gross profit for the three months ended March 31, 2022, as compared to the prior year period, is primarily due to PYLARIFY post commercial launch sales volume and the $24.0 million pursuant to the Novartis Agreement, which are partially offset by amortization expense of acquired intangible assets in the Progenics Acquisition.
Sales and Marketing
Sales and marketing expenses consist primarily of salaries and other related costs for personnel in field sales, marketing and customer service functions. Other costs in sales and marketing expenses include the development and printing of advertising and promotional material, professional services, market research and sales meetings.
Sales and marketing expenses increased $6.2 million for the three months ended March 31, 2022 as compared to the prior year period. This was primarily driven by the commercialization activities for the launch of PYLARIFY and increased employee-related costs (including the hiring of new employees during 2021 in connection with the commercialization activities for PYLARIFY), as well as the reduced level of marketing promotional programs and travel during the prior year due to the impact of the COVID-19 pandemic.
29

General and Administrative
General and administrative expenses consist of salaries and other related costs for personnel in executive, finance, legal, information technology and human resource functions. Other costs included in general and administrative expenses are professional fees for information technology services, external legal fees, consulting and accounting services as well as bad debt expense, certain facility and insurance costs, including director and officer liability insurance.
General and administrative expenses increased $21.5 million for the three months ended March 31, 2022 compared to the prior period. This was primarily driven by the $18.4 million net expense for the fair value adjustments to the contingent asset and liabilities in the first quarter of 2022 (an increase of $18.1 million from the prior year period) (refer to Note 4, “Fair Value of Financial Instruments”, for further details on contingent consideration liabilities, including CVRs) and increased employee-related costs, offset by acquisition-related costs associated with the Progenics Acquisition in the prior year.
Research and Development
Research and development expenses relate primarily to the development of new products to add to our portfolio and costs related to our medical affairs, medical information and regulatory functions.
Research and development expenses increased $1.8 million for the three months ended March 31, 2022 as compared to the prior year period. This was primarily driven by the level of activity of the ARROW Phase 2 study of 1095, investment in medical affairs related to PYLARIFY and higher overall headcount related costs, offset by the expenses related to filing fees for the PYLARIFY New Drug Application and preparation activities for the launch of PYLARIFY during the prior year period.
Interest Expense
Interest expense decreased by approximately $1.2 million for the three months ended March 31, 2022 as compared to the prior year period due to lower interest rates on our long-term debt and the repayment of the Royalty-Backed Loan on March 31, 2021.
Income Tax Expense
The income tax expense recorded for the three months ended March 31, 2022 was primarily due to pre-tax profits reported during the quarter, partially offset by the benefit associated with stock compensation deductions.
We regularly assess our ability to realize our deferred tax assets. Assessing the realizability of deferred tax assets requires significant management judgment. In determining whether our deferred tax assets are more-likely-than-not realizable, we evaluate all available positive and negative evidence, and weigh the objective evidence and expected impact. We continue to record a valuation allowance against certain of our foreign net deferred tax assets and a small component of our domestic deferred tax assets.
Our effective tax rate for each reporting period is presented as follows:
            
Three Months Ended
March 31,
20222021
Effective tax rate25.8%37.2%
Our effective tax rate in fiscal 2022 differs from the U.S. statutory rate of 21% principally due to the accrual of state taxes and the impact of non-deductible contingency reserve expense.
The decrease in the effective income tax rate for the three months ended March 31, 2022 is primarily due to the increased amount of stock compensation benefits recorded during that quarter.
30

Liquidity and Capital Resources
Cash Flows
The following table provides information regarding our cash flows:
Three Months Ended
March 31,
(in thousands)20222021
Net cash provided by operating activities$10,264 $9,818 
Net cash (used in) provided by investing activities$(1,390)$13,303 
Net cash used in financing activities$(2,179)$(34,791)
Net Cash Provided by Operating Activities
Net cash provided by operating activities of $10.3 million in the three months ended March 31, 2022 was primarily comprised of net income adjusted for the net effect of non-cash items such as the change in fair value of contingent assets and liabilities of $18.4 million (refer to Note 4, “Fair Value of Financial Instruments”, for further details on contingent consideration liabilities, including CVRs). The primary working capital sources of cash were the timing of payments to large vendors. The primary working capital uses of cash were an increase in trade receivables from timing of sale orders and an increase in collection period as well as the timing of inventory purchases.
Net cash provided by operating activities of $9.8 million in the three months ended March 31, 2021 was driven primarily by net income of $9.0 million, depreciation, amortization and accretion expense of $8.1 million, stock-based compensation expense of $3.3 million, and deferred income taxes of $4.6 million. These net sources of cash were offset by a gain on sale of assets of $15.3 million and a net decrease of $1.5 million related to movements in our working capital accounts during the period. The overall decreases in cash from our working capital accounts were primarily driven by the payment of prior year annual bonuses as well as increased receivables from sales offset by a reduction in inventory due to obsolescence as well as the timing of inventory purchases.
Net Cash (Used in) Provided by Investing Activities
Net cash used in investing activities during the three months ended March 31, 2022 was primarily due to $3.2 million of capital expenditures offset by cash proceeds of $1.8 million received from the sale of our Puerto Rico subsidiary.
Net cash provided by investing activities during the three months ended March 31, 2021 was primarily due to cash proceeds of $15.8 million received from the sale of our Puerto Rico subsidiary, which was offset by $2.5 million of capital expenditures.
Net Cash Used in Financing Activities
Net cash used in financing activities during the three months ended March 31, 2022 is primarily attributable to the payments on long-term debt and other borrowings of $2.6 million related to the 2019 Term Facility and payments for minimum statutory tax withholding related to net share settlement of equity awards of $5.5 million offset by proceeds of $5.4 million from stock option exercises.
Net cash used in financing activities during the three months ended March 31, 2021 is primarily attributable to the payments on long-term debt and other borrowings of $35.6 million related to the 2019 Term Facility and Royalty-Backed Loan, including a voluntary repayment of the outstanding principal on the Royalty-Backed Loan and payments for minimum statutory tax withholding related to net share settlement of equity awards of $1.6 million offset by proceeds of $2.0 million from stock option exercises.
External Sources of Liquidity
In June 2019, we refinanced our 2017 $275.0 million five-year term loan facility with the 2019 Term Facility. In addition, we replaced our $75.0 million revolving facility with our current five-year revolving credit facility (the “2019 Revolving Facility” and together with the 2019 Term Facility, the “2019 Facility”). The terms of the 2019 Term Facility are set forth in the Credit Agreement, dated as of June 27, 2019, by and among us, the lenders from time to time party thereto and Wells Fargo Bank, N.A., as administrative agent and collateral agent, which was amended on June 19, 2020 (as amended, the “2019 Credit Agreement”). We have the right to request an increase to the 2019 Term Facility or request the establishment of one or more new incremental term loan facilities, in an aggregate principal amount of up to $100.0 million, plus additional amounts, in certain circumstances.
We are permitted to voluntarily repay the 2019 Term Loans, in whole or in part, without premium or penalty. The 2019 Term Facility requires us to make mandatory prepayments of the outstanding 2019 Term Loans in certain circumstances. The 2019 Term Facility amortizes at 5.0% per year through September 30, 2022 and 7.5% thereafter, until its June 27, 2024 maturity date.
31

Under the terms of the 2019 Revolving Facility, the lenders thereunder agreed to extend credit to us from time to time until June 27, 2024 consisting of revolving loans in an aggregate principal amount not to exceed $200.0 million at any time outstanding. The 2019 Revolving Facility includes a $20.0 million sub-facility for the issuance of letters of credit (the “Letters of Credit”). The 2019 Revolving Facility includes a $10.0 million sub-facility for swingline loans (the “Swingline Loans”). The Letters of Credit, Swingline Loans and the borrowings under the 2019 Revolving Facility are expected to be used for working capital and other general corporate purposes.
Under the 2019 Credit Agreement, loans bear interest at LIBOR plus a spread that ranges from 1.50% to 3.00% or the Base Rate (as defined in the 2019 Credit Agreement) plus a spread that ranges from 0.50% to 2.00%, and the commitment fee ranges from 0.15% to 0.40%, in each case based on our Total Net Leverage Ratio (as defined in the 2019 Credit Agreement).
The maximum total net leverage ratio and interest coverage ratio permitted by the financial covenant in our 2019 Credit Agreement is displayed in the table below:
2019 Credit Agreement
PeriodTotal Net Leverage Ratio
Q3 2021 and thereafter
3.50 to 1.00
PeriodInterest Coverage Ratio
Q2 2021 and thereafter
3.00 to 1.00
As of March 31, 2022, we were in compliance with all financial and other covenants under the 2019 Credit Agreement.
Please refer to our Form 10-K for fiscal year ended December 31, 2021 for further details on the 2019 Facility and the 2019 Credit Agreement.
On June 19, 2020, as a result of the Progenics Acquisition, we assumed Progenics outstanding debt as of such date in the amount of $40.2 million. On November 4, 2016, Progenics, through its wholly-owned subsidiary, MNTX Royalties Sub LLC, entered into the Royalty-Backed Loan. The Royalty-Backed Loan bore interest at an annual rate of 9.5% and was scheduled to mature on June 30, 2025.
On March 31, 2021, we voluntarily repaid in full the entire outstanding principal on the Royalty-Backed Loan in the amount of $30.9 million, which included a prepayment amount of $0.5 million, and terminated the agreement.
Our ability to fund our future capital needs will be affected by our ability to continue to generate cash from operations and may be affected by our ability to access the capital markets, money markets or other sources of funding, as well as the capacity and terms of our financing arrangements.
We may from time to time repurchase or otherwise retire our debt and take other steps to reduce our debt or otherwise improve our balance sheet. These actions may include prepayments of our term loans or other retirements or refinancing of outstanding debt, privately negotiated transactions or otherwise. The amount of debt that may be retired, if any, could be material and would be decided at the sole discretion of our Board of Directors and will depend on market conditions, our cash position and other considerations.
Funding Requirements
Our future capital requirements will depend on many factors, including:
The level of product sales and the pricing environment of our currently marketed products, particularly DEFINITY and PYLARIFY, as well as any additional products that we may market in the future, including decreased product sales resulting from the COVID-19 pandemic;
Revenue mix shifts and associated volume and selling price changes that could result from contractual status changes with key customers and additional competition;
The continued costs of the ongoing commercialization of PYLARIFY;
The costs of acquiring or in-licensing, developing, obtaining regulatory approval for, and commercializing, new products, businesses or technologies, together with the costs of pursuing opportunities that are not eventually consummated;
Our investment in the further clinical development and commercialization of products and development candidates, including AZEDRA, 1095, and LMI 1195;
32

The costs of investing in our facilities, equipment and technology infrastructure;
The costs and timing of establishing or amending manufacturing and supply arrangements for commercial supplies of our products and raw materials and components;
Our ability to have product manufactured and released from manufacturing sites in a timely manner in the future, or to manufacture products at our in-house manufacturing facilities in amounts sufficient to meet our supply needs;
The costs of further commercialization of our existing products, particularly in international markets, including product marketing, sales and distribution and whether we obtain local partners to help share such commercialization costs;
The extent to which we choose to establish collaboration, co-promotion, distribution or other similar arrangements for our marketed products;
The legal costs relating to maintaining, expanding and enforcing our intellectual property portfolio, pursuing insurance or other claims and defending against product liability, regulatory compliance, intellectual property or other claims;
The cost of interest on any additional borrowings which we may incur under our financing arrangements; and
The impact of sustained inflation on our costs of goods sold and operating expenses.
We are vulnerable to future supply chain shortages, disruptions or delays, especially for our single sourced products, raw materials and components. Disruption in our financial performance could also occur if we experience significant adverse changes in product or customer mix, broad economic downturns, sustained inflation, adverse industry or company conditions or catastrophic external events, including pandemics such as COVID-19, natural disasters and political or military conflict. If we experience one or more of these events in the future, we may be required to further implement expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives.
If our capital resources become insufficient to meet our future capital requirements, we would need to finance our cash needs through public or private equity offerings, debt financings, assets securitizations, sale-leasebacks or other financing or strategic alternatives, to the extent such transactions are permissible under the covenants of our 2019 Credit Agreement. Additional equity or debt financing, or other transactions, may not be available on acceptable terms, if at all. If any of these transactions require an amendment or waiver under the covenants in our 2019 Credit Agreement, which could result in additional expenses associated with obtaining the amendment or waiver, we will seek to obtain such a waiver to remain in compliance with those covenants. However, we cannot be assured that such an amendment or waiver would be granted, or that additional capital will be available on acceptable terms, if at all.
At March 31, 2022, our only current committed external source of funds is our borrowing availability under our 2019 Revolving Facility. We had $105.4 million of cash and cash equivalents at March 31, 2022. Our 2019 Facility, as amended, contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the 2019 Revolving Facility, as amended, may affect our ability to comply with the covenants in the 2019 Facility, as amended, including the financial covenants restricting consolidated net leverage and interest coverage. Accordingly, we may be limited in utilizing the full amount of our 2019 Revolving Facility, as amended, as a source of liquidity.
The CVRs we issued in the Progenics Acquisition entitle holders thereof to future cash payments of 40% of PYLARIFY net sales over (i) $100.0 million in 2022 and (ii) $150.0 million in 2023, which, if payable, we currently intend to fund from our then-available cash. In no event will our aggregate payments under the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Acquisition, exceed 19.9% (which we currently estimate could be approximately $100.0 million) of the total consideration we pay in the Progenics Acquisition. Refer to Note 4, “Fair Value of Financial Instruments”, for further details on contingent consideration liabilities.
Based on our current operating plans, we believe our balance of cash and cash equivalents, which totaled $105.4 million as of March 31, 2022, along with cash generated by ongoing operations and continued access to our 2019 Revolving Facility, will be sufficient to satisfy our cash requirements over the next twelve months and beyond.
Critical Accounting Policies and Estimates
The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect our reported assets and liabilities, revenues and expenses, and other financial information. Actual results may differ materially from these estimates under different assumptions and conditions. In addition, our reported financial condition and results of operations could vary due to a change in the application of a particular accounting standard.
33

There have been no other significant changes to our critical accounting policies or in the underlying accounting assumptions and estimates used in such policies in the three months ended March 31, 2022. For further information, refer to our summary of significant accounting policies and estimates in our Annual Report on Form 10-K filed for the year ended December 31, 2021.
Off-Balance Sheet Arrangements
We are required to provide the Massachusetts Department of Public Health and New Jersey Department of Environmental Protection financial assurance demonstrating our ability to fund the decommissioning of our North Billerica, Massachusetts and Somerset, New Jersey production facilities upon closure, though we do not intend to close the facilities. We have provided this financial assurance in the form of a $28.2 million surety bond.
Since inception, we have not engaged in any other off-balance sheet arrangements, including structured finance, special purpose entities or variable interest entities.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
For quantitative and qualitative disclosures about market risk, see Part II, Item 7A. “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year ended December 31, 2021. Our exposures to market risk have not changed materially since December 31, 2021.
Item 4. Controls and Procedures
Disclosure Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), its principal executive officer and principal financial officer, respectively, has evaluated the effectiveness of the Company’s disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the Company’s CEO and CFO concluded that the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) were effective as of the period covered by this report.
Changes in Internal Controls Over Financial Reporting
There were no changes in our internal control over financial reporting during the three months ended March 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
We are continually monitoring and assessing the pandemic status and geopolitical environment to determine any potential impact on the design and operating effectiveness of our internal controls over financial reporting.
34

PART II. OTHER INFORMATION
Item 1. Legal Proceedings
Information with respect to certain legal proceedings is included in Note 19, “Commitments and Contingencies”, to the condensed consolidated financial statements contained in Part I, Item 1. Financial Statements of this Quarterly Report on Form 10-Q and is incorporated herein by reference.
35

Item 1A. Risk Factors
There have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2021, except as set forth below:
Our ability to continue to grow PYLARIFY as a commercial product is dependent on (A) our ability to obtain FDA approval for additional PMFs to manufacture PYLARIFY, (B) the ability of PMFs to manufacture PYLARIFY to meet product demand, (C) our ability to sell PYLARIFY to customers, (D) our ability to obtain and maintain adequate coding, coverage and payment for PYLARIFY, and (E) our ability to establish PYLARIFY as a leading PSMA PET imaging agent in a competitive environment in which other PSMA PET imaging agents have been approved and additional ones are in development.
The commercial launch of PYLARIFY has been complex and expensive. To manufacture PYLARIFY, we assembled and qualified a nationwide network of PMFs with radioisotope-producing cyclotrons that make F 18, which has a 110-minute half-life, so PYLARIFY is manufactured and distributed rapidly to end-users. Because each of the PMFs manufacturing these products is deemed by the FDA to be a separate manufacturing site, each has to be separately approved by the FDA. Although we successfully qualified 21 PMFs in 2021 and continue to qualify additional PMFs in 2022, such that PYLARIFY is broadly available across the U.S. (including through our efforts to fly doses to certain markets ahead of PMF activation), we can give no assurance that the FDA will continue to approve PMFs in accordance with our planned roll-out schedule. If FDA approval of manufacturing sites is delayed or withdrawn, our future business, results of operations, financial condition and cash flows could be adversely affected.
PYLARIFY is sold in the U.S. to hospitals, independent imaging centers and government facilities and some sales are generated through a PYLARIFY direct sales team as well as a sales team at some of our PMF partners. We generally do not use group purchasing arrangements to sell PYLARIFY and require each customer to enter into a contract directly with us or our PMFs. During 2021, we hired additional employees to assist us with this commercialization of PYLARIFY. Our ability to continue to successfully grow PYLARIFY depends, in part, on our ability to continue to enter into arrangements directly with the hospitals, independent imaging centers and government facilities that we serve. Any delay or inability to enter into these arrangements could have an adverse impact on our future business, results of operations, financial condition and cash flows.
In addition, obtaining adequate coding, coverage and payment for PYLARIFY is critical, including not only coverage from Medicare, Medicaid and other government payors, as well as private payors, but also appropriate payment levels to adequately cover our customers’ costs of using PYLARIFY in PET/CT imaging procedures. We received notification that our HCPCS code, which enables streamlined billing, went into effect as of January 1, 2022. In addition, effective January 1, 2022, CMS granted Transitional Pass-Through Payment Status for PYLARIFY, enabling traditional Medicare to provide an incremental payment for PET/CT scans performed with PYLARIFY in the hospital outpatient setting. If other government payors or private payors do not provide adequate reimbursement for the use of PYLARIFY, our future business, results of operations, financial condition and cash flows could be adversely affected.
The successful growth of PYLARIFY is also dependent on our ability to establish PYLARIFY as a leading PSMA PET imaging agent in a competitive environment in which other PSMA PET imaging agents have been approved and additional ones are in development. PYLARIFY currently competes with Telix Pharmaceuticals Limited’s recently-approved Illuccix (gallium-68 PSMA-11 injection), Novartis AG’s recently-approved Locametz (gallium-68 PSMA-11 injection) and Bracco’s Axumin (fluciclovine F 18). We also face potential competition from an F 18 PSMA PET imaging agent that Bracco has in late stage clinical development, which we believe could be approved by the FDA for commercialization later in 2022 or in 2023. To the extent we lose market share to existing or future competitors, such loss of market share could have an adverse impact on our future business, results of operations, financial condition and cash flows. Moreover, because we are still early in the commercialization of PYLARIFY, we can give no assurance as to how clinical practice may evolve or what our ultimate market penetration or market share may be.
Our success in growing PYLARIFY also depends, in part, on our successfully establishing the use of PYLARIFY for approved indications and potentially for additional indications. For example, we believe the recent approval of Pluvicto for the treatment of adult patients with PSMA-positive mCRPC who have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy) creates a new addressable market for the use of PSMA PET imaging in patient selection for PSMA-targeted therapy that increases the total addressable market in the U.S. by an additional 30,000 new scans per year for patients with mCRPC. However, the prescribing information for Pluvicto specifies that a PSMA-11 based PSMA PET imaging agent be used for patient selection, and PYLARIFY is not a PSMA-11 based imaging agent. In March 2022, we announced a strategic collaboration with Novartis to include PYLARIFY in prostate cancer trials with Pluvicto. While we note that FDA-approved labels for F 18 based and PSMA-11 based PSMA PET imaging agents have generally been treated as a class of drugs, including recently by the Society for Nuclear Medicine and Molecular Imaging in its appropriate use criteria, we can give no assurances that the Novartis prostate cancer trials using PYLARIFY will be successful, that the Pluvicto prescribing information will be expanded to incorporate F 18 based PSMA PET imaging agents like PYLARIFY or how clinical practice may evolve. To
36

the extent we are unsuccessful in establishing the use of PYLARIFY for approved or new indications, such lack of success could have an adverse impact on our future business, results of operations, financial condition and cash flows.
We face significant competition in our business and may not be able to compete effectively.

The markets for our products are highly competitive and continually evolving. Our principal competitors for our current commercial products and leading clinical development candidates include large, global companies that are more diversified than we are and that have substantial financial, manufacturing, sales and marketing, distribution and other resources:
For DEFINITY, our competitors currently include GE Healthcare and Bracco.
For PYLARIFY, our competitors currently include approved imaging agents from Telix Pharmaceuticals Limited, Novartis AG and Bracco, and may in the future include an F 18 PSMA PET imaging agent that Bracco has in late stage clinical development, which we believe could be approved by the FDA for commercialization later in 2022 or in 2023. In addition, the University of California, San Francisco and the University of California, Los Angeles have approved NDAs for a gallium-68 PSMA-11 injection for PSMA PET imaging, which we believe will primarily be used within their hospital systems.
For a number of our radiopharmaceutical commercial products, our competitors currently include Curium, GE Healthcare, Bracco and Jubilant Life Sciences, an affiliate of JHS and Jubilant Radiopharma, as well as other competitors, including NorthStar and potentially BWXT Medical.
For RELISTOR, our principal competitors include Nektar Therapeutics, in collaboration with AstraZeneca PLC; Cubist Pharmaceuticals, a subsidiary of Merck & Co., Inc.; Mallinckrodt plc, in collaboration with Takeda Pharmaceutical Company Limited; and BioDelivery Sciences International, Inc.; together with other prescription, as well as over-the-counter, laxatives used as first line therapy for OIC.
For AZEDRA, there are currently no FDA approved anticancer treatments in the U.S. for malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma.
For 1095, our principal competitors in the field of radiopharmaceutical therapeutics for mCRPC include Novartis AG, which recently received FDA approval for its PSMA-targeted therapeutic; and may include POINT Biopharma, Telix Pharmaceuticals Limited, and Bayer HealthCare Pharmaceuticals Inc., each of which have product candidates in development.
For LMI 1195, our principal competitors may include GE Healthcare’s iobenguane 123 injection.
For flurpiridaz, our principal competitors may include rubidium generators from Bracco and Jubilant Radiopharma.
We cannot anticipate the actions of our current or future competitors in the same or competing diagnostic modalities, such as significant price reductions on products that are comparable to our own, development of new products that are more cost-effective or have superior performance than our current products or the introduction of generic versions after our proprietary products lose their patent protection. In addition, distributors of our products could attempt to shift end-users to competing diagnostic modalities and products, or bundle the sale of a portfolio of products, in either case to the detriment of our specific products. Our current or future products could be rendered obsolete or uneconomical as a result of these activities.
Further, the radiopharmaceutical industry continues to evolve strategically, with several market participants either recently sold or for sale. In addition, the supply-demand dynamics of the industry are complex because of large market positions of some participants, legacy businesses, government subsidies (in particular, relating to the manufacture of radioisotopes), and group purchasing arrangements. We cannot predict what impact new owners and new operators may have on the strategic decision-making of our competitors, customers and suppliers, and such decision-making could have a material adverse effect on our business, results of operations, financial condition and cash flows.
37

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Repurchases
The following table presents information with respect to purchases of common stock we made during the three months ended March 31, 2022. The Company does not currently have a share repurchase program in effect. The 2015 Equity Incentive Plan, adopted by the Company on June 24, 2015, as amended on April 26, 2016 and as further amended on April 27, 2017, April 24, 2019, April 28, 2021 and April 28, 2022 (the “2015 Plan”), provides for the withholding of shares to satisfy minimum statutory tax withholding obligations. It does not specify a maximum number of shares that can be withheld for this purpose. The shares of common stock withheld to satisfy minimum tax withholding obligations may be deemed to be “issuer purchases” of shares that are required to be disclosed pursuant to this Item 2.
PeriodTotal Number of 
Shares Purchased
Average Price Paid 
per Share
Total Number of 
Shares Purchased as
Part of Publicly
Announced Programs
Approximate Dollar
Value of Shares that 
May Yet Be Purchased Under
the Program
January 2022**382 $29.16 **
February 2022**33,400 $47.46 **
March 2022**75,908 $51.49 **
Total109,690 *
    ________________________________
*     These amounts are not applicable as the Company does not have a share repurchase program in effect.
**    Reflects shares withheld to satisfy minimum statutory tax withholding amounts due from employees related to the receipt of stock which resulted from the exercise or vesting of equity awards.
Dividend Policy
We did not declare or pay any dividends, and we do not currently intend to pay dividends in the foreseeable future. We currently expect to retain future earnings, if any, for the foreseeable future, to finance the growth and development of our business and to repay indebtedness. Our ability to pay dividends is restricted by our financing arrangements. See Part I, Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Liquidity and Capital Resources-External Sources of Liquidity” for further information.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None.
38

Item 6. Exhibits
INCORPORATED BY REFERENCE
EXHIBIT
NUMBER
DESCRIPTION OF EXHIBITSFORMFILE
NUMBER
EXHIBITFILING
DATE
10.1* †
10.2* +
10.3* +
10.4* +
31.1*
31.2*
32.1**
101.INS*Inline XBRL Instance Document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*Cover Page Interactive Data File (embedded within the Inline XBRL document)
*    Filed herewith.
**    Furnished herewith.
† Portions of this exhibit have been omitted for confidential treatment pursuant to Item 601(b)(10)(iv) of Regulation S-K.
+ Indicates management contract or compensatory plan or arrangements
39

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
LANTHEUS HOLDINGS, INC.
By:/s/ MARY ANNE HEINO
Name:Mary Anne Heino
Title:
President and Chief Executive Officer
(Principal Executive Officer)
Date: April 29, 2022
LANTHEUS HOLDINGS, INC.
By:/s/ ROBERT J. MARSHALL, JR.
Name:Robert J. Marshall, Jr.
Title:Chief Financial Officer and Treasurer
(Principal Financial Officer)
Date:April 29, 2022

40
EX-10.1 2 lnth10q-033122ex101.htm EX-10.1 Document


CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “****”, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO LANTHEUS HOLDINGS, INC. IF PUBLICLY DISCLOSED.

MANUFACTURE AND SUPPLY AGREEMENT

THIS AGREEMENT is effective as of the date it is signed, by the last party to do so (the “Effective Date”)


B E T W E E N:    JUBILANT HOLLISTERSTIER LLC, with its principal place of business located at 3525 N Regal St, Spokane, WA 99207, United States (“Supplier”);

AND:

LANTHEUS MEDICAL IMAGING, INC., having its head office at 331 Treble Cove Rd., N. Billerica, MA 01862 (“Purchaser”)

WHEREAS Purchaser desires to have Supplier manufacture and supply certain pharmaceutical products;
AND WHEREAS Supplier desires to manufacture and supply Purchaser with certain pharmaceutical products;
AND WHEREAS the Parties are willing to carry out the foregoing pursuant to the terms and conditions set forth in this Agreement.
NOW THEREFORE in consideration of the mutual covenants and agreements in this Agreement, Purchaser and Supplier agree with each other as follows:
Article I- INTERPRETATION
1.1Defined Terms.
As used in this Agreement and in the Quality Agreement (as defined below), the following terms have the following meanings unless the context clearly requires otherwise:
Accepted Purchase Order(s)” shall have the meaning ascribed hereto in Section 4.3(c) of this Agreement.
Active Pharmaceutical Ingredient” means the Product active pharmaceutical ingredient(s) supplied by Purchaser for the Manufacturing of the Products.
Affiliate” means any corporation or other business entity directly or indirectly controlled by, controlling, or under common control with a Party or its parent corporation. The term “control” (including, with correlative meaning, the terms “controlled by,” “controlling” and “under common control with”) means the direct or indirect ownership of more than fifty (50%) percent of the outstanding shares or other voting rights of the subject entity or possession, directly or indirectly, of the power to elect or appoint fifty percent (50%) or more of the members of the governing body of the corporation or other entity or the power to direct or cause the direction of the management and policies of such Party, whether through the ownership of voting securities, by contract or otherwise, or such other relationship as, in fact, constitutes actual control.
Agreement” means this Manufacture and Supply Agreement and all schedules and instruments supplemental to or amending thereto.
Annual Minimum Purchase” has the meaning referenced thereto in Section 3.2 of this Agreement.





Batch” means a batch of Products as specified in Schedule “C” attached hereto (with a theoretical maximum production size as set forth in Schedule “C).
Business Day” or “Business Days” means any day other than Saturday, Sunday or a holiday generally recognized in the United States of America.
Calendar Year(s)” means January 1 to December 31 of any given year or years, as the case may be.
CFR” means the U.S. Code of Federal Regulations.
Current Good Manufacturing Practices” or “cGMP” or “GMP” means, as applicable in accordance with the Territory in which the Products will be distributed in, the practices set out in the guidelines (i) published as the Good Manufacturing Practices for Drug Manufacturers and Importers by the HPFBI, as amended from time to time, (ii) for the manufacture of pharmaceutical products and the Current Good Manufacturing Practices as defined in United States 21 CFR 210, et seq., as amended from time to time, and (iii) the EEC Guide to Good Manufacturing Practices for Medical Products, as amended from time to time.
DEFINITY” shall have the meaning ascribed to it in Schedule “D”.

Designated Supplier” shall have the meaning ascribed to it in the Quality Agreement.

Designated Supplier’s Audit” shall have the meaning ascribed to it in the Quality Agreement.

Facility” means Supplier’s facility located at **** used in the Manufacturing of the Products hereunder and, subject to Purchaser’s prior written approval, such other facilities used by Supplier in the Manufacturing of Products hereunder
FDA” means the United States Food and Drug Administration, or any successor to it.
Firm Zone” has the meaning ascribed thereto in Section 4.2(a) of this Agreement.
Force Majeure” has the meaning ascribed thereto in Section 11.2(a) of this Agreement.
Governmental Authority” or “Regulatory Authority” means any court, tribunal, arbitrator, agency, commission, official or other instrumentality of The United States of America, any relevant foreign country or territory, or any domestic or foreign state, province, country, city or other political subdivision thereof, having responsibility for regulation or otherwise as to the Parties including as to the Manufacturing, marketing, distribution or sale of the Product and/or the services provided under this Agreement.
Incoterms® 2020” means the International Commercial Terms published by the International Chamber of Commerce, as amended from time to time, codifying the contractual rules for the interpretation of standardized commercial terms for transactions. Incoterms® 2020 shall be deemed to have been incorporated by reference in this Agreement except in so far as they may conflict with any other provision of this Agreement, in which case the Agreement provision shall prevail.
Indemnitees” means either Party, as the case may be, and that Party’s shareholders, directors, officers, employees, agents and representatives.
Intellectual Property” means all domestic or foreign (i) trademarks, service marks, trade names, trade dress, logos and slogans and all goodwill associated therewith; (ii) patent, patent rights, industrial and other designs, including any and all applications, applications for registration, registrations, divisions, continuations, continuations-in-part, extensions, substitutions, renewals, revalidations, re-examinations, reissues or additions, including supplementary certificates of protection, or of to any of the foregoing items; (iii) copyright, any original work or authorship fixed in any tangible medium of expression, including literary works, all forms and types of computer





software, all source code, object code, firmware, development tools, files, records and data, and all documentation related to any of the foregoing, all musical, dramatic, pictorial, graphic and artistic works; (iv) trade secrets, technology, discoveries and improvements, know-how, proprietary rights, formulae, confidential and proprietary information, technical information, techniques, inventions, designs, drawings, procedures, processes, models, formulations, manuals and systems, whether or not patentable or copyrightable, including all biological, chemical, biochemical, toxicological, pharmacological and metabolic material and information and data relating thereto and formulation, clinical, analytical and stability information and data which have actual or potential commercial value and are not available in the public domain; and (v) all other intellectual property or proprietary rights, in each case whether or not subject to statutory registration or protection.
Inventory Carrying Fee(s)” shall have the meaning ascribed thereto in Section 4.2(g).
Law(s)” means any international, national, federal, state, provincial and local law, statute, code, rule, regulation, orders, decrees, guideline (including Current Good Manufacturing Practices), ordinance or other pronouncement of any Governmental Authority having the effect of law in the United States, any relevant foreign country or any territory or any domestic or foreign state, province, county, city or other political subdivision, as may be amended from time to time, that govern the Parties’ respective obligations under this Agreement.
Licences” means the licences, permits, certificates, authorizations or approvals issued to Supplier by the relevant Governmental Authority in respect of its site of manufacture of the Products.
Long Lead Time Materials” has the meaning referenced thereto in Section 4.2(d) of this Agreement.
Losses” mean any and all damages, fines, fees, settlements, payments, obligations, penalties, deficiencies, losses, costs and expenses (including without limitation, interest, court costs, reasonable fees of attorneys, accountants and other experts and other reasonable expenses of litigation or other proceedings or of any claim, default or assessment).
Manufacture” or “Manufactured” means to effect the operation required in the manufacture, processing, filling, testing, packaging, labelling or storage, as the case may be, of the Products by Supplier.
Manufacturing” means any operation required in the manufacture, processing, filling, testing, packaging, labelling or storage, as the case may be, of the Products by Supplier.
Manufacturing Records” shall have the meaning ascribed to it in Section 5.8.
Material Zone” has the meaning ascribed thereto in Section 4.2(b) of this Agreement.
Materials” mean all materials and ingredients used in the Manufacturing of Products by Supplier including, but not limited to, Active Pharmaceutical Ingredient(s), raw materials, components, packaging, labeling materials, and shipping materials.
Materially Adversely Affect Supplier’s Business” means a consequence or series of consequences that have a meaningful negative impact on Supplier’s business in any given year, as determined by Supplier, in its discretion, acting reasonably.
MOQ” or “Minimum Order Quantity” has the meaning ascribed to it in Section 4.2(e) of this Agreement.
Ongoing Forecast” has the meaning ascribed thereto in Section 4.1 of this Agreement.
Open Zone” has the meaning ascribed thereto in Section 4.2(c) of this Agreement.





Party” means either Purchaser or Supplier, individually; “Parties” means Purchaser and Supplier collectively.
Person” means any natural person, entity, corporation, general partnership, limited partnership, proprietorship, other business organization, trust, union, association or Governmental Authority.
“Prices” or “Price” means the total aggregate cost of each Product as set out in Schedule “C”.
Prior Agreement” means each of the following agreements between the Parties: (i) Manufacturing and Supply Agreement, dated as of February 1, 2012, as amended, for DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension; (ii) Manufacturing and Supply Agreement, dated as of May 3, 2012, as amended, for CARDIOLITE® Kit for the Preparation of Technetium Tc99m Sestamibi for Injection; (iii) Manufacturing and Supply Agreement, dated as of May 3, 2012, as amended, for NEUROLITE® Kit for the Preparation of Technetium Tc99m Bicisate for Injection; and (iv) Manufacturing and Supply Agreement, dated as of March 29, 2010, as amended, for 30mL Sterile EVAC Vials.

“Proceeding” means applicable action, claim, suit, proceeding, arbitration or Governmental Authority action, notification, investigation or audit.
Producer Price Index” or “PPI” means the Producer Price Index for Pharmaceutical Preparation Manufacturing (pcu325412325412) as published by the U.S. Department of Labor, Bureau of Labor Statistics, or a successor agency. In the event that the Bureau of Labor Statistics stops publishing the Producer Price Index or substantially changes its content or format, the Parties will substitute another comparable index published monthly by a mutually agreeable source. If the Bureau of Labor Statistics redefines the base year for the Producer Price Index from 1981 to another year, the Parties will continue to use the Producer Price Index but will convert to the new base year using an appropriate conversion formula.
Product(s)” means the Products listed in Schedule “C”.
Product Developments” shall have the meaning ascribed hereto in Section 8.1(c) of this Agreement.
Purchase Order(s)” shall have the meaning ascribed hereto in Section 4.3(a) of this Agreement.
Purchaser Intellectual Property” means any and all Intellectual Property (i) owned by Purchaser prior to or as of the Effective Date; (ii) developed or acquired by Purchaser after the Effective Date provided that such Intellectual Property does not utilize nor is based on any Supplier Intellectual Property; or (iii) Product Developments.
“Quality Agreement” means the agreement which sets out the details of the allocation of tasks between the Parties as related to the Manufacturing of the Product, including responsibilities for quality assurance and control of Materials, packaging components, bulk Product and finished Product, a copy of which is attached hereto as Schedule “B”.
Rejected Batch” has the meaning ascribed thereto in Section 5.2(b) of this Agreement.
Rejection Notice” has the meaning ascribed thereto in Section 5.2(b) of this Agreement.
Replacement Batch” has the meaning ascribed thereto in Section 5.2(e) of this Agreement.
Specifications” means, with respect to any Products, all specifications for materials, manufacturing procedures, sampling plans for the Products as well as the procedures, requirements (regulatory or otherwise), standards and other items necessary to Manufacture the Products, as approved by the Parties and attached as Schedule “A” and the quality standards, including tests, analytical





procedures and acceptance criteria, that are established to confirm the quality of the Product which are mutually agreed to in writing and contained or referenced in the Master Batch Record for the Product or as otherwise mutually agreed to in writing by the Parties.
Supplier Intellectual Property” means: (i) all Intellectual Property owned by Supplier prior to and as of the Effective Date; or (ii) all Intellectual Property developed or acquired by Supplier after the Effective Date independent of the performance of its obligations under this Agreement, provided that such Intellectual Property does not utilize nor is based on any Purchaser Intellectual Property or Product Developments.
Technology” means, collectively, all information, designs, formulae, algorithms, procedures, methods, techniques, ideas, know-how, research and development, technical data, programs, subroutines, tool design, material specifications, processes, inventions (whether patentable or unpatentable and whether or not reduced to practice), apparatus design, creations, improvements, works of authorship and other similar materials, and all recordings, graphs, drawings, reports, analyses, and other writings, and other tangible embodiments of the foregoing, in any form whether or not specifically listed herein, and all related technology, that are used in, incorporated in, embodied in, displayed by or relate to, or are used in connection with the foregoing. For clarification Technology specifically excludes actual equipment.
Term” means, collectively, the Initial Term and any Renewal Term, as the case may be.
Territory” means the countries or regions described in Schedule “E”. Additional countries or regions may be added to the Territory at Purchaser’s request and reasonable cost and expense (including, as evidenced by reasonable documentation made available to Purchaser, Supplier’s reasonable internal personnel costs and out-of-pocket expenses) upon at least **** (****) days prior written notice.

1.2Incorporation of Schedules.
The terms of the Schedules attached or referred to herein are an integral part of this Agreement. The following Schedules are attached hereto:
Schedule “A” – Product Specifications
Schedule “B” – Quality Agreement
Schedule “C” – Product Prices
Schedule “D” – Definitions and List of Materials
Schedule “E” – List of countries/regions

1.3Currency.
Except as otherwise expressly stated, all dollar amounts referred to in this Agreement are in US dollars.
1.4General.
Article headings in this Agreement are for convenience only and shall not be used in interpreting this Agreement. The Agreement shall be read with such changes in gender or number as the context requires. The definitions in Article 1 shall apply equally to both the singular and plural forms of the terms defined. The words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation”. All references herein to Articles, Sections, paragraphs, clauses and Schedules shall be deemed references to Articles, Sections, paragraphs and clauses of this Agreement and Schedules to this Agreement unless the context shall otherwise require. Any reference herein to any person or entity will be construed to include the person’s or entity’s successors and assigns. The words “herein”, “hereof” and “hereunder”, and words of similar import,





will be construed to refer to this Agreement in each of their entirety, as the context requires, and not to any particular provision hereof. The word “notice” means notice in writing (whether or not specifically stated) and will include notices, consents, approvals, and other written communications contemplated under this Agreement. The provisions that require that a Party, the Parties, or any committee hereunder “agree,” “consent” or “approve” or the like will require that such agreement, consent, or approval be specific and in writing, whether by written agreement, letter, approved minutes, or otherwise (but excluding instant messaging), and, unless expressly stated otherwise in the relevant provision of this Agreement, that such agreement, consent, or approval not be unreasonably withheld, conditioned, or delayed. All references to any specific law, rule or regulation, article, Section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof. The term “or” is disjunctive but not necessarily exclusive.


Article II- MANUFACTURING
2.1Agreement to Manufacture Products.
For the Term of this Agreement, Supplier agrees to Manufacture (i) DEFINITY **** for Purchaser and (ii) the other Products identified in Schedule “A” **** for Purchaser, in each case, in the Facility in accordance with the terms set out in this Agreement and Purchaser agrees to purchase the Products from Supplier during the Term.
2.2Conformance with Specifications.
Supplier shall Manufacture the Products in accordance with the Specifications. Either of the Parties shall have the right to request changes to any of the Specifications. Recommendations to change any of the Specifications shall be in writing. Supplier shall not implement any change to the Specifications before both Parties have agreed to such changes in accordance with the procedures set forth in the Quality Agreement.
2.3Conformance with cGMP.
Supplier shall Manufacture the Products in accordance with applicable Current Good Manufacturing Practices and applicable Laws as reasonably interpreted by the Parties. Each Party shall promptly notify the other of knowledge of any new instructions or specifications required in order to comply with Current Good Manufacturing Practices or applicable Laws, and shall cooperate in agreeing on the best means to comply with any new requirements.
2.4Supply of Active Pharmaceutical Ingredients.
Purchaser shall provide to Supplier, at ****, the APIs and such other Materials to be supplied by Purchaser listed in Schedule “D” (the “LMI Materials”) in quantities sufficient to meet Purchaser's requirements for each Product as further set forth in Article IV. Supplier will provide Purchaser with an inventory report for the LMI Materials on a **** (or as otherwise agreed to by the Parties). Prior to delivery of the LMI Materials to Supplier, Purchaser shall provide to Supplier a copy of the Material Safety Data Sheet (“MSDS”) for such LMI Material, and follow up with any subsequent revisions thereto. Purchaser shall supply the LMI Materials, including the APIs, and Certificates of Analysis and Certificates of Compliance therefore DDP (as defined in Incoterms 2020) the Facility no later than **** (****) days before the scheduled Manufacturing date. Upon receipt of the API, Supplier’s sole obligation with respect to evaluation of the API shall be to perform an identification testing, as agreed to by the Parties in writing, upon the receipt of API. Supplier will not be responsible for confirming that the API and LMI Materials meets applicable Specifications. Supplier shall use the Purchaser’s API solely and exclusively to Manufacture the Product under this





Agreement. Title to and risk of loss of API and LMI Materials shall at all times remain with Purchaser, and Supplier shall have no liability with respect to cost, loss, or damage of API and LMI Materials at any time, except to the extent such loss/damage is the result of the negligence or willful misconduct of Supplier or breach of this Agreement or the applicable Quality Agreement by Supplier. In the event of loss/damage of API or LMI Materials resulting from the negligence or willful misconduct of Supplier or breach of this Agreement or the applicable Quality Agreement by Supplier, Supplier shall issue a credit to Purchaser (at Purchaser’s election) for an amount equal to ****; provided that the credit will be limited to the lesser of (i) (a) **** ($****) or (b) **** (as demonstrated by reasonable evidence and documentation therefore provided to Supplier), per Batch, (ii) **** ($****) in the aggregate in any calendar year, or (iii) **** ($****) in the aggregate for the Term of this Agreement. Any credits hereunder not settled within **** of issuance, or within **** (****) days of the effective date of any termination or expiration of this Agreement, will be refunded to Purchaser.
2.5Supply of Materials.
The Parties shall supply the Materials as set forth in Schedule “D”.
2.6Third Party Suppliers and Designated Suppliers.
Third party suppliers and Designated Suppliers of Materials (other than LMI Materials) must be agreed upon between the Parties, including any changes thereto during the Term of this Agreement.
Article III- CONSIDERATION
3.1Price of Products and Adjustment.
(a)Price of Products. The price of the Products shall be as set out in Schedule “C” (the “Price”).
(b)Price Increase. Supplier may implement a Price increase **** annually, on **** of each Calendar Year starting on **** (“Price Increase Date”), in an amount equal to the lesser of (a) **** percent (****%) or (b) **** in the PPI during the immediately preceding **** (****) month period ending **** (or if such PPI data is not available for the timely implementation of the increase in Unit Pricing, the most recent **** (****) month period for which such PPI data is available). In addition but only to the extent not already covered by the PPI increase, if Supplier’s cost for any Materials (not covered by the PPI calculation, and not supplied by Supplier Affiliates) increases by more than **** percent (****%) during the relevant foregoing period, Supplier shall be entitled to increase (no more than **** annually, on **** of each Calendar Year starting on ****) the Price by the amount of such price increase for such Materials, over and above the increase on account of PPI, and as to any such increase tied to a change in Supplier’s cost Materials, Supplier shall provide Purchaser copies of invoices evidencing the increased cost of such Materials.
Supplier also reserves the right to increase the Price or other fees if change(s) to applicable Laws or regulations, including, but not limited to changes in cGMP, or changes to the process increase the cost of Manufacturing the Product or of any other activities contemplated under this Agreement.
(c)Samples. The Price shall also be payable for all samples of Products required to be maintained by Supplier under the terms of this Agreement, if applicable, or any applicable Law, if applicable, as well as any additional samples which the Purchaser requires, as the case may be, in addition to shipping and handling costs.
3.2Annual Minimum Purchases.
The Prices is dependent on the following annual minimum purchases:
DEFINITY (applicable on Purchaser’s worldwide demand):
Calendar year 2022: ****%
Calendar year 2023: ****%





Calendar year 2024: ****% with a minimum of **** batches for the year at USD**** per vial
Calendar year 2025 and Terminal Supply Year (if applicable): ****% with a minimum of **** batches for the year at the price of the previous year, after applying the price increase mechanism set forth in section 3.1(b)
Calendar years 2026 and 2027, a minimum commitment of **** batches applying the price increase mechanism set forth in section 3.1(b),
and

Cardiolite: **** batches
Neurolite: **** batches
Neurolite buffer: **** batches
EVAC Vials: **** batches

during each Calendar Year of the Term and the Terminal Supply Year, if applicable (collectively the “Annual Minimum Purchase”).
Subject to the provisions of Section 4.3(a), if Purchaser fails to purchase from Supplier in any given Calendar Year the Annual Minimum Purchases, Purchaser shall ****. However, if Supplier, in any given Calendar Year, is not able to fulfil a Purchase Order by the specified delivery date (other than as a result of Purchaser’s own fault or negligence), such orders shall be taken into account when calculating if the Annual Minimum Purchase has been met, as if such order had been actually purchased by Purchaser. For greater certainty, the **** shall not be reduced in any way if Supplier is not able to fulfil a Purchase Order by the specified delivery date as the result of (i) delays in delivery by Purchaser of any LMI Materials or (ii) delays caused by changes requested by Purchaser to be provided pursuant to this Agreement.
3.3Minimum Batch Size.
Minimum Batch sizes shall be based on the minimum Manufacturing Batch size as agreed by the Parties and set forth in Schedule “C” hereto. A Manufacturing Batch may not be divided for different markets unless expressly agreed to in writing by Supplier.
3.4Payment.
Supplier may invoice Purchaser upon delivery of the Product (****Incoterm 2020). Purchaser shall pay Supplier, for all Products Manufactured under the terms of this Agreement, within **** (****) days of the invoice date for all undisputed invoices, provided, however, that Purchaser will have the obligation to pay within the foregoing delay any undisputed amount of a disputed invoice. In addition, the interest rates set forth in the next sentence will apply to any disputed amount paid after the **** (****)-day delay, if it is ultimately concluded that the disputed amount of a disputed invoice shouldn’t have been disputed in the first place. Supplier shall issue invoices in respect of the Product upon shipment of such Product with interest at the rate of **** percent (****%) per month (****percent (****%) per annum) payable on all undisputed amounts not paid on the due date.
3.5Taxes.
In addition to the amounts paid by Purchaser pursuant to Section 3.1, Purchaser shall pay to Supplier all applicable use, consumption, sales or excise taxes of any taxing authority (but not including any tax related to Supplier’s income). The amount of such taxes will be added to the Price in effect at the time of shipment thereof and will be reflected in the invoices submitted to Purchaser by Supplier pursuant to Section 3.4 hereof. Purchaser shall pay the amount of such taxes to Supplier in accordance with the payment provisions set forth in Section 3.4 hereof.
3.6Capital Expenditures.
Intentionally left blank.





3.7Additional Services.
Any additional services requested by Purchaser that are not contemplated under this Agreement shall be payable separately, following the receipt of a Purchase Order from Purchaser. No additional services will be performed by Supplier before a Purchase Order has been placed by Purchaser for such additional service(s).
The cost for the additional services shall be payable by Purchaser within **** (****) days of the date of an invoice received by Purchaser from Supplier.
3.8Cost of Changes to Specifications.
(a)Changes Requested by Purchaser. **** associated with changes requested by Purchaser to Materials or components of the Products, process and other Specifications and/or controls, as well as the Manufacturing and/or packaging of Products shall be borne by ****. In addition, **** shall be responsible for **** related to Materials purchased or ordered by Supplier for the Manufacturing of the Products which are unusable as a result of such changes made, including without limitation, changes to the graphics used on packaging, films, dies, proofs, provided that such changes were made at Purchaser’s request. **** agrees to use reasonable efforts to minimize these costs to ****.
(b)Changes to Comply with cGMP. **** shall be responsible for **** associated with changes required in the Specifications of the Products in order to comply with changes to cGMP occurring after the date of this Agreement, solely to the extent such changes are directly related to the Manufacture of the Products and not to the extent such changes are associated with the Manufacture of pharmaceuticals products generally.
(c)Changes to Comply with Applicable Laws. **** shall be responsible for **** associated with the Manufacture of the Products in order to comply with changes in applicable Laws occurring after the date of this Agreement (including with respect to any of the Materials used in that Product), solely to the extent such changes are directly related to the Manufacture of the Products, and not to the extent such changes are associated with the Manufacture of pharmaceuticals products generally.
3.9Annual Product Maintenance
Purchaser shall pay to Supplier an annual product maintenance fee (“APMF”) for the Products.  The APMF will cover an array of Product support activities, which are irrespective of manufactured product volumes, and includes the following:

Dedicated primary point of contact for all commercial manufacturing activities
Scheduling, planning, and communicating all commercial manufacturing activities
Drug Master File (DMF) updates with the FDA, EU and JP.
Annual GUDFA fee participation
Annual audit.
Annual Product Review in accordance with 21 CFR § 211.180.
Host all Person-in-Plant activities
Product license or permits from local, state and all federal authorities.
Access to document library (additional copies of batch paperwork or other batch documentation when requested).
Product documentation and sample storage (retains) relating to cGMP requirements.
Re-qualification of raw material vendors.
Maintenance and storage of raw material vendor audit reports.
The APMF will be payable **** annually beginning February 2, 2022. The APMF for all Products combined is fixed at **** (USD ****) per **** (****) months, for the Term of the Agreement.   In the event that this Agreement is terminated prior to the expiration of the Term, then the APMF shall





be prorated up to the date of termination for such partial calendar year, unless Supplier terminates under Section 11.2, in which case, no such proration shall occur.
Article IV - PRODUCT SUPPLY
4.1Ongoing Forecasts.
Ongoing Forecasts. Purchaser shall provide Supplier with a copy of its forecast of its anticipated Product Manufacturing requirements for the **** (****) month period commencing the following month (the “Ongoing Forecast”) on or before the **** (****) Friday of each month of the Term of the Agreement. Each Ongoing Forecast shall provide delivery dates for each Firm Zone (as defined in Section 4.2(a)), in addition to quantity and purchase order specifics for the Material Zone and the Open Zone. In the event that an Ongoing Forecast is not delivered on the **** (****) week of a given calendar month in accordance with this provision, the prior month’s Ongoing Forecast will constitute that month’s Ongoing Forecast.


4.2Order Procedures.
(a)Firm Zone. **** percent (****%) of the Product quantities forecasted for the **** months of an Ongoing Forecast, and **** percent (****%) of the Product quantities forecasted for the **** (****) months of an Ongoing Forecast, are deemed to be firm orders, and as such Purchaser is committed to same and Supplier is committed to providing the same. The Parties shall use reasonable best efforts to negotiate any change in the delivery date of any firm order; provided, however, that:
(i)****; and
(ii)****.
(b)Material Zone. Excluding the Firm Zone, Product quantities forecasted for the **** (****) months of an Ongoing Forecast (the “Material Zone”) are deemed to be firm as they relate to the quantities of Materials to be ordered. Changes of timing for delivery of Materials within the Material Zone may be made to respond to changing Purchaser demand; provided, however, that if any order made by Purchaser for Products to be delivered during the Material Zone of an Ongoing Forecast is cancelled, deferred or reduced, so as to result in a lesser quantity of Products ordered by Purchaser than indicated in the corresponding month of such Material Zone, ****. For greater clarity, ****.
(c)Open Zone. Product quantities forecasted for the **** (****) months of an Ongoing Forecast (the “Open Zone”) are deemed to be open as they relate to the quantities of Materials to be ordered and Purchaser is not committed to same. The Parties acknowledge and agree that the requirements specified in the Open Zone of an Ongoing Forecast are for the purposes of Supplier’s internal scheduling and planning only and Purchaser shall not be responsible for any costs of Materials procured or other expenses incurred by Supplier for the purpose of meeting the requirements specified in the Open Zone, unless related to Long Lead Time Materials or Materials ordered based on MOQ, as referenced in Section 4.2(d) and 4.2(e) or agreed to by both Parties.
(d)Long Lead Time Materials. Any inventory of Materials held by Supplier beyond requirements necessary for the supply of the Products required under the Firm Zone, the Material Zone or any pre-approved safety stock (“Long Lead Time Materials”), excluding Materials ordered based on MOQ, is the responsibility of ****. However, if the Parties





agree on the purchase or entering into of commitments to purchase any Long Lead Time Materials based on the Ongoing Forecast for a specified month and those Long Lead Time Materials cannot be ****.
(e)Minimum Order Quantity. Purchaser acknowledges and agrees that some Materials to be purchased by Supplier for the Manufacture of the Products may be subject to a minimum quantity per order (“Minimum Order Quantity” or “MOQ”). The Parties acknowledge and agree that a Minimum Order Quantity of Materials may exceed the requirements for such Materials for the Manufacture of the Product quantities forecasted in the Firm Zone and in the Material Zone. **** shall be responsible for the cost of any such unused, obsolete or excess Materials procured by Supplier based on a Minimum Order Quantity for the purpose of meeting the requirements specified in the corresponding months of Firm Zone and Material Zone of an Ongoing Forecast, provided that ****.
(f)Safety Stock. Purchaser will carry sufficient safety stock of the Products to support the necessary Purchaser service levels and Firm Zone and Material Zone lead times. Supplier will carry the necessary safety stock of Materials to support the Firm Zone and Material Zone lead times and to ensure timely delivery of orders of Products. Any safety stock of Long Lead Time Materials may be carried by Supplier, but must be approved in writing by Purchaser.
(g)Inventory Carrying Fees. If Supplier is required to store at the Facility Materials supplied to it by Purchaser for a period longer than **** (****) Business Days, or store finished Products for a period longer than **** (****) Business Days after the Product has been released to Purchaser by Supplier, then Purchaser shall pay to Supplier a reasonable and customary inventory carrying fee, such fee being in addition to the Price (“Inventory Carrying Fee”). Said Inventory Carrying Fee as be established at **** US dollars (USD ****) per pallet per month for Calendar Year and may be increased by Supplier from time to time by a **** (****) day notice, but not by more than ****% for each Calendar Year.
During the Term of this Agreement, Supplier will provide Purchaser with a system generated **** inventory report for the Materials and Products stored in its Facility. Supplier will perform a physical inventory of the Materials stored in its Facility on **** basis only, except in the event of significant discrepancies between the physical inventory and the system generated **** inventory reports. Additional physical inventories may be performed by Supplier upon Purchaser’s written request and subject to payment by Purchaser of an additional fee through an agreed upon quote.
(h)Delays in delivery of Materials by Third Party Supplier. Delivery dates specified in Purchase Orders are subject to Supplier’s receipt of Materials from the third-party supplier thereof (as the case may be) not less than **** (****) weeks prior to the specified delivery date. Supplier agrees to use commercial reasonable efforts to Manufacture the Product as soon as possible in the event that the supplier of the Materials fails to deliver the Materials in accordance with this schedule.
(i)Graphic Changes. If there is to be change to any artwork for any Product, at least **** (****) weeks prior to the intended first delivery date of such Product with such changed artwork, Purchaser shall provide to Supplier, at no cost, digital artwork in a format acceptable to Supplier and in compliance with the packaging specifications for such Product. All one time costs and expenses associated with any such artwork changes shall be the responsibility of Purchaser and shall be charged directly to the Purchaser and are not included in the Price.
4.3Purchase Orders
(a)General. Purchaser shall deliver to Supplier purchase orders (each a “Purchase Order”) for the aggregate Product volumes in each Firm Zone. Each Purchase Order shall specify the volumes of Products ordered, the Price, the requested delivery date, the destination of





delivery of the Products and Purchaser’s instructions for such delivery, in accordance with the provisions of Section 5.1(b) of this Agreement. Purchase Orders shall be issued a minimum of **** (****) months prior to the requested delivery date.
(b)Delivery of Purchase Order. The Purchase Orders may be delivered electronically or by other means in such location, as Supplier shall designate from time to time. Supplier shall promptly acknowledge acceptance of each Purchase Order by sending to Purchaser electronic (email and/or fax) written notice of acknowledgement and acceptance for each Purchase Order promptly (but in any event, no later than **** (****) Business Days) after its receipt.
(c)Rejection and Deemed Acceptance. Notwithstanding anything in this Agreement to the contrary, Supplier reserves the right at its discretion to reject without liability any Purchase Order for reasons related to production scheduling limitations or otherwise; provided, however, that failure by Supplier to deliver to Purchaser a written notice objecting to a Purchase Order within **** (****) Business Days after receipt of the Purchase Order shall constitute Supplier’s deemed acceptance of said Purchase Order (“Accepted Purchase Order”), and provided further, that in the event Supplier rejects a Purchase Order (unless such rejection is due to excess volume requirements substantially inconsistent with the amounts set forth in the **** months of an Ongoing Forecast, and subject to 4.3(a)), Purchaser will be deemed to have ordered such order for purposes of determining Purchaser’s satisfaction of Annual Minimum Purchase requirements within the annual period.
(d)Capacity Constraints.
(i)Subject to an event of Force Majeure, Supplier shall Manufacture the Products and shall use commercially reasonable efforts to deliver Products, which are subject to an Accepted Purchase Order, by the specified delivery date referenced therein. In the event that Supplier is not able to fulfil an Accepted Purchase Order by the specified delivery date (for any reason):
A.Supplier shall notify Purchaser promptly upon discovery of its inability to comply with the terms of the Accepted Purchase Order; and
B.Supplier will take such actions as may be reasonably requested by Purchaser to minimize the damage to Purchaser caused by Supplier’s inability to comply with the terms of the Accepted Purchase Order.
C.If Supplier is unable to fill a Purchase Order within **** (****) days of the scheduled delivery date Purchaser has the right to cancel the order without penalty and will be deemed to have ordered such order for purposes of determining Purchaser’s satisfaction of Annual Minimum Purchase requirements within the annual period.
(e)Accommodations. From time to time, due to significant unforeseen circumstances, Purchaser may deliver to Supplier a Purchase Order for Product volumes in excess of those specified in any Firm Zone or Material Zone. Supplier will work with Purchaser on a reasonable commercial basis to assist with delivery of such volume excesses provided, however, that, until Supplier accepts (or is deemed to have accepted) such Purchase Order:
(i)Supplier shall have no obligation to use commercially reasonable efforts to assist Purchaser with meeting such excess volume requirements; and
(ii)Supplier shall have no obligation to use commercially reasonable efforts to assist Purchaser with meeting such excess volume requirements if to accommodate such





request would Materially Adversely Affect Supplier’s Business including, without limitation, Supplier’s ability to fulfill its commitment to its other customers; or
(iii)to the extent such demand exceeds **** percent (****%) of the Product volumes specified in the Firm Zone or Material Zone.
(f)Conflict. In ordering and delivering the Products pursuant hereto, Supplier and Purchaser may employ their standard forms, but nothing in those forms shall be construed to modify, amend or supplement the terms of this Agreement. Other than with respect to quality matters, which is addressed in Section 5.4, in the event of any conflict between the terms and conditions of this Agreement and the terms and conditions of any Purchase Order, the terms and conditions of this Agreement shall prevail to the extent of such conflict.
(g)Rescheduling by Purchaser. Should Purchaser reschedule any part of their Accepted Purchase Order (other than as a result of Supplier’s request to reschedule such Accepted Purchase Order or Supplier’s inability to satisfy such Accepted Purchase Order), the following will apply; provided however, that Supplier will make a good faith effort to use the capacity created by any such cancellation, in which case the fees below will be reduced commensurately:
Should Purchaser postpone all or part of any Purchase Order less than **** (****) days prior to Supplier’s scheduled fill date, Purchaser shall pay Supplier a non-refundable and non-creditable fee equivalent to ****% of the purchase price for the entire purchase order;
Should Purchaser postpone all or part of any Purchase Order **** (****) to **** (****) days prior to Supplier’s scheduled fill date, Purchaser shall pay Supplier a non-refundable and non-creditable fee equivalent to ****% of the purchase price for the entire purchase order; or
Should Purchaser postpone all or part of any Purchase Order **** (****) to **** (****) **** prior to Supplier’s scheduled fill date, Purchaser shall pay Supplier a non-refundable and non-creditable fee equivalent to ****% of the purchase price for the entire purchase order.
If Supplier is unable to fill a Purchase Order within **** of the scheduled delivery date Purchaser has the right to cancel the order without penalty and will be deemed to have ordered such order for purposes of determining Purchaser’s satisfaction of Annual Minimum Purchase requirements within the annual period.
4.4**** Qualification. Purchaser shall have the right to qualify **** as a manufacture of Products and to seek and obtain regulatory approval(s) of such ****. If Purchaser desires to exercise its rights in this Section 4.4, Purchaser shall notify Supplier of such decision in writing.
Article V - DELIVERY, TITLE AND ACCEPTANCE
5.1Product Storage and Shipment.
(a)Storage Conditions. The Materials and Products Manufactured by Supplier are to be stored and transported in accordance with the conditions agreed between Purchaser and Supplier and in accordance with the Specifications.
(b)Shipping Responsibilities. The Products ordered by Purchaser pursuant to this Agreement and any small parcels shall be deemed delivered by Supplier to Purchaser once delivered on the Facility’s loading dock **** (Incoterms® 2020). Shipment of the Products and small parcels shall be at **** sole cost and expenses. **** shall be liable for any and all





transportation charges, including without limitation freight, duties and taxes levied in connection with the supply of Products and any small parcels and shipment of same. Supplier shall arrange for the shipment of the Products in accordance with Purchaser’s instructions. Purchaser shall select and retain the carrier and insurance company for shipping of the Products in accordance with the terms of this Agreement. Purchaser shall provide Supplier with its carrier’s name and account number and its insurance company contact information. Supplier will schedule freight pick up with Purchaser’s selected carrier and complete the documentation on behalf of Purchaser for each shipment of Product by using Purchaser’s account number. All costs and invoices shall be charged by Purchaser’s selected carrier directly to **** for all third party costs related to same. If Purchaser wishes the delivery of the Products to be on any unique pallets, Purchaser shall, at its own cost and expense, make such pallets available to Supplier. Notwithstanding the above, Supplier will use treated-wood pallets, unless a different type of pallet is made available by Purchaser. Purchaser shall be responsible for the supply of single use data loggers, if required by Purchaser. Supplier may supply a single use data logger and/or dry ice with each Batch of Product shipped if requested by Purchaser in writing subject to payment by Purchaser of an additional fee to be quoted to Purchaser prior to shipment per data logger and per bag of twelve (12) kilos of dry ice.
(c)Transfer of Title. Notwithstanding anything to the contrary, title to and risk for the Products supplied to Purchaser under this Agreement passes to Purchaser **** (Incoterms® 2020) ****, at the time the Products ****, not cleared for export and not loaded on any collecting vehicle. Supplier shall not be liable to Purchaser for the costs of loss of any kind arising out of or in relation to damage to or loss of the Products, however caused, which occurs after title to and risk for the Products passes to Purchaser, nor shall any liability of Purchaser to Supplier under this Agreement be diminished or extinguished by reason of such loss or damage. For greater certainty, **** shall be liable for all costs and risks of loss while Products are in transit.
5.2Purchaser Acceptance.
(a)Quantitative Defects. Purchaser shall inform Supplier in writing of any claim relating to quantitative defects in shipments of Products within **** (****) days from the receipt of such shipment by Purchaser and Purchaser shall provide to Supplier copies of any appropriate documents relating to such defects. Supplier shall at its own expense provide Purchaser with any missing quantities of such Products as soon as reasonably possible after receipt of notice from Purchaser. Any claim for a quantitative defect which is not made within such **** (****) day period shall be deemed to have been waived by Purchaser, provided, however, that failure to make a quantitative defect claim shall not be construed as a waiver of any indemnification rights, breach claim or other remedies that Purchaser may have available to it.
(b)Qualitative Defects. Purchaser shall have **** (****) days from the receipt of each shipment of Products in which to determine by appropriate validated tests and assays whether or not each Batch delivered conforms to the Specifications (“Conformity Determination”). In the case of hidden or latent defects, such Conformity Determination must be made within **** (****) days from the receipt of each shipment of Products. If Purchaser deems that a Batch does not conform to the Specifications (“Rejected Batch”), unless such non-conformance is the result of a change in the Active Pharmaceutical Ingredient or any LMI Materials supplied by Purchaser or any Designated Supplier hereunder or a defect in the formula for the Manufacturing of the Product, Purchaser may reject such Batch by giving written notice to Supplier within **** (****) Business Days of the Conformity Determination (“Rejection Notice”). Purchaser must specify in reasonable detail the manner in which such Batch fails to meet the Specifications. Purchaser may withhold payment for any Batch of Products for which a Rejection Notice has been given to Supplier until the matter is resolved. Purchaser shall be deemed to have accepted any Batch with respect to which it fails to notify Supplier as provided above, provided, however, that failure





to make a qualitative defect claim shall not be construed as a waiver of any indemnification rights, breach claim or other remedies that Purchaser may have available to it.
(c)Disposition of Rejected Batch. Supplier shall have **** (****) days from the receipt of the Rejection Notice to accept or reject Purchaser’s claims and submit a report on the Rejected Batch indicating the investigation and testing done and the recommended disposition to Purchaser, as the case may be. Purchaser shall review such report and notify Supplier that Purchaser either requests additional data, approves the recommended disposition of the Rejected Batch or will otherwise direct Supplier as to how Purchaser wishes the Rejected Batch to be disposed of.
(d)Dispute of Test Results. If the Parties fail to agree on whether a Batch of Products fails in whole or part to meet the Specifications and on the disposition of such Rejected Batch, such dispute shall be resolved promptly by an independent testing organization of recognized repute within the pharmaceutical industry of the Territory in which such Batch is to be distributed, mutually agreed upon by the Parties. The appointment of such organization shall not be unreasonably delayed by either Party. The decision of such testing organization shall be binding on both Parties. The fees and costs of the testing organization, and storage and handling of the Products during the resolve of the dispute shall be borne by the Party whose position is not sustained by the testing organization.
(e)Rework and Replacement of Rejected Batch.
(i)If the Parties agree that a Rejected Batch fails in whole or in part to conform to the Specifications, or if a dispute between the Parties in this regard has been resolved pursuant to Section 5.2(d) in favour of Purchaser, Supplier agrees to use **** to destroy the Rejected Batch and deliver a replacement Batch for the Rejected Batch (“Replacement Batch”) within **** (****) days of the date Supplier accepts Purchaser’s written Rejection Notice or the date of the final resolution of the dispute, whichever is later, provided that Supplier has all Materials in inventory, including, when applicable the Active Pharmaceutical Ingredient and Long Lead Time Materials. Any costs related to any additional API or Materials needed as a result of such Rejected Batch shall be borne by ****.
(ii)Notwithstanding the existence of a dispute concerning Products rejected by Purchaser, pending resolution of such dispute, Supplier shall, within **** (****) days of issue by Purchaser of a Purchase Order for additional Products of the type and quantity claimed to be rejected as contemplated by 5.2(b) hereof, deliver such additional Products, and Purchaser shall be obligated to pay for such Products in accordance with 3.4 hereof. In the event that it is ultimately determined that the Rejected Batch was properly rejected by Purchaser, Supplier shall issue a credit to Purchaser against a future batch of Product in the amount equivalent to the price paid for the rejected batch.
(iii)Notwithstanding anything to the contrary contained herein, should the Rejected Batch have failed to meet the Specifications due to defects in the Purchaser’s formula for the Manufacturing of the Product, a Force Majeure applicable to Purchaser or Purchaser’s negligence or willful misconduct, Supplier shall have no obligation to deliver a Replacement Batch to Purchaser and Purchaser shall provide payment for the Rejected Batch.
(f)Batch Yield. Supplier makes no warranty as to the achievement of a certain yield.

5.3Recalls.





(a)Purchaser shall be responsible for recalls, withdrawals and field corrections (each, a “Recall Event”) of the Products. Supplier shall cooperate with Purchaser in the event of any Recall Event with respect to the quality of the Products Manufactured by Supplier and provide such reasonable assistance in connection therewith as Purchaser may reasonably request. The costs of any Recall Event shall be borne by Purchaser; provided, however, that Supplier shall be responsible to the extent the Recall Event is related to the negligence, wilful misconduct or breach of this Agreement or the Quality Agreement. For greater certainty, Supplier shall not be responsible if it Manufactured the Products in accordance with the Specifications provided by Purchaser for the Products.
5.4Form of Quality Agreement.
The Parties agree to fairly and in good faith work towards finalizing the terms of a quality agreement related to the Products (”Quality Agreement”) to be executed in a timely fashion and in a manner which allocates the task relating to the Manufacturing of the Products in accordance with and subject to the terms of this Agreement. The Parties agree that to the extent of an inconsistency with the terms of the Quality Agreement and the Agreement, the terms of the Quality Agreement shall prevail with respect to quality matters and the latter shall prevail to the extent of non-quality matters. Any default under the Quality Agreement shall be deemed a default under this Agreement.
5.5Testing.
Supplier shall perform the quality control tests and assays identified in the Quality Agreement and in accordance therewith. No reduced testing will be performed by Supplier on Materials supplied by Purchaser, including without limitation the Active Pharmaceutical Ingredients, unless Purchaser supplies Supplier with reduced testing indications and protocol and subject to Purchaser’s written confirmation that it has a valid vendor certification program pursuant to applicable Law.
5.6Product Batch Release.
Supplier shall be responsible for the technical release to Purchaser of each production Batch of Products, and Purchaser shall be responsible for the release of the Products to the market. To the extent necessary in relation to the release of any Product by Purchaser, each Batch of Product delivered by Supplier to Purchaser shall be accompanied by a “Certificate of Manufacture” which certifies the date of Manufacturing, expiration date of the Product and that the Batch was Manufactured in conformance with the Specifications and cGMP, and a “Certificate of Analysis” for in-process testing which lists the in-process tests performed by Supplier and sets forth the results of those tests and a list of the quality events.
A full Batch record (i.e. Certificate of Analysis, Certificate of Manufacture, list of quality events, Manufacturing Records and packaging records) will be provided by Supplier to Purchaser per Product and per dosage form with every shipment.
5.7Designated Suppliers Audit.
If Purchaser and Supplier agree that Supplier shall be responsible for the performance of a Designated Supplier’s Audit, Purchaser agrees that such Designated Supplier’s Audit shall be performed ****, including without limitation travelling expenses and accommodations, incurred as a result of such Designated Supplier’s Audit. Supplier will provide a quote for the fees and expenses prior to the audit.

5.8Manufacturing Records.
Supplier shall maintain true, accurate and complete records regarding the Manufacturing of the Products as required by applicable Law and in accordance with cGMP (“Manufacturing Records”) including, without limitation, the information required to be maintained pursuant to the Quality Agreement.





Article VI- REGULATORY MATTERS
6.1Audit and Inspection except as otherwise set forth in the Quality Agreement:
(a)Purchaser Audit. Supplier grants Purchaser the right to audit or to appoint third parties to audit the Facility and the documentation demonstrating Supplier’s satisfactory performance of its obligations under Article II. Such audit shall be conducted during normal business and/or manufacturing hours for a period not to exceed **** (****) Business Days and by a maximum of two (2) auditors (in addition to any qualified person, who may require additional days). Additional auditors or Business Days may be agreed upon between the Parties in writing subject to payment by Purchaser of an additional fee of $****USD per additional auditor per additional Business Day. Purchaser shall notify Supplier in writing at least **** in advance of such an audit. The Parties agree that audits may only be performed during the months of February through June and September through November inclusively. Notwithstanding anything to the contrary contained herein, Purchaser may exercise such right not more than once in any Calendar Year, save and except for situations where a single audit reveals significant concerns from the perspective of Purchaser, acting reasonably, that require appropriate additional audit follow-up, or when an audit for cause is warranted. Any third party appointed by Purchaser to perform such an audit shall at all times be bound by the obligations of confidentiality and non-disclosure of Supplier’s confidential information and agree to disclose to Purchaser only such information as is necessary to determine if Supplier is performing its obligations under Article II. Such third party shall also agree to disclose to Supplier the results of its review. It is furthermore agreed that the on-site availability of Purchaser or such third party shall have no bearing on Supplier’s production schedule as Supplier shall be authorized and entitled to proceed with same in the absence of Purchaser’s representative.
(b)Inspection by Governmental Authorities. Supplier shall permit inspections of the Facility by Governmental Authorities of all relevant territories (such as the FDA, HPFBI or equivalent foreign regulatory authorities) with respect to the fulfillment of any requirement for any License during the Term of this Agreement and, if necessary, thereafter, and unless prohibited by applicable Law, shall permit Purchaser to have representatives on-site for such inspection.
(c)Inspection Notification. Supplier agrees to promptly (but in any event within 48 hours) notify Purchaser of any inspection by any Governmental Authority pending as of the date hereof or as notice of same may arise, and of any communications to or from any Governmental Authority (including the reporting of adverse drug experiences or field alerts) which might adversely affect Supplier’s ability to perform its obligations under this Agreement. Supplier shall keep Purchaser informed of the resolution of the matter with the relevant Governmental Authority.
6.2Regulatory Support Services.
Supplier will provide reasonable support for any submissions required to the HPFBI, FDA and other applicable Governmental Authority to support contract manufacturing of Purchaser’s Products by Supplier at the Facility. Supplier shall not be responsible for any regulatory efforts required in respect of the Manufacturing of the Products, other than regulatory efforts associated with requests by Purchaser for changes to the Specifications.
The Parties agree that all regulatory support services, including without limitation the gathering of documents in support of a Product submission, notarization of documents, company registration (such as CoA’s and form 2657), auxiliary regulatory services (such as sterility packages, clarifax, question answering), will be charged to Purchaser at Supplier’s then applicable rate in addition to any and all reasonable legal fees and notary fees, where applicable and all reasonable costs and expenses associated therewith. The rate to be charged by Supplier for the preparation of a Product submission will be provided by Supplier upon request and is subject to change from time to time.





Article VII - REPRESENTATIONS AND WARRANTIES
7.1Supplier Representations and Warranties.
(a)Representations and Warranties. Supplier represents, warrants and covenants, while acknowledging that Purchaser is relying on such representations and warranties in entering into this Agreement, that:
(i)in performing its services hereunder, Supplier shall comply with all provincial, state, local and federal Laws and the cGMP applicable to such services (including all applicable laws and regulations regarding conflict minerals and will assist Purchaser in meeting its obligations under such laws and regulations) and shall hold, and shall continue to hold during the Term of this Agreement, all material Licenses necessary or required for the Manufacturing of the Products and the performance of its obligations hereunder, and, to its knowledge, the services provided by Supplier and the use, practice or exploitation of Supplier’s Technology or Supplier’s Intellectual Property will not infringe, violate or misappropriate the intellectual property rights of any third party;
(ii)the Facility, all equipment and tooling utilized in the Manufacturing of the Products hereunder, and the procedures and processes (including installation, operation and performance qualifications) instituted by Supplier in connection herewith are, and shall continue during the term of this Agreement, to be in material compliance with all applicable Laws and maintained in good operating condition;
(iii)Supplier shall carry and keep in good force during the Term of this Agreement and for a period of one year following the expiration or other termination of this Agreement insurance coverage in such form and amount as a reasonable party in similar circumstances would carry and keep to fulfil its obligations hereunder, including insurance coverage for the Active Pharmaceutical Ingredient it supplies while it is stored in Supplier’s Facility and including commercial general liability insurance (including Products Completed Operations) with an insurance carrier reasonably acceptable to Purchaser, with limits of liability, including excess coverage, of not less than $**** combined single limit bodily injury and property damage covering its duties and obligations under the Agreement Within **** (****) days of receipt of written request by Purchaser, Supplier shall submit a certificate of such insurance (which shall include such information) to Purchaser. If such certificate is not furnished within **** (****) days, Purchaser shall notify Supplier in writing and give Supplier **** (****) days to cure such breach. If Supplier fails to provide the certificate during such **** (****) day cure period, Purchaser may, at its option, immediately terminate this Agreement or any amendment thereof;
(iv)Upon delivery ****, **** (Incoterms® 2020), Products Manufactured by Supplier under the terms of this Agreement:
A.will comply with the Specifications;
B.will have been manufactured in accordance with the terms of this Agreement, the Quality Agreement, the Master Batch Record and cGMPs applicable in the Territory;
C.will have been manufactured, packaged, labeled, tested and/or re-tested in compliance with applicable provisions of the Federal Food, Drug and Cosmetic Act (the “Act”), regulations thereunder, and any other comparable laws and regulations applicable in the Territory where the Product is being distributed, relating to development, manufacture and supply under this Agreement, and in compliance





with the specific U.S. or other applicable regulatory approvals regarding the Product;
D.shall not contain any material that would cause the Products to be adulterated within the meaning of the FDA or other applicable law where the Product is being distributed;
E.shall be free from material defects in Materials and workmanship not otherwise caused by Materials supplied by Purchaser or by any Designated Suppliers or defect in the Specifications and/or in Purchaser’s formula for the Manufacturing of the Product; and
F.will have minimum shelf life provided on Schedule “C”, provided however, that if after the manufacture of Product, Supplier launches an investigation that causes Product shipment to be delayed and the investigation results in delayed release of one or more Batches of Product and the investigation determines that the deviations in such Batch that triggered the investigation were the fault of LMI Materials that did not meet specifications or Purchaser’s specified process was at fault then Supplier must specify in reasonable detail the manner in which such LMI Materials failed to meet the Specifications or that Purchaser’s specific process was at fault. If Purchaser agrees with the results of such investigation, it shall accept and pay for such Product, even if Product has less than the minimum shelf life set forth on Schedule “C”. Supplier shall use commercially reasonable efforts to expeditiously determine the cause of any such failures. In addition to the foregoing, in all other cases, Purchaser shall use commercially reasonable efforts to accept Product with less than the minimum shelf life set forth on Schedule “C”. If Purchaser does not agree with such results, then the independent testing provisions of Section 5.2(d) shall apply.
(b)Exclusions. The warranties with respect to the Products shall not apply to any Product which, through no fault of Supplier:
(i)has been tampered with or otherwise altered;
(ii)has been subject to misuse, negligence or accident;
(iii)has been stored, handled or used in a manner contrary to the Specifications, HBFBI, FDA or other Governmental Authority’s requirements;
(iv)has expired its stated shelf life;
(v)fails due to defects in the Specifications or as the result of problems with the LMI Materials, including without limitation the Active Pharmaceutical Ingredient, that could not be detected by the quality control tests provided for herein.
(c)Limitation. Subject to applicable Law, the foregoing representations and warranties are limited and are in lieu of any other warranty, and except as set forth above. Except as set forth above, Supplier makes no warranty or representation, express or implied, with respect to the Products, whether as to merchantability, quality, fitness for a particular purpose or otherwise.
7.2Purchaser Representations and Warranties.





(a)Representations and Warranties. Purchaser represents and warrants, while acknowledging that Supplier is relying on such representations and warranties in entering into this Agreement, that:
(i)it shall provide all information necessary for Supplier to Manufacture the Products in accordance with the Specifications and all applicable Laws, including cGMP, and shall make its employees available on a timely basis to respond to questions concerning such information;
(ii)to the extent that Purchaser supplies any Materials, including the Active Pharmaceutical Ingredient, or other information to Supplier (including packaging and labelling requirements) or engages in Manufacturing with respect to any of the Products (either directly or indirectly through a third party), all such Materials or other information and Manufacturing will comply with the Specifications and applicable Laws, including cGMP;
(iii)it shall obtain and maintain all necessary permits, registrations and licences required for it to perform its obligations to Supplier under this Agreement and shall comply with all applicable Laws in carrying out its obligations under this Agreement;
(iv)to the best of its knowledge, the Technology provided by Purchaser to Supplier pursuant to this Agreement does not infringe, misappropriate or violate any Intellectual Property of a third party;
(v)the Purchaser Intellectual Property licensed to Supplier pursuant to Section 8.1(e) is free and clear of any lien, encumbrance, security interest or restriction on license inconsistent with the rights granted to Supplier and Purchaser has not previously granted and will not grant to any third party during the Term of this Agreement any right, license or interest in or to the Purchaser Intellectual Property or any portion thereof, inconsistent with the rights granted to Supplier herein;
(vi)Except for the Technology and Intellectual Property provided by Supplier, to its knowledge, Purchaser has all necessary Technology and Intellectual Property rights to enable Supplier to Manufacture the Product for Purchaser in accordance with the terms and condition of this Agreement; and
(vii)Purchaser shall carry and keep in good force during the term of this Agreement and for a period of one year following the expiration or other termination of this Agreement insurance coverage, including product liability insurance coverage, in such form and amount as a reasonable party in similar circumstances would carry and keep to fulfil its obligations hereunder, including without limitation insurance coverage for the Active Pharmaceutical Ingredient while it is stored in Supplier’s Facility in an amount of no less than $**** US dollars. Within **** (****) days of receipt of written request by Supplier, Purchaser shall submit a certificate of such insurance (which shall include such information) to Supplier. If such certificate is not furnished within **** (****) days, Supplier shall notify Purchaser in writing and give Purchaser **** (****) days to cure such breach. If Purchaser fails to provide the certificate during such **** (****) day cure period, Supplier may, at its option, immediately terminate this Agreement or any amendment thereof;
(viii)after diligent inquiry, Purchaser represents that the sale, distribution, marketing, promotion and use of the Product does not and will not infringe any third party Intellectual Property rights or other rights and that it is not aware of any patents existing in the Territory which could adversely impact upon or prevent Supplier from Manufacturing the Product as contemplated by the terms hereof; and
(ix)Purchaser has the lawful right to enter into this Agreement for the Manufacturing of the Product without breach of any other contractual obligations it may have.





(b)Debarment. Each Party represents and warrants that neither of its officers, directors or employees performing services under this Agreement has been debarred or convicted of a crime which could lead to debarment. Each Party shall notify the other immediately in the event that such Party or any of its officers, directors, employees performing services under this Agreement:
(i)becomes debarred or receives notice of action or threat of action with respect to its debarment; or
(ii)becomes the object of any investigation or subject of any report regarding such Party or any of its officers, directors, employees performing services under this Agreement, in connection with any activity that could result in debarment or suspension or refusal of approval.
(c)No Conflict. Each Party warrants and represents that no trade secrets or other confidential information of any other person, firm, corporation, institution or other entity will be wrongfully disclosed by it to the other Party or any third party in connection with any of the services called for hereunder. Each Party further warrants and represents that none of the provisions of this Agreement, nor the services which will be performed by Supplier pursuant to the work to be performed hereunder, contravenes or is in conflict with any agreement of such Party or its Affiliates with, or obligation to, any other person, firm, corporation, institution or other entity including, without limiting the generality of the foregoing, employment agreements, consulting agreements, service agreements, disclosure agreements or agreements for assignment of inventions. Supplier shall not subcontract with any third party or use Affiliates or agents to perform any of its obligations hereunder without the prior written consent of Purchaser. Supplier shall cause all of its employees and any permitted subcontractor, agent or Affiliate to be bound by, and to comply with, all confidentiality, quality assurance, regulatory and other obligations and requirements as set forth in this Agreement.
Article VIII - INTELLECTUAL PROPERTY; NONDISCLOSURE; CONFIDENTIALITY
8.1Ownership
(a)Purchaser Rights. Supplier acknowledges that Purchaser is the sole owner of Purchaser Intellectual Property and of all data and information relating to the Products, including the Specifications and any other information relating thereto delivered by Purchaser to Supplier under this Agreement, except to the extent such information is in the public domain or owned by a third party.
(b)Supplier Rights. Purchaser acknowledges that Supplier is the sole owner of the Supplier Intellectual Property except to the extent such information is in the public domain.
(c)Product Developments. All Intellectual Property relating to a Product conceived, reduced to practice, authored or otherwise generated or developed in the course of activities under this Agreement, either by or on behalf of Supplier, except to the extent it has general applicability to the manufacture of pharmaceutical products other than the Products, shall be Product Developments. Purchaser shall own all right, title and interest in and to all ****. Supplier will, and hereby does, assign to Purchaser all of its rights, title and interest in and to Product Developments and rights to Intellectual Property arising therefrom. Supplier will provide reasonable assistance to Purchaser, at Purchaser’s expense, in obtaining and enforcing Purchaser’s ownership of the Product Developments including as applicable the assignment to Purchaser of the right, title and interest of its employees or independent contractors in and to such Product Developments.
(d)Patents. As soon as practicable, Supplier shall inform Purchaser in writing of such Product Development. Upon Purchaser’s reasonable request and at Purchaser’s expense, Supplier shall take such reasonable actions as Purchaser deems necessary or appropriate to assist





Purchaser in obtaining patent or other proprietary protection in Purchaser’s name with respect to all Product Developments.
(e)License. Under the terms and subject to the conditions of this Agreement, Purchaser hereby grants Supplier a **** license to use the Purchaser Intellectual Property and the Product Developments solely for the purposes of performing its obligations hereunder. Supplier shall have no right to make, manufacture, supply, distribute, use or sell the Products or use any Purchaser Intellectual Property for any other purpose.
8.2Reproduction of and Right to Use Trademarks.
Solely in connection with Supplier’s performance of this Agreement, Purchaser hereby grants Supplier the right to reproduce and print on the Products and/or Product packaging such trademarks, trade dress, brand names, and/or trade names that Purchaser may designate in writing from time to time, strictly in accordance with trademark usage and packaging guidelines set forth in the Specifications or otherwise provided by Purchaser in writing. Samples of all such uses of Purchaser’s trademarks, trade dress, brand names and/or trade names on the Products or Product packaging shall be submitted to Purchaser for its written approval prior to production. The permission granted to Supplier herein is restricted to usage of such trademarks, trade dress, brand names and/or trade names on or in connection with the Products supplied under this Agreement, and such permission extends only for the Term of this Agreement or such shorter period as may be designated or required by Purchaser.
8.3Supplier’s Ownership of Other Property.
Except as otherwise specified herein, it is agreed that Supplier is the sole owner of any and all machinery and equipment used by Supplier in connection with the Manufacturing of the Products in accordance with this Agreement.
8.4Infringement.
(a)Notice. In the event that either Party becomes aware if actual or threatened infringement of Intellectual Property related to any Product, that Party shall promptly so notify the other in writing. Purchaser shall have the right, but not the obligation, to bring at its own expense an infringement action or file any other appropriate action or claim related to infringement of such Intellectual Property against any third party. Supplier shall have the option to join in (but not control) such action to the extent Supplier believes it has been damaged by the actions of such third party.
(b)Settlement. Each Party shall cooperate and provide reasonable assistance in any action as described above. No settlement or other voluntary final disposition of any suit defended or action brought by or against either Party may be entered into without the consent of the other party if such settlement would require such other Party to be subject to an injunction or to make a monetary payment, or would adversely affect such other Party’s rights under this Agreement.
(c)Damages. Purchaser shall retain any damages or other monetary awards that it recovers pursuant to any action under this Section 8.4(a).
8.5Right to not Manufacture.
(a)Situations Related to Specific Product. On a Product-by-Product and country-by-country basis, Supplier shall not be required to Manufacture or otherwise be involved in the distribution of a Product to which:
(i)any Person (that is not an Affiliate of Supplier) claims the Manufacturing or distribution of such Product infringes or otherwise violates any third party





Intellectual Property right unless Purchaser confirms its applicable indemnification obligations hereunder with respect to same (such limitation only applicable in the country or region of the Territory in which the third party Intellectual Property is claimed); or
(ii)any Governmental Authority alleges such Manufacturing or distribution of such Product violates any applicable Law (such limitation only applicable in the country or region of the Territory in which the Governmental Authority has jurisdiction). Each Party shall provide prompt written notice of any claim of any Governmental Authority to the other Party in this regard and the Parties shall reasonably work together as contemplated by Section 2.3 and will split any applicable costs as set forth in Section 3.8(c).
(b)Situations Related to All Products. With respect to all Products, Supplier shall not be required to Manufacture or otherwise be involved in the distribution of such Products to which:
(i)to the extent of new Purchase Orders received from Purchaser after Supplier has sent a valid notice of material breach in accordance with Section 10.2(a) hereof until Purchaser cures such breach.
(c)Reimbursement. Purchaser shall promptly reimburse Supplier for all of Supplier’s costs and expenses (including without limitation reasonable attorney’s fees and expenses) incurred as a result of any actions or allegations described in this Section 8.5 and shall defend, indemnify and hold Supplier, its Affiliates and the officers, directors, employees, agents, representatives and shareholders of each and hold Supplier harmless in connection therewith, to the extent not otherwise payable by Purchaser pursuant to this Agreement.
8.6Nondisclosure and **** Obligations.
(a)During the Term of this Agreement and for a period of **** thereafter, both Parties shall maintain in confidence (i.e., not disclose to any third party) and use only for purposes specifically authorized under this Agreement information and data received from or on behalf of the other Party, including under the Prior Agreements, whether such information is contained in a written or electronic document, whether it is oral or whether it is disclosed by means of inspection.
(b)For purposes of this Section 8.6, information and data described in clause (a) shall be referred to as “Information.” For purposes of clarity, Supplier acknowledges and agrees that Purchaser’s Information includes, without limitation, the Product-related information and **** developed by Supplier specifically for Purchaser, including Product Development, (provided such Information shall not include information developed independently by Supplier without reference to Purchaser’s pre-existing Intellectual Property and Technology or other Information). Purchaser shall not use the format of Supplier’s underlying forms provided to it other than for the Product, and the same shall be Supplier’s Information. To the extent it is reasonably necessary or appropriate to fulfill its obligations or exercise its rights under this Agreement, a Party may disclose Information it is otherwise obligated under this Section not to disclose, to its Affiliates, employees, officers, directors, lenders, sublicensees, consultants, outside contractors and clinical investigators on a need-to-know basis and on condition that such entities or persons agree in writing to only use such Information for purposes specifically authorized under this Agreement and to keep the Information confidential for the same time periods and to the same extent as such Party is required to keep the Information confidential; notwithstanding the foregoing the Party so disclosing Information will be liable to the other Party hereunder for any misuse or improper disclosure of any such Information by any such firms or individuals. A Party or its sublicensees may disclose such Information to government or other regulatory authorities to the extent that such disclosure is reasonably necessary to obtain patents or authorizations to conduct clinical trials of, and to commercially market, the Product on





behalf of Purchaser. The obligation not to disclose Information shall not apply to any part of such Information that (i) is or becomes part of the public domain other than by unauthorized acts of the Party obligated not to disclose such Information or its Affiliates or sublicensees, (ii) can be shown by written documents to have been disclosed to the receiving Party or its Affiliates or sublicensees by a third party, provided such Information was not obtained by such third party directly or indirectly from the other Party under this Agreement pursuant to a confidentiality agreement, (iii) prior to disclosure under this Agreement can be shown by written documents to have been already in the possession of the receiving Party or its Affiliates or sublicensees, provided such Information was not obtained directly or indirectly from the other Party under this Agreement pursuant to a confidentiality agreement, or (iv) can be shown by written documents to have been independently developed outside of this Agreement by the receiving Party or its Affiliates without breach of any of the provisions of this Agreement or any Prior Agreement. The Party asserting the applicability of one of the exclusions set forth in the immediately preceding sentence shall have the burden of proving the applicability of any such exclusion in any particular circumstance. If a receiving Party is required to disclose Information of the other Party pursuant to interrogatories, requests for information or documents, subpoena, civil investigative demand of a court or governmental agency, it shall use commercially reasonable efforts to do so, at the disclosing Party’s reasonable cost and expense, on a confidential basis (and use reasonable efforts to provide that the receiving Party furnishes only that portion of the Information which is legally required), and, in any event, it shall provide the other Party prompt notice after receipt of any such official requests to enable the other Party to seek a protective order or similar relief.
(c)Supplier understands and acknowledges that Purchaser’s Information, Intellectual Property, and Technology related to the Products has been developed or obtained by the investment of significant time, effort and expense by Purchaser, and that such Information, Intellectual Property, and Technology is a valuable, special and unique asset of Purchaser which provides Purchaser with a significant commercial advantage, and needs to be protected from improper use and disclosure (including, but not limited to, any improper use by Supplier or its Affiliates). Supplier will not disclose the Purchaser’s Intellectual Property or Technology to its Affiliates or otherwise use the Purchaser’s Information, Intellectual Property or Technology for the benefit of such Affiliates. Supplier further recognizes that **** and, as a result, Supplier agrees and agrees to cause **** for the Term of the Agreement and for ****. For purposes of clarity, an **** shall include **** or **** as applicable. Supplier agrees that there may be no adequate remedy at law for any such breach and, upon any such breach or any threat thereof, Purchaser shall be entitled to appropriate equitable relief in courts located in Delaware, including injunctive relief, in addition to whatever other remedies it might be entitled. In addition, in order to protect against the disclosure of Purchaser’s Information, upon termination or expiration of this Agreement, or as otherwise requested by Purchaser, Supplier will promptly deliver to Purchaser or, at the request of Purchaser, destroy all copies of Purchaser’s Information in its possession; provided, in each case, that Supplier may retain, in a secure location, a copy of such documents and records for purposes of defending any legal proceedings or as is required to be maintained in order to satisfy any law, rule, or regulation to which Supplier is subject.
(d)Injunctive Relief. The Parties hereto understand and agree that remedies at law may be inadequate to protect against any breach of any of the provisions of this Section 8.6 by a Party or its employees, agents, officers or directors or any other person acting in concert with it or on its behalf. Accordingly, each Party shall be entitled to seek injunctive relief or any other equitable relief appropriate under the circumstances by a court of competent jurisdiction against or with respect to any action that constitutes any such breach of this Section 8.6.
Article IX - INDEMNITIES
9.1Indemnity of Supplier.





Subject to the limitations provided for in Section 9.4 hereof, Purchaser shall defend, indemnify and hold Supplier, its Affiliates, and their officers, directors, employees, and agents harmless from and against any and all Losses suffered, incurred or sustained by any of them or to which any of them becomes subject at any time by reason of any third party Proceeding to the extent arising out of or resulting from:
(a)the use, manufacture, processing, testing, packaging, labelling or storage of or any other dealing with any or all of the Products, but only to the extent that such liability does not arise as a result of Supplier’s negligent act or omission, breach of representation or warranty or failure to perform a covenant under this Agreement or the Quality Agreement;
(b)any Recall Event, subject to Section 5.3;
(c)any claim from a third party that a Product under this Agreement or its sale, distribution, marketing, promotion or use actually or allegedly infringes such party’s Intellectual Property, or any actual or alleged infringement by Purchaser of third party intellectual property rights; or
(d)the breach by Purchaser of any of the terms of the Quality Agreement or this Agreement including, without limitation, the Purchaser representations and warranties provided for in Section 7.2 hereof.
9.2Indemnity of Purchaser.
Subject to the limitations provided for in Section 9.4 hereof, Supplier shall defend, indemnify and hold Purchaser, its Affiliates, and their officers, directors, employees, and agents harmless from and against any and all Losses suffered, incurred or sustained by any of them or to which any of them becomes subject at any time by reason of any third party Proceeding to the extent arising out of or resulting from:
(a)the negligence or willful misconduct of Supplier in performing its obligations under this Agreement;
(b)a breach by Supplier of any of the terms of the Quality Agreement or this Agreement including, without limitation, the Supplier representations and warranties provided for in Section 7.1 hereof;
(c)any Recall Event, subject to Section 5.3; or
(d)any claim made against Purchaser for the actual or alleged infringement by the Supplier of a third party’s Intellectual Property except to the extent arising from use by the Supplier of any Purchaser Intellectual Property or Technology.
9.3Indemnity Proceedings.
(a)Notice of Claim. If a claim by a third party is made against an Indemnitee, and if the Indemnitee intends to seek indemnity with respect thereto under this Agreement, the Indemnitee shall promptly (and in any case within thirty (30) days of such claim being made) notify the Indemnitor of such claim with reasonable particulars. The Indemnitor shall have **** days after receipt of such notice to undertake, conduct and control, through counsel of its own choosing (reasonably acceptable to Indemnitee) and at their own expense, the settlement or defense thereof, and the Indemnitee shall reasonably cooperate with them in connection therewith, except that with respect to settlements entered into by the Indemnitor: (i) the consent of the Indemnitee shall be required if the settlement provides for equitable relief against the Indemnitee or an admission of liability, which consent shall not be unreasonably withheld or delay; and (ii) the Indemnitor shall obtain the release of the Indemnitee.





(b)Conduct of Proceedings. If the Indemnitor undertakes, conducts and controls the settlement or defense of such claim, (i) the Indemnitor shall permit the Indemnitee to participate in such settlement or defense through counsel chosen by the Indemnitee, provided that the fees and expenses of such counsel shall be borne by the Indemnitee; provided, however, that to the extent that joint legal representation presents a conflict of interest, the Indemnitee will have the right to select its own counsel at the Indemnitor’s expense; and (ii) the Indemnitor shall promptly reimburse the Indemnitee for the full amount of any loss resulting from any claim and all related expenses (other than the fees and expenses of counsel as aforesaid) incurred by the Indemnitee. The Indemnitee shall not pay or settle any claim so long as the Indemnitor is reasonably contesting any such claim in good faith on a timely basis. Notwithstanding the two immediately preceding sentences, the Indemnitee shall have the right to pay or settle any such claim, provided that in such event it shall waive any right to indemnity therefor by the Indemnitor.
(c)Indemnitee Rights. With respect to third party claims, if the Indemnitor does not notify the Indemnitee within **** days after the receipt of the Indemnitee’s notice of a claim of indemnity hereunder that it elects to undertake the defense thereof, the Indemnitee shall have the right, but not the obligation, to contest, settle or compromise the claim in the exercise of its reasonable judgement using counsel of its choice at the reasonable expense of the Indemnitor.
(d)Employee Assistance. In the event of any claim by a third party against an Indemnitee, the defense of which is being undertaken and controlled by the Indemnitor, the Indemnitee will use all reasonable efforts to make available to the Indemnitor those employees whose assistance, testimony or presence is necessary to assist the Indemnitor in evaluation and in defending any such claim; provided that the Indemnitor shall be responsible for the expense associated with any employees made available by the Indemnitee to the Indemnitor hereunder, which expense shall be equal to an amount to be mutually agreed upon per person per hour or per day or each day or portion thereof that such employees are assisting, and which shall not exceed the actual cost to the Indemnitee associated with such employees.
9.4Limitation of Liability.
(a)Indirect Damages. Notwithstanding the provisions of this Agreement which might otherwise be to the contrary, neither Party shall be liable to the other, or have any obligation to indemnify any Indemnitee, as the case may be, for any indirect, special, consequential, exemplary or punitive damages or Losses, including any loss of profits or revenue arising from this Agreement whether it has been advised of the possibility of such damages or Losses suffered by either Party however caused and on any theory of liability; except to the extent necessary to satisfy a third party claim under this Article IX or to the extent such liability arises from Supplier’s willful misconduct, fraud or grossly negligent acts or omissions or a Party’s breach of Sections 8.1 (Ownership), 8.2 (Reproduction of and Right to Use Trademarks) and 8.6 (Nondisclosure and **** Obligations).
(b)Aggregate Liability. Supplier’s aggregate liability under this Agreement shall not exceed **** dollars****, except to the extent such liability arises from Supplier’s willful misconduct, fraud or grossly negligent acts or omissions or breach of Sections 8.1 (Ownership), 8.2 (Reproduction of and Right to Use Trademarks) and 8.6 (Nondisclosure and **** Obligations), in which case Supplier’s liability will be uncapped.
Article X - TERM AND TERMINATION
10.1Term of Agreement.
(a)Initial Term. This Agreement is effective as of January 1st, 2022 until December 31st, 2027 (“Initial Term”) unless earlier terminated in accordance with the terms of the Agreement. Thereafter, this Agreement may be renewed for additional periods of time (each, a





Renewal Term”) by the mutual consent of both Parties. The Parties agree to discuss the renewal of this Agreement at least twelve (12) months before the end of the Initial Term and any Renewal Term of at least twenty-four (24) months. The Initial Term and every Renewal Term shall collectively be referred to as the “Term”.
10.2Termination of Agreement.
(a)Termination for Breach. Either Party may terminate this Agreement, in whole or on a Product-by-Product basis, at the terminating Party’s discretion, with written notice to the other Party, if the other Party defaults or breaches in a material respect in the performance or observance of any of its obligations under this Agreement and such default or breach continues, unremedied, for a period of sixty (60) Business Days following written notice of such default to the defaulting Party. Such cure period shall be reduced to thirty (30) Business Days in the event of a payment default by Purchaser.
(b)Bankruptcy, etc. Either Party may terminate this Agreement upon notice to the other Party, if the other Party makes an assignment for the benefit of its creditors, is adjudged bankrupt, becomes insolvent, ceases or threatens to cease to carry on business, files or consents to the filing of a petition in bankruptcy, seeks to take advantage of any legislation relating to insolvency, arrangement or relief of debtors, winds-up or liquidates, or if any receiver, trustee, liquidator or similar official is appointed of such other Party or any of its property.
(c)Under Section 8.5: In addition to Supplier’s right to not Manufacture under Section 8.5(a)(i), Supplier may also, at its sole discretion, terminate this Agreement on a Product-by-Product and country-by-country basis, based on the Product(s) and country(ies) affected by the actual or alleged infringement if Purchaser has not confirmed its applicable indemnification obligations hereunder in accordance with Article IX with respect to same.
(d)Effect of Termination.
Following termination or expiration of this Agreement for any reason:
(i)Purchaser shall purchase from Supplier all remaining Materials, including without limitation Long Lead Time Materials, purchased in accordance with the terms of this Agreement and all of the finished Products (including those finished after termination pursuant to (v) below);
(ii)Purchaser will have access to any Manufacturing Records and Batch retention samples relating to the Manufacturing of the Products under this Agreement for the period during which the Manufacturing Records and Batch retention sample must be kept by Supplier in accordance with this Agreement or the Quality Agreement;
(iii)Supplier shall provide to Purchaser the originals of all Specifications; provided, however, that a copy of such document may be retained by Supplier for archival purposes, as means of determining any continuing obligation or confidentiality, but for no other purpose; and
(iv)Purchaser shall, within **** days of the date of termination of this Agreement, pay to Supplier any outstanding payments to be made pursuant to this Agreement, including without limitation, any and all payment due pursuant to this Section 10.2(d) or Section 3.2 hereof; and
(v)Orders in Progress. In the event of any termination or expiration of this Agreement, Supplier shall, unless such termination has occurred because of a material uncured breach or default by Purchaser under this Agreement, or Purchaser’s insolvency, notwithstanding the effective date of any termination or expiration, upon written request of Purchaser, complete any purchase orders for Product that were placed by





Purchaser and accepted by Supplier prior to such date and Purchaser shall pay Supplier for any Product produced in accordance with such purchase orders at the applicable price as set forth in this Agreement; and
(vi)Terminal Supply; Post-Termination or Expiration Acceptance of Orders. If this Agreement has not been renewed pursuant to Section 10.1(a), then upon Purchaser’s request, Supplier shall use commercially reasonable efforts to provide Purchaser with a terminal supply of Products for a period of ****.
Article XI - MISCELLANEOUS
11.1Relationship of the Parties.
The relationship between Supplier and Purchaser created pursuant to this Agreement is intended to be and shall be solely that of independent contractors. Neither Party, nor its employees, agents or representatives shall under any circumstances be considered employees, agents, partners, joint venturers or representatives of the other Party. Neither Party, nor its employees, agents or representative shall act or attempt to act, or represent themselves, directly or by implication, as an employee, agent, joint venturer, partner or representative of the other Party or in any manner assume or create, or attempt to assume or create, any obligation or liability of any kind, express or implied, on behalf of or in the name of the other Party. No person other than Supplier or Purchaser may rely on or enforce any provision of this Agreement.
11.2Force Majeure.
(a)Defined. In this Agreement, “Force Majeure” means an event or occurrence beyond the reasonable control of a Party which by the exercise of reasonable diligence and maintenance could not be overcome, including, but not limited to, strikes, lock-outs, labour disruptions, acts of God, changes in the law, restraints of governments, riots, arrests of people, acts of war, civil disturbances, terrorist actions, rebellion or sabotage, severe breakage of or accidents to machinery, plant or equipment, pipeline or pipe failure, failure of fuel or water supply or transportation, fire, flood, ice, lightning, epidemic, explosion, hydro electric power failures, defaults by third party suppliers, including Designated Suppliers, not caused by the act or omission of the Party or any delay or failure by a Governmental Authority to issue any relevant permit or order not caused by the act or omission of the Party.
(b)Non-Default. A Party shall be deemed not to be in default with respect to non-performance of any of its obligations under this Agreement, if and so long as such non-performance is due in whole or in some material way to an event of Force Majeure and that Party has used commercially reasonable efforts to remove the event of Force Majeure and to perform its obligations under the Agreement. If an event of Force Majeure occurs, the Party affected shall promptly notify the other Party of the occurrence of the event, its extent and probable duration.
(c)Cessation of Force Majeure. Subject to Section 11.2(b) hereof, if Supplier is unable to supply Purchaser with its requirements of Products by reason of Force Majeure, Force Majeure shall excuse Supplier’s performance until the Force Majeure has ceased and for a reasonable period of time thereafter, to allow Supplier to restore itself to the position it was in with respect to the Manufacturing of Products immediately prior to the Force Majeure. Within thirty (30) days of notification by Supplier that it is able to resume the necessary supply of the Products to Purchaser, Purchaser shall resume obtaining its requirements of Products from Supplier pursuant to the terms of this Agreement. Supplier shall suffer no penalty or incur any liability for its inability to perform hereunder by reason of Force Majeure.
(d)Termination. If a Party fails to perform any of its obligations under this Agreement by reason of Force Majeure and such non-performance continues for a period of ninety (90) days from the first occurrence of the event of Force Majeure, the other Party may, if itself is





not in default under the Agreement, terminate this Agreement by providing written notice to that effect to the non-performing Party. In the event of such termination, both Parties’ respective rights and obligations under this Agreement shall terminate except for any amounts previously due and owing by one Party to the other and except for any other obligations which this Agreement expressly provides shall survive termination.
11.3Further Assurances.
Each Party will at any time and from time to time, upon the request of the other Party, execute and deliver such further documents and do such further acts and things as the other Party may reasonably request to evidence, carry out and give full effect to the terms, conditions, intent and meaning of this Agreement.

11.4Intentionally omitted.
11.5Notices.
Any notice or other communication made under this Agreement (other than routine business communication) shall be in writing and shall be properly given: (i) when delivered if sent by personal delivery; (ii) when transmitted if sent by facsimile with confirmation of transmission; (iii) the next day if sent by recognized overnight courier; or (iv) three days after being posted if sent by registered mail return receipt requested, addressed:


(a)if to Supplier, to it at:    Jubilant HollisterStier LLC
3525 N Regal St, Spokane, WA 99207, United States
Attn: President

    with a copy to:        Jubilant HollisterStier General Partnership
            16751 Trans Canada Highway
            Kirkland, Québec, Canada H9H 4J4
                Attn: Legal Department
            

(b)if to Purchaser, to it at:
Lantheus Medical Imaging, Inc.
331 Treble Cove Road
North Billerica, MA 01862
United States of America
Attention: VP of Manufacturing Supply Chain
With a copy at the same address to:
Attention: General Counsel

A Party may change its address for notice by notifying the other Party at any time in accordance with the provisions of this Agreement.

11.6Entire Agreement.
This Agreement, together with the Quality Agreement, and any and all Schedules attached hereto and thereto, supersede any prior agreements between the Parties with respect to the subject matter of the Agreement and the Quality Agreement, whether oral or in writing, and contains the entire understanding between the Parties with respect to the subject matter of the Agreement. The Prior Agreements are each hereby terminated and superseded by this Agreement, provided,





however, such termination is without prejudice to any rights or remedies that have accrued to the benefit of any Party prior to such termination.
11.7Waiver.
No delay or failure on the part of a Party in exercising any rights under this Agreement shall affect any of such Party’s rights.
11.8Amendment.
This Agreement may not be modified or amended except by further written statement signed by both Parties.
11.9Severability.
Any provision of this Agreement that is held to be inoperative, unenforceable or invalid in any jurisdiction shall be inoperative, unenforceable or invalid in that jurisdiction without affecting any other provision hereof in that jurisdiction or the operation, enforceability or validity of that provision in any other jurisdiction, and to this end the provisions hereof are declared to be severable.
11.10Enurement.
This Agreement is binding on and enures to the benefit of each Party and its successors and permitted assigns.
11.11Assignment.
Neither Purchaser nor Supplier shall assign or otherwise transfer any rights under or interest in this Agreement without the other Party’s prior written consent, such consent not to be unreasonably withheld or delayed. Notwithstanding the foregoing, either Party (a) may assign this Agreement without the consent of the other Party in whole or in part to any Affiliate of such Party, it being agreed that no such assignment to a Party’s Affiliate shall release the assigning Party from its obligations hereunder, and (b) will assign this Agreement in connection with the direct or indirect (x) transfer and sale of all or substantially all of the assets or business of such Party or any of its Affiliates; provided, however, that Purchaser may assign this Agreement in whole or in part (or may bifurcate this Agreement by Product) in connection with the transfer and sale of all or substantially all of the assets or business of the specific business line, division or unit of Purchaser or any of its Affiliates to which this Agreement or Products manufactured under this Agreement relate; and provided further that with respect to any assignment by Supplier, all Manufacturing remains at the Facility.
11.12Counterparts.
This Agreement may be executed in counterparts and by facsimile transmission, each of which shall be deemed to be an original and which together shall constitute one and the same agreement.
11.13Contra Proferentum.
This Agreement is the result of mutual negotiations between the Parties, and each Party agrees that no part of this Agreement shall be interpreted against the other Party on the grounds that particular language was drafted by such Party.
11.14Subcontracting.
Supplier may be permitted to subcontract in whole or in part its obligations under this Agreement upon the consent of Purchaser, such consent not to be unreasonably withheld or delayed.





11.15Governing Law.
This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware applicable to agreements made and to be performed entirely in such state, without giving effect to any conflict of law principles. Any disputes arising between the Parties relating to this Agreement shall be subject to the exclusive jurisdiction and venue of the state and federal courts located in the State of Delaware, and the Parties hereby waive any objection which they may have now or hereafter to the laying of venue or jurisdiction of any proceedings in said courts and to any claim that such proceedings have been brought in an inconvenient forum, and further irrevocably agree that a judgment or order in any such proceedings shall be conclusive and binding upon each of them and may be enforced in the courts of any other jurisdiction. EACH PARTY, TO THE EXTENT PERMITTED BY APPLICABLE LAW, KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES ITS RIGHT TO A TRIAL BY JURY IN ANY ACTION OR OTHER LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS IT CONTEMPLATES. THIS WAIVER APPLIES TO ANY ACTION OR LEGAL PROCEEDING, WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE.
11.16Non-Solicitation.
Neither Supplier nor Purchaser shall solicit (either directly or indirectly) for employment or employ any of each other’s employees during the Term of this Agreement; provided, however, the foregoing will not prohibit a Party from soliciting (but not hiring) any such employee through general solicitations or through services of a recruiting firm that has not been provided with the names of, or instructed to target, any such employee. In the event Supplier or Purchaser desire to solicit for employment or employ one of such Supplier’s employees or Purchaser’s employees, as the case may be, then Supplier must obtain Purchaser’s prior written approval of such solicitation or employment and vice versa.
11.17Survival.
The following provisions shall survive the expiration or termination of this Agreement: Sections 8.1, 8.3, 8.6, 9, 10, 11.5, 11.15 and 11.17.

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date written above, by their authorized officers, who by signing confirm their authority and intention to bind the Party they represent.


JUBILANT HOLLISTERSTIER LLC



Per:    /s/Amit Arora                        
Amit Arora
President
    

LANTHEUS MEDICAL IMAGING, INC.


Per:    /s/ Mary Anne Heino                
Name: Mary Anne Heino
Title: Chief Executive Officer and President






SCHEDULE “A”

SPECIFICATIONS

****







SCHEDULE “B”

QUALITY AGREEMENT

The Quality Agreement is attached herein by reference, as last amended on September 25, 2019.
image_0b.jpg











SCHEDULE “C”

PRICES

The Prices per unit set forth below are only for the markets identified below. If the Products are to be sold in other markets, Supplier will provide prices upon request.


Prices For ****:

Product(s)****Price in USD
DEFINITY 160L
********
DEFINITY 260L********
Cardiolite********
Neurolite Ligand
********
Neurolite Buffer********
EVAC********







SCHEDULE “D”

DEFINITIONS AND LIST OF MATERIALS

DEFINITY means “DEFINITY® (perflutren lipid microsphere) Injectable Suspension (and all other USAN or trade names Purchaser may choose to use in Territory) is the final dosage form manufactured pursuant to the DEFINITY NDA and suitable for distribution in commerce in the Territory. For clarity, DEFINTY does not include DEFINITY RT.”

****









SCHEDULE “E”

LIST OF COUNTRIES/REGIONS

****



EX-10.2 3 lnth10q-033122ex102.htm EX-10.2 Document
Exhibit 10.2
Lantheus Holdings, Inc.
2015 Equity Incentive Plan
Restricted Stock Unit Award Agreement
(
Employee Time-Based Vesting)

This Restricted Stock Unit Award Agreement (this “Agreement”) is made by and between Lantheus Holdings, Inc., a Delaware corporation (the “Company”), and [] (the “Participant”), effective as of [] (the “Date of Grant”).
RECITALS
WHEREAS, the Company has adopted the Lantheus Holdings, Inc. 2015 Equity Incentive Plan (as the same may be amended and/or amended and restated from time to time, the “Plan”), which Plan is incorporated herein by reference and made a part of this Agreement, and capitalized terms not otherwise defined in this Agreement will have the meanings ascribed to those terms in the Plan; and
WHEREAS, the Committee has authorized and approved the grant of an Award to the Participant of Restricted Stock Units, subject to the terms and conditions set forth in the Plan and this Agreement.
NOW THEREFORE, in consideration of the premises and the mutual covenants set forth in this Agreement, the parties agree as follows:
1.Grant of RSUs. The Company has granted to the Participant, effective as of the Date of Grant, [] Restricted Stock Units (the “RSUs”), giving the Participant the conditional right to receive, on the terms and conditions set forth in the Plan and this Agreement, one share of Common Stock with respect to each RSU subject to this Award, subject to adjustment as set forth in the Plan.
2.Vesting of RSUs. Subject to the terms and conditions set forth in the Plan and this Agreement, the RSUs will vest as follows:
(a)General. Except as otherwise provided in Section 2(b) below, one-third (1/3) of the RSUs will vest on each of the first three (3) anniversaries of the Date of Grant, subject to the Participant’s continued Service through the applicable vesting date, with the number of RSUs that vest on the first two vesting dates rounded down to the nearest whole RSU and with 100% of the remaining RSUs becoming vested on the third (3rd) anniversary of the Date of Grant.
(b)Change in Control. Subject to the Participant’s continued Service through the date of a Change in Control (except as otherwise provided in this Section 2(b)(ii)):
(i)If (x) the consideration paid in connection with that Change in Control is all cash or (y) the then-outstanding RSUs are not assumed, continued or substituted for by the acquirer in that Change in Control, then all then-outstanding RSUs will become fully vested as of immediately prior to the consummation of that Change in Control; or
(ii)If (x) the consideration paid in connection with that Change in Control is not all cash, and (y) the then-outstanding RSUs are assumed,
Page 1 of 5



Exhibit 10.2
continued or substituted for by the acquirer in that Change in Control, and (z) the Participant’s Service is terminated (1) by the Company without Cause or, (2) to the extent the Participant is then party to an employment letter or agreement with the Company or any Subsidiary that defines “Good Reason” (or any similar term), by the Participant for Good Reason, then in either case, within twelve (12) months following that Change in Control, all then-outstanding RSUs will become fully vested as of immediately prior to that termination of Service.
3.Forfeiture. Except as set forth in Section 2(b)(ii) above, all unvested RSUs and Dividend Equivalents (whether or not earned) will be forfeited automatically and without consideration immediately upon a termination of the Participant’s Service for any reason. All shares of Common Stock received in respect of the RSUs and any Dividend Equivalents (and resulting proceeds thereof) are and will continue to be subject to Section 13 of the Plan, regardless of whether a termination of the Participant’s Service has occurred.
4.Adjustments. In the event of any change with respect to the outstanding shares of Common Stock contemplated by Section 4.5 of the Plan, this Award may be adjusted in accordance with Section 4.5 of the Plan.
5.Delivery of Shares and Dividend Equivalents. The Company will, as soon as practicable following the vesting of any RSUs subject to this Award (but in no event later than thirty (30) days following the date on which such RSUs vest), effect delivery of shares of Common Stock with respect to such vested RSUs (and any Dividend Equivalents credited with respect to such RSUs payable in Common Stock or, with respect to Dividend Equivalents credited with respect to such RSUs payable in cash, make a cash payment in respect thereof) to the Participant (or, in the event of the Participant’s death, to the person described in Section 15.3 of the Plan).
6.Tax Withholding. As a condition to the grant, vesting and settlement of the RSUs and any Dividend Equivalents, the Participant will make such arrangements as the Committee may require for the satisfaction of any federal, state, local or foreign withholding tax obligations that may arise in connection with the RSUs and any Dividend Equivalents, which arrangements may include entering into a 10b5-1 trading plan to implement any sell-to-cover arrangements intended to satisfy those tax withholding obligations. Unless the Participant otherwise elects to satisfy his or her tax withholding obligations in cash by notifying the Company in writing at least ninety (90) days prior to the applicable vesting date, the Company will automatically satisfy those tax withholding obligations:
(a)with respect to the RSUs and any Dividend Equivalents payable in shares of Common Stock, by either (i) withholding from the shares of Common Stock otherwise deliverable in connection with that vesting date, a number of shares of Common Stock having a Fair Market Value equal to the minimum statutory amount required to be withheld to satisfy such those withholding obligations (or any higher amount properly and timely specified by the Participant) and/or (ii) causing that number of shares of Common Stock to be sold in accordance with a sell-to-cover arrangement; and
(b)with respect to any Dividend Equivalents payable in cash, by withholding an amount in cash from such Dividend Equivalents equal to the minimum statutory amount required to be withheld to satisfy such tax withholding obligations (or any higher amount properly and timely specified by the Participant).
Page 2 of 5



Exhibit 10.2
7.Shareholder Rights. The Participant will not have any rights of a stockholder with respect to the RSUs unless and until shares of Common Stock are actually delivered in respect of the RSUs; provided that the Participant will be entitled to receive Dividend Equivalents with respect to unvested RSUs in accordance with this Section 7. In connection with (x) any regular dividend declared on shares of Common Stock that is payable in cash or (y) any regular dividend declared on shares of Common Stock that is payable in shares of Common Stock, for each share of Common Stock deliverable in respect of an unvested RSU, the Participant will receive a dividend equivalent (a “Dividend Equivalent”). Any such Dividend Equivalents will entitle the Participant to receive, subject to the terms of this Agreement, a payment of cash or issuance of shares of Common Stock equal to the amount or number of shares that the Participant would have received as a regular dividend had the Participant held the shares of Common Stock deliverable in respect of such unvested RSUs at the time such dividend was paid. Any Dividend Equivalents will be subject to the same vesting and other terms and conditions as the unvested RSUs to which they relate and will be paid, if at all, in cash, in the case of a cash dividend or Common Stock in the case of a distribution of shares of Common Stock, in either case, in accordance with Section 5 of this Agreement.
8.Miscellaneous Provisions
(a)Non-transferability. Any shares of Common Stock delivered hereunder will be subject to such stop transfer orders and other restrictions as the Committee may deem advisable under the Plan or the rules, regulations and other requirements of the Securities and Exchange Commission, any stock exchange upon which such shares are listed, any applicable federal or state laws, and any agreement with, or policy of, the Company or the Committee to which the Participant is a party or subject, and the Committee may cause orders or designations to be placed upon any certificate(s) or other document(s) delivered to the Participant, or on the books and records of the Company’s transfer agent, to make appropriate reference to such restrictions.
(b)No Right to Continued Service. Nothing in this Agreement or the Plan confers upon the Participant any right to continue in Service for any period of specific duration or interferes with or otherwise restricts in any way the rights of the Company (or any Subsidiary employing or retaining the Participant) or of the Participant, which rights are hereby expressly reserved by each, to terminate his or her Service at any time and for any reason, with or without Cause.
(c)Entire Agreement. This Agreement and the Plan constitute the entire agreement between the parties hereto with regard to the subject matter of this Agreement. This Agreement and the Plan supersede any other agreements, representations or understandings (whether oral or written and whether express or implied) that relate to the subject matter of this Agreement (including any letter or other notice notifying the Participant of this Award).
(d)Waiver. No waiver of any breach or condition of this Agreement will be deemed to be a waiver of any other or subsequent breach or condition whether of like or different nature.
(e)Successors and Assigns. The provisions of this Agreement will inure to the benefit of, and be binding upon, the Company and its successors and assigns and upon the Participant, the Participant’s executor, personal representative(s), distributees, administrator, permitted transferees, assignees, beneficiaries, and legatee(s), as applicable, whether or not any such person will have become a party
Page 3 of 5



Exhibit 10.2
to this Agreement and have agreed in writing to be joined herein and be bound by the terms hereof.
(f)Severability. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, then the remaining provisions will nevertheless be binding and enforceable.
(g)Amendment. Except as otherwise provided in the Plan, this Agreement will not be amended unless the amendment is agreed to in writing by both the Participant and the Company.
(h)Choice of Law; Jurisdiction. This Agreement and all claims, causes of action or proceedings (whether in contract, in tort, at law or otherwise) that may be based upon, arise out of or relate to this Agreement will be governed by the internal laws of the State of Delaware, excluding any conflicts or choice-of-law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The Participant (or his or her beneficiary, legatee, executor, personal representative or distribute, as applicable) and the Company agree that he, she or it will bring all claims, causes of action and proceedings (whether in contract, in tort, at law or otherwise) that may be based upon, arise out of or be related to the Plan or this Agreement, exclusively in the Delaware Court of Chancery or, in the event (but only in the event) that such court does not have subject matter jurisdiction over such claim, cause of action or proceeding, exclusively in the United States District Court for the District of Delaware (either of the foregoing, the “Chosen Court”), and hereby (i) irrevocably submit to the exclusive jurisdiction of the Chosen Court, (ii) waive any objection to laying venue in any such proceeding in the Chosen Court, (iii) waive any objection that the Chosen Court is an inconvenient forum or does not have jurisdiction over any party and (iv) agree that service of process upon such party in any such claim or cause of action will be effective if notice is given in accordance with this Agreement. 
(i)Signature in Counterparts. This Agreement may be signed in counterparts, manually or electronically, and each of which will be an original, with the same effect as if the signatures to each were upon the same instrument.
(j)Acceptance. The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and understands the terms and provisions of the Plan and this Agreement, and accepts this Award subject to all of the terms and conditions of the Plan and this Agreement. In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan, the applicable term and provision of the Plan will govern and prevail.

Page 4 of 5



Exhibit 10.2
    IN WITNESS WHEREOF, the Company and the Participant have executed this Agreement as of the Date of Grant.

Lantheus Holdings, Inc.



By:________________________________
        
      
_________________________

Participant


Page 5 of 5


EX-10.3 4 lnth10q-033122ex103.htm EX-10.3 Document
Exhibit 10.3

Lantheus Holdings, Inc. 2015 Equity Incentive Plan

Restricted Stock Unit Award Agreement
(Relative Total Shareholder Return Performance-Based Vesting)




This Restricted Stock Unit Award Agreement including Exhibits A and B hereto (this “Agreement”) is made by and between Lantheus Holdings, Inc., a Delaware corporation (the “Company”), and [] (the “Participant”), effective as of [] (the “Date of Grant”).

RECITALS

WHEREAS, the Company has adopted the Lantheus Holdings, Inc. 2015 Equity Incentive Plan (as the same may be amended and/or amended and restated from time to time, the “Plan”), which Plan is incorporated herein by reference and made a part of this Agreement, and capitalized terms not otherwise defined in this Agreement will have the meanings ascribed to those terms in the Plan; and

WHEREAS, the Committee has authorized and approved the grant of an Award to the Participant of Restricted Stock Units, subject to the terms and conditions set forth in the Plan and this Agreement.

NOW THEREFORE, in consideration of the premises and the mutual covenants set forth in this Agreement, the parties agree as follows:

1.Grant of Performance-Based RSUs. The Company has granted to the Participant, effective as of the Date of Grant, performance-based Restricted Stock Units (the “RSUs”), giving the Participant the conditional right to receive, on the terms and conditions set forth in the Plan and this Agreement, one share of Common Stock with respect to each RSU subject to this Award. Subject to adjustment as set forth in the Plan, the target number of RSUs subject to this Award is [] (“Target RSUs”) and the maximum number of RSUs subject to this Award is 200% of the Target RSUs.

2.Vesting of RSUs.

(a)General.    Subject to the terms and conditions set forth in the Plan and this Agreement, all or a portion of the RSUs subject to this Award will vest, if at all, on the third (3rd) anniversary of the Date of Grant (the “Cliff Vesting Date”), to the extent earned based on the achievement of the performance criteria set forth on Exhibit A (the “Performance Criteria”), and, except as otherwise provided in Section 2(b) or Section 2(c) below, subject to the Participant’s continued Service through the Cliff Vesting Date. The number of RSUs that are earned based on the achievement of the Performance Criteria and are eligible to vest hereunder are referred to in this Agreement as the “Earned RSUs.
1


Exhibit 10.3

(b)Qualified Retirement. Notwithstanding Section 2(a) and Section 3 of the Agreement, in the case of a Participant whose Service terminates due to a Qualified Retirement (as defined below) (a “Qualified Retiree”), the Participant’s RSUs and Dividend Equivalents (as defined below) will continue to vest (subject to pro-ration as provided in Exhibit A (Determinations)), except as specifically provided in Section 2(c), until the earlier of (a) the Cliff Vesting Date and (b) the date on which the Participant violates any restrictive covenant or other continuing obligation to the Company on or after the Participant’s Qualified Retirement Date (as defined below) (the “Qualified Retirement Vesting Period”). Upon the expiration of the Qualified Retirement Vesting Period, any unvested RSUs or Dividend Equivalents will be immediately and automatically forfeited without consideration in the manner contemplated in Section 3. As used herein, “Qualified Retirement” means that, as of the date Participant ceases to provide Services to the Company due to voluntary retirement (and not a termination by the Company with or without Cause) (the “Qualified Retirement Date”), (i) Participant is at least fifty-five (55) years of age and (ii) Participant has provided Services to the Company or any Subsidiary for at least ten (10) years.

(c)Change in Control. In the event of a Change in Control, subject to the Participant’s continued Service through the date of a Change in Control (except as otherwise provided in this Sections 2(b)(ii), (iv), (v) and (vii)):

(i)Except in the case of a Qualified Retiree, if, prior to the Performance Period End Date (as defined in Exhibit A), a Change in Control occurs, to the extent the RSUs have not been forfeited under Section 3 below prior to that Change in Control, then the Committee will determine the extent to which the Performance Criteria has been achieved as of the date of that Change in Control as if the Performance Period End Date were the date of that Change in Control and will determine the number of Earned RSUs, if any.

(ii)In the case of a Qualified Retiree, in the event of a Change in Control during the Qualified Retirement Vesting Period but prior to the Performance Period End Date (as defined in Exhibit A), to the extent RSUs have not been forfeited under Section 3 below prior to the Change in Control, then the Committee will determine the extent to which the Performance Criteria for such RSUs has been achieved as of the date of that Change in Control as if the Performance Period End Date were the date of that Change in Control and will determine the number of Earned RSUs, if any, subject to the pro-ration provided in Exhibit A (Determinations).

(iii)Except in the case of a Qualified Retiree or as otherwise provided in Sections 2(b)(iv) through 2(b)(viii), the number of Earned RSUs, if any, will continue to vest based solely on time and will vest in full on the Cliff Vesting Date, subject to the Participant’s continued Service through the Cliff Vesting Date.

(iv)Except in the case of a Qualified Retiree, if, (A) in connection with a Change in Control described in subsection (i) above, the Earned RSUs are assumed or continued, or a new award is substituted for the Earned RSUs by the surviving company or its parent in accordance with the provisions of Section 12 of the Plan, (B) the Participant remains in continued Service through the date of that Change in Control and, (C) within the twelve (12) month period following the date of that Change in Control and prior to the
2


Exhibit 10.3

Cliff Vesting Date, the Participant’s Service is terminated by the Company without Cause or, if the Participant is party to an effective employment letter or agreement with the Company or any Subsidiary that defines “Good Reason” (or any similar term), by the Participant for Good Reason, then the Earned RSUs (or the new award substituted for the Earned RSUs) will vest in full upon such termination of Service.

(v)In the case of a Qualified Retiree, if, (A) in connection with a Change in Control described in subsection (ii) above, the Earned RSUs are assumed or continued, or a new award is substituted for the Earned RSUs by the surviving company or its parent in accordance with the provisions of Section 12 of the Plan, then the Earned RSUs (or the new award substituted for the Earned RSUs will continue to vest through the Cliff Vesting Date, subject to pro-ration as provided in Exhibit A (Determinations).

(vi)Except in the case of a Qualified Retiree, if, in connection with a Change in Control described in subsection (i) above, the Earned RSUs are not assumed or continued, or a new award is not substituted for the Earned RSUs by the surviving company or its parent in accordance with the provisions of Section 12 of the Plan, then the Earned RSUs will vest in full as of immediately prior to the Change in Control.

(vii)In the case of a Qualified Retiree, if, in connection with a Change in Control described in subsection (ii) above, the Earned RSUs are not assumed or continued, or a new award is not substituted for the Earned RSUs by the surviving company or its parent in accordance with the provisions of Section 12 of the Plan, then the Earned RSUs will vest in full as of immediately prior to the Change in Control, subject to pro-ration as provided in Exhibit A (Determinations).

(viii)If a Change in Control occurs following the Performance Period End Date but on or before the Cliff Vesting Date, then the Earned RSUs, to the extent they have not been forfeited under Section 3 below as of immediately prior to the Change in Control, will vest in full as of immediately prior to such Change in Control, subject, in the case RSUs earned by a Qualified Retiree, to pro-ration as provided in Exhibit A (Determinations).

3.Forfeiture. Except as set forth in Section 2(b) and Section 2(c) above, all unvested RSUs and Dividend Equivalents (whether or not earned) will be forfeited, automatically and without consideration immediately upon (a) termination of the Participant’s Service for any reason other than a Qualified Retirement prior to the Cliff Vesting Date and, (b) in the case of a Qualified Retiree, expiration of the Qualified Retirement Vesting Period prior to the Cliff Vesting Date. All shares of Common Stock received in respect of the RSUs and any Dividend Equivalents (and resulting proceeds thereof) are and will continue to be subject to Section 13 of the Plan, regardless of whether a termination of the Participant’s Service has occurred.

4.Adjustments. In the event of any change with respect to the outstanding shares of Common Stock contemplated by Section 4.5 of the Plan, this Award may be adjusted in accordance with Section 4.5 of the Plan.

5.Delivery of Shares and Dividend Equivalents. The Company will, as soon as practicable following the vesting of any RSUs subject to this Award (but in no event later than thirty
3


Exhibit 10.3

(30) days following the date on which such RSUs vest), effect delivery of shares of Common Stock with respect to such vested RSUs (and any Dividend Equivalents credited with respect to such RSUs payable in Common Stock or, with respect to Dividend Equivalents credited with respect to such RSUs payable in cash, make a cash payment in respect thereof) to the Participant (or, in the event of the Participant’s death, to the person described in Section 15.3 of the Plan).

6.Tax Withholding. As a condition to the grant, vesting and settlement of the RSUs and any Dividend Equivalents, the Participant will make such arrangements as the Committee may require for the satisfaction of any federal, state, local or foreign withholding tax obligations that may arise in connection with the RSUs and any Dividend Equivalents, which arrangements may include entering into a 10b5-1 trading plan to implement any sell-to-cover arrangements intended to satisfy those tax withholding obligations. Unless the Participant otherwise elects to satisfy his or her tax withholding obligations in cash by notifying the Company in writing at least ninety (90) days prior to the applicable vesting date, the Company will automatically satisfy those tax withholding obligations:

(a)with respect to the RSUs and any Dividend Equivalents payable in shares of Common Stock, by either (i) withholding from the shares of Common Stock otherwise deliverable in connection with that vesting date, a number of shares of Common Stock having a Fair Market Value equal to the minimum statutory amount required to be withheld to satisfy such those withholding obligations (or any higher amount properly and timely specified by the Participant) and/or (ii) causing that number of shares of Common Stock to be sold in accordance with a sell-to-cover arrangement; and

(b)with respect to any Dividend Equivalents payable in cash, by withholding an amount in cash from such Dividend Equivalents equal to the minimum statutory amount required to be withheld to satisfy such tax withholding obligations (or any higher amount properly and timely specified by the Participant).

7.Shareholder Rights. The Participant will not have any rights of a stockholder with respect to the RSUs unless and until shares of Common Stock are actually delivered in respect of the RSUs; provided that the Participant will be entitled to receive Dividend Equivalents with respect to unvested RSUs in accordance with this Section 7. In connection with (x) any regular dividend declared on shares of Common Stock that is payable in cash or (y) any regular dividend declared on shares of Common Stock that is payable in shares of Common Stock, for each share of Common Stock deliverable in respect of an unvested RSU, the Participant will receive a dividend equivalent (a “Dividend Equivalent”). Any such Dividend Equivalents will
entitle the Participant to receive, subject to the terms of this Agreement, a payment of cash or issuance of shares of Common Stock equal to the amount or number of shares that the Participant would have received as a regular dividend had the Participant held the shares of Common Stock deliverable in respect of such unvested RSUs at the time such dividend was paid. Any Dividend Equivalents will be subject to the same vesting and other terms and conditions as the unvested RSUs to which they relate and will be paid, if at all, in cash, in the case of a cash dividend or Common Stock in the case of a distribution of shares of Common Stock, in either case, in accordance with Section 5 of this Agreement.

8.Miscellaneous Provisions

(a)Non-transferability. Any shares of Common Stock delivered hereunder will be subject to such stop transfer orders and other restrictions as the Committee may deem advisable under the Plan or the rules, regulations and other requirements of
4


Exhibit 10.3

the Securities and Exchange Commission, any stock exchange upon which such shares are listed, any applicable federal or state laws, and any agreement with, or policy of, the Company or the Committee to which the Participant is a party or subject, and the Committee may cause orders or designations to be placed upon any certificate(s) or other document(s) delivered to the Participant, or on the books and records of the Company’s transfer agent, to make appropriate reference to such restrictions.

(b)No Right to Continued Service. Nothing in this Agreement or the Plan confers upon the Participant any right to continue in Service for any period of specific duration or interferes with or otherwise restricts in any way the rights of the Company (or any Subsidiary employing or retaining the Participant) or of the Participant, which rights are hereby expressly reserved by each, to terminate his or her Service at any time and for any reason, with or without Cause.

(c)Entire Agreement. This Agreement and the Plan constitute the entire agreement between the parties hereto with regard to the subject matter of this Agreement. This Agreement and the Plan supersede any other agreements, representations or understandings (whether oral or written and whether express or implied) that relate to the subject matter of this Agreement (including any letter or other notice notifying the Participant of this Award).

(d)Waiver. No waiver of any breach or condition of this Agreement will be deemed to be a waiver of any other or subsequent breach or condition whether of like or different nature.

(e)Successors and Assigns. The provisions of this Agreement will inure to the benefit of, and be binding upon, the Company and its successors and assigns and upon the Participant, the Participant’s executor, personal representative(s), distributees, administrator, permitted transferees, assignees, beneficiaries, and legatee(s), as applicable, whether or not any such person will have become a party to this Agreement and have agreed in writing to be joined herein and be bound by the terms hereof.

(f)Severability. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, then the remaining provisions will nevertheless be binding and enforceable.

(g)Amendment. Except as otherwise provided in the Plan, this Agreement will not be amended unless the amendment is agreed to in writing by both the Participant and the Company.

(h)Choice of Law; Jurisdiction. This Agreement and all claims, causes of action or proceedings (whether in contract, in tort, at law or otherwise) that may be based upon, arise out of or relate to this Agreement will be governed by the internal laws of the State of Delaware, excluding any conflicts or choice-of-law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The Participant (or his or her beneficiary, legatee, executor, personal representative or distribute, as applicable) and the Company agree that he, she or it will bring all claims, causes of action and proceedings (whether in contract, in tort, at law or otherwise) that may be based upon, arise out of or be related to the Plan or this Agreement, exclusively in the Delaware Court of Chancery or, in the event (but only in the event) that such court does not have subject matter jurisdiction over such claim, cause of action or proceeding, exclusively in the United States District Court for
5


Exhibit 10.3

the District of Delaware (either of the foregoing, the “Chosen Court”), and hereby (i) irrevocably submit to the exclusive jurisdiction of the Chosen Court, (ii) waive any objection to laying venue in any such proceeding in the Chosen Court, (iii) waive any objection that the Chosen Court is an inconvenient forum or does not have jurisdiction over any party and (iv) agree that service of process upon such party in any such claim or cause of action will be effective if notice is given in accordance with this Agreement.

(i)Signature in Counterparts. This Agreement may be signed in counterparts, manually or electronically, and each of which will be an original, with the same effect as if the signatures to each were upon the same instrument.

(j)Acceptance. The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and understands the terms and provisions of the Plan and this Agreement, and accepts this Award subject to all of the terms and conditions of the Plan and this Agreement. In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan, the applicable term and provision of the Plan will govern and prevail.



[Signature Page Follows.]

6


Exhibit 10.3

IN WITNESS WHEREOF, the Company and the Participant have executed this Agreement as of the Date of Grant.




Lantheus Holdings, Inc.
                     By:


image_0a.jpgParticipant

7


Exhibit 10.3

EXHIBIT A



This Exhibit A describes the terms and conditions upon which the RSUs will become earned and eligible to vest as set forth in Section 2 of the Restricted Stock Unit Award Agreement of which this Exhibit A is a part (the “Agreement”). All capitalized terms used in this Exhibit A, unless separately defined, have the meanings set forth in the Agreement.

1.General. The RSUs will be eligible to be earned under the Agreement subject to the terms and conditions of Section 3 of this Exhibit A based on the Total Shareholder Return of the Company as compared to the Total Shareholder Return of the Specified Companies (as measured by rTSR Percentile Rank). Total Shareholder Return (as measured by rTSR Percentile Rank) will be the Performance Criteria under the Award.

2.Definitions. The terms set forth below, as used in this Exhibit A, will have the following meanings:

(a)Performance Period” will mean the period beginning on the Performance Period Start Date and ending on (i) the Performance Period End Date, or, if earlier, (ii) the date on which a Change in Control is consummated.

(b)Performance Period End Date” will mean December 31, 2024 (or, if earlier, the date on which a Change in Control is consummated).

(c)Performance Period Start Date” will mean January 1, 2022.

(d)rTSR Percentile Rank” will mean the percentage of Total Shareholder Return values among the Specified Companies at the Performance Period End Date (or, if earlier, the date of a Change in Control) that are equal to or lower than the Company’s Total Shareholder Return at the Performance Period End Date (or, if earlier, the date of a Change in Control), expressed as a percentage and calculated as follows:

rTSR Percentile Rank = ((N – R) / (N – 1)) * 100 where:
N” is the aggregate number of Specified Companies plus one (1); and

R” is the number of Specified Companies with a Total Shareholder Return that is higher than the Company’s Total Shareholder Return at the Performance Period End Date (or, if earlier, the date of a Change in Control) plus one (1).

(e)Specified Companies” will mean each of the companies included in the S&P SmallCap 600 Health Care of the Performance Period Start Date, excluding the Company itself. If a company in such index ceases to be publicly traded during the Performance Period, or if it publicly announced
A-1

Exhibit 10.3

that any such company will be acquired, whether or not such acquisition occurs during the Performance Period, such company will not be treated as a Specified Company for purposes of the determinations herein and such company’s Total Shareholder Return will not be included for purposes of the calculations herein.

(f)Total Shareholder Return” will mean, with respect to any company, the change in value expressed as a percentage of a given dollar amount invested in a company’s most widely publicly traded stock over the Performance Period, taking into account both stock price appreciation (or depreciation) and the reinvestment of dividends (including the cash value of non-cash dividends) in such stock of the company. The thirty (30) trading-day average closing price of shares of Common Stock and of the most widely publicly traded stock of the Specified Companies, as applicable,
(i)beginning on and including the Performance Period Start Date, and (ii) except as set forth in the proviso below, ending on and including the Performance Period End Date, will be used to value shares of Common Stock and such stock of the Specified Companies, as applicable; provided that, in the event that a Change in Control is consummated during the Performance Period, the fair value of the actual consideration received by holders of Common Stock in that Change in Control (as determined by the Committee in its sole discretion) will be used in calculating the Company’s Total Shareholder Return in lieu of the thirty (30) trading-day average closing price described in clause (ii) above. Dividend reinvestment will be calculated using the closing price of a share of Common Stock or the stock of the applicable Specified Company, as applicable, on the ex-dividend date or, if no trades were reported on such date, the latest preceding date for which a trade was reported.

3.Earning of RSUs. No RSUs will become earned unless the rTSR Percentile Rank is at or above the 25th percentile. If the rTSR Percentile Rank is at or above the 25th percentile, the aggregate number of RSUs that will become earned will be equal to the Target RSUs, multiplied by the “Applicable Percentage” set forth in the table below. In the event that rTSR Percentile Rank falls between two of the percentiles listed in the table below, the Applicable Percentage will be interpolated on a straight-line basis and the number of RSUs earned will be based on such interpolated percentage.


rTSR Percentile Rank

Applicable Percentage of Target RSUs

≥ 75th Percentile

200%

50th Percentile

100%

≥ 25th Percentile

50%


4.Determinations. At the end of the Performance Period, the Committee will determine the extent to which, if any, the Performance Criteria has been achieved and the number of


A-2

Exhibit 10.3

RSUs that become Earned RSUs; provided, however, in the event of a Qualified Retirement, the Earned RSUs will be pro-rated by multiplying the Earned RSUs by an amount equal to the number of days Participant renders Services to the Company during the Performance Period, divided by the total number of days in the Performance Period. For clarity, in the case of a Change in Control under Section 2(c), when calculating pro-ration with respect to a Qualified Retiree, the Change in Control Date shall be deemed the end of the Performance Period.

Any RSUs that do not become Earned RSUs (after determination and pro-ration) hereunder, and any related Dividend Equivalents, will be automatically forfeited. No RSUs or any related Dividend Equivalents will be earned and/or vest until the Committee certifies the extent to which the Performance Criteria been achieved. The Committee will make such determination and certification not later than March 15th following the end of the Performance Period. Earned RSUs will vest as set forth in Section 2 of this Agreement. Any Earned RSUs will be rounded down to the nearest whole number of RSUs and any fractional Earned RSUs will be disregarded. All determinations under the Agreement, including this Exhibit A, will be made by the Committee and will be final and binding on the Participant.












    
A-3
EX-10.4 5 lnth10q-033122ex104.htm EX-10.4 Document
Exhibit 10.4

Lantheus Holdings, Inc.
2015 Equity Incentive Plan
Stock Option Award Agreement
(Time Vesting)

This Stock Option Award Agreement (this “Agreement”) is made by and between Lantheus Holdings, Inc., a Delaware corporation (the “Company”), and [] (the “Participant”), effective as of [] (the “Date of Grant”).
RECITALS
WHEREAS, the Company has adopted the Lantheus Holdings, Inc. 2015 Equity Incentive Plan (as the same may be amended and/or amended and restated from time to time, the “Plan”), which Plan is incorporated herein by reference and made a part of this Agreement, and capitalized terms not otherwise defined in this Agreement will have the meanings ascribed to those terms in the Plan; and
WHEREAS, the Committee has authorized and approved the grant of an Award to the Participant of a Stock Option to purchase shares of Common Stock (“Shares”), subject to the terms and conditions set forth in the Plan and this Agreement.
NOW THEREFORE, in consideration of the premises and mutual covenants set forth in this Agreement, the parties agree as follows:
1.Grant of Stock Option Award. The Company has granted to the Participant, effective as of the Date of Grant, the right and option to purchase, on the terms and conditions set forth in the Plan and this Agreement, all or any part of an aggregate of [] Shares, subject to adjustment as set forth in the Plan (the “Option”). The Option is intended to be a Nonqualified Stock Option.
2.Exercise Price. The exercise price of the Option is [] per Share, subject to adjustment as set forth in the Plan (the “Exercise Price”).
3.Vesting of Option. Subject to the terms and conditions set forth in the Plan and this Agreement, the Option will vest as follows:
(a)General. Except as otherwise provided in Sections 3(b) and 4, the Option will vest on each of the first three (3) anniversaries of the Date of Grant, subject to the Participant’s continued Service through each applicable vesting date, except as set forth in Section 3(b) below, with the number of Shares that vest on the first two vesting dates rounded down to the nearest whole Share and with 100% of the remaining Shares becoming vested on the third (3rd) anniversary of the Date of Grant.
(b)Change in Control. Subject to the Participant’s continued Service through the date of a Change in Control:

(i)if the consideration paid in connection with that Change in Control for the same class of the Company’s equity securities underlying the then-outstanding portion of the Option is all cash, then the Option will become
1
LNQ22SVP


fully vested immediately prior the consummation of that Change in Control;
(ii)if (x) the consideration paid in connection with that Change in Control for the same class of the Company’s equity securities underlying the then outstanding portion of the Option is all equity securities, or part cash and part equity securities, (y) the then-outstanding portion of the Option is assumed or substituted by the acquirer in that Change in Control for awards with substantially the same or comparable terms (including with respect to the then-current economic value) and (z) the Participant’s Service is terminated (1) without Cause or, (2) to the extent the Participant is party to an employment letter or agreement with the Company or any of its Subsidiaries that defines “Good Reason” (or any similar term), by the Participant for Good Reason, then within twelve (12) months following that Change in Control, the unvested portion of the Option will become fully vested upon that termination of Service.
(iii)For clarity, in the case of a Qualified Retiree (as defined below), no additional vesting shall occur in the case of a Change in Control.
4.Forfeiture; Expiration.
(a)Termination of Service. Except as set forth in Section 3(b)(ii) above, any unvested portion of the Option will be forfeited immediately, automatically and without consideration upon termination of the Participant’s Service for any reason. Without limiting the generality of the foregoing, the Option and the Shares (and any resulting proceeds) will continue to be subject to Section 13 of the Plan.

(b)Expiration. Any unexercised portion of the Option will expire on the tenth (10th) anniversary of the Date of Grant (the “Expiration Date”), or earlier as provided in this Agreement or the Plan.
5.Period of Exercise. Subject to the provisions of the Plan and this Agreement, the Participant may exercise all or any part of the vested portion of the Option at any time prior to the earliest to occur of:
(a)the first trading day on or after the Expiration Date;
(b)the first trading day on or after the date that is one (1) year following termination of the Participant’s Service due to death or Disability;
(c)the first trading day on or after the date that is sixty (60) days following termination of the Participant’s Service without Cause or, to the extent applicable, for Good Reason (except as provided in Section 5(e) as relates to Qualified Retirement (as defined below));
(d)the first trading day on or after the date of termination of the Participant’s Service for Cause;
(e)notwithstanding Section 5(c) of the Agreement, for a Participant whose Service terminates due to a Qualified Retirement (a “Qualified Retiree”), with respect to any options of Participant that vested pursuant to Section 3(a) prior to the Qualified Retirement Date (as defined below) (the “Vested Options”), the last
2




trading day of the earliest to occur of (i) the third anniversary of the Qualified Retirement Date; (ii) the date on which the Participant violates any restrictive covenant or other continuing obligation to the Company on or after such Qualified Retirement Date; and (iii) the Expiration Date (the “Qualified Retirement Exercise Period”); provided that, upon the expiration of the Qualified Retirement Exercise Period, all Options will be immediately and automatically forfeited without consideration in the manner contemplated in Section 4; or

(f)the first trading day on or after the date that is forty-five (45) days following the termination of the Participant’s Service for any reason other than pursuant to Sections 5(b), 5(c), 5(d) or 5(e) above.

As used herein, “Qualified Retirement” means that, as of the date Participant ceases to provide Services to the Company due to a voluntary retirement (and not a termination by the Company with or without Cause) (the “Qualified Retirement Date”), (i) Participant is at least fifty-five (55) years of age and (ii) Participant has provided Services to the Company or any Subsidiary for at least ten (10) years.

For clarity, in the event any date specified above is not on a trading day, then the date provided above shall be the first trading day following such date specified above.

6.Exercise of Option
(a)Exercise Process. Subject to Section 4 and 5, the Participant or, in the case of the Participant’s death or Disability, the Participant’s representative may exercise all or any part of the vested portion of the Option by following such procedures as are required by the Company’s equity administrator. In the event that the Option is being exercised by the Participant’s representative, the Participant’s representative will provide proof (satisfactory to the Committee) of the representative’s right to exercise the Option. The Participant or the Participant’s representative will deliver to the Committee, at the time of requesting to exercise such Options, payment in a form permissible under Section 7 for the full amount of the Purchase Price and applicable withholding taxes as provided below.
(b)Issuance of Common Stock. After satisfying all requirements with respect to the exercise of the Option, the Committee will cause to be issued the Shares as to which the Option has been exercised (or, in the Committee’s discretion, in un-certificated form, upon the books of the Company’s transfer agent), registered in the name of the person exercising the Option (or in the names of such person and his or her spouse as community property or as joint tenants with right of survivorship). Neither the Company nor the Committee will be liable to the Participant or any other Person for damages relating to any delays in issuing the Shares or any mistakes or errors in the issuance of the Shares.
(c)Withholding Requirements. The Company will have the power and the right to deduct or withhold automatically from any Shares deliverable under this Agreement, or to require the Participant or the Participant’s representative to remit to the Company, the minimum statutory amount necessary to satisfy federal, state and local taxes, domestic or foreign, required by law or regulation to be withheld with respect to any taxable event arising as a result of this Agreement (collectively, “Withheld Taxes”); provided that any obligations to pay Withheld Taxes may be satisfied in the manner in which the Purchase Price is permitted to be paid under Section 7 or any other manner permitted by the Plan.
3




7.Payment for Shares. The “Purchase Price” will be the Exercise Price multiplied by the number of Shares with respect to which the Option is being exercised. All or part of the Purchase Price and any Withheld Taxes may be paid as follows:
(a)Cash or Check. In cash or by bank certified check.
(b)Brokered Cashless Exercise. To the extent permitted by applicable law and unless otherwise provided by the Committee, from the proceeds of a sale through a broker on the date of exercise of some or all of the Shares to which the exercise relates. In that case, the Participant will follow all such procedures as required by the Company’s equity administrator including, without limitation, providing a copy of irrevocable instructions to a broker to deliver promptly to the Company the amount of sale proceeds to pay the aggregate purchase price or Withheld Taxes, as applicable. To facilitate the foregoing, the Company may, to the extent permitted by applicable law, enter into agreements or coordinate procedures with one or more brokerage firms.
(c)Net Exercise. By reducing the number of Shares otherwise deliverable upon the exercise of the Option by the number of Shares having a Fair Market Value equal to the amount of the Purchase Price and/or Withheld Taxes, as applicable.
(d)Surrender of Stock. In each instance, at the sole discretion of the Committee, by surrendering, or attesting to the ownership of, Shares that are already owned by the Participant free and clear of any restriction or limitation, unless the Committee specifically agrees to accept such Shares subject to such restriction or limitation. Such Shares will be surrendered to the Company in good form for transfer and will be valued by the Company at their Fair Market Value on the date of the applicable exercise of the Option, or to the extent applicable, on the date the Withheld Taxes is to be determined. The Participant will not surrender, or attest to the ownership of, Shares in payment of the Purchase Price (or Withheld Taxes) if such action would cause the Company to recognize compensation expense (or additional compensation expense) with respect to this Option for financial reporting purposes that otherwise would not have occurred.
8.Adjustment to Option. In the event of any change with respect to the outstanding shares of Common Stock contemplated by Section 4.5 of the Plan, the Option may be adjusted in accordance with Section 4.5 of the Plan.
9.Miscellaneous Provisions
(a)Securities Laws Requirements. No Shares will be issued or transferred pursuant to this Agreement unless and until all then applicable requirements imposed by Federal and state securities and other laws, rules and regulations and by any regulatory agencies having jurisdiction, and by any exchanges upon which the Shares may be listed, have been fully met. As a condition precedent to the issuance of Shares pursuant to this Agreement, the Company may require the Participant to take any reasonable action to meet those requirements. The Committee may impose such conditions on any Shares issuable pursuant to this Agreement as it may deem advisable, including, without limitation, restrictions under the Securities Act of 1933, as amended, under the requirements of any exchange upon which shares of the same class are then listed and under any blue sky or other securities laws applicable to those Shares.
4




(b)Rights of a Shareholder of the Company. Neither the Participant nor the Participant’s representative will have any rights as a shareholder of the Company with respect to any Shares subject to the Option until the Participant or the Participant’s representative becomes entitled to receive those Shares by (i) following all such procedures as required by the Company’s equity administrator, (ii) paying the Purchase Price and Withheld Taxes as provided in this Agreement, and the Company actually receiving those amounts, (iii) the Company issuing those Shares and entering the name of the Participant in the register of shareholders of the Company as the registered holder of those Shares and (iv) satisfying any other conditions as the Committee reasonably requires.
(c)Transfer Restrictions. The Shares purchased by exercise of the Option will be subject to such stop transfer orders and other restrictions as the Committee may deem advisable under the Plan or the rules, regulations and other requirements of the Securities and Exchange Commission, any stock exchange upon which such shares are listed, and any applicable Federal or state laws, and any agreement with, or policy of, the Company or the Committee to which the Participant is a party or subject, and the Committee may cause orders or designations to be placed upon any certificate(s) or other document(s) delivered to the Participant, or on the books and records of the Company’s transfer agent to make appropriate reference to such restrictions.
(d)No Right to Continued Service. Nothing in this Agreement or the Plan confers upon the Participant any right to continue in Service for any period of specific duration or interferes with or otherwise restricts in any way the rights of the Company (or any Subsidiary employing or retaining the Participant) or of the Participant, which rights are hereby expressly reserved by each, to terminate his or her Service at any time and for any reason, with or without Cause.
(e)Notification. Any notification required by the terms of this Agreement will be given by the Participant (i) in a writing addressed to the Company at its principal executive office and will be deemed effective upon actual receipt when delivered by personal delivery or by registered or certified mail, with postage and fees prepaid, or (ii) by electronic transmission to the Company’s e-mail address of the Company’s General Counsel and will be deemed effective upon actual receipt. Any notification required by the terms of this Agreement will be given by the Company (i) in a writing addressed to the address that the Participant most recently provided to the Company and will be deemed effective upon personal delivery or within three (3) days of deposit with the United States Postal Service, by registered or certified mail, with postage and fees prepaid, or (ii) by facsimile or electronic transmission to the Participant’s primary work fax number or e-mail address (as applicable) and will be deemed effective upon confirmation of receipt by the sender of such transmission.
(f)Entire Agreement. This Agreement and the Plan constitute the entire agreement between the parties hereto with regard to the subject matter of this Agreement. This Agreement and the Plan supersede any other agreements, representations or understandings (whether oral or written and whether express or implied) that relate to the subject matter of this Agreement.
(g)Waiver. No waiver of any breach or condition of this Agreement will be deemed to be a waiver of any other or subsequent breach or condition whether of like or different nature.
5




(h)Successors and Assigns. The provisions of this Agreement will inure to the benefit of, and be binding upon, the Company and its successors and assigns and upon the Participant, the Participant’s executor, personal representative(s), distributees, administrator, permitted transferees, assignees, beneficiaries, and legatee(s), as applicable, whether or not any such person will have become a party to this Agreement and have agreed in writing to be joined herein and be bound by the terms hereof.
(i)Severability. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, then the remaining provisions will nevertheless be binding and enforceable.
(j)Amendment. Except as otherwise provided in the Plan, this Agreement will not be amended unless the amendment is agreed to in writing by both the Participant and the Company.
(k)Choice of Law; Jurisdiction. This Agreement and all claims, causes of action or proceedings (whether in contract, in tort, at law or otherwise) that may be based upon, arise out of or relate to this Agreement will be governed by the internal laws of the State of Delaware, excluding any conflicts or choice-of-law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The Participant (or her or his beneficiary, legatee, executor, personal representative or distributee, as applicable) and each party to this Agreement agrees that it will bring all claims, causes of action and proceedings (whether in contract, in tort, at law or otherwise) that may be based upon, arise out of or be related to the Plan or this Agreement exclusively in the Delaware Court of Chancery or, in the event (but only in the event) that such court does not have subject matter jurisdiction over such claim, cause of action or proceeding, exclusively in the United States District Court for the District of Delaware (either of the foregoing, the “Chosen Court”), and hereby (i) irrevocably submits to the exclusive jurisdiction of the Chosen Court, (ii) waives any objection to laying venue in any such proceeding in the Chosen Court, (iii) waives any objection that the Chosen Court is an inconvenient forum or does not have jurisdiction over any party and (iv) agrees that service of process upon such party in any such claim or cause of action will be effective if notice is given in accordance with this Agreement. 
(l)Signature in Counterparts. This Agreement may be signed in counterparts, manually or electronically, and each of which will be an original, with the same effect as if the signatures to each were upon the same instrument.
(m)Acceptance. The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and understands the terms and provisions of the Plan and this Agreement, and accepts the Option subject to all of the terms and conditions of the Plan and this Agreement. In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan, the applicable term and provision of the Plan will govern and prevail.
[Signature page follows.]
6




    IN WITNESS WHEREOF, the Company and the Participant have executed this Stock Option Award Agreement as of the date first written above.

PARTICIPANT                    LANTHEUS HOLDINGS, INC.


_________________________________        By: ______________________________

7


EX-31.1 6 lnth10q-033122ex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mary Anne Heino, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Lantheus Holdings, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:  
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): 
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: April 29, 2022
 
/s/ MARY ANNE HEINO
Name: Mary Anne Heino
Title: President and Chief Executive Officer
 (Principal Executive Officer)


EX-31.2 7 lnth10q-033122ex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Robert J. Marshall, Jr., certify that: 
1.I have reviewed this Quarterly Report on Form 10-Q of Lantheus Holdings, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): 
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
 Date: April 29, 2022
 
/s/ ROBERT J. MARSHALL, JR.
Name: Robert J. Marshall, Jr.
Title: Chief Financial Officer and Treasurer
(Principal Financial Officer)


EX-32.1 8 lnth10q-033122ex321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Mary Anne Heino, the Chief Executive Officer, and Robert J. Marshall, Jr., the Chief Financial Officer, of Lantheus Holdings, Inc. (the “Company”), hereby certify, that, to their knowledge:
 
1.The Quarterly Report on Form 10-Q for the period ended March 31, 2022 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: April 29, 2022

/s/ MARY ANNE HEINO
Name: Mary Anne Heino
Title: President and Chief Executive Officer
 (Principal Executive Officer)
Date: April 29, 2022
 
/s/ ROBERT J. MARSHALL, JR.
Name: Robert J. Marshall, Jr.
Title: Chief Financial Officer and Treasurer
(Principal Financial Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


EX-101.SCH 9 lnth-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Changes In Stockholders' Equity (Statement) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2105103 - Disclosure - Revenue from Contracts with Customers link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Revenue from Contracts with Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Revenue from Contracts with Customers (Detail) link:presentationLink link:calculationLink link:definitionLink 2108104 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on A Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Fair Value of Financial Instruments - Quantitative Information and Assumptions Pertaining To The Fair Value Measurement of The Level 3 Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - Fair Value of Financial Instruments - Financial Instruments With Significant Level 3 Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 2114105 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2315303 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2416407 - Disclosure - Income Taxes (Detail) link:presentationLink link:calculationLink link:definitionLink 2117106 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 2318304 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 2419408 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 2120107 - Disclosure - Property, Plant and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 2321305 - Disclosure - Property, Plant and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2422409 - Disclosure - Property, Plant and Equipment, Net (Detail) link:presentationLink link:calculationLink link:definitionLink 2123108 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities link:presentationLink link:calculationLink link:definitionLink 2324306 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2425410 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2126109 - Disclosure - Sale of Puerto Rico Subsidiary link:presentationLink link:calculationLink link:definitionLink 2327307 - Disclosure - Sale of Puerto Rico Subsidiary (Tables) link:presentationLink link:calculationLink link:definitionLink 2428411 - Disclosure - Sale of Puerto Rico Subsidiary (Details) link:presentationLink link:calculationLink link:definitionLink 2129110 - Disclosure - Asset Retirement Obligations link:presentationLink link:calculationLink link:definitionLink 2330308 - Disclosure - Asset Retirement Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 2431412 - Disclosure - Asset Retirement Obligations - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2432413 - Disclosure - Asset Retirement Obligations - Asset Retirement Obligation (Detail) link:presentationLink link:calculationLink link:definitionLink 2133111 - Disclosure - Intangibles, Net link:presentationLink link:calculationLink link:definitionLink 2334309 - Disclosure - Intangibles, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2435414 - Disclosure - Intangibles, Net - Schedule of Intangibles, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2435414 - Disclosure - Intangibles, Net - Schedule of Intangibles, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2436415 - Disclosure - Intangibles, Net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2437416 - Disclosure - Intangibles, Net - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2138112 - Disclosure - Long-Term Debt, Net, and Other Borrowings link:presentationLink link:calculationLink link:definitionLink 2339310 - Disclosure - Long-Term Debt, Net, and Other Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 2440417 - Disclosure - Long-Term Debt, Net, and Other Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 2440417 - Disclosure - Long-Term Debt, Net, and Other Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 2141113 - Disclosure - Derivative Instruments link:presentationLink link:calculationLink link:definitionLink 2342311 - Disclosure - Derivative Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2443418 - Disclosure - Derivative Instruments (Detail) link:presentationLink link:calculationLink link:definitionLink 2144114 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2345312 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2446419 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Detail) link:presentationLink link:calculationLink link:definitionLink 2147115 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2348313 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2449420 - Disclosure - Stock-Based Compensation (Detail) link:presentationLink link:calculationLink link:definitionLink 2150116 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2351314 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2452421 - Disclosure - Leases - Operating and Finance Lease Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2153117 - Disclosure - Net Income Per Common Share link:presentationLink link:calculationLink link:definitionLink 2354315 - Disclosure - Net Income Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2455422 - Disclosure - Net Income Per Common Share (Detail) link:presentationLink link:calculationLink link:definitionLink 2156118 - Disclosure - Other Income link:presentationLink link:calculationLink link:definitionLink 2357316 - Disclosure - Other Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2458423 - Disclosure - Other Income (Details) link:presentationLink link:calculationLink link:definitionLink 2159119 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2460424 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2161120 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2462425 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 lnth-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 lnth-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 lnth-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Commitments and Contingencies Legal Matters and Contingencies [Text Block] Accounts receivable, net Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net income Net income Net income Net Income (Loss) Attributable to Parent Operating Operating Lease, Right-of-Use Asset Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Freight, distribution and operations Accrued Freight Costs Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for freight and distribution costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Compensation and benefits Employee-related Liabilities, Current Income Statement Location [Axis] Income Statement Location [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Statistical Measurement [Domain] Statistical Measurement [Domain] Schedule of maturities of principal obligations Schedule of Maturities of Long-term Debt [Table Text Block] TechneLite Techne Lite [Member] Techne Lite [Member] Progenics Progenics [Member] Progenics IPR & D IPR & D [Member] IPR & D Security Exchange Name Security Exchange Name Disposal group consideration Disposal Group, Including Discontinued Operation, Consideration Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Deferred taxes Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities, Deferred Income Tax Expense (Benefit) Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities, Deferred Income Tax Expense (Benefit) Number of patents Loss Contingency, Patents Allegedly Infringed, Number Other long-term assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Total leased assets Lease Right Of Use Assets Lease Right Of Use Assets Schedule of financial instruments with significant Level 3 inputs Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity File Number Entity File Number Schedule of other loss (income) Schedule of Other Nonoperating Income (Expense) [Table Text Block] 2024 Long-Term Debt, Maturity, Year Two Financial Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Changes in fair value included in net income Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Gain on sale of assets Gain on sale of assets Gain (Loss) on Disposition of Assets Royalty-Backed Loan Royalty-Backed Loan [Member] Royalty-Backed Loan Financial assurance in form of surety bond Financial Assurance In Form Of Surety Bond Represents the amount of financial assurance given in the form of surety bond. Sale of Puerto Rico Subsidiary Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Interest income Interest Income, Other 2022 Long-Term Debt, Maturity, Remainder of Fiscal Year Amortization expense Amortization of Intangible Assets Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Long-term debt, net and other borrowings Total long-term debt, net and other borrowings Long-term Debt and Lease Obligation Antidilutive securities excluded from diluted net income per common share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Effect of dilutive restricted stock (in shares) Incremental Common Shares Attributable To Restricted Stock Awards Incremental common shares attributable to restricted stock awards. Schedule of inventory Schedule of Inventory, Current [Table Text Block] Research and development Research and Development Expense [Member] Buildings Building [Member] Business Acquisition [Axis] Business Acquisition [Axis] Cash Flow Hedge Cash Flow Hedging [Member] MIP Molecular Insight Pharmaceuticals, Inc. [Member] Molecular Insight Pharmaceuticals, Inc. Disposal Group Name [Axis] Disposal Group Name [Axis] Valuation Allowance [Line Items] Valuation Allowance [Line Items] Changes in fair value included in net income Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Schedule of intangibles Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Local Phone Number Local Phone Number Credit Facility [Domain] Credit Facility [Domain] Assets Assets [Abstract] Land Land [Member] Long-term income tax payable and other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Derivative Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Other precision diagnostics Other Precision Diagnostics [Member] Other Precision Diagnostics Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding) Preferred Stock, Value, Issued Finance lease, liability, noncurrent, statement of financial position [Extensible Enumeration] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Accumulated Deficit Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Accretion expense Asset Retirement Obligation, Accretion Expense Non-Current Liabilities: Liabilities, Noncurrent [Abstract] Valuation Allowance [Table] Valuation Allowance [Table] Accumulated other comprehensive loss, tax AOCI Tax, Attributable to Parent Liability measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Inventory, Current [Table] Inventory, Current [Table] Accounts receivable Increase (Decrease) in Accounts Receivable Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Property, Plant & Equipment [Line Items] Property, Plant and Equipment [Line Items] Shares withheld to cover taxes (in shares) Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Average fixed interest rate Derivative, Average Fixed Interest Rate Other current assets Increase (Decrease) in Other Current Assets Pre-tax deferred losses expected to be reclassified to earnings during the next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Operating segments Number of Operating Segments Total radiopharmaceutical oncology Radiopharmaceutical Oncology [Member] Radiopharmaceutical Oncology Pre-tax book gain on disposal Gain (Loss) on Disposition of Business Short-term contingent liability (Note 4) Business Combination, Contingent Consideration, Liability, Current Basic (in dollars per share) Basic income per common share (in dollars per share) Earnings Per Share, Basic Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Revenue from Contracts with Customers Revenue from Contract with Customer [Text Block] Fair value, beginning of period Fair value, end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Other Other Nonoperating Income (Expense), Miscellaneous Other Nonoperating Income (Expense), Miscellaneous 2023 Long-Term Debt, Maturity, Year One Unamortized debt issuance costs Unamortized Debt Issuance Expense Percentage of total contingent consideration under CVRs Business Combination, Contingent Liability, Contingent Value Right, Percentage Of Total Consideration Business Combination, Contingent Liability, Contingent Value Right, Percentage Of Total Consideration Reconciliation to amounts within the condensed consolidated balance sheets Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract] Accrued rebates, discounts and chargebacks Accrued Rebates Discounts And Chargebacks Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for rebates, discounts and chargebacks. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Schedule of disaggregation of revenue Disaggregation of Revenue [Table Text Block] Royalty percentage Royalty Percentage Royalty Percentage Prepayment of debt Prepayment Of Debt, Amount Prepayment Of Debt, Amount PYLARIFY PYLARIFY [Member] PYLARIFY Shares withheld to cover taxes Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Other Other Noncash Income (Expense) Restricted cash included in other long-term assets Restricted Cash and Cash Equivalents Shares to be received from acquisition conversion (in shares) Business Combination, Right To Receive, Share Business Combination, Right To Receive, Share Accounts payable Disposal Group, Including Discontinued Operation, Accounts Payable, Current Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Financial Assets Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Total principal outstanding Long-term Debt, Gross Contingent receivable Business Combination, Contingent Consideration, Asset Less: current portion Long-term Debt and Lease Obligation, Current Fair Value, Option, Quantitative Disclosures [Line Items] Fair Value, Option, Quantitative Disclosures [Line Items] Finance Finance Lease, Right-of-Use Asset, after Accumulated Amortization ARO acceleration Accelerated Costs Asset Retirement Obligation, Acceleration Expense Asset Retirement Obligation, Acceleration Expense Total assets Assets, Fair Value Disclosure Level 1 Fair Value, Inputs, Level 1 [Member] Weighted-average common shares outstanding: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Small Business Entity Small Business Other radiopharmaceutical oncology Other Radiopharmaceutical Oncology [Member] Other Radiopharmaceutical Oncology Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total liabilities and stockholders’ equity Liabilities and Equity Other Other Accrued Liabilities, Current Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Machinery, equipment and fixtures Machinery Equipment And Fixtures [Member] Machinery Equipment And Fixtures [Member] Strategic partnerships and other revenue Strategic Partnerships And Other [Member] Strategic Partnerships And Other Stock option exercises and employee stock plan purchases Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Ownership Plan Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Ownership Plan Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Stock option exercises and employee stock plan purchases (in shares) Stock Issued During Period, Shares, Options Exercises During Period and Employee Stock Ownership Plan Stock Issued During Period, Shares, Options Exercises During Period and Employee Stock Ownership Plan Accounts payable Increase (Decrease) in Accounts Payable Derivative [Line Items] Derivative [Line Items] Hedging Relationship [Domain] Hedging Relationship [Domain] Interest rate swaps Interest Rate Swap [Member] Basis of Presentation Business Description and Basis of Presentation [Text Block] Operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net Income Per Common Share Earnings Per Share [Text Block] Total assets held for sale Disposal Group, Including Discontinued Operation, Assets Operating expenses Operating Expenses [Abstract] Entity Interactive Data Current Entity Interactive Data Current 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Minimum Minimum [Member] Currently marketed products Currently Marketed Product [Member] Currently Marketed Product Changes in fair value of contingent assets and liabilities Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Gross profit Gross Profit Effect of foreign exchange rates on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Balance Sheet Location [Domain] Balance Sheet Location [Domain] Total liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Proceeds from sale of assets, net Proceeds from Sale of Productive Assets Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding 1095 commercialization milestone 1095 Commercialization [Member] 1095 Commercialization Entity Address, State or Province Entity Address, State or Province Leases Lessee, Finance Leases [Text Block] Amounts reclassified to earnings Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Deferred tax assets, net Deferred Income Tax Assets, Net UNITED KINGDOM UNITED KINGDOM Current liabilities Liabilities, Current [Abstract] General and administrative General and Administrative Expense Foreign currency translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Long-Term Debt, Net, and Other Borrowings Debt Disclosure [Text Block] Schedule of income tax expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Stock-Based Compensation Share-based Payment Arrangement [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Inventory Inventory Disclosure [Text Block] Accounting Policies [Abstract] Accounting Policies [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Accrued professional fees Accrued Professional Fees, Current Document Transition Report Document Transition Report Foreign currency (gains) losses Foreign Currency Transaction Gain (Loss), before Tax Common stock ($0.01 par value, 250,000 shares authorized; 68,570 and 67,739 shares issued and outstanding, respectively) Common Stock, Value, Issued Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Total liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities Goodwill acquired Goodwill, Acquired During Period Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Commitments and contingencies (See Note 19) Commitments and Contingencies Leases Lessee, Operating Leases [Text Block] Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Emerging Growth Company Entity Emerging Growth Company Court deposit Loss Contingency, Deposit With Court Loss Contingency, Deposit With Court Royalties Royalties [Member] Royalties Provision for excess and obsolete inventory Inventory Write-down Total precision diagnostics Total Precision Diagnostics [Member] Total Precision Diagnostics Non-cash adjustment Asset Retirement Obligation, Revision of Estimate Disposal Group Classification [Axis] Disposal Group Classification [Axis] Legal Entity [Axis] Legal Entity [Axis] Cover [Abstract] Cover [Abstract] Effect of dilutive stock options (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Finance lease, liability, current, statement of financial position [Extensible Enumeration] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Puerto Rican Radiopharmacy Servicing Subsidiary Puerto Rican Radiopharmacy Servicing Subsidiary [Member] Puerto Rican Radiopharmacy Servicing Subsidiary Work in process Inventory, Work in Process, Net of Reserves Business combination common stock under contingent value right (in shares) Business Combination, Consideration Transferred, Contingent Value Right Business Combination, Consideration Transferred, Contingent Value Right Capital expenditures Payments to Acquire Productive Assets Financial Instrument [Axis] Financial Instrument [Axis] Entity [Domain] Entity [Domain] Revenues Company acquired right to receive certain future milestone Revenue from Contract with Customer, Excluding Assessed Tax Finished goods Inventory, Finished Goods, Net of Reserves Equity [Abstract] Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Document Quarterly Report Document Quarterly Report Measurement Input Type [Domain] Measurement Input Type [Domain] Common Stock Common Stock [Member] Segment Information Segment Reporting Disclosure [Text Block] Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Operating income Operating Income (Loss) Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Operating Operating Lease, Liability, Current Total Long-term Debt and Lease Obligation, Including Current Maturities Summary of changes in asset retirement obligations Schedule of Change in Asset Retirement Obligation [Table Text Block] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Stock-based compensation Total stock-based compensation expense Share-based Payment Arrangement, Noncash Expense AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Inventory Disposal Group, Including Discontinued Operation, Inventory, Current Inventory [Axis] Inventory [Axis] Additional Paid-In Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Asset retirement obligations Disposal Group, Including Discontinued Operation, Postretirement Plan Benefit Obligation, Noncurrent Total amount awarded Litigation Settlement, Amount Awarded from Other Party Cash Payments 2023 Cash Payments 2023 [Member] Cash Payments 2023 [Member] Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities Operating lease, liability, current, statement of financial position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Notional amount Derivative, Notional Amount Other income Total other income Other Nonoperating Income (Expense) Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Asset Retirement Obligation, Roll Forward Analysis [Roll Forward] Asset Retirement Obligation, Roll Forward Analysis [Roll Forward] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Property, plant & equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent Total liabilities Liabilities Raw materials Inventory, Raw Materials, Net of Reserves Aggregate cash payments percentage Business Combination, Contingent Liability, Contingent Value Right, Percentage Of Net Sales Business Combination, Contingent Liability, Contingent Value Right, Percentage Of Net Sales Schedule of accrued liabilities Schedule of Accrued Liabilities [Table Text Block] 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One Measurement Input Type [Axis] Measurement Input Type [Axis] Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Cash Payments 2022 Cash Payments 2022 [Member] Cash Payments 2022 [Member] Common stock, shares issued (in shares) Common Stock, Shares, Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued City Area Code City Area Code Other current assets Disposal Group, Including Discontinued Operation, Other Assets, Current Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Entity Address, City or Town Entity Address, City or Town Gain on extinguishment of debt Gain on extinguishment of debt Gain (Loss) on Extinguishment of Debt Intangibles, Net Intangible Assets Disclosure [Text Block] Share price (in dollars per share) Business Acquisition, Share Price Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Schedule of accumulated other comprehensive income (loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Computer software Software and Software Development Costs [Member] Unrealized gain on cash flow hedges, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Balance Sheet Location [Axis] Balance Sheet Location [Axis] Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Operating lease liabilities (Note 16) Operating Lease, Liability, Noncurrent Debt instrument face amount Debt Instrument, Face Amount Non-Current Assets: Assets, Noncurrent [Abstract] Change in fair value of the contingent financial asset and contingent financial liabilities Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) Interest expense Interest Expense Licenses Licensing Agreements [Member] Vesting of restricted stock awards and units (in shares) Vesting Of Restricted Stock Awards Vesting of restricted stock awards. Discontinued Operations and Disposal Groups [Abstract] Net sales targets - AZEDRA and 1095 Contingent Consideration, Net Sales Targets [Member] Contingent Consideration, Net Sales Targets Accumulated deficit Retained Earnings (Accumulated Deficit) Increase in finite lived assets Finite-Lived Intangible Assets, Period Increase (Decrease) Vesting of restricted stock awards and units Vesting Of Restricted Stock Awards Value, Net Vesting of restricted stock awards value. Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Entity Filer Category Entity Filer Category Finance lease liabilities Finance Lease, Liability Business Acquisition [Line Items] Business Acquisition [Line Items] Probability adjusted discounted cash flow model Valuation Technique, Discounted Cash Flow [Member] Income Statement [Abstract] Income Statement [Abstract] Asset Retirement Obligations Asset Retirement Obligation Disclosure [Text Block] Entity Registrant Name Entity Registrant Name Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Other Noncurrent Assets Other Noncurrent Assets [Member] Indefinite lived, Cost Indefinite-lived Intangible Assets (Excluding Goodwill) Proceeds from stock option exercises Proceeds from Stock Options Exercised Decrease in indefinite lived assets Indefinite-lived Intangible Assets, Period Increase (Decrease) Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income tax expense Income tax expense Income Tax Expense (Benefit) Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag Equity Components [Axis] Equity Components [Axis] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Entity Tax Identification Number Entity Tax Identification Number Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Sales and marketing Selling and Marketing Expense [Member] Gain on extinguishment of debt Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Inventory Total inventory Inventory, Net Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Long-term contingent liability (Note 4) Business Combination, Contingent Consideration, Liability, Noncurrent Current portion of long-term debt and other borrowings Long-term Debt, Current Maturities Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Other Income Other Income and Other Expense Disclosure [Text Block] Fair Value Option, Disclosures [Table] Fair Value Option, Disclosures [Table] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Monte Carlo simulation Monte Carlo Simulation [Member] Monte Carlo Simulation Equity Component [Domain] Equity Component [Domain] Sales and marketing Selling and Marketing Expense Disposal Group Name [Domain] Disposal Group Name [Domain] European European [Member] European Accrued expense and other liabilities Disposal Group, Including Discontinued Operation, Accrued Expense and Other Liabilities, Current Disposal Group, Including Discontinued Operation, Accrued Expense and Other Liabilities, Current Statement [Line Items] Statement [Line Items] Potential payment not reasonably possible Business Combination, Contingent Consideration Arrangements, Range Of Outcomes Not Reasonably Possible, Value Business Combination, Contingent Consideration Arrangements, Range Of Outcomes Not Reasonably Possible, Value Property, plant and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Schedule of derivative instruments Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Liabilities Liabilities [Abstract] Potential payments, high Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Total, cost Intangible Assets, Gross (Excluding Goodwill) Debt Disclosure [Abstract] Debt Disclosure [Abstract] Finance Finance Lease, Liability, Current Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] Obligation expected to be incurred Asset Retirement Obligation Liabilities Expected Present Value Represents the amount of expected present value of asset retirement obligations. Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Deferred tax asset, valuation allowance Deferred Tax Assets, Valuation Allowance Total current liabilities Disposal Group, Including Discontinued Operation, Liabilities, Current Regulatory milestone Regulatory Milestone [Member] Regulatory Milestone Segment Reporting [Abstract] Segment Reporting [Abstract] Intangible asset, useful life Finite-Lived Intangible Asset, Useful Life Summary of net income per common share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Total other comprehensive income Other comprehensive income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of stock-based compensation expense recognized Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Net Sales Targets For Azedra Net Sales Targets For Azedra [Member] Net Sales Targets For Azedra Disposed of by Sale Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Title of 12(b) Security Title of 12(b) Security Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Total assets Assets Current Liabilities Current Liabilities [Member] Current Liabilities Common stock, shares authorized (in shares) Common Stock, Shares Authorized SWEDEN SWEDEN Geographical [Domain] Geographical [Domain] Net income Net Income (Loss) Available to Common Stockholders, Basic Document Type Document Type Accrued Expenses and Other Liabilities and Other Long-Term Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Product and Service [Domain] Product and Service [Domain] Research and development Research and Development Expense Depreciation and amortization expense Depreciation, Depletion and Amortization, Nonproduction Interest rate Debt Instrument, Interest Rate, Stated Percentage Derivative Contract [Domain] Derivative Contract [Domain] Total leased liabilities Lease Liability Lease Liability Contingent consideration liabilities Business Combination, Contingent Consideration, Liability Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Geographical [Axis] Geographical [Axis] Basic (in shares) Basic weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in dollars per share) Diluted income per common share (in dollars per share) Earnings Per Share, Diluted Amortization of debt related costs Amortization of Debt Issuance Costs and Discounts Product revenue, net Product [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Intangibles, net Total, net Intangible Assets, Net (Excluding Goodwill) Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Business combination, consideration transferred, equity interests issued (in shares) Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Shares Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Shares Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] License and royalty revenues(2) License and Royalty Revenues [Member] License and Royalty Revenues [Member] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Accounts payable Accounts Payable, Current 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three Schedule of assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Probability of success Measurement Input, Probability Of Success [Member] Measurement Input, Probability Of Success Accumulated Other Comprehensive Income (Loss) Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Remainder of 2022 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year DEFINITY DEFINITY [Member] DEFINITY [Member] Inventory Increase (Decrease) in Inventories Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Financial Instruments [Domain] Financial Instruments [Domain] Derivative [Table] Derivative [Table] Cost of goods sold Cost of Goods and Services Sold Other long-term liabilities Other Sundry Liabilities, Noncurrent Document Period End Date Document Period End Date Number of CVRs Number Of Contingent Value Rights Number Of Contingent Value Rights Entity Central Index Key Entity Central Index Key Inventory [Domain] Inventory [Domain] Schedule of operating and finance lease assets and liabilities Assets And Liabilities Lessee [Table Text Block] Assets And Liabilities Lessee Investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Disposal group holdback amount Disposal Group, Including Discontinued Operation, Consideration, Holdback Amount Disposal Group, Including Discontinued Operation, Consideration, Holdback Amount Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Schedule of property, plant, and equipment, net Property, Plant and Equipment [Table Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Debt instrument term Debt Instrument, Term Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Customer relationships Customer Relationships [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Total property, plant and equipment, net Property, Plant and Equipment, Net Property, Plant and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Other long-term liabilities Total other long-term liabilities Other Liabilities, Noncurrent Schedule of expected future amortization expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Payments on long-term debt and other borrowings Repayments of Long-term Debt Trading Symbol Trading Symbol Earnings Per Share [Abstract] Earnings Per Share [Abstract] Interest rate swaps Interest rate swap Derivative Asset Total operating expenses Operating Expenses Before Gain Loss On Sale Of Assets Operating Expenses Before Gain Loss On Sale Of Assets Property, plant & equipment, gross Property, Plant and Equipment, Gross Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent CVRs Contingent Value Right [Member] Contingent Value Right Trademarks Trademarks [Member] 2019 Term Loan Facility Two Thousand and Nineteen Term Facility [Member] Two Thousand and Nineteen Term Facility [Member] Operating lease, liability, noncurrent, statement of financial position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Current Reporting Status Entity Current Reporting Status Net income per common share: Earnings Per Share, Basic and Diluted [Abstract] Other long-term liabilities Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent Asset measurement input Business Combination Contingent Consideration Asset Measurement Input Value of input used to measure contingent consideration asset from business combination. Payables and Accruals [Abstract] Construction in progress Construction in Progress [Member] Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Beginning balance (in shares) Ending balance (in shares) Shares, Issued Noncurrent Liabilities Noncurrent Liabilities [Member] Noncurrent Liabilities Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Discount rate Measurement Input, Discount Rate [Member] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Current assets Assets, Current [Abstract] Cost Finite-Lived Intangible Assets, Gross Leases [Abstract] Leases [Abstract] Cash and cash equivalents Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Schedule of intangibles Schedule of Finite-Lived Intangible Assets [Table Text Block] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Money market Cash and Cash Equivalents, Fair Value Disclosure Entity Address, Postal Zip Code Entity Address, Postal Zip Code Asset Retirement Obligation Disclosure [Abstract] Asset Retirement Obligation Disclosure [Abstract] Diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Fair value, beginning of period Fair value, end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Intangibles, net Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent Income Taxes Income Tax Disclosure [Text Block] Finance lease, right-of-use asset, statement of financial position [Extensible Enumeration] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Disposal groups including discontinued operations Disposal Groups, Including Discontinued Operations [Table Text Block] Unrealized loss on cash flow hedges Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] 2027 and thereafter Finite-Lived Intangible Asset, Expected Amortization, Year Five Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Asset retirement obligations Asset retirement obligations, beginning balance Asset retirement obligations, ending balance Asset Retirement Obligations, Noncurrent Credit Facility [Axis] Credit Facility [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Royalty Royalty [Member] Entity Address, Address Line One Entity Address, Address Line One Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities (Decreases) increases in cash from operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment General and administrative General and Administrative Expense [Member] Entity Shell Company Entity Shell Company Business combination contingent value right of total consideration Business Combination, Contingent Liability, Contingent Value Right, Consideration Business Combination, Contingent Liability, Contingent Value Right, Consideration Tax indemnification income, net Tax Indemnification Agreement, Income (Expense) Represents the tax indemnification income (loss) earned during the period. Long-term income tax receivable Increase (Decrease) in Income Taxes Receivable Total current liabilities Liabilities, Current Payments for minimum statutory tax withholding related to net share settlement of equity awards Payment, Tax Withholding, Share-based Payment Arrangement 1404 Commercialization Milestone 1404 Commercialization Milestone [Member] 1404 Commercialization Milestone Money market Money Market Funds [Member] Loss Contingencies [Table] Loss Contingencies [Table] Current Fiscal Year End Date Current Fiscal Year End Date Total current assets Disposal Group, Including Discontinued Operation, Assets, Current Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Statement [Table] Statement [Table] Other current assets Other Assets, Current Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Other long-term assets Increase (Decrease) in Other Noncurrent Assets Statistical Measurement [Axis] Statistical Measurement [Axis] Other long-term assets Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent Finance Finance Lease, Liability, Noncurrent Total Finite-Lived Intangible Assets, Net Goodwill Goodwill Extinguishment of debt Extinguishment of Debt, Amount Operating lease, right-of-use asset, statement of financial position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Depreciation, amortization and accretion Depreciation, Amortization and Accretion, Net Fair value measurement inputs and valuation techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Cost of goods sold Cost of Sales [Member] Adjustments to reconcile net income to net cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Developed technology Developed Technology Rights [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Accrued expenses and other liabilities Total accrued expenses and other liabilities Accounts Payable and Other Accrued Liabilities, Current Unamortized debt discount Debt Instrument, Unamortized Discount Inventory [Line Items] Inventory [Line Items] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] EX-101.PRE 13 lnth-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 image_0a.jpg begin 644 image_0a.jpg MB5!.1PT*&@H -24A$4@ !!T +" ( "\IV)< 8DE$051X7NW7 ML0D ,1 #P>N_:3].Q7-@E,YD4@<[!P H#-Y /-(5 ! 2U< "MGZX8 M " 549$['L! "L,B)BWPL &"5$1$; #@E:X !:N@( &CI"@ H/4! 4Q[V]I,) !$, 245.1*Y"8((! end GRAPHIC 15 image_0b.jpg begin 644 image_0b.jpg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end XML 16 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover Page - shares
3 Months Ended
Mar. 31, 2022
Apr. 22, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2022  
Document Transition Report false  
Entity File Number 001-36569  
Entity Registrant Name LANTHEUS HOLDINGS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 35-2318913  
Entity Address, Address Line One 331 Treble Cove Road  
Entity Address, Postal Zip Code 01862  
Entity Address, City or Town North Billerica,  
Entity Address, State or Province MA  
City Area Code (978)  
Local Phone Number 671-8001  
Title of 12(b) Security Common stock, par value $0.01 per share  
Trading Symbol LNTH  
Security Exchange Name NASDAQ  
Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   68,634,063
Amendment Flag false  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0001521036  
Current Fiscal Year End Date --12-31  
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Current assets    
Cash and cash equivalents $ 105,355 $ 98,508
Accounts receivable, net 172,283 89,336
Inventory 34,249 35,129
Other current assets 12,860 12,818
Total current assets 324,747 235,791
Property, plant and equipment, net 116,959 116,772
Intangibles, net 340,204 348,510
Goodwill 61,189 61,189
Deferred tax assets, net 47,868 62,764
Other long-term assets 42,199 38,758
Total assets 933,166 863,784
Current liabilities    
Current portion of long-term debt and other borrowings 12,878 11,642
Accounts payable 22,383 20,787
Accrued expenses and other liabilities 142,396 58,068
Total current liabilities 177,657 90,497
Asset retirement obligations 21,514 20,833
Long-term debt, net and other borrowings 159,369 163,121
Other long-term liabilities 58,776 124,894
Total liabilities 417,316 399,345
Commitments and contingencies (See Note 19)
Stockholders’ equity    
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding) 0 0
Common stock ($0.01 par value, 250,000 shares authorized; 68,570 and 67,739 shares issued and outstanding, respectively) 686 677
Additional paid-in capital 691,516 685,472
Accumulated deficit (178,263) (221,225)
Accumulated other comprehensive income (loss) 1,911 (485)
Total stockholders’ equity 515,850 464,439
Total liabilities and stockholders’ equity $ 933,166 $ 863,784
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 25,000,000 25,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 250,000,000 250,000,000
Common stock, shares issued (in shares) 68,570,000 67,739,000
Common stock, shares outstanding (in shares) 68,570,000 67,739,000
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Revenues $ 208,880 $ 92,509
Cost of goods sold 79,810 51,479
Gross profit 129,070 41,030
Operating expenses    
Sales and marketing 20,354 14,173
General and administrative 37,588 16,138
Research and development 12,203 10,360
Total operating expenses 70,145 40,671
Gain on sale of assets 0 15,263
Operating income 58,925 15,622
Interest expense 1,509 2,718
Gain on extinguishment of debt 0 (889)
Other income (485) (549)
Income before income taxes 57,901 14,342
Income tax expense 14,939 5,334
Net income $ 42,962 $ 9,008
Net income per common share:    
Basic (in dollars per share) $ 0.63 $ 0.13
Diluted (in dollars per share) $ 0.61 $ 0.13
Weighted-average common shares outstanding:    
Basic (in shares) 68,008 67,094
Diluted (in shares) 70,051 67,714
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Statement of Comprehensive Income [Abstract]    
Net income $ 42,962 $ 9,008
Other comprehensive income:    
Foreign currency translation 140 102
Unrealized gain on cash flow hedges, net of tax 2,256 706
Total other comprehensive income 2,396 808
Comprehensive income $ 45,358 $ 9,816
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Changes In Stockholders' Equity (Statement) - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2020   66,875      
Beginning balance at Dec. 31, 2020 $ 514,205 $ 669 $ 665,530 $ (149,946) $ (2,048)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 9,008     9,008  
Other comprehensive income 808       808
Stock option exercises and employee stock plan purchases (in shares)   155      
Stock option exercises and employee stock plan purchases 2,380 $ 1 2,379    
Vesting of restricted stock awards and units (in shares)   489      
Vesting of restricted stock awards and units 0 $ 5 (5)    
Shares withheld to cover taxes (in shares)   (85)      
Shares withheld to cover taxes (1,599) $ (1) (1,598)    
Stock-based compensation 3,317   3,317    
Ending balance (in shares) at Mar. 31, 2021   67,434      
Ending balance at Mar. 31, 2021 528,119 $ 674 669,623 (140,938) (1,240)
Beginning balance (in shares) at Dec. 31, 2021   67,739      
Beginning balance at Dec. 31, 2021 464,439 $ 677 685,472 (221,225) (485)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 42,962     42,962  
Other comprehensive income 2,396       2,396
Stock option exercises and employee stock plan purchases (in shares)   296      
Stock option exercises and employee stock plan purchases 5,934 $ 3 5,931    
Vesting of restricted stock awards and units (in shares)   645      
Vesting of restricted stock awards and units 0 $ 7 (7)    
Shares withheld to cover taxes (in shares)   (110)      
Shares withheld to cover taxes (5,504) $ (1) (5,503)    
Stock-based compensation 5,623   5,623    
Ending balance (in shares) at Mar. 31, 2022   68,570      
Ending balance at Mar. 31, 2022 $ 515,850 $ 686 $ 691,516 $ (178,263) $ 1,911
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows
$ in Thousands
3 Months Ended
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Operating activities    
Net income $ 42,962 $ 9,008
Adjustments to reconcile net income to net cash flows from operating activities:    
Depreciation, amortization and accretion 11,786 8,123
ARO acceleration 293 0
Amortization of debt related costs 246 (61)
Changes in fair value of contingent assets and liabilities 18,400 300
Gain on extinguishment of debt 0 (889)
Provision for excess and obsolete inventory 2,519 1,395
Stock-based compensation 5,623 3,317
Gain on sale of assets 0 (15,263)
Deferred taxes 14,180 4,581
Long-term income tax receivable (396) (573)
Long-term income tax payable and other long-term liabilities 779 728
Other 829 655
(Decreases) increases in cash from operating assets and liabilities:    
Accounts receivable (85,155) (2,346)
Inventory (1,634) 3,889
Other current assets (104) (536)
Other long-term assets (533) 0
Accounts payable 1,506 4,110
Accrued expenses and other liabilities (1,037) (6,620)
Net cash provided by operating activities 10,264 9,818
Investing activities    
Capital expenditures (3,190) (2,520)
Proceeds from sale of assets, net 1,800 15,823
Net cash (used in) provided by investing activities (1,390) 13,303
Financing activities    
Payments on long-term debt and other borrowings (2,609) (35,572)
Proceeds from stock option exercises 5,357 2,043
Proceeds from issuance of common stock 577 337
Payments for minimum statutory tax withholding related to net share settlement of equity awards (5,504) (1,599)
Net cash used in financing activities (2,179) (34,791)
Effect of foreign exchange rates on cash, cash equivalents and restricted cash 151 (21)
Net increase (decrease) in cash, cash equivalents and restricted cash 6,846 (11,691)
Cash, cash equivalents and restricted cash, beginning of period 100,651 82,694
Cash, cash equivalents and restricted cash, end of period 107,497 71,003
Reconciliation to amounts within the condensed consolidated balance sheets    
Cash and cash equivalents 105,355 68,861
Restricted cash included in other long-term assets 2,142 2,142
Cash, cash equivalents and restricted cash at end of period $ 107,497 $ 71,003
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Basis of Presentation
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying unaudited condensed consolidated financial statements include the accounts of Holdings and its direct and indirect wholly-owned subsidiaries, including Progenics (as of the Closing Date, as defined below), and have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all of the information and notes required by generally accepted accounting principles in the United States of America (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement have been included. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ended December 31, 2022 or any future period.
The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities Exchange Commission (“SEC”) on February 24, 2022.
Progenics Acquisition
On June 19, 2020 (the “Closing Date”), pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the “Merger Agreement”), by and among Holdings, Plato Merger Sub, Inc., a wholly-owned subsidiary of Holdings (“Merger Sub”), and Progenics, Holdings completed the acquisition of Progenics by means of a merger of Merger Sub with and into Progenics, with Progenics surviving such merger as a wholly-owned subsidiary of Holdings (the “Progenics Acquisition”). Subsequently, on June 22, 2020, Holdings contributed all of the capital stock of Progenics to LMI, thereby making Progenics an indirect subsidiary of Holdings.
In accordance with the Merger Agreement, at the effective time of the Progenics Acquisition (the “Effective Time”), each share of Progenics common stock, par value $0.0013 per share, issued and outstanding immediately prior to the Effective Time (other than shares of Progenics common stock owned by Holdings, Progenics or any of their wholly-owned subsidiaries) was automatically cancelled and converted into the right to receive (i) 0.31 (the “Exchange Ratio”) of a share of Holdings common stock, par value $0.01 per share, and (ii) one contingent value right (a “CVR”) tied to the financial performance of PyL (18F-DCFPyL), Progenics’ prostate-specific membrane antigen (“PSMA”) targeted imaging agent designed to visualize prostate cancer. This agent was approved by the U.S. Food and Drug Administration (“FDA”) on May 26, 2021 under the name PYLARIFY (piflufolastat F 18), and the commercial launch of this agent began in June 2021. Each CVR entitles its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively. In no event will the Company’s aggregate payments in respect of the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Acquisition, exceed 19.9% of the total consideration the Company pays in the Progenics Acquisition (which the Company currently estimates could be approximately $100.0 million). The Company expects to issue any applicable cash payments related to the CVRs as early as the first quarter of 2023 and the first quarter of 2024. No fractional shares of Holdings common stock were issued in the Progenics Acquisition, and Progenics’ former stockholders have received cash in lieu of any fractional shares of Holdings common stock. In addition, in accordance with the Merger Agreement, at the Effective Time, each Progenics stock option with a per share exercise price less than or equal to $4.42 (an “in-the-money Progenics stock option”) received in exchange for each such in-the money Progenics stock option: (i) an option to purchase Holdings common stock (each, a “Replacement Stock Option”) converted based on the Exchange Ratio, and (ii) a vested or unvested CVR depending on whether the underlying in-the-money Progenics stock option was vested or unvested at the Effective Time. Each Progenics stock option with a per share exercise price greater than $4.42 (an “out-of-the-money Progenics stock option”) received in exchange for such out-of-the-money Progenics stock options a Replacement Stock Option converted at an exchange ratio determined based on the average of the
volume weighted average price per share of common stock of Progenics and Lantheus Holdings prior to the Effective Time, which exchange ratio was 0.31, the same as the Exchange Ratio. As a result of the acquisition, Holdings issued 26,844,877 shares of Holdings common stock and 86,630,633 CVRs to former Progenics stockholders and option holders.
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting PoliciesRecent Accounting PronouncementsThe Company has not adopted any new accounting standards during the three months ended March 31, 2022
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue from Contracts with Customers
3 Months Ended
Mar. 31, 2022
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers Revenue from Contracts with Customers
The following table summarizes revenue by revenue source as follows:
Three Months Ended
March 31,
Major Products/Service Lines (in thousands)20222021
    Product revenue, net(1)
$180,009 $87,319 
    License and royalty revenues(2)
28,871 5,190 
Total revenues$208,880 $92,509 
________________________________
(1)The Company’s principal products include PYLARIFY, DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the same revenue recognition policies and judgments for all its principal products.
(2)The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG. Please refer to Note 19, “Commitments and Contingencies” for further details on the license agreement.
The Company classifies its revenues into three product categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other revenue. Precision diagnostics includes DEFINITY, TechneLite and other imaging diagnostic products. Radiopharmaceutical oncology consists primarily of PYLARIFY and AZEDRA. Strategic partnerships and other revenue includes strategic partnerships and other arrangements related to other products of the Company, such as royalty revenue from our license of RELISTOR.
On January 31, 2022, the Company entered into a global settlement agreement with Novartis Pharma AG (“Novartis”), Advanced Accelerator Applications USA, Inc. (“AAA”), Endocyte, Inc. (“Endocyte”) and their affiliates (the “Novartis Agreement”) to settle certain disputes between the parties. Under the Novartis Agreement, Novartis agreed to make a lump sum payment to the Company, as well as to reimburse the Company for certain fees and expenses in connection with the German litigation (please refer to Note 19 “Commitments and Contingencies”) and the Company agreed to license certain intellectual property to Novartis. In addition, the Company agreed to supply PYLARIFY for clinical purposes at an arms-length value which will be recorded in the future as product is provided. In accordance with the Company's ASC 606, Revenue from Contracts with Customers, assessment, Novartis is considered to be a customer. The Company determined that the $24.0 million constituted a single element which was satisfied on the date of the execution of the Novartis Agreement. The Company determined that the license of intellectual property carried a fair value of $24.0 million. As such, the Company assigned the value to the fair value of the license, which constitutes the entire transaction price and does not require further allocation. The Company determined that the $24.0 million represented the point at which the licensee was able to use and benefit from the license and recognized revenue when the license was granted to Novartis upon execution of the Novartis Agreement. The Company recognized the $24.0 million fee as revenue on its consolidated statement of operations for the quarter ended March 31, 2022. The Company received the $24.0 million payment in April 2022.
Revenue by product category on a net basis is as follows:
Three Months Ended
March 31,
(in thousands)20222021
   DEFINITY$58,328 $55,971 
   TechneLite22,605 22,800 
   Other precision diagnostics5,265 6,984 
Total precision diagnostics86,198 85,755 
   PYLARIFY92,777 — 
   Other radiopharmaceutical oncology1,327 1,500 
Total radiopharmaceutical oncology94,104 1,500 
Strategic partnerships and other revenue28,578 5,254 
Total revenues$208,880 $92,509 
The Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Instruments
3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability of fair value measurements, financial instruments are categorized based on a hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:
Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
Level 3 — Unobservable inputs that reflect a Company’s estimates about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.
The Company’s financial assets and liabilities measured at fair value on a recurring basis consist of money market funds, interest rate swaps, a contingent receivable and contingent consideration liabilities. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the condensed consolidated balance sheets at fair value using quoted prices in active markets for identical assets. The fair value of the interest rate swaps is determined based on observable market-based inputs, including interest rate curves and reflects the contractual terms of these instruments, including the period to maturity. Please refer to Note 13, “Derivative Instruments”, for further details on the interest rate swaps. The Company recorded a contingent receivable and the contingent consideration liabilities resulting from the Progenics Acquisition at fair value based on inputs that are not observable in the market.
The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:
March 31, 2022
(in thousands)Total Fair
Value
Level 1Level 2Level 3
Assets:
   Money market$38,986 $38,986 $— $— 
   Interest rate swaps3,387 — 3,387 — 
   Contingent receivable8,900 — — 8,900 
Total assets$51,273 $38,986 $3,387 $8,900 
Liabilities:
   Contingent consideration liabilities$104,200 $— $— $104,200 
Total liabilities$104,200 $— $— $104,200 
December 31, 2021
(in thousands)Total Fair
Value
Level 1Level 2Level 3
Assets:
   Money market$40,140 $40,140 $— $— 
   Interest rate swaps357 — 357 — 
   Contingent receivable9,300 — — 9,300 
Total assets$49,797 $40,140 $357 $9,300 
Liabilities:
   Contingent consideration liabilities$86,200 $— $— $86,200 
Total liabilities$86,200 $— $— $86,200 

During the three months ended March 31, 2022, there were no transfers into or out of Level 3.
As part of the Progenics Acquisition, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics from CytoDyn Inc. related to a prior sale of certain intellectual property. The Company has the right to receive $5.0 million upon regulatory approval and a 5% royalty on net sales of approved products. The Company considers the contingent receivable a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flows that included significant estimates and assumptions pertaining to regulatory events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success.
As part of the Progenics Acquisition, the Company issued CVRs and recorded the fair value as part of consideration transferred. Each CVR entitles its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively, subject to a maximum cap (which the Company currently estimates could be approximately $100.0 million). Refer to Note 1, “Basis of Presentation” for further details on the CVRs. Additionally, the Company assumed contingent consideration liabilities related to a previous acquisition completed by Progenics in 2013 (“2013 Acquisition”). These contingent consideration liabilities include potential payments of up to $70.0 million if the Company attains certain net sales targets primarily for AZEDRA and 1095 and a $5.0 million 1095 commercialization milestone. Additionally, there is a potential payment of up to $10.0 million related to a 1404 commercialization milestone. The Company’s total potential payments related to the 2013 Acquisition are approximately $85.0 million. The Company considers the contingent consideration liabilities relating to the CVRs and the 2013 Acquisition, each a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value of these was determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs with respect to 1095 and 1404 are the probabilities of achieving regulatory approval of those development projects and subsequent commercial success.
Significant changes in any of the probabilities of success, the probabilities as to the periods in which sales targets and milestones will be achieved, discount rates or underlying revenue forecasts would result in a significantly higher or lower fair value measurement. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in general and administrative expenses in the condensed consolidated statements of operations. The Company can give no assurance that the actual
amounts paid, if any, in connection with the contingent consideration liabilities, including the CVRs, will be consistent with any recurring fair value estimate of such contingent consideration liabilities.
The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of assets and liabilities using Level 3 inputs at March 31, 2022.

Fair Value atAssumptions
(in thousands)March 31, 2022December 31, 2021Valuation TechniqueUnobservable InputMarch 31, 2022December 31, 2021
Contingent receivable:
Regulatory milestone$2,500 $2,500 Probability adjusted discounted cash flow modelPeriod of expected milestone achievement20222022
Probability of success70 %70 %
Discount rate18 %17 %
Royalties6,400 6,800 Probability adjusted discounted cash flow model
Probability of success
10% - 60%
10% - 60%
Discount rate18 %17 %
Total$8,900 $9,300 

Fair Value atAssumptions
(in thousands)March 31, 2022December 31, 2021Valuation TechniqueUnobservable InputMarch 31, 2022December 31, 2021
Contingent consideration liability:
Net sales targets - PYLARIFY (CVRs)$91,700 $73,200 Monte Carlo simulationPeriod of expected milestone achievement and sales targets2022 - 20232022 - 2023
Discount rate18 %17 %
1095 commercialization milestone1,800 1,900 Probability adjusted discounted cash flow model
Period of expected milestone achievement20262026
Probability of success40 %40 %
Discount rate2.1 %1.3 %
Net sales targets - AZEDRA and 109510,700 11,100 Monte Carlo simulation
Probability of success and sales targets
40% - 100%
40% - 100%
Discount rate
17% - 18%
16% - 17%
Total$104,200 $86,200 
For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:
Financial AssetsFinancial Liabilities
(in thousands)Three Months Ended
March 31,
Three Months Ended
March 31,
2022202120222021
Fair value, beginning of period$9,300 $11,300 $86,200 $15,800 
Changes in fair value included in net income(400)900 18,000 1,200 
Fair value, end of period$8,900 $12,200 $104,200 $17,000 
The change in fair value of the contingent financial asset and contingent financial liabilities, including the CVRs, resulted in an expense of $18.4 million for the three months ended March 31, 2022 and was primarily due to changes in revenue forecasts, changes in market conditions, an increase in discount rates and the passage of time. The Company expects to issue any applicable cash payments related to the CVRs as early as the first quarter of 2023 and the first quarter of 2024. As of March 31, 2022, the Company has $83.3 million in current liabilities and $8.4 million in long term liabilities to account for the expected payments related to the CVRs.
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
3 Months Ended
Mar. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The Company calculates income taxes at the end of each reporting period based on the estimated effective tax rate for the full year, adjusted for any discrete events which are recorded in the period they occur. Cumulative adjustments to the tax provision are recorded in the reporting period in which a change in the estimated annual effective tax rate is determined. The Company’s income tax expense is presented below:            
Three Months Ended
March 31,
(in thousands)20222021
Income tax expense$14,939 $5,334 
The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realizability of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more-likely-than-not realizable, the Company evaluated all available positive and negative evidence, and weighed the objective evidence and expected impact. The Company assessed the need for a valuation allowance against certain state tax credit carryforwards added through the Progenics Acquisition. The Company continues to retain other valuation allowances of $1.2 million against the net deferred tax assets of its U.K. subsidiary, and $2.0 million against the net deferred tax assets of its Sweden subsidiary.
In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb (“BMS”) in 2008, the Company recorded a liability for uncertain tax positions related to the acquired business and simultaneously entered into a tax indemnification agreement with BMS under which BMS agreed to indemnify the Company for any payments made to settle those uncertain tax positions with the state taxing authorities. Accordingly, a long-term receivable is recorded to account for the expected value to the Company of future indemnification payments to be paid on behalf of the Company by BMS, net of actual tax benefits received by the Company. The tax indemnification receivable is recorded within other long-term assets.
In accordance with the Company’s accounting policy, the change in the tax liabilities, penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within income tax expense. As these reserves change adjustments are included in income tax expense while the offsetting adjustment is included in other income. Assuming that the remaining receivable from BMS continues to be considered recoverable by the Company, there will be no effect on net income and no net cash outflows related to these liabilities.
The Company finalized the accounting for the Progenics Acquisition for income taxes in the first quarter of 2021 resulting in a reduction of deferred tax assets, primarily related to state research credit carryforwards and an increase to goodwill of $2.6 million.
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Inventory
3 Months Ended
Mar. 31, 2022
Inventory Disclosure [Abstract]  
Inventory Inventory
Inventory consisted of the following:
        
(in thousands)March 31,
2022
December 31,
2021
Raw materials$13,861 $15,505 
Work in process13,071 13,042 
Finished goods7,317 6,582 
Total inventory$34,249 $35,129 
Inventory costs associated with products that have not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefit of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. As of December 31, 2021, the Company had $6.1 million of such product costs included in inventories related to DEFINITY that had been manufactured through the Company’s in-house manufacturing capabilities. The Company received regulatory approval for the manufacture of DEFINITY at its new in-house manufacturing facility during the first quarter of 2022 and has no inventory pending regulatory approval as of March 31, 2022.
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Property, Plant and Equipment, Net
3 Months Ended
Mar. 31, 2022
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment, Net Property, Plant and Equipment, Net
Property, plant and equipment, net, consisted of the following:
(in thousands)March 31,
2022
December 31,
2021
Land$13,450 $13,450 
Buildings73,560 73,559 
Machinery, equipment and fixtures84,983 83,608 
Computer software24,766 24,384 
Construction in progress12,186 10,686 
208,945 205,687 
Less: accumulated depreciation and amortization(91,986)(88,915)
Total property, plant and equipment, net$116,959 $116,772 
Depreciation and amortization expense related to property, plant and equipment, net, was $3.1 million and $3.0 million for the three months ended March 31, 2022 and 2021, respectively.
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses and Other Liabilities and Other Long-Term Liabilities
3 Months Ended
Mar. 31, 2022
Payables and Accruals [Abstract]  
Accrued Expenses and Other Liabilities and Other Long-Term Liabilities Accrued Expenses and Other Liabilities and Other Long-Term Liabilities
Accrued expenses and other liabilities and other long-term liabilities are comprised of the following:
(in thousands)March 31,
2022
December 31,
2021
Compensation and benefits$10,629 $22,730 
Freight, distribution and operations26,581 16,157 
Accrued rebates, discounts and chargebacks10,793 10,977 
Accrued professional fees3,596 2,850 
Short-term contingent liability (Note 4)83,300 — 
Other7,497 5,354 
Total accrued expenses and other liabilities$142,396 $58,068 
Operating lease liabilities (Note 16)$16,207 $16,546 
Long-term contingent liability (Note 4)20,900 86,200 
Other long-term liabilities21,669 22,148 
Total other long-term liabilities$58,776 $124,894 
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Sale of Puerto Rico Subsidiary
3 Months Ended
Mar. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]  
Sale of Puerto Rico Subsidiary Sale of Puerto Rico SubsidiaryDuring the fourth quarter of 2020, the Company entered into a stock purchase agreement (the “SPA”) with one of its existing radiopharmacy customers to sell all the stock of its Puerto Rico radiopharmacy subsidiary. The assets were classified as held for sale
and the Company determined that the fair value of the net assets being sold significantly exceeded the carrying value as of December 31, 2020. The transaction was consummated on January 29, 2021.
The purchase price for the stock sale was $18.0 million in cash, including a holdback amount of $1.8 million which the Company received during the first quarter of 2022; the purchase price also included a working capital adjustment. The SPA contains customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company’s representations, warranties and covenants in the SPA.
The Company determined that this sale of certain net assets did not constitute a strategic shift that had a major effect on the Company’s operations or financial results. As a result, this transaction was not classified as discontinued operations in the Company’s accompanying condensed consolidated financial statements.
The following table summarizes the major classes of assets and liabilities sold as of January 29, 2021 (date of sale):
(in thousands)
January 29, 2021
Current Assets:
Cash and cash equivalents
$540 
Accounts receivable, net
1,959 
Inventory
530 
Other current assets
65 
Total current assets
3,094 
Non-Current Assets:
Property, plant & equipment, net
780 
Intangibles, net
96 
Other long-term assets
774 
Total assets held for sale
$4,744 
Current Liabilities:
Accounts payable
$185 
Accrued expense and other liabilities
369 
Total current liabilities
554 
Non-Current Liabilities:
Asset retirement obligations
306 
Other long-term liabilities
588 
Total liabilities held for sale
$1,448 

The sale resulted in a pre-tax book gain of $15.3 million, which was recorded within operating income in the condensed consolidated statements of operations for the three months ended March 31, 2021.
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Asset Retirement Obligations
3 Months Ended
Mar. 31, 2022
Asset Retirement Obligation Disclosure [Abstract]  
Asset Retirement Obligations Asset Retirement Obligations
The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts and Somerset, New Jersey sites. As of March 31, 2022, the liability is measured at the present value of the obligation expected to be incurred, of approximately $26.4 million.
The following table provides a summary of the changes in the Company’s asset retirement obligations:
(in thousands)Amount
Balance at January 1, 2022$20,833 
Accretion expense388 
Accelerated Costs293 
Balance at March 31, 2022$21,514 
In December 2021, the Company evaluated the accretion timeline of an asset group due to a revision in the planned period of use at the North Billerica site. As a result of the accelerated timeline, the Company determined the asset group’s present value exceeded the current value recorded as of December 31, 2021. Accordingly, the Company recorded a non-cash adjustment of $5.3 million to anticipate a revision in the end of useful life by the end of 2022.
The Company is required to provide the Massachusetts Department of Public Health and New Jersey Department of Environmental Protection financial assurance demonstrating the Company’s ability to fund the decommissioning of its North Billerica, Massachusetts and Somerset, New Jersey production facilities upon closure, although the Company has no current plans to close the facilities. The Company has provided this financial assurance in the form of a $28.2 million surety bond.
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Intangibles, Net
3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangibles, Net Intangibles, Net
Intangibles, net, consisted of the following:
March 31, 2022
(in thousands)Useful Lives
(in years)
Amortization MethodCostAccumulated AmortizationNet
Trademarks
15 - 25
Straight-Line$13,540 $(11,648)$1,892 
Customer relationships
15 - 25
Accelerated96,962 (94,856)2,106 
Currently marketed products
9 - 15
Straight-Line275,700 (29,416)246,284 
Licenses
11 - 16
Straight-Line85,800 (13,441)72,359 
Developed technology9Straight-Line2,400 (477)1,923 
IPR&DN/AN/A15,640 — 15,640 
   Total$490,042 $(149,838)$340,204 


December 31, 2021
(in thousands)Useful Lives
(in years)
Amortization MethodCostAccumulated AmortizationNet
Trademarks
15 - 25
Straight-Line$13,540 $(11,510)$2,030 
Customer relationships
15 - 25
Accelerated96,880 (94,630)2,250 
Currently marketed product
9 - 15
Straight-Line275,700 (23,345)252,355 
Licenses
11 - 16
Straight-Line85,800 (11,555)74,245 
Developed technology9Straight-Line2,400 (410)1,990 
IPR&DN/AN/A15,640 — 15,640 
   Total$489,960 $(141,450)$348,510 


The Company recorded amortization expense for its intangible assets of $8.3 million and $4.7 million for the three months ended March 31, 2022 and 2021, respectively.
In May 2021, PyL (18F-DCFPyL) was approved by the FDA under the name PYLARIFY. Accordingly, the Company reclassified the associated asset of $132.8 million from IPR&D to currently marketed products and commenced amortization of the asset.
The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:
(in thousands)Amount
Remainder of 2022$24,923 
202332,634 
202432,563 
202532,508 
202632,497 
2027 and thereafter169,439 
   Total$324,564 
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Long-Term Debt, Net, and Other Borrowings
3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
Long-Term Debt, Net, and Other Borrowings Long-Term Debt, Net, and Other Borrowings
As of March 31, 2022, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows:
(in thousands)Amount
Remainder of 2022$8,750 
202315,000 
2024148,750 
Total principal outstanding172,500 
Unamortized debt discount(448)
Unamortized debt issuance costs(387)
Finance lease liabilities582 
Total172,247 
Less: current portion(12,878)
Total long-term debt, net and other borrowings$159,369 


At March 31, 2022, the Company’s interest rate under the five-year secured term loan facility, which matures on June 30, 2024 (the “2019 Term Facility” and the loans thereunder, the “2019 Term Loans”) was 2.2%.
On March 31, 2021, the Company voluntarily repaid in full the entire outstanding principal on the original $50.0 million loan agreement (the “Royalty-Backed Loan”) with a fund managed by HealthCare Royalty Partners III, L.P. in the amount of $30.9 million, which included a prepayment amount of $0.5 million, and terminated the agreement governing the Royalty-Backed Loan. The Company recorded a gain on extinguishment of debt of $0.9 million related to the write-off of an unamortized debt premium offset by the prepayment amount.
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Derivative Instruments
3 Months Ended
Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments Derivative Instruments
The Company uses interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. In March 2020, the Company entered into interest rate swap contracts to fix the LIBOR rate on a notional amount of $100.0 million through May 31, 2024. The average fixed LIBOR rate on the interest rate swaps is approximately 0.82%. This agreement involves the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the agreement without an exchange of the underlying principal amount. The interest rate swaps were designated as cash flow hedges. In accordance with hedge accounting, the interest rate swaps are recorded on the Company’s condensed consolidated balance sheets at fair value, and changes in the fair value of the swap agreements are recorded to other comprehensive loss and reclassified to interest expense in the period during which the hedged transaction affected earnings or it will become probable that the forecasted transaction would not occur. At March 31, 2022, accumulated other comprehensive income included $1.0 million of pre-tax deferred gains that are expected to be reclassified to earnings during the next 12 months.
The following table presents the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheets:
(in thousands)March 31, 2022December 31, 2021
Derivatives typeClassification
Assets:
   Interest rate swapOther long-term assets$3,387 $357 
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Accumulated Other Comprehensive Income (Loss)
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)
The components of accumulated other comprehensive income (loss), net of tax of $0.9 million and $0.2 million for the three months ended March 31, 2022 and 2021, respectively, consisted of the following:
(in thousands)Foreign currency translationUnrealized loss on cash flow hedgesAccumulated other comprehensive loss
Balance at January 1, 2022$(754)$269 $(485)
Other comprehensive income before reclassifications140 2,086 2,226 
Amounts reclassified to earnings— 170 170 
Balance at March 31, 2022$(614)$2,525 $1,911 
Balance at January 1, 2021$(630)$(1,418)$(2,048)
Other comprehensive loss before reclassifications102 533 635 
Amounts reclassified to earnings— 173 173 
Balance at March 31, 2021$(528)$(712)$(1,240)
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation
3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations:
         
Three Months Ended
March 31,
(in thousands)20222021
Cost of goods sold$912 $622 
Sales and marketing1,013 350 
General and administrative3,002 1,920 
Research and development696 425 
Total stock-based compensation expense$5,623 $3,317 
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Leases
3 Months Ended
Mar. 31, 2022
Leases [Abstract]  
Leases LeasesOperating and finance lease assets and liabilities are as follows:
(in thousands)ClassificationMarch 31,
2022
December 31,
2021
Assets
OperatingOther long-term assets$8,675 $8,788 
FinanceProperty, plant and equipment, net602 556 
Total leased assets$9,277 $9,344 
Liabilities
Current                     
     OperatingAccrued expenses and other liabilities$1,619 $1,599 
     FinanceCurrent portion of long-term debt and other borrowings378 392 
Noncurrent
     OperatingOther long-term liabilities16,207 16,546 
     FinanceLong-term debt, net and other borrowings204 299 
Total leased liabilities$18,408 $18,836 
Leases LeasesOperating and finance lease assets and liabilities are as follows:
(in thousands)ClassificationMarch 31,
2022
December 31,
2021
Assets
OperatingOther long-term assets$8,675 $8,788 
FinanceProperty, plant and equipment, net602 556 
Total leased assets$9,277 $9,344 
Liabilities
Current                     
     OperatingAccrued expenses and other liabilities$1,619 $1,599 
     FinanceCurrent portion of long-term debt and other borrowings378 392 
Noncurrent
     OperatingOther long-term liabilities16,207 16,546 
     FinanceLong-term debt, net and other borrowings204 299 
Total leased liabilities$18,408 $18,836 
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Net Income Per Common Share
3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Net Income Per Common Share Net Income Per Common Share
A summary of net income per common share is presented below:
Three Months Ended
March 31,
(in thousands, except per share amounts)20222021
Net income$42,962 $9,008 
Basic weighted-average common shares outstanding68,008 67,094 
Effect of dilutive stock options406 82 
Effect of dilutive restricted stock1,637 538 
Diluted weighted-average common shares outstanding70,051 67,714 
Basic income per common share$0.63 $0.13 
Diluted income per common share$0.61 $0.13 
Antidilutive securities excluded from diluted net income per common share377 1,349 
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Other Income
3 Months Ended
Mar. 31, 2022
Other Income and Expenses [Abstract]  
Other Income Other Income
Other income consisted of the following:
Three Months Ended
March 31,
(in thousands)20222021
Foreign currency (gains) losses$(81)$42 
Tax indemnification income, net(396)(573)
Interest income(8)(17)
Other— (1)
Total other income$(485)$(549)
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Legal Proceedings
From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The costs and outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements.
As of March 31, 2022, the Company did not have any material ongoing litigation in which the Company was a party. During the first quarter of 2022, the Company was able to resolve certain litigation matters as set forth below:
On January 31, 2022, the Company entered into a global settlement agreement with Novartis, AAA, Endocyte and certain of their affiliates to settle certain disputes between the parties, as further described below:
German PSMA-617 Litigation
On November 8, 2018, Molecular Insight Pharmaceuticals, Inc., a subsidiary of Progenics (“MIP”), filed a complaint against the University of Heidelberg (the “University”) in the District Court in Mannheim, Germany (the “German District Court” and, such litigation, the “German Litigation”). In this Complaint, MIP claimed that the discovery and development of PSMA-617 was related to work performed under a research collaboration sponsored by MIP. MIP alleged that the University breached certain contracts with MIP and that MIP is the co-owner of inventions embodied in certain worldwide patent filings related to PSMA-617 that were filed by the University. On February 27, 2019, Endocyte, a wholly owned subsidiary of Novartis, filed a motion to intervene in the German Litigation. Endocyte is the exclusive licensee of the patent rights that are the subject of the German proceedings.
In connection with this dispute, MIP filed a Confirmation of Ownership with the United States Patent and Trademark Office (“USPTO”) for certain U.S. patent applications filed by the University to support MIPs claim that it is the co-owner of these pending U.S. patent applications (the “Ownership Claim”).
On February 27, 2019, the German District Court set €0.4 million as the amount MIP must deposit with the German District Court as security in the event of an unfavorable final decision on the merits of the dispute. On August 24, 2020, the German District Court issued its decision dismissing MIP’s claims, stating that MIP failed to discharge its burden of proof in the matter.
MIP filed a Notice of Appeal of the German District Court’s decision on September 24, 2020 and filed its appeal brief on November 26, 2020. The University and Endocyte each filed oppositions to MIP’s Notice of Appeal on March 12, 2021 and an oral hearing for the appeal was scheduled for September 28, 2022, at the Higher Regional Court Karlsruhe.
Pursuant to the terms of the Novartis Agreement, the German Litigation was dismissed and the Ownership Claim withdrawn.
Post-Grant Review Proceeding
On February 4, 2021, AAA, a wholly-owned subsidiary of Novartis and parent of Endocyte, filed a petition for post-grant review of U.S. Patent No. 10,640,461 (the “’461 patent”) with the Patent Trial and Appeal Board (“PTAB”) of the USPTO. The ’461 patent is owned by MIP. In the petition, AAA challenged the patentability of certain claims of the ’461 patent. The PTAB instituted Post-Grant Review proceedings (the “PGR Proceeding”) on July 29, 2021. Pursuant to the terms of the Novartis Agreement, the PGR Proceeding was terminated.
Global Settlement Agreement
In addition to the dismissal of the German Litigation, the withdrawal of the Ownership Claim and the termination of the PGR Proceeding, under the Novartis Agreement, the parties, among other things, cross-licensed certain patent rights to one another, and Novartis made a $24.0 million lump sum payment to the Company and also reimbursed the Company for certain fees and expenses the Company is required to pay to the University in connection with the German Litigation. The Company received the $24.0 million payment in April 2022.
RELISTOR European Opposition Proceedings
In October 2015, Progenics received notices of opposition to three European patents relating to methylnaltrexone: EP1615646, EP2368553 and EP2368554. Notices of opposition were filed separately at the European Patent Office (the “EPO”) by each of Actavis Group PTC ehf and Fresenius Kabi Deutschland GmbH. Between May 11, 2017 and July 4, 2017, the Opposition Division of the EPO (the “Opposition Division”) provided notice that the three European patents would be revoked. Each of these matters was appealed to the Appeal Board of the EPO. On November 13, 2020, Progenics withdrew the appeal for EP2368553 and EP2368554. Notices of termination of the proceedings with revocation of the patent were issued on November 23, 2020 for both patents. Progenics continued its appeal on the revocation of the third patent, EP1615646. Oral proceedings for EP1615646 were held at the Appeal Board of the EPO on September 22, 2020. The revocation decision under appeal was set aside and the case was remitted to the Opposition Division for further prosecution. An oral hearing was held before the Opposition Division on September 27, 2021. The Opposition Division issued its final written opinion on November 11, 2021, indicating that the patent will be maintained in amended form. The final written decision of the Opposition Division was appealable to the Appeal Board of the EPO by either party. Progenics appealed this decision on January 20, 2022 to hold open its option to file Grounds for Appeal.
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Segment Information
3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
Segment Information Segment InformationIn the first quarter of fiscal year 2021, the Company completed the evaluation of its operating and reporting structure, including the impact on the Company’s business of the acquisition of Progenics described in Note 1, and the sale of the Puerto Rico subsidiary in the first quarter, which resulted in a change in operating and reportable segments. The Company now operates as one business segment: the development, manufacture and sale of innovative imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to Find, Fight and Follow serious medical conditions. This conclusion reflects the Company’s focus on the performance of the business on a consolidated worldwide basis. The results of this operating segment are regularly reviewed by the Company’s chief operating decision maker, the President and Chief Executive Officer. The Company’s chief operating decision maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements include the accounts of Holdings and its direct and indirect wholly-owned subsidiaries, including Progenics (as of the Closing Date, as defined below), and have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all of the information and notes required by generally accepted accounting principles in the United States of America (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement have been included. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ended December 31, 2022 or any future period.
The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities Exchange Commission (“SEC”) on February 24, 2022.
Recent Accounting Pronouncements Recent Accounting PronouncementsThe Company has not adopted any new accounting standards during the three months ended March 31, 2022
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue from Contracts with Customers (Tables)
3 Months Ended
Mar. 31, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of disaggregation of revenue
The following table summarizes revenue by revenue source as follows:
Three Months Ended
March 31,
Major Products/Service Lines (in thousands)20222021
    Product revenue, net(1)
$180,009 $87,319 
    License and royalty revenues(2)
28,871 5,190 
Total revenues$208,880 $92,509 
________________________________
(1)The Company’s principal products include PYLARIFY, DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the same revenue recognition policies and judgments for all its principal products.
(2)The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG. Please refer to Note 19, “Commitments and Contingencies” for further details on the license agreement.
Revenue by product category on a net basis is as follows:
Three Months Ended
March 31,
(in thousands)20222021
   DEFINITY$58,328 $55,971 
   TechneLite22,605 22,800 
   Other precision diagnostics5,265 6,984 
Total precision diagnostics86,198 85,755 
   PYLARIFY92,777 — 
   Other radiopharmaceutical oncology1,327 1,500 
Total radiopharmaceutical oncology94,104 1,500 
Strategic partnerships and other revenue28,578 5,254 
Total revenues$208,880 $92,509 
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Instruments (Tables)
3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
Schedule of assets and liabilities measured at fair value on a recurring basis
The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:
March 31, 2022
(in thousands)Total Fair
Value
Level 1Level 2Level 3
Assets:
   Money market$38,986 $38,986 $— $— 
   Interest rate swaps3,387 — 3,387 — 
   Contingent receivable8,900 — — 8,900 
Total assets$51,273 $38,986 $3,387 $8,900 
Liabilities:
   Contingent consideration liabilities$104,200 $— $— $104,200 
Total liabilities$104,200 $— $— $104,200 
December 31, 2021
(in thousands)Total Fair
Value
Level 1Level 2Level 3
Assets:
   Money market$40,140 $40,140 $— $— 
   Interest rate swaps357 — 357 — 
   Contingent receivable9,300 — — 9,300 
Total assets$49,797 $40,140 $357 $9,300 
Liabilities:
   Contingent consideration liabilities$86,200 $— $— $86,200 
Total liabilities$86,200 $— $— $86,200 
Fair value measurement inputs and valuation techniques
The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of assets and liabilities using Level 3 inputs at March 31, 2022.

Fair Value atAssumptions
(in thousands)March 31, 2022December 31, 2021Valuation TechniqueUnobservable InputMarch 31, 2022December 31, 2021
Contingent receivable:
Regulatory milestone$2,500 $2,500 Probability adjusted discounted cash flow modelPeriod of expected milestone achievement20222022
Probability of success70 %70 %
Discount rate18 %17 %
Royalties6,400 6,800 Probability adjusted discounted cash flow model
Probability of success
10% - 60%
10% - 60%
Discount rate18 %17 %
Total$8,900 $9,300 

Fair Value atAssumptions
(in thousands)March 31, 2022December 31, 2021Valuation TechniqueUnobservable InputMarch 31, 2022December 31, 2021
Contingent consideration liability:
Net sales targets - PYLARIFY (CVRs)$91,700 $73,200 Monte Carlo simulationPeriod of expected milestone achievement and sales targets2022 - 20232022 - 2023
Discount rate18 %17 %
1095 commercialization milestone1,800 1,900 Probability adjusted discounted cash flow model
Period of expected milestone achievement20262026
Probability of success40 %40 %
Discount rate2.1 %1.3 %
Net sales targets - AZEDRA and 109510,700 11,100 Monte Carlo simulation
Probability of success and sales targets
40% - 100%
40% - 100%
Discount rate
17% - 18%
16% - 17%
Total$104,200 $86,200 
Schedule of financial instruments with significant Level 3 inputs For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:
Financial AssetsFinancial Liabilities
(in thousands)Three Months Ended
March 31,
Three Months Ended
March 31,
2022202120222021
Fair value, beginning of period$9,300 $11,300 $86,200 $15,800 
Changes in fair value included in net income(400)900 18,000 1,200 
Fair value, end of period$8,900 $12,200 $104,200 $17,000 
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Tables)
3 Months Ended
Mar. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of income tax expense
Three Months Ended
March 31,
(in thousands)20222021
Income tax expense$14,939 $5,334 
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Inventory (Tables)
3 Months Ended
Mar. 31, 2022
Inventory Disclosure [Abstract]  
Schedule of inventory
Inventory consisted of the following:
        
(in thousands)March 31,
2022
December 31,
2021
Raw materials$13,861 $15,505 
Work in process13,071 13,042 
Finished goods7,317 6,582 
Total inventory$34,249 $35,129 
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Property, Plant and Equipment, Net (Tables)
3 Months Ended
Mar. 31, 2022
Property, Plant and Equipment [Abstract]  
Schedule of property, plant, and equipment, net
Property, plant and equipment, net, consisted of the following:
(in thousands)March 31,
2022
December 31,
2021
Land$13,450 $13,450 
Buildings73,560 73,559 
Machinery, equipment and fixtures84,983 83,608 
Computer software24,766 24,384 
Construction in progress12,186 10,686 
208,945 205,687 
Less: accumulated depreciation and amortization(91,986)(88,915)
Total property, plant and equipment, net$116,959 $116,772 
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Tables)
3 Months Ended
Mar. 31, 2022
Payables and Accruals [Abstract]  
Schedule of accrued liabilities
Accrued expenses and other liabilities and other long-term liabilities are comprised of the following:
(in thousands)March 31,
2022
December 31,
2021
Compensation and benefits$10,629 $22,730 
Freight, distribution and operations26,581 16,157 
Accrued rebates, discounts and chargebacks10,793 10,977 
Accrued professional fees3,596 2,850 
Short-term contingent liability (Note 4)83,300 — 
Other7,497 5,354 
Total accrued expenses and other liabilities$142,396 $58,068 
Operating lease liabilities (Note 16)$16,207 $16,546 
Long-term contingent liability (Note 4)20,900 86,200 
Other long-term liabilities21,669 22,148 
Total other long-term liabilities$58,776 $124,894 
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Sale of Puerto Rico Subsidiary (Tables)
3 Months Ended
Mar. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]  
Disposal groups including discontinued operations
The following table summarizes the major classes of assets and liabilities sold as of January 29, 2021 (date of sale):
(in thousands)
January 29, 2021
Current Assets:
Cash and cash equivalents
$540 
Accounts receivable, net
1,959 
Inventory
530 
Other current assets
65 
Total current assets
3,094 
Non-Current Assets:
Property, plant & equipment, net
780 
Intangibles, net
96 
Other long-term assets
774 
Total assets held for sale
$4,744 
Current Liabilities:
Accounts payable
$185 
Accrued expense and other liabilities
369 
Total current liabilities
554 
Non-Current Liabilities:
Asset retirement obligations
306 
Other long-term liabilities
588 
Total liabilities held for sale
$1,448 
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Asset Retirement Obligations (Tables)
3 Months Ended
Mar. 31, 2022
Asset Retirement Obligation Disclosure [Abstract]  
Summary of changes in asset retirement obligations The following table provides a summary of the changes in the Company’s asset retirement obligations:
(in thousands)Amount
Balance at January 1, 2022$20,833 
Accretion expense388 
Accelerated Costs293 
Balance at March 31, 2022$21,514 
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Intangibles, Net (Tables)
3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangibles
Intangibles, net, consisted of the following:
March 31, 2022
(in thousands)Useful Lives
(in years)
Amortization MethodCostAccumulated AmortizationNet
Trademarks
15 - 25
Straight-Line$13,540 $(11,648)$1,892 
Customer relationships
15 - 25
Accelerated96,962 (94,856)2,106 
Currently marketed products
9 - 15
Straight-Line275,700 (29,416)246,284 
Licenses
11 - 16
Straight-Line85,800 (13,441)72,359 
Developed technology9Straight-Line2,400 (477)1,923 
IPR&DN/AN/A15,640 — 15,640 
   Total$490,042 $(149,838)$340,204 


December 31, 2021
(in thousands)Useful Lives
(in years)
Amortization MethodCostAccumulated AmortizationNet
Trademarks
15 - 25
Straight-Line$13,540 $(11,510)$2,030 
Customer relationships
15 - 25
Accelerated96,880 (94,630)2,250 
Currently marketed product
9 - 15
Straight-Line275,700 (23,345)252,355 
Licenses
11 - 16
Straight-Line85,800 (11,555)74,245 
Developed technology9Straight-Line2,400 (410)1,990 
IPR&DN/AN/A15,640 — 15,640 
   Total$489,960 $(141,450)$348,510 
Schedule of intangibles
Intangibles, net, consisted of the following:
March 31, 2022
(in thousands)Useful Lives
(in years)
Amortization MethodCostAccumulated AmortizationNet
Trademarks
15 - 25
Straight-Line$13,540 $(11,648)$1,892 
Customer relationships
15 - 25
Accelerated96,962 (94,856)2,106 
Currently marketed products
9 - 15
Straight-Line275,700 (29,416)246,284 
Licenses
11 - 16
Straight-Line85,800 (13,441)72,359 
Developed technology9Straight-Line2,400 (477)1,923 
IPR&DN/AN/A15,640 — 15,640 
   Total$490,042 $(149,838)$340,204 


December 31, 2021
(in thousands)Useful Lives
(in years)
Amortization MethodCostAccumulated AmortizationNet
Trademarks
15 - 25
Straight-Line$13,540 $(11,510)$2,030 
Customer relationships
15 - 25
Accelerated96,880 (94,630)2,250 
Currently marketed product
9 - 15
Straight-Line275,700 (23,345)252,355 
Licenses
11 - 16
Straight-Line85,800 (11,555)74,245 
Developed technology9Straight-Line2,400 (410)1,990 
IPR&DN/AN/A15,640 — 15,640 
   Total$489,960 $(141,450)$348,510 
Schedule of expected future amortization expense
The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:
(in thousands)Amount
Remainder of 2022$24,923 
202332,634 
202432,563 
202532,508 
202632,497 
2027 and thereafter169,439 
   Total$324,564 
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Long-Term Debt, Net, and Other Borrowings (Tables)
3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
Schedule of maturities of principal obligations
As of March 31, 2022, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows:
(in thousands)Amount
Remainder of 2022$8,750 
202315,000 
2024148,750 
Total principal outstanding172,500 
Unamortized debt discount(448)
Unamortized debt issuance costs(387)
Finance lease liabilities582 
Total172,247 
Less: current portion(12,878)
Total long-term debt, net and other borrowings$159,369 
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Derivative Instruments (Tables)
3 Months Ended
Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of derivative instruments The following table presents the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheets:
(in thousands)March 31, 2022December 31, 2021
Derivatives typeClassification
Assets:
   Interest rate swapOther long-term assets$3,387 $357 
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Accumulated Other Comprehensive Income (Loss) (Tables)
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Schedule of accumulated other comprehensive income (loss)
The components of accumulated other comprehensive income (loss), net of tax of $0.9 million and $0.2 million for the three months ended March 31, 2022 and 2021, respectively, consisted of the following:
(in thousands)Foreign currency translationUnrealized loss on cash flow hedgesAccumulated other comprehensive loss
Balance at January 1, 2022$(754)$269 $(485)
Other comprehensive income before reclassifications140 2,086 2,226 
Amounts reclassified to earnings— 170 170 
Balance at March 31, 2022$(614)$2,525 $1,911 
Balance at January 1, 2021$(630)$(1,418)$(2,048)
Other comprehensive loss before reclassifications102 533 635 
Amounts reclassified to earnings— 173 173 
Balance at March 31, 2021$(528)$(712)$(1,240)
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Schedule of stock-based compensation expense recognized
The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations:
         
Three Months Ended
March 31,
(in thousands)20222021
Cost of goods sold$912 $622 
Sales and marketing1,013 350 
General and administrative3,002 1,920 
Research and development696 425 
Total stock-based compensation expense$5,623 $3,317 
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Leases (Tables)
3 Months Ended
Mar. 31, 2022
Leases [Abstract]  
Schedule of operating and finance lease assets and liabilities Operating and finance lease assets and liabilities are as follows:
(in thousands)ClassificationMarch 31,
2022
December 31,
2021
Assets
OperatingOther long-term assets$8,675 $8,788 
FinanceProperty, plant and equipment, net602 556 
Total leased assets$9,277 $9,344 
Liabilities
Current                     
     OperatingAccrued expenses and other liabilities$1,619 $1,599 
     FinanceCurrent portion of long-term debt and other borrowings378 392 
Noncurrent
     OperatingOther long-term liabilities16,207 16,546 
     FinanceLong-term debt, net and other borrowings204 299 
Total leased liabilities$18,408 $18,836 
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Net Income Per Common Share (Tables)
3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Summary of net income per common share
A summary of net income per common share is presented below:
Three Months Ended
March 31,
(in thousands, except per share amounts)20222021
Net income$42,962 $9,008 
Basic weighted-average common shares outstanding68,008 67,094 
Effect of dilutive stock options406 82 
Effect of dilutive restricted stock1,637 538 
Diluted weighted-average common shares outstanding70,051 67,714 
Basic income per common share$0.63 $0.13 
Diluted income per common share$0.61 $0.13 
Antidilutive securities excluded from diluted net income per common share377 1,349 
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Other Income (Tables)
3 Months Ended
Mar. 31, 2022
Other Income and Expenses [Abstract]  
Schedule of other loss (income)
Other income consisted of the following:
Three Months Ended
March 31,
(in thousands)20222021
Foreign currency (gains) losses$(81)$42 
Tax indemnification income, net(396)(573)
Interest income(8)(17)
Other— (1)
Total other income$(485)$(549)
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Basis of Presentation (Details)
$ / shares in Units, $ in Thousands
Feb. 20, 2020
USD ($)
contingent_value_right
$ / shares
shares
Mar. 31, 2022
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
$ / shares
Jun. 19, 2020
$ / shares
Business Acquisition [Line Items]        
Common stock, par value (in dollars per share) | $ / shares   $ 0.01 $ 0.01  
Contingent consideration liabilities | $   $ 104,200 $ 86,200  
Business combination, consideration transferred, equity interests issued (in shares) | shares 26,844,877      
Business combination common stock under contingent value right (in shares) | shares 86,630,633      
Progenics        
Business Acquisition [Line Items]        
Common stock, par value (in dollars per share) | $ / shares $ 0.0013      
Progenics        
Business Acquisition [Line Items]        
Common stock, par value (in dollars per share) | $ / shares $ 0.01      
Shares to be received from acquisition conversion (in shares) | shares 0.31      
Number of CVRs | contingent_value_right 1      
Aggregate cash payments percentage 40.00%      
Percentage of total contingent consideration under CVRs 19.90%      
Business combination contingent value right of total consideration | $ $ 100,000      
Share price (in dollars per share) | $ / shares       $ 4.42
Progenics | Cash Payments 2022        
Business Acquisition [Line Items]        
Contingent consideration liabilities | $ 100,000      
Progenics | Cash Payments 2023        
Business Acquisition [Line Items]        
Contingent consideration liabilities | $ $ 150,000      
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue from Contracts with Customers (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Disaggregation of Revenue [Line Items]    
Revenues $ 208,880 $ 92,509
Total amount awarded 24,000  
Product revenue, net    
Disaggregation of Revenue [Line Items]    
Revenues 180,009 87,319
License and royalty revenues(2)    
Disaggregation of Revenue [Line Items]    
Revenues 28,871 5,190
Total precision diagnostics    
Disaggregation of Revenue [Line Items]    
Revenues 86,198 85,755
DEFINITY    
Disaggregation of Revenue [Line Items]    
Revenues 58,328 55,971
TechneLite    
Disaggregation of Revenue [Line Items]    
Revenues 22,605 22,800
Other precision diagnostics    
Disaggregation of Revenue [Line Items]    
Revenues 5,265 6,984
PYLARIFY    
Disaggregation of Revenue [Line Items]    
Revenues 92,777 0
Other radiopharmaceutical oncology    
Disaggregation of Revenue [Line Items]    
Revenues 1,327 1,500
Total radiopharmaceutical oncology    
Disaggregation of Revenue [Line Items]    
Revenues 94,104 1,500
Strategic partnerships and other revenue    
Disaggregation of Revenue [Line Items]    
Revenues $ 28,578 $ 5,254
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on A Recurring Basis (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent receivable $ 8,900 $ 9,300
Total assets 51,273 49,797
Contingent consideration liabilities 104,200 86,200
Total liabilities 104,200 86,200
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent receivable 0 0
Total assets 38,986 40,140
Contingent consideration liabilities 0 0
Total liabilities 0 0
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent receivable 0 0
Total assets 3,387 357
Contingent consideration liabilities 0 0
Total liabilities 0 0
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent receivable 8,900 9,300
Total assets 8,900 9,300
Contingent consideration liabilities 104,200 86,200
Total liabilities 104,200 86,200
Interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Interest rate swaps 3,387 357
Interest rate swaps | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Interest rate swaps 0 0
Interest rate swaps | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Interest rate swaps 3,387 357
Interest rate swaps | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Interest rate swaps 0 0
Money market    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Money market 38,986 40,140
Money market | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Money market 38,986 40,140
Money market | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Money market 0 0
Money market | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Money market $ 0 $ 0
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Instruments - Narrative (Details)
$ in Thousands
3 Months Ended
Feb. 20, 2020
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Fair Value, Option, Quantitative Disclosures [Line Items]        
Company acquired right to receive certain future milestone   $ 208,880 $ 92,509  
Contingent consideration liabilities   $ 104,200   $ 86,200
Progenics        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Royalty percentage   0.05    
Aggregate cash payments percentage 40.00%      
Potential payments, high $ 100,000 $ 85,000    
Progenics | Current Liabilities        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Contingent consideration liabilities   83,300    
Progenics | Noncurrent Liabilities        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Contingent consideration liabilities   8,400    
Progenics | Cash Payments 2022        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Contingent consideration liabilities 100,000      
Progenics | Cash Payments 2023        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Contingent consideration liabilities $ 150,000      
Progenics | Net Sales Targets For Azedra        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Potential payments, high   70,000    
Progenics | 1095 commercialization milestone        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Potential payments, high   5,000    
Progenics | 1404 Commercialization Milestone        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Potential payment not reasonably possible   10,000    
Royalty | Progenics        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Company acquired right to receive certain future milestone   $ 5,000    
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Instruments - Quantitative Information and Assumptions Pertaining To The Fair Value Measurement of The Level 3 Inputs (Details)
$ in Thousands
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Fair Value, Option, Quantitative Disclosures [Line Items]    
Contingent receivable $ 8,900 $ 9,300
Contingent consideration liabilities 104,200 86,200
Level 3    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Contingent receivable 8,900 9,300
Contingent consideration liabilities 104,200 86,200
Level 3 | Regulatory milestone    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Contingent receivable 2,500 2,500
Level 3 | Royalties    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Contingent receivable 6,400 6,800
Level 3 | CVRs    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Contingent consideration liabilities 91,700 73,200
Level 3 | 1095 commercialization milestone    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Contingent consideration liabilities 1,800 1,900
Level 3 | Net sales targets - AZEDRA and 1095    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Contingent consideration liabilities $ 10,700 $ 11,100
Level 3 | Probability adjusted discounted cash flow model | Probability of success | Regulatory milestone    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Asset measurement input 0.70 0.70
Level 3 | Probability adjusted discounted cash flow model | Probability of success | Royalties | Minimum    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Asset measurement input 0.10 0.10
Level 3 | Probability adjusted discounted cash flow model | Probability of success | Royalties | Maximum    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Asset measurement input 0.60 0.60
Level 3 | Probability adjusted discounted cash flow model | Probability of success | 1095 commercialization milestone    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Liability measurement input 0.40 0.40
Level 3 | Probability adjusted discounted cash flow model | Discount rate | Regulatory milestone    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Asset measurement input 0.18 0.17
Level 3 | Probability adjusted discounted cash flow model | Discount rate | Royalties    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Asset measurement input 0.18 0.17
Level 3 | Probability adjusted discounted cash flow model | Discount rate | 1095 commercialization milestone    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Liability measurement input 0.021 0.013
Level 3 | Monte Carlo simulation | Probability of success | Net sales targets - AZEDRA and 1095 | Minimum    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Liability measurement input 0.40 0.40
Level 3 | Monte Carlo simulation | Probability of success | Net sales targets - AZEDRA and 1095 | Maximum    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Liability measurement input 1 1
Level 3 | Monte Carlo simulation | Discount rate | CVRs    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Liability measurement input 0.18 0.17
Level 3 | Monte Carlo simulation | Discount rate | Net sales targets - AZEDRA and 1095 | Minimum    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Liability measurement input 0.17 0.16
Level 3 | Monte Carlo simulation | Discount rate | Net sales targets - AZEDRA and 1095 | Maximum    
Fair Value, Option, Quantitative Disclosures [Line Items]    
Liability measurement input 0.18 0.17
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Instruments - Financial Instruments With Significant Level 3 Inputs (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Financial Assets    
Fair value, beginning of period $ 9,300 $ 11,300
Changes in fair value included in net income (400) 900
Fair value, end of period 8,900 12,200
Financial Liabilities    
Fair value, beginning of period 86,200 15,800
Changes in fair value included in net income 18,000 1,200
Fair value, end of period 104,200 $ 17,000
Change in fair value of the contingent financial asset and contingent financial liabilities $ 18,400  
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Valuation Allowance [Line Items]    
Income tax expense $ 14,939 $ 5,334
Goodwill acquired   $ 2,600
UNITED KINGDOM    
Valuation Allowance [Line Items]    
Deferred tax asset, valuation allowance 1,200  
SWEDEN    
Valuation Allowance [Line Items]    
Deferred tax asset, valuation allowance $ 2,000  
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.22.1
Inventory (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Inventory [Line Items]    
Raw materials $ 13,861 $ 15,505
Work in process 13,071 13,042
Finished goods 7,317 6,582
Total inventory $ 34,249 35,129
DEFINITY    
Inventory [Line Items]    
Total inventory   $ 6,100
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.22.1
Property, Plant and Equipment, Net (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Property, Plant & Equipment [Line Items]      
Property, plant & equipment, gross $ 208,945   $ 205,687
Less: accumulated depreciation and amortization (91,986)   (88,915)
Total property, plant and equipment, net 116,959   116,772
Depreciation and amortization expense 3,100 $ 3,000  
Land      
Property, Plant & Equipment [Line Items]      
Property, plant & equipment, gross 13,450   13,450
Buildings      
Property, Plant & Equipment [Line Items]      
Property, plant & equipment, gross 73,560   73,559
Machinery, equipment and fixtures      
Property, Plant & Equipment [Line Items]      
Property, plant & equipment, gross 84,983   83,608
Computer software      
Property, Plant & Equipment [Line Items]      
Property, plant & equipment, gross 24,766   24,384
Construction in progress      
Property, Plant & Equipment [Line Items]      
Property, plant & equipment, gross $ 12,186   $ 10,686
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Compensation and benefits $ 10,629 $ 22,730
Freight, distribution and operations 26,581 16,157
Accrued rebates, discounts and chargebacks 10,793 10,977
Accrued professional fees 3,596 2,850
Short-term contingent liability (Note 4) 83,300 0
Other 7,497 5,354
Total accrued expenses and other liabilities 142,396 58,068
Operating lease liabilities (Note 16) 16,207 16,546
Long-term contingent liability (Note 4) 20,900 86,200
Other long-term liabilities 21,669 22,148
Total other long-term liabilities $ 58,776 $ 124,894
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.22.1
Sale of Puerto Rico Subsidiary (Details) - Puerto Rican Radiopharmacy Servicing Subsidiary - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Jan. 29, 2021
Non-Current Liabilities:    
Pre-tax book gain on disposal $ 15,300  
Disposed of by Sale    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Disposal group consideration   $ 18,000
Disposal group holdback amount   1,800
Current assets    
Cash and cash equivalents   540
Accounts receivable, net   1,959
Inventory   530
Other current assets   65
Total current assets   3,094
Non-Current Assets:    
Property, plant & equipment, net   780
Intangibles, net   96
Other long-term assets   774
Total assets held for sale   4,744
Current liabilities    
Accounts payable   185
Accrued expense and other liabilities   369
Total current liabilities   554
Non-Current Liabilities:    
Asset retirement obligations   306
Other long-term liabilities   588
Total liabilities held for sale   $ 1,448
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.22.1
Asset Retirement Obligations - Additional Information (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Mar. 31, 2022
Asset Retirement Obligation Disclosure [Abstract]    
Obligation expected to be incurred   $ 26.4
Non-cash adjustment $ 5.3  
Financial assurance in form of surety bond   $ 28.2
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.22.1
Asset Retirement Obligations - Asset Retirement Obligation (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]    
Asset retirement obligations, beginning balance $ 20,833  
Accretion expense 388  
Accelerated Costs 293 $ 0
Asset retirement obligations, ending balance $ 21,514  
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.22.1
Intangibles, Net - Schedule of Intangibles, Net (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]      
Indefinite lived, Cost $ 15,640   $ 15,640
Total, cost 490,042   489,960
Accumulated Amortization (149,838)   (141,450)
Total 324,564    
Total, net 340,204   348,510
Trademarks      
Finite-Lived Intangible Assets [Line Items]      
Cost 13,540   13,540
Accumulated Amortization (11,648)   (11,510)
Total $ 1,892   2,030
Trademarks | Minimum      
Finite-Lived Intangible Assets [Line Items]      
Intangible asset, useful life 15 years 15 years  
Trademarks | Maximum      
Finite-Lived Intangible Assets [Line Items]      
Intangible asset, useful life 25 years 25 years  
Customer relationships      
Finite-Lived Intangible Assets [Line Items]      
Cost $ 96,962   96,880
Accumulated Amortization (94,856)   (94,630)
Total $ 2,106   2,250
Customer relationships | Minimum      
Finite-Lived Intangible Assets [Line Items]      
Intangible asset, useful life 15 years 15 years  
Customer relationships | Maximum      
Finite-Lived Intangible Assets [Line Items]      
Intangible asset, useful life 25 years 25 years  
Currently marketed products      
Finite-Lived Intangible Assets [Line Items]      
Cost $ 275,700   275,700
Accumulated Amortization (29,416)   (23,345)
Total $ 246,284   252,355
Currently marketed products | Minimum      
Finite-Lived Intangible Assets [Line Items]      
Intangible asset, useful life 9 years 9 years  
Currently marketed products | Maximum      
Finite-Lived Intangible Assets [Line Items]      
Intangible asset, useful life 15 years 15 years  
Licenses      
Finite-Lived Intangible Assets [Line Items]      
Cost $ 85,800   85,800
Accumulated Amortization (13,441)   (11,555)
Total $ 72,359   74,245
Licenses | Minimum      
Finite-Lived Intangible Assets [Line Items]      
Intangible asset, useful life 11 years 11 years  
Licenses | Maximum      
Finite-Lived Intangible Assets [Line Items]      
Intangible asset, useful life 16 years 16 years  
Developed technology      
Finite-Lived Intangible Assets [Line Items]      
Intangible asset, useful life 9 years 9 years  
Cost $ 2,400   2,400
Accumulated Amortization (477)   (410)
Total $ 1,923   $ 1,990
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.22.1
Intangibles, Net - Additional Information (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Amortization expense $ 8.3 $ 4.7
IPR & D    
Finite-Lived Intangible Assets [Line Items]    
Decrease in indefinite lived assets 132.8  
Currently marketed products    
Finite-Lived Intangible Assets [Line Items]    
Increase in finite lived assets $ 132.8  
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.22.1
Intangibles, Net - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Details)
$ in Thousands
Mar. 31, 2022
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
Remainder of 2022 $ 24,923
2023 32,634
2024 32,563
2025 32,508
2026 32,497
2027 and thereafter 169,439
Total $ 324,564
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.22.1
Long-Term Debt, Net, and Other Borrowings (Details) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Debt Instrument [Line Items]        
2022   $ 8,750,000    
2023   15,000,000    
2024   148,750,000    
Total principal outstanding   172,500,000    
Unamortized debt discount   (448,000)    
Unamortized debt issuance costs   (387,000)    
Finance lease liabilities   582,000    
Total   172,247,000    
Less: current portion   (12,878,000)    
Total long-term debt, net and other borrowings   159,369,000   $ 163,121,000
Gain on extinguishment of debt   $ 0 $ 889,000  
Royalty-Backed Loan        
Debt Instrument [Line Items]        
Debt instrument face amount $ 50,000,000   $ 50,000,000  
Extinguishment of debt 30,900,000      
Prepayment of debt 500,000      
Gain on extinguishment of debt $ 900,000      
2019 Term Loan Facility        
Debt Instrument [Line Items]        
Debt instrument term   5 years    
Interest rate   2.20%    
XML 77 R62.htm IDEA: XBRL DOCUMENT v3.22.1
Derivative Instruments (Detail) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Mar. 31, 2020
Derivative [Line Items]      
Pre-tax deferred losses expected to be reclassified to earnings during the next 12 months $ 1,000,000.0    
Cash Flow Hedge | Interest rate swaps      
Derivative [Line Items]      
Notional amount     $ 100,000,000
Average fixed interest rate     0.82%
Cash Flow Hedge | Interest rate swaps | Other Noncurrent Assets      
Derivative [Line Items]      
Interest rate swap $ 3,387,000 $ 357,000  
XML 78 R63.htm IDEA: XBRL DOCUMENT v3.22.1
Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Accumulated other comprehensive loss, tax $ 900 $ 200
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 464,439 514,205
Other comprehensive income (loss) before reclassifications 2,226 635
Amounts reclassified to earnings 170 173
Ending balance 515,850 528,119
Foreign currency translation    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (754) (630)
Other comprehensive income (loss) before reclassifications 140 102
Amounts reclassified to earnings 0 0
Ending balance (614) (528)
Unrealized loss on cash flow hedges    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 269 (1,418)
Other comprehensive income (loss) before reclassifications 2,086 533
Amounts reclassified to earnings 170 173
Ending balance 2,525 (712)
Accumulated other comprehensive loss    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (485) (2,048)
Ending balance $ 1,911 $ (1,240)
XML 79 R64.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense $ 5,623 $ 3,317
Cost of goods sold    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 912 622
Sales and marketing    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 1,013 350
General and administrative    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 3,002 1,920
Research and development    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense $ 696 $ 425
XML 80 R65.htm IDEA: XBRL DOCUMENT v3.22.1
Leases - Operating and Finance Lease Assets and Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Assets    
Operating $ 8,675 $ 8,788
Finance 602 556
Total leased assets 9,277 9,344
Current liabilities    
Operating 1,619 1,599
Finance 378 392
Non-Current Liabilities:    
Operating lease liabilities (Note 16) 16,207 16,546
Finance 204 299
Total leased liabilities $ 18,408 $ 18,836
Operating lease, right-of-use asset, statement of financial position [Extensible Enumeration] Other long-term assets Other long-term assets
Finance lease, right-of-use asset, statement of financial position [Extensible Enumeration] Property, plant and equipment, net Property, plant and equipment, net
Operating lease, liability, current, statement of financial position [Extensible Enumeration] Accrued expenses and other liabilities Accrued expenses and other liabilities
Finance lease, liability, current, statement of financial position [Extensible Enumeration] Current portion of long-term debt and other borrowings Current portion of long-term debt and other borrowings
Operating lease, liability, noncurrent, statement of financial position [Extensible Enumeration] Other long-term liabilities Other long-term liabilities
Finance lease, liability, noncurrent, statement of financial position [Extensible Enumeration] Long-term debt, net and other borrowings Long-term debt, net and other borrowings
XML 81 R66.htm IDEA: XBRL DOCUMENT v3.22.1
Net Income Per Common Share (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Earnings Per Share [Abstract]    
Net income $ 42,962 $ 9,008
Basic weighted-average common shares outstanding (in shares) 68,008 67,094
Effect of dilutive stock options (in shares) 406 82
Effect of dilutive restricted stock (in shares) 1,637 538
Diluted weighted-average common shares outstanding (in shares) 70,051 67,714
Basic income per common share (in dollars per share) $ 0.63 $ 0.13
Diluted income per common share (in dollars per share) $ 0.61 $ 0.13
Antidilutive securities excluded from diluted net income per common share (in shares) 377 1,349
XML 82 R67.htm IDEA: XBRL DOCUMENT v3.22.1
Other Income (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Other Income and Expenses [Abstract]    
Foreign currency (gains) losses $ (81) $ 42
Tax indemnification income, net (396) (573)
Interest income (8) (17)
Other 0 (1)
Total other income $ (485) $ (549)
XML 83 R68.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies (Details)
€ in Millions, $ in Millions
1 Months Ended 3 Months Ended
Oct. 31, 2015
patent
Mar. 31, 2022
USD ($)
Feb. 27, 2019
EUR (€)
Loss Contingencies [Line Items]      
Total amount awarded | $   $ 24.0  
European      
Loss Contingencies [Line Items]      
Number of patents | patent 3    
MIP      
Loss Contingencies [Line Items]      
Court deposit | €     € 0.4
XML 84 R69.htm IDEA: XBRL DOCUMENT v3.22.1
Segment Information (Details)
3 Months Ended
Mar. 31, 2022
segment
Segment Reporting [Abstract]  
Operating segments 1
XML 85 lnth-20220331_htm.xml IDEA: XBRL DOCUMENT 0001521036 2022-01-01 2022-03-31 0001521036 2022-04-22 0001521036 2022-03-31 0001521036 2021-12-31 0001521036 2021-01-01 2021-03-31 0001521036 us-gaap:CommonStockMember 2021-12-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001521036 us-gaap:RetainedEarningsMember 2021-12-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001521036 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001521036 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001521036 us-gaap:CommonStockMember 2022-03-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001521036 us-gaap:RetainedEarningsMember 2022-03-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001521036 us-gaap:CommonStockMember 2020-12-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001521036 us-gaap:RetainedEarningsMember 2020-12-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001521036 2020-12-31 0001521036 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001521036 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001521036 us-gaap:CommonStockMember 2021-03-31 0001521036 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001521036 us-gaap:RetainedEarningsMember 2021-03-31 0001521036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001521036 2021-03-31 0001521036 lnth:ProgenicsMember 2020-02-20 0001521036 lnth:ProgenicsMember 2020-02-20 2020-02-20 0001521036 lnth:ProgenicsMember 2020-02-20 0001521036 lnth:ProgenicsMember lnth:CashPayments2022Member 2020-02-20 0001521036 lnth:ProgenicsMember lnth:CashPayments2023Member 2020-02-20 0001521036 lnth:ProgenicsMember 2020-06-19 0001521036 2020-02-20 2020-02-20 0001521036 us-gaap:ProductMember 2022-01-01 2022-03-31 0001521036 us-gaap:ProductMember 2021-01-01 2021-03-31 0001521036 lnth:LicenseandRoyaltyRevenuesMember 2022-01-01 2022-03-31 0001521036 lnth:LicenseandRoyaltyRevenuesMember 2021-01-01 2021-03-31 0001521036 lnth:DefinityMember 2022-01-01 2022-03-31 0001521036 lnth:DefinityMember 2021-01-01 2021-03-31 0001521036 lnth:TechneLiteMember 2022-01-01 2022-03-31 0001521036 lnth:TechneLiteMember 2021-01-01 2021-03-31 0001521036 lnth:OtherPrecisionDiagnosticsMember 2022-01-01 2022-03-31 0001521036 lnth:OtherPrecisionDiagnosticsMember 2021-01-01 2021-03-31 0001521036 lnth:TotalPrecisionDiagnosticsMember 2022-01-01 2022-03-31 0001521036 lnth:TotalPrecisionDiagnosticsMember 2021-01-01 2021-03-31 0001521036 lnth:PYLARIFYMember 2022-01-01 2022-03-31 0001521036 lnth:PYLARIFYMember 2021-01-01 2021-03-31 0001521036 lnth:OtherRadiopharmaceuticalOncologyMember 2022-01-01 2022-03-31 0001521036 lnth:OtherRadiopharmaceuticalOncologyMember 2021-01-01 2021-03-31 0001521036 lnth:RadiopharmaceuticalOncologyMember 2022-01-01 2022-03-31 0001521036 lnth:RadiopharmaceuticalOncologyMember 2021-01-01 2021-03-31 0001521036 lnth:StrategicPartnershipsAndOtherMember 2022-01-01 2022-03-31 0001521036 lnth:StrategicPartnershipsAndOtherMember 2021-01-01 2021-03-31 0001521036 us-gaap:MoneyMarketFundsMember 2022-03-31 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-03-31 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2022-03-31 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001521036 us-gaap:InterestRateSwapMember 2022-03-31 0001521036 us-gaap:FairValueInputsLevel1Member us-gaap:InterestRateSwapMember 2022-03-31 0001521036 us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateSwapMember 2022-03-31 0001521036 us-gaap:FairValueInputsLevel3Member us-gaap:InterestRateSwapMember 2022-03-31 0001521036 us-gaap:FairValueInputsLevel1Member 2022-03-31 0001521036 us-gaap:FairValueInputsLevel2Member 2022-03-31 0001521036 us-gaap:FairValueInputsLevel3Member 2022-03-31 0001521036 us-gaap:MoneyMarketFundsMember 2021-12-31 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001521036 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001521036 us-gaap:InterestRateSwapMember 2021-12-31 0001521036 us-gaap:FairValueInputsLevel1Member us-gaap:InterestRateSwapMember 2021-12-31 0001521036 us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateSwapMember 2021-12-31 0001521036 us-gaap:FairValueInputsLevel3Member us-gaap:InterestRateSwapMember 2021-12-31 0001521036 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001521036 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001521036 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001521036 us-gaap:RoyaltyMember lnth:ProgenicsMember 2022-01-01 2022-03-31 0001521036 lnth:ProgenicsMember 2022-01-01 2022-03-31 0001521036 lnth:ProgenicsMember lnth:NetSalesTargetsForAzedraMember 2022-03-31 0001521036 lnth:ProgenicsMember lnth:A1095CommercializationMember 2022-03-31 0001521036 lnth:ProgenicsMember lnth:A1404CommercializationMilestoneMember 2022-03-31 0001521036 lnth:ProgenicsMember 2022-03-31 0001521036 lnth:RegulatoryMilestoneMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001521036 lnth:RegulatoryMilestoneMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001521036 lnth:RegulatoryMilestoneMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-03-31 0001521036 lnth:RegulatoryMilestoneMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-12-31 0001521036 lnth:RegulatoryMilestoneMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-03-31 0001521036 lnth:RegulatoryMilestoneMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-12-31 0001521036 lnth:RoyaltiesMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001521036 lnth:RoyaltiesMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001521036 srt:MinimumMember lnth:RoyaltiesMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-03-31 0001521036 srt:MaximumMember lnth:RoyaltiesMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-03-31 0001521036 srt:MinimumMember lnth:RoyaltiesMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-12-31 0001521036 srt:MaximumMember lnth:RoyaltiesMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-12-31 0001521036 lnth:RoyaltiesMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-03-31 0001521036 lnth:RoyaltiesMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-12-31 0001521036 lnth:ContingentValueRightMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001521036 lnth:ContingentValueRightMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001521036 lnth:ContingentValueRightMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember lnth:MonteCarloSimulationMember 2022-03-31 0001521036 lnth:ContingentValueRightMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember lnth:MonteCarloSimulationMember 2021-12-31 0001521036 lnth:A1095CommercializationMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001521036 lnth:A1095CommercializationMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001521036 lnth:A1095CommercializationMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-03-31 0001521036 lnth:A1095CommercializationMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-12-31 0001521036 lnth:A1095CommercializationMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-03-31 0001521036 lnth:A1095CommercializationMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-12-31 0001521036 lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001521036 lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001521036 srt:MinimumMember lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember lnth:MonteCarloSimulationMember 2022-03-31 0001521036 srt:MaximumMember lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember lnth:MonteCarloSimulationMember 2022-03-31 0001521036 srt:MinimumMember lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember lnth:MonteCarloSimulationMember 2021-12-31 0001521036 srt:MaximumMember lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member lnth:MeasurementInputProbabilityOfSuccessMember lnth:MonteCarloSimulationMember 2021-12-31 0001521036 srt:MinimumMember lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember lnth:MonteCarloSimulationMember 2022-03-31 0001521036 srt:MaximumMember lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember lnth:MonteCarloSimulationMember 2022-03-31 0001521036 srt:MinimumMember lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember lnth:MonteCarloSimulationMember 2021-12-31 0001521036 srt:MaximumMember lnth:ContingentConsiderationNetSalesTargetsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember lnth:MonteCarloSimulationMember 2021-12-31 0001521036 lnth:CurrentLiabilitiesMember lnth:ProgenicsMember 2022-03-31 0001521036 lnth:NoncurrentLiabilitiesMember lnth:ProgenicsMember 2022-03-31 0001521036 country:GB 2022-03-31 0001521036 country:SE 2022-03-31 0001521036 lnth:DefinityMember 2021-12-31 0001521036 us-gaap:LandMember 2022-03-31 0001521036 us-gaap:LandMember 2021-12-31 0001521036 us-gaap:BuildingMember 2022-03-31 0001521036 us-gaap:BuildingMember 2021-12-31 0001521036 lnth:MachineryEquipmentAndFixturesMember 2022-03-31 0001521036 lnth:MachineryEquipmentAndFixturesMember 2021-12-31 0001521036 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-03-31 0001521036 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-12-31 0001521036 us-gaap:ConstructionInProgressMember 2022-03-31 0001521036 us-gaap:ConstructionInProgressMember 2021-12-31 0001521036 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember lnth:PuertoRicanRadiopharmacyServicingSubsidiaryMember 2021-01-29 0001521036 lnth:PuertoRicanRadiopharmacyServicingSubsidiaryMember 2021-01-01 2021-03-31 0001521036 2021-01-01 2021-12-31 0001521036 srt:MinimumMember us-gaap:TrademarksMember 2022-01-01 2022-03-31 0001521036 srt:MaximumMember us-gaap:TrademarksMember 2022-01-01 2022-03-31 0001521036 us-gaap:TrademarksMember 2022-03-31 0001521036 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2022-01-01 2022-03-31 0001521036 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2022-01-01 2022-03-31 0001521036 us-gaap:CustomerRelationshipsMember 2022-03-31 0001521036 srt:MinimumMember lnth:CurrentlyMarketedProductMember 2022-01-01 2022-03-31 0001521036 srt:MaximumMember lnth:CurrentlyMarketedProductMember 2022-01-01 2022-03-31 0001521036 lnth:CurrentlyMarketedProductMember 2022-03-31 0001521036 srt:MinimumMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-03-31 0001521036 srt:MaximumMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-03-31 0001521036 us-gaap:LicensingAgreementsMember 2022-03-31 0001521036 us-gaap:DevelopedTechnologyRightsMember 2022-01-01 2022-03-31 0001521036 us-gaap:DevelopedTechnologyRightsMember 2022-03-31 0001521036 srt:MinimumMember us-gaap:TrademarksMember 2021-01-01 2021-03-31 0001521036 srt:MaximumMember us-gaap:TrademarksMember 2021-01-01 2021-03-31 0001521036 us-gaap:TrademarksMember 2021-12-31 0001521036 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2021-01-01 2021-03-31 0001521036 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2021-01-01 2021-03-31 0001521036 us-gaap:CustomerRelationshipsMember 2021-12-31 0001521036 srt:MinimumMember lnth:CurrentlyMarketedProductMember 2021-01-01 2021-03-31 0001521036 srt:MaximumMember lnth:CurrentlyMarketedProductMember 2021-01-01 2021-03-31 0001521036 lnth:CurrentlyMarketedProductMember 2021-12-31 0001521036 srt:MinimumMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-03-31 0001521036 srt:MaximumMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-03-31 0001521036 us-gaap:LicensingAgreementsMember 2021-12-31 0001521036 us-gaap:DevelopedTechnologyRightsMember 2021-01-01 2021-03-31 0001521036 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0001521036 lnth:CurrentlyMarketedProductMember 2022-01-01 2022-03-31 0001521036 lnth:IPRDMember 2022-01-01 2022-03-31 0001521036 lnth:TwoThousandandNineteenTermFacilityMember 2022-01-01 2022-03-31 0001521036 lnth:TwoThousandandNineteenTermFacilityMember 2022-03-31 0001521036 lnth:RoyaltyBackedLoanMember 2021-03-31 0001521036 lnth:RoyaltyBackedLoanMember 2021-03-31 2021-03-31 0001521036 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-03-31 0001521036 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2022-03-31 0001521036 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2021-12-31 0001521036 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0001521036 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0001521036 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0001521036 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-03-31 0001521036 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0001521036 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-03-31 0001521036 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0001521036 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0001521036 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-03-31 0001521036 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-03-31 0001521036 us-gaap:AccumulatedTranslationAdjustmentMember 2021-03-31 0001521036 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-03-31 0001521036 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0001521036 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0001521036 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-03-31 0001521036 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-03-31 0001521036 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001521036 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001521036 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001521036 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001521036 lnth:MolecularInsightPharmaceuticalsIncMember 2019-02-27 0001521036 lnth:EuropeanMember 2015-10-01 2015-10-31 shares iso4217:USD iso4217:USD shares lnth:contingent_value_right pure iso4217:EUR lnth:patent lnth:segment false 2022 Q1 0001521036 --12-31 http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#LongTermDebtCurrent http://fasb.org/us-gaap/2021-01-31#LongTermDebtCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligations 10-Q true 2022-03-31 false 001-36569 LANTHEUS HOLDINGS, INC. DE 35-2318913 331 Treble Cove Road 01862 North Billerica, MA (978) 671-8001 Common stock, par value $0.01 per share LNTH NASDAQ Yes Yes Large Accelerated Filer false false false 68634063 105355000 98508000 172283000 89336000 34249000 35129000 12860000 12818000 324747000 235791000 116959000 116772000 340204000 348510000 61189000 61189000 47868000 62764000 42199000 38758000 933166000 863784000 12878000 11642000 22383000 20787000 142396000 58068000 177657000 90497000 21514000 20833000 159369000 163121000 58776000 124894000 417316000 399345000 0.01 0.01 25000000 25000000 0 0 0 0 0 0 0.01 0.01 250000000 250000000 68570000 68570000 67739000 67739000 686000 677000 691516000 685472000 -178263000 -221225000 1911000 -485000 515850000 464439000 933166000 863784000 208880000 92509000 79810000 51479000 129070000 41030000 20354000 14173000 37588000 16138000 12203000 10360000 70145000 40671000 0 15263000 58925000 15622000 1509000 2718000 0 889000 485000 549000 57901000 14342000 14939000 5334000 42962000 9008000 0.63 0.13 0.61 0.13 68008000 67094000 70051000 67714000 42962000 9008000 140000 102000 2256000 706000 2396000 808000 45358000 9816000 67739000 677000 685472000 -221225000 -485000 464439000 42962000 42962000 2396000 2396000 296000 3000 5931000 5934000 645000 7000 -7000 0 110000 1000 5503000 5504000 5623000 5623000 68570000 686000 691516000 -178263000 1911000 515850000 66875000 669000 665530000 -149946000 -2048000 514205000 9008000 9008000 808000 808000 155000 1000 2379000 2380000 489000 5000 -5000 0 85000 1000 1598000 1599000 3317000 3317000 67434000 674000 669623000 -140938000 -1240000 528119000 42962000 9008000 11786000 8123000 293000 0 246000 -61000 18400000 300000 0 889000 2519000 1395000 5623000 3317000 0 15263000 14180000 4581000 396000 573000 779000 728000 -829000 -655000 85155000 2346000 1634000 -3889000 104000 536000 533000 0 1506000 4110000 -1037000 -6620000 10264000 9818000 3190000 2520000 1800000 15823000 -1390000 13303000 2609000 35572000 5357000 2043000 577000 337000 5504000 1599000 -2179000 -34791000 151000 -21000 6846000 -11691000 100651000 82694000 107497000 71003000 105355000 68861000 2142000 2142000 107497000 71003000 Basis of Presentation <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Holdings and its direct and indirect wholly-owned subsidiaries, including Progenics (as of the Closing Date, as defined below), and have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all of the information and notes required by generally accepted accounting principles in the United States of America (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement have been included. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ended December 31, 2022 or any future period.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities Exchange Commission (“SEC”) on February 24, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Progenics Acquisition</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020 (the “Closing Date”), pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the “Merger Agreement”), by and among Holdings, Plato Merger Sub, Inc., a wholly-owned subsidiary of Holdings (“Merger Sub”), and Progenics, Holdings completed the acquisition of Progenics by means of a merger of Merger Sub with and into Progenics, with Progenics surviving such merger as a wholly-owned subsidiary of Holdings (the “Progenics Acquisition”). Subsequently, on June 22, 2020, Holdings contributed all of the capital stock of Progenics to LMI, thereby making Progenics an indirect subsidiary of Holdings.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Merger Agreement, at the effective time of the Progenics Acquisition (the “Effective Time”), each share of Progenics common stock, par value $0.0013 per share, issued and outstanding immediately prior to the Effective Time (other than shares of Progenics common stock owned by Holdings, Progenics or any of their wholly-owned subsidiaries) was automatically cancelled and converted into the right to receive (i) 0.31 (the “Exchange Ratio”) of a share of Holdings common stock, par value $0.01 per share, and (ii) one contingent value right (a “CVR”) tied to the financial performance of PyL (18F-DCFPyL), Progenics’ prostate-specific membrane antigen (“PSMA”) targeted imaging agent designed to visualize prostate cancer. This agent was approved by the U.S. Food and Drug Administration (“FDA”) on May 26, 2021 under the name PYLARIFY (piflufolastat F 18), and the commercial launch of this agent began in June 2021. Each CVR entitles its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively. In no event will the Company’s aggregate payments in respect of the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Acquisition, exceed 19.9% of the total consideration the Company pays in the Progenics Acquisition (which the Company currently estimates could be approximately $100.0 million). The Company expects to issue any applicable cash payments related to the CVRs as early as the first quarter of 2023 and the first quarter of 2024. No fractional shares of Holdings common stock were issued in the Progenics Acquisition, and Progenics’ former stockholders have received cash in lieu of any fractional shares of Holdings common stock. In addition, in accordance with the Merger Agreement, at the Effective Time, each Progenics stock option with a per share exercise price less than or equal to $4.42 (an “in-the-money Progenics stock option”) received in exchange for each such in-the money Progenics stock option: (i) an option to purchase Holdings common stock (each, a “Replacement Stock Option”) converted based on the Exchange Ratio, and (ii) a vested or unvested CVR depending on whether the underlying in-the-money Progenics stock option was vested or unvested at the Effective Time. Each Progenics stock option with a per share exercise price greater than $4.42 (an “out-of-the-money Progenics stock option”) received in exchange for such out-of-the-money Progenics stock options a Replacement Stock Option converted at an exchange ratio determined based on the average of the </span></div>volume weighted average price per share of common stock of Progenics and Lantheus Holdings prior to the Effective Time, which exchange ratio was 0.31, the same as the Exchange Ratio. As a result of the acquisition, Holdings issued 26,844,877 shares of Holdings common stock and 86,630,633 CVRs to former Progenics stockholders and option holders. <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Holdings and its direct and indirect wholly-owned subsidiaries, including Progenics (as of the Closing Date, as defined below), and have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all of the information and notes required by generally accepted accounting principles in the United States of America (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement have been included. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ended December 31, 2022 or any future period.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities Exchange Commission (“SEC”) on February 24, 2022.</span></div> 0.0013 0.31 0.01 1 0.40 100000000 150000000 0.199 100000000 4.42 4.42 0.31 26844877 86630633 Summary of Significant Accounting PoliciesRecent Accounting PronouncementsThe Company has not adopted any new accounting standards during the three months ended March 31, 2022 Recent Accounting PronouncementsThe Company has not adopted any new accounting standards during the three months ended March 31, 2022 Revenue from Contracts with Customers <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by revenue source as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.972%"><tr><td style="width:1.0%"/><td style="width:49.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.063%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Major Products/Service Lines (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Product revenue, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,009 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,319 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    License and royalty revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,880 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,509 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">The Company’s principal products include PYLARIFY, DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the same revenue recognition policies and judgments for all its principal products.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG. Please refer to Note 19, “Commitments and Contingencies” for further details on the license agreement.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its revenues into three product categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other revenue. Precision diagnostics includes DEFINITY, TechneLite and other imaging diagnostic products. Radiopharmaceutical oncology consists primarily of PYLARIFY and AZEDRA. Strategic partnerships and other revenue includes strategic partnerships and other arrangements related to other products of the Company, such as royalty revenue from our license of RELISTOR.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2022, the Company entered into a global settlement agreement with Novartis Pharma AG (“Novartis”), Advanced Accelerator Applications USA, Inc. (“AAA”), Endocyte, Inc. (“Endocyte”) and their affiliates (the “Novartis Agreement”) to settle certain disputes between the parties. Under the Novartis Agreement, Novartis agreed to make a lump sum payment to the Company, as well as to reimburse the Company for certain fees and expenses in connection with the German litigation (please refer to Note 19 “Commitments and Contingencies”) and the Company agreed to license certain intellectual property to Novartis. In addition, the Company agreed to supply PYLARIFY for clinical purposes at an arms-length value which will be recorded in the future as product is provided. In accordance with the Company's ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, assessment, Novartis is considered to be a customer. The Company determined that the $24.0 million constituted a single element which was satisfied on the date of the execution of the Novartis Agreement. The Company determined that the license of intellectual property carried a fair value of $24.0 million. As such, the Company assigned the value to the fair value of the license, which constitutes the entire transaction price and does not require further allocation. The Company determined that the $24.0 million represented the point at which the licensee was able to use and benefit from the license and recognized revenue when the license was granted to Novartis upon execution of the Novartis Agreement. The Company recognized the $24.0 million fee as revenue on its consolidated statement of operations for the quarter ended March 31, 2022. The Company received the $24.0 million payment in April 2022.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product category on a net basis is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.972%"><tr><td style="width:1.0%"/><td style="width:54.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.995%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   DEFINITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,971 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   TechneLite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Other precision diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total precision diagnostics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,198 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,755 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   PYLARIFY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,777 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Other radiopharmaceutical oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total radiopharmaceutical oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategic partnerships and other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,578 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,254 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,880 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,509 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.</span></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by revenue source as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.972%"><tr><td style="width:1.0%"/><td style="width:49.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.063%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Major Products/Service Lines (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Product revenue, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,009 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,319 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    License and royalty revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,880 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,509 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">The Company’s principal products include PYLARIFY, DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the same revenue recognition policies and judgments for all its principal products.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG. Please refer to Note 19, “Commitments and Contingencies” for further details on the license agreement.</span></div>Revenue by product category on a net basis is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.972%"><tr><td style="width:1.0%"/><td style="width:54.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.995%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   DEFINITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,971 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   TechneLite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Other precision diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total precision diagnostics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,198 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,755 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   PYLARIFY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,777 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Other radiopharmaceutical oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total radiopharmaceutical oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategic partnerships and other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,578 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,254 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,880 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,509 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 180009000 87319000 28871000 5190000 208880000 92509000 24000000 24000000 24000000 24000000 24000000 24000000 58328000 55971000 22605000 22800000 5265000 6984000 86198000 85755000 92777000 0 1327000 1500000 94104000 1500000 28578000 5254000 208880000 92509000 Fair Value of Financial Instruments <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability of fair value measurements, financial instruments are categorized based on a hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Unobservable inputs that reflect a Company’s estimates about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial assets and liabilities measured at fair value on a recurring basis consist of money market funds, interest rate swaps, a contingent receivable and contingent consideration liabilities. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the condensed consolidated balance sheets at fair value using quoted prices in active markets for identical assets. The fair value of the interest rate swaps is determined based on observable market-based inputs, including interest rate curves and reflects the contractual terms of these instruments, including the period to maturity. Please refer to Note 13, “Derivative Instruments”, for further details on the interest rate swaps. The Company recorded a contingent receivable and the contingent consideration liabilities resulting from the Progenics Acquisition at fair value based on inputs that are not observable in the market.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.666%"><tr><td style="width:1.0%"/><td style="width:38.211%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Money market</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Contingent receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,273 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,986 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.388%"><tr><td style="width:1.0%"/><td style="width:37.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Money market</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Contingent receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, there were no transfers into or out of Level 3.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Progenics Acquisition, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics from CytoDyn Inc. related to a prior sale of certain intellectual property. The Company has the right to receive $5.0 million upon regulatory approval and a 5% royalty on net sales of approved products. The Company considers the contingent receivable a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flows that included significant estimates and assumptions pertaining to regulatory events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Progenics Acquisition, the Company issued CVRs and recorded the fair value as part of consideration transferred. Each CVR entitles its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively, subject to a maximum cap (which the Company currently estimates could be approximately $100.0 million). Refer to Note 1, “Basis of Presentation” for further details on the CVRs. Additionally, the Company assumed contingent consideration liabilities related to a previous acquisition completed by Progenics in 2013 (“2013 Acquisition”). These contingent consideration liabilities include potential payments of up to $70.0 million if the Company attains certain net sales targets primarily for AZEDRA and 1095 and a $5.0 million 1095 commercialization milestone. Additionally, there is a potential payment of up to $10.0 million related to a 1404 commercialization milestone. The Company’s total potential payments related to the 2013 Acquisition are approximately $85.0 million. The Company considers the contingent consideration liabilities relating to the CVRs and the 2013 Acquisition, each a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value of these was determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs with respect to 1095 and 1404 are the probabilities of achieving regulatory approval of those development projects and subsequent commercial success.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant changes in any of the probabilities of success, the probabilities as to the periods in which sales targets and milestones will be achieved, discount rates or underlying revenue forecasts would result in a significantly higher or lower fair value measurement. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in general and administrative expenses in the condensed consolidated statements of operations. The Company can give no assurance that the actual </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts paid, if any, in connection with the contingent consideration liabilities, including the CVRs, will be consistent with any recurring fair value estimate of such contingent consideration liabilities.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of assets and liabilities using Level 3 inputs at March 31, 2022.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"/><td style="width:15.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.470%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.577%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.577%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.912%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumptions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent receivable:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory milestone</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability adjusted discounted cash flow model</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period of expected milestone achievement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability adjusted discounted cash flow model</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10% - 60%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10% - 60%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,900 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumptions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent consideration liability:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales targets - PYLARIFY (CVRs)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo simulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period of expected milestone achievement and sales targets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1095 commercialization milestone</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability adjusted discounted cash flow model</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period of expected milestone achievement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales targets - AZEDRA and 1095</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo simulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success and sales targets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40% - 100%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40% - 100%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17% - 18%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16% - 17%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.055%"><tr><td style="width:1.0%"/><td style="width:38.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.347%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.347%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.366%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value included in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,900 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table>The change in fair value of the contingent financial asset and contingent financial liabilities, including the CVRs, resulted in an expense of $18.4 million for the three months ended March 31, 2022 and was primarily due to changes in revenue forecasts, changes in market conditions, an increase in discount rates and the passage of time. The Company expects to issue any applicable cash payments related to the CVRs as early as the first quarter of 2023 and the first quarter of 2024. As of March 31, 2022, the Company has $83.3 million in current liabilities and $8.4 million in long term liabilities to account for the expected payments related to the CVRs. <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.666%"><tr><td style="width:1.0%"/><td style="width:38.211%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Money market</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Contingent receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,273 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,986 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.388%"><tr><td style="width:1.0%"/><td style="width:37.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Money market</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Contingent receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 38986000 38986000 0 0 3387000 0 3387000 0 8900000 0 0 8900000 51273000 38986000 3387000 8900000 104200000 0 0 104200000 104200000 0 0 104200000 40140000 40140000 0 0 357000 0 357000 0 9300000 0 0 9300000 49797000 40140000 357000 9300000 86200000 0 0 86200000 86200000 0 0 86200000 5000000 0.05 0.40 100000000 150000000 100000000 70000000 5000000 10000000 85000000 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of assets and liabilities using Level 3 inputs at March 31, 2022.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"/><td style="width:15.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.470%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.577%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.577%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.912%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumptions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent receivable:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory milestone</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability adjusted discounted cash flow model</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period of expected milestone achievement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability adjusted discounted cash flow model</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10% - 60%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10% - 60%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,900 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,300 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumptions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent consideration liability:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales targets - PYLARIFY (CVRs)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo simulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period of expected milestone achievement and sales targets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1095 commercialization milestone</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability adjusted discounted cash flow model</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period of expected milestone achievement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales targets - AZEDRA and 1095</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monte Carlo simulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success and sales targets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40% - 100%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40% - 100%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17% - 18%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16% - 17%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div> 2500000 2500000 0.70 0.70 0.18 0.17 6400000 6800000 0.10 0.60 0.10 0.60 0.18 0.17 8900000 9300000 91700000 73200000 0.18 0.17 1800000 1900000 0.40 0.40 0.021 0.013 10700000 11100000 0.40 1 0.40 1 0.17 0.18 0.16 0.17 104200000 86200000 For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.055%"><tr><td style="width:1.0%"/><td style="width:38.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.347%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.347%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.366%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value included in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,900 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 9300000 11300000 86200000 15800000 400000 -900000 -18000000 -1200000 8900000 12200000 104200000 17000000 -18400000 83300000 8400000 Income Taxes<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates income taxes at the end of each reporting period based on the estimated effective tax rate for the full year, adjusted for any discrete events which are recorded in the period they occur. Cumulative adjustments to the tax provision are recorded in the reporting period in which a change in the estimated annual effective tax rate is determined. The Company’s income tax expense is presented below:            </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"/><td style="width:45.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.735%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,939 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,334 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realizability of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more-likely-than-not realizable, the Company evaluated all available positive and negative evidence, and weighed the objective evidence and expected impact. The Company assessed the need for a valuation allowance against certain state tax credit carryforwards added through the Progenics Acquisition. The Company continues to retain other valuation allowances of $1.2 million against the net deferred tax assets of its U.K. subsidiary, and $2.0 million against the net deferred tax assets of its Sweden subsidiary.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb (“BMS”) in 2008, the Company recorded a liability for uncertain tax positions related to the acquired business and simultaneously entered into a tax indemnification agreement with BMS under which BMS agreed to indemnify the Company for any payments made to settle those uncertain tax positions with the state taxing authorities. Accordingly, a long-term receivable is recorded to account for the expected value to the Company of future indemnification payments to be paid on behalf of the Company by BMS, net of actual tax benefits received by the Company. The tax indemnification receivable is recorded within other long-term assets. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Company’s accounting policy, the change in the tax liabilities, penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within income tax expense. As these reserves change adjustments are included in income tax expense while the offsetting adjustment is included in other income. Assuming that the remaining receivable from BMS continues to be considered recoverable by the Company, there will be no effect on net income and no net cash outflows related to these liabilities.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company finalized the accounting for the Progenics Acquisition for income taxes in the first quarter of 2021 resulting in a reduction of deferred tax assets, primarily related to state research credit carryforwards and an increase to goodwill of $2.6 million.</span></div> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"/><td style="width:45.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.735%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,939 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,334 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 14939000 5334000 1200000 2000000 2600000 Inventory <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.027%"><tr><td style="width:1.0%"/><td style="width:50.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.327%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.884%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,505 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,071 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,042 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,249 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,129 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory costs associated with products that have not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefit of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. As of December 31, 2021, the Company had $6.1 million of such product costs included in inventories related to DEFINITY that had been manufactured through the Company’s in-house manufacturing capabilities. The Company received regulatory approval for the manufacture of DEFINITY at its new in-house manufacturing facility during the first quarter of 2022 and has no inventory pending regulatory approval as of March 31, 2022.</span></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.027%"><tr><td style="width:1.0%"/><td style="width:50.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.327%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.884%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,505 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,071 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,042 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,249 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,129 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 13861000 15505000 13071000 13042000 7317000 6582000 34249000 35129000 6100000 Property, Plant and Equipment, Net <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, consisted of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.111%"><tr><td style="width:1.0%"/><td style="width:56.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.407%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.410%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,450 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,450 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,608 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,384 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,945 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,687 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,986)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,915)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,959 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,772 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense related to property, plant and equipment, net, was $3.1 million and $3.0 million for the three months ended March 31, 2022 and 2021, respectively.</span></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, consisted of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.111%"><tr><td style="width:1.0%"/><td style="width:56.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.407%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.410%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,450 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,450 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,608 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,384 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,945 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,687 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,986)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,915)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,959 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,772 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 13450000 13450000 73560000 73559000 84983000 83608000 24766000 24384000 12186000 10686000 208945000 205687000 91986000 88915000 116959000 116772000 3100000 3000000 Accrued Expenses and Other Liabilities and Other Long-Term Liabilities <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities and other long-term liabilities are comprised of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.388%"><tr><td style="width:1.0%"/><td style="width:58.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.583%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.931%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.584%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,730 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Freight, distribution and operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates, discounts and chargebacks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,793 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,977 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contingent liability (Note 4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,396 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,068 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities (Note 16)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,546 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term contingent liability (Note 4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,776 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,894 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities and other long-term liabilities are comprised of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.388%"><tr><td style="width:1.0%"/><td style="width:58.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.583%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.931%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.584%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,730 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Freight, distribution and operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates, discounts and chargebacks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,793 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,977 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contingent liability (Note 4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,396 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,068 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities (Note 16)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,546 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term contingent liability (Note 4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,776 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,894 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 10629000 22730000 26581000 16157000 10793000 10977000 3596000 2850000 83300000 0 7497000 5354000 142396000 58068000 16207000 16546000 20900000 86200000 21669000 22148000 58776000 124894000 Sale of Puerto Rico SubsidiaryDuring the fourth quarter of 2020, the Company entered into a stock purchase agreement (the “SPA”) with one of its existing radiopharmacy customers to sell all the stock of its Puerto Rico radiopharmacy subsidiary. The assets were classified as held for sale <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the Company determined that the fair value of the net assets being sold significantly exceeded the carrying value as of December 31, 2020. The transaction was consummated on January 29, 2021. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price for the stock sale was $18.0 million in cash, including a holdback amount of $1.8 million which the Company received during the first quarter of 2022; the purchase price also included a working capital adjustment. The SPA contains customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company’s representations, warranties and covenants in the SPA. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that this sale of certain net assets did not constitute a strategic shift that had a major effect on the Company’s operations or financial results. As a result, this transaction was not classified as discontinued operations in the Company’s accompanying condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the major classes of assets and liabilities sold as of January 29, 2021 (date of sale): </span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(in thousands)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 29, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts receivable, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,959 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventory</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,094 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-Current Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property, plant &amp; equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangibles, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total assets held for sale</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,744 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts payable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expense and other liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-Current Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Asset retirement obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total liabilities held for sale</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale resulted in a pre-tax book gain of $15.3 million, which was recorded within operating income in the condensed consolidated statements of operations for the three months ended March 31, 2021.</span></div> 18000000 1800000 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the major classes of assets and liabilities sold as of January 29, 2021 (date of sale): </span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(in thousands)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 29, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts receivable, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,959 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventory</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,094 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-Current Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property, plant &amp; equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangibles, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total assets held for sale</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,744 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accounts payable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expense and other liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-Current Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Asset retirement obligations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total liabilities held for sale</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,448 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 540000 1959000 530000 65000 3094000 780000 96000 774000 4744000 185000 369000 554000 306000 588000 1448000 15300000 Asset Retirement Obligations<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts and Somerset, New Jersey sites. As of March 31, 2022, the liability is measured at the present value of the obligation expected to be incurred, of approximately $26.4 million. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the changes in the Company’s asset retirement obligations:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.555%"><tr><td style="width:1.0%"/><td style="width:72.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,833 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated Costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,514 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company evaluated the accretion timeline of an asset group due to a revision in the planned period of use at the North Billerica site. As a result of the accelerated timeline, the Company determined the asset group’s present value exceeded the current value recorded as of December 31, 2021. Accordingly, the Company recorded a non-cash adjustment of $5.3 million to anticipate a revision in the end of useful life by the end of 2022.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to provide the Massachusetts Department of Public Health and New Jersey Department of Environmental Protection financial assurance demonstrating the Company’s ability to fund the decommissioning of its North Billerica, Massachusetts and Somerset, New Jersey production facilities upon closure, although the Company has no current plans to close the facilities. The Company has provided this financial assurance in the form of a $28.2 million surety bond.</span></div> 26400000 The following table provides a summary of the changes in the Company’s asset retirement obligations:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.555%"><tr><td style="width:1.0%"/><td style="width:72.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,833 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated Costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,514 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 20833000 388000 293000 21514000 5300000 28200000 Intangibles, Net<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles, net, consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Lives <br/>(in years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization Method</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,648)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,962 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currently marketed products</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 - 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 - 16</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,441)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(477)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490,042 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,838)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,204 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.472%"><tr><td style="width:1.0%"/><td style="width:20.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.787%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Lives <br/>(in years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization Method</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,510)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,030 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,880 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currently marketed product</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 - 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 - 16</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,960 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,450)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,510 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization expense for its intangible assets of $8.3 million and $4.7 million for the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, PyL (18F-DCFPyL) was approved by the FDA under the name PYLARIFY. Accordingly, the Company reclassified the associated asset of $132.8 million from IPR&amp;D to currently marketed products and commenced amortization of the asset.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.166%"><tr><td style="width:1.0%"/><td style="width:61.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.224%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,923 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,564 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles, net, consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Lives <br/>(in years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization Method</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,648)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,962 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currently marketed products</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 - 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 - 16</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,441)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(477)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490,042 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,838)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,204 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.472%"><tr><td style="width:1.0%"/><td style="width:20.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.787%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Lives <br/>(in years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization Method</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,510)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,030 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,880 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currently marketed product</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 - 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 - 16</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,960 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,450)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,510 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles, net, consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Lives <br/>(in years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization Method</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,648)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,962 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currently marketed products</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 - 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 - 16</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,441)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(477)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490,042 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,838)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,204 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.472%"><tr><td style="width:1.0%"/><td style="width:20.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.787%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Lives <br/>(in years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization Method</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,510)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,030 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,880 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currently marketed product</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 - 15</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 - 16</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-Line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,960 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,450)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,510 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P15Y P25Y 13540000 11648000 1892000 P15Y P25Y 96962000 94856000 2106000 P9Y P15Y 275700000 29416000 246284000 P11Y P16Y 85800000 13441000 72359000 P9Y 2400000 477000 1923000 15640000 15640000 490042000 149838000 340204000 P15Y P25Y 13540000 11510000 2030000 P15Y P25Y 96880000 94630000 2250000 P9Y P15Y 275700000 23345000 252355000 P11Y P16Y 85800000 11555000 74245000 P9Y 2400000 410000 1990000 15640000 15640000 489960000 141450000 348510000 8300000 4700000 132800000 -132800000 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.166%"><tr><td style="width:1.0%"/><td style="width:61.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.224%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,923 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,564 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 24923000 32634000 32563000 32508000 32497000 169439000 324564000 Long-Term Debt, Net, and Other Borrowings<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows:</span></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.777%"><tr><td style="width:1.0%"/><td style="width:73.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.427%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,247 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net and other borrowings</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,369 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022, the Company’s interest rate under the five-year secured term loan facility, which matures on June 30, 2024 (the “2019 Term Facility” and the loans thereunder, the “2019 Term Loans”) was 2.2%.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, the Company voluntarily repaid in full the entire outstanding principal on the original $50.0 million loan agreement (the “Royalty-Backed Loan”) with a fund managed by HealthCare Royalty Partners III, L.P. in the amount of $30.9 million, which included a prepayment amount of $0.5 million, and terminated the agreement governing the Royalty-Backed Loan. The Company recorded a gain on extinguishment of debt of $0.9 million related to the write-off of an unamortized debt premium offset by the prepayment amount.</span></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows:</span></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.777%"><tr><td style="width:1.0%"/><td style="width:73.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.427%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,247 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net and other borrowings</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,369 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 8750000 15000000 148750000 172500000 448000 387000 582000 172247000 12878000 159369000 P5Y 0.022 50000000 30900000 500000 900000 Derivative Instruments<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. In March 2020, the Company entered into interest rate swap contracts to fix the LIBOR rate on a notional amount of $100.0 million through May 31, 2024. The average fixed LIBOR rate on the interest rate swaps is approximately 0.82%. This agreement involves the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the agreement without an exchange of the underlying principal amount. The interest rate swaps were designated as cash flow hedges. In accordance with hedge accounting, the interest rate swaps are recorded on the Company’s condensed consolidated balance sheets at fair value, and changes in the fair value of the swap agreements are recorded to other comprehensive loss and reclassified to interest expense in the period during which the hedged transaction affected earnings or it will become probable that the forecasted transaction would not occur. At March 31, 2022, accumulated other comprehensive income included $1.0 million of pre-tax deferred gains that are expected to be reclassified to earnings during the next 12 months.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheets:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.388%"><tr><td style="width:1.0%"/><td style="width:22.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.320%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives type</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Interest rate swap</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 100000000 0.0082 -1000000.0 The following table presents the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheets:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.388%"><tr><td style="width:1.0%"/><td style="width:22.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.320%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives type</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Interest rate swap</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 3387000 357000 Accumulated Other Comprehensive Income (Loss)<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income (loss), net of tax of $0.9 million and $0.2 million for the three months ended March 31, 2022 and 2021, respectively, consisted of the following:</span></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"><tr><td style="width:1.0%"/><td style="width:37.348%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.179%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.037%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.179%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.075%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized loss on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(754)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,525 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,911 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,048)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(712)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,240)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income (loss), net of tax of $0.9 million and $0.2 million for the three months ended March 31, 2022 and 2021, respectively, consisted of the following:</span></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"><tr><td style="width:1.0%"/><td style="width:37.348%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.179%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.037%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.179%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.075%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized loss on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(754)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,525 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,911 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,048)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(712)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,240)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 900000 200000 -754000 269000 -485000 140000 2086000 2226000 0 -170000 -170000 -614000 2525000 1911000 -630000 -1418000 -2048000 102000 533000 635000 0 -173000 -173000 -528000 -712000 -1240000 Stock-Based Compensation<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations:</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">          </span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.305%"><tr><td style="width:1.0%"/><td style="width:61.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.826%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.045%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,002 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,623 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,317 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations:</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">          </span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.305%"><tr><td style="width:1.0%"/><td style="width:61.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.826%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.045%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,002 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,623 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,317 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 912000 622000 1013000 350000 3002000 1920000 696000 425000 5623000 3317000 Leases<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease assets and liabilities are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"/><td style="width:24.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.798%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.817%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMi0xLTEtMS0zNjAzNA_0923fc9d-fd91-47da-a64b-b8c91c35d208"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMi0xLTEtMS0zNjAzNA_f8bb8d3d-addf-4e52-88e4-48a738d2efcb">Other long-term assets</span></span></span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,675 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,788 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMy0xLTEtMS0zNjAzNA_45d3b36b-8f14-4779-8234-f02bb3e841dc"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMy0xLTEtMS0zNjAzNA_9fa04253-ab9a-441c-a2e8-42a90f6ffe5c">Property, plant and equipment, net</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,277 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,344 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">                     </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfNy0xLTEtMS0zNjAzNA_4bd2b40b-a4d8-4301-a7f5-448a3a778f42"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfNy0xLTEtMS0zNjAzNA_d8643d33-da6c-4551-a3bb-41215b46444b">Accrued expenses and other liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,619 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Finance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfOC0xLTEtMS0zNjAzNA_152c9113-7466-4028-95be-cef3095d3c13"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfOC0xLTEtMS0zNjAzNA_796294ae-9824-4a97-b2f9-c0e62410580e">Current portion of long-term debt and other borrowings</span></span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Operating</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMTAtMS0xLTEtMzYwMzQ_417772c0-be19-4f05-aab5-7ab0055adc4c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMTAtMS0xLTEtMzYwMzQ_9e3a5a90-829f-4e10-9112-3135165a69b4">Other long-term liabilities</span></span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,207 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,546 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMTEtMS0xLTEtMzYwMzQ_ce57e687-526e-4c9e-a3a9-d4b6cff40515"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMTEtMS0xLTEtMzYwMzQ_e69baf9f-7084-48c0-a17e-002ea6b56217">Long-term debt, net and other borrowings</span></span></span></td><td colspan="2" style="background-color:#ccecff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#ccecff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="2" style="background-color:#ccecff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ccecff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,408 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,836 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> Leases<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease assets and liabilities are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"/><td style="width:24.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.798%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.817%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMi0xLTEtMS0zNjAzNA_0923fc9d-fd91-47da-a64b-b8c91c35d208"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMi0xLTEtMS0zNjAzNA_f8bb8d3d-addf-4e52-88e4-48a738d2efcb">Other long-term assets</span></span></span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,675 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,788 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMy0xLTEtMS0zNjAzNA_45d3b36b-8f14-4779-8234-f02bb3e841dc"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMy0xLTEtMS0zNjAzNA_9fa04253-ab9a-441c-a2e8-42a90f6ffe5c">Property, plant and equipment, net</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,277 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,344 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">                     </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfNy0xLTEtMS0zNjAzNA_4bd2b40b-a4d8-4301-a7f5-448a3a778f42"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfNy0xLTEtMS0zNjAzNA_d8643d33-da6c-4551-a3bb-41215b46444b">Accrued expenses and other liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,619 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Finance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfOC0xLTEtMS0zNjAzNA_152c9113-7466-4028-95be-cef3095d3c13"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfOC0xLTEtMS0zNjAzNA_796294ae-9824-4a97-b2f9-c0e62410580e">Current portion of long-term debt and other borrowings</span></span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Operating</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMTAtMS0xLTEtMzYwMzQ_417772c0-be19-4f05-aab5-7ab0055adc4c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMTAtMS0xLTEtMzYwMzQ_9e3a5a90-829f-4e10-9112-3135165a69b4">Other long-term liabilities</span></span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,207 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,546 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMTEtMS0xLTEtMzYwMzQ_ce57e687-526e-4c9e-a3a9-d4b6cff40515"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMTEtMS0xLTEtMzYwMzQ_e69baf9f-7084-48c0-a17e-002ea6b56217">Long-term debt, net and other borrowings</span></span></span></td><td colspan="2" style="background-color:#ccecff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#ccecff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="2" style="background-color:#ccecff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ccecff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,408 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,836 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease assets and liabilities are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"/><td style="width:24.464%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.798%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.817%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMi0xLTEtMS0zNjAzNA_0923fc9d-fd91-47da-a64b-b8c91c35d208"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMi0xLTEtMS0zNjAzNA_f8bb8d3d-addf-4e52-88e4-48a738d2efcb">Other long-term assets</span></span></span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,675 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,788 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMy0xLTEtMS0zNjAzNA_45d3b36b-8f14-4779-8234-f02bb3e841dc"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMy0xLTEtMS0zNjAzNA_9fa04253-ab9a-441c-a2e8-42a90f6ffe5c">Property, plant and equipment, net</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,277 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,344 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">                     </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfNy0xLTEtMS0zNjAzNA_4bd2b40b-a4d8-4301-a7f5-448a3a778f42"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfNy0xLTEtMS0zNjAzNA_d8643d33-da6c-4551-a3bb-41215b46444b">Accrued expenses and other liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,619 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Finance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfOC0xLTEtMS0zNjAzNA_152c9113-7466-4028-95be-cef3095d3c13"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfOC0xLTEtMS0zNjAzNA_796294ae-9824-4a97-b2f9-c0e62410580e">Current portion of long-term debt and other borrowings</span></span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Operating</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMTAtMS0xLTEtMzYwMzQ_417772c0-be19-4f05-aab5-7ab0055adc4c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMTAtMS0xLTEtMzYwMzQ_9e3a5a90-829f-4e10-9112-3135165a69b4">Other long-term liabilities</span></span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,207 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,546 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMTEtMS0xLTEtMzYwMzQ_ce57e687-526e-4c9e-a3a9-d4b6cff40515"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRmMGQ2ZDIzMjk3NzQ0MzViMjk3ZDM4M2M1NTU3ZmQyL3NlYzpkZjBkNmQyMzI5Nzc0NDM1YjI5N2QzODNjNTU1N2ZkMl84NS9mcmFnOjYzZjllMjhmMWMzNzQ1MTdhOWJlOTU2MWE1OWY0Zjc2L3RhYmxlOjZhZTkyMjZjZTZkZTQyMmE5NjAyZDNlY2NhNTE1ZjhkL3RhYmxlcmFuZ2U6NmFlOTIyNmNlNmRlNDIyYTk2MDJkM2VjY2E1MTVmOGRfMTEtMS0xLTEtMzYwMzQ_e69baf9f-7084-48c0-a17e-002ea6b56217">Long-term debt, net and other borrowings</span></span></span></td><td colspan="2" style="background-color:#ccecff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#ccecff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td colspan="2" style="background-color:#ccecff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ccecff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,408 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,836 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 8675000 8788000 602000 556000 9277000 9344000 1619000 1599000 378000 392000 16207000 16546000 204000 299000 18408000 18836000 Net Income Per Common Share<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of net income per common share is presented below: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.916%"><tr><td style="width:1.0%"/><td style="width:74.611%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.792%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.460%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,962 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,008 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,094 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,637 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,051 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,714 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic income per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted income per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.61 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidilutive securities excluded from diluted net income per common share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of net income per common share is presented below: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.916%"><tr><td style="width:1.0%"/><td style="width:74.611%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.792%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.460%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,962 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,008 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,094 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,637 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,051 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,714 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic income per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted income per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.61 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidilutive securities excluded from diluted net income per common share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 42962000 9008000 68008000 67094000 406000 82000 1637000 538000 70051000 67714000 0.63 0.13 0.61 0.13 377000 1349000 Other Income<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income consisted of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.916%"><tr><td style="width:1.0%"/><td style="width:61.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.887%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency (gains) losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax indemnification income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(549)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income consisted of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.916%"><tr><td style="width:1.0%"/><td style="width:61.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.887%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency (gains) losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax indemnification income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(549)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 81000 -42000 396000 573000 8000 17000 0 1000 485000 549000 Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The costs and outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company did not have any material ongoing litigation in which the Company was a party. During the first quarter of 2022, the Company was able to resolve certain litigation matters as set forth below:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2022, the Company entered into a global settlement agreement with Novartis, AAA, Endocyte and certain of their affiliates to settle certain disputes between the parties, as further described below:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">German PSMA-617 Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 8, 2018, Molecular Insight Pharmaceuticals, Inc., a subsidiary of Progenics (“MIP”), filed a complaint against the University of Heidelberg (the “University”) in the District Court in Mannheim, Germany (the “German District Court” and, such litigation, the “German Litigation”). In this Complaint, MIP claimed that the discovery and development of PSMA-617 was related to work performed under a research collaboration sponsored by MIP. MIP alleged that the University breached certain contracts with MIP and that MIP is the co-owner of inventions embodied in certain worldwide patent filings related to PSMA-617 that were filed by the University. On February 27, 2019, Endocyte, a wholly owned subsidiary of Novartis, filed a motion to intervene in the German Litigation. Endocyte is the exclusive licensee of the patent rights that are the subject of the German proceedings. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this dispute, MIP filed a Confirmation of Ownership with the United States Patent and Trademark Office (“USPTO”) for certain U.S. patent applications filed by the University to support MIPs claim that it is the co-owner of these pending U.S. patent applications (the “Ownership Claim”).</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2019, the German District Court set €0.4 million as the amount MIP must deposit with the German District Court as security in the event of an unfavorable final decision on the merits of the dispute. On August 24, 2020, the German District Court issued its decision dismissing MIP’s claims, stating that MIP failed to discharge its burden of proof in the matter.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIP filed a Notice of Appeal of the German District Court’s decision on September 24, 2020 and filed its appeal brief on November 26, 2020. The University and Endocyte each filed oppositions to MIP’s Notice of Appeal on March 12, 2021 and an oral hearing for the appeal was scheduled for September 28, 2022, at the Higher Regional Court Karlsruhe. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Novartis Agreement, the German Litigation was dismissed and the Ownership Claim withdrawn.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Grant Review Proceeding</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 4, 2021, AAA, a wholly-owned subsidiary of Novartis and parent of Endocyte, filed a petition for post-grant review of U.S. Patent No. 10,640,461 (the “’461 patent”) with the Patent Trial and Appeal Board (“PTAB”) of the USPTO. The ’461 patent is owned by MIP. In the petition, AAA challenged the patentability of certain claims of the ’461 patent. The PTAB instituted Post-Grant Review proceedings (the “PGR Proceeding”) on July 29, 2021. Pursuant to the terms of the Novartis Agreement, the PGR Proceeding was terminated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global Settlement Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the dismissal of the German Litigation, the withdrawal of the Ownership Claim and the termination of the PGR Proceeding, under the Novartis Agreement, the parties, among other things, cross-licensed certain patent rights to one another, and Novartis made a $24.0 million lump sum payment to the Company and also reimbursed the Company for certain fees and expenses the Company is required to pay to the University in connection with the German Litigation. The Company received the $24.0 million payment in April 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RELISTOR European Opposition Proceedings</span></div>In October 2015, Progenics received notices of opposition to three European patents relating to methylnaltrexone: EP1615646, EP2368553 and EP2368554. Notices of opposition were filed separately at the European Patent Office (the “EPO”) by each of Actavis Group PTC ehf and Fresenius Kabi Deutschland GmbH. Between May 11, 2017 and July 4, 2017, the Opposition Division of the EPO (the “Opposition Division”) provided notice that the three European patents would be revoked. Each of these matters was appealed to the Appeal Board of the EPO. On November 13, 2020, Progenics withdrew the appeal for EP2368553 and EP2368554. Notices of termination of the proceedings with revocation of the patent were issued on November 23, 2020 for both patents. Progenics continued its appeal on the revocation of the third patent, EP1615646. Oral proceedings for EP1615646 were held at the Appeal Board of the EPO on September 22, 2020. The revocation decision under appeal was set aside and the case was remitted to the Opposition Division for further prosecution. An oral hearing was held before the Opposition Division on September 27, 2021. The Opposition Division issued its final written opinion on November 11, 2021, indicating that the patent will be maintained in amended form. The final written decision of the Opposition Division was appealable to the Appeal Board of the EPO by either party. Progenics appealed this decision on January 20, 2022 to hold open its option to file Grounds for Appeal. 400000 24000000 24000000 3 3 Segment InformationIn the first quarter of fiscal year 2021, the Company completed the evaluation of its operating and reporting structure, including the impact on the Company’s business of the acquisition of Progenics described in Note 1, and the sale of the Puerto Rico subsidiary in the first quarter, which resulted in a change in operating and reportable segments. The Company now operates as one business segment: the development, manufacture and sale of innovative imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to Find, Fight and Follow serious medical conditions. This conclusion reflects the Company’s focus on the performance of the business on a consolidated worldwide basis. The results of this operating segment are regularly reviewed by the Company’s chief operating decision maker, the President and Chief Executive Officer. The Company’s chief operating decision maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. 1 EXCEL 86 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 88 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 89 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 197 292 1 false 68 0 false 8 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.lantheus.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.lantheus.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.lantheus.com/role/CondensedConsolidatedStatementsofComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Changes In Stockholders' Equity (Statement) Sheet http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement Condensed Consolidated Changes In Stockholders' Equity (Statement) Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101101 - Disclosure - Basis of Presentation Sheet http://www.lantheus.com/role/BasisofPresentation Basis of Presentation Notes 8 false false R9.htm 2103102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.lantheus.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2105103 - Disclosure - Revenue from Contracts with Customers Sheet http://www.lantheus.com/role/RevenuefromContractswithCustomers Revenue from Contracts with Customers Notes 10 false false R11.htm 2108104 - Disclosure - Fair Value of Financial Instruments Sheet http://www.lantheus.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 11 false false R12.htm 2114105 - Disclosure - Income Taxes Sheet http://www.lantheus.com/role/IncomeTaxes Income Taxes Notes 12 false false R13.htm 2117106 - Disclosure - Inventory Sheet http://www.lantheus.com/role/Inventory Inventory Notes 13 false false R14.htm 2120107 - Disclosure - Property, Plant and Equipment, Net Sheet http://www.lantheus.com/role/PropertyPlantandEquipmentNet Property, Plant and Equipment, Net Notes 14 false false R15.htm 2123108 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities Sheet http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilities Accrued Expenses and Other Liabilities and Other Long-Term Liabilities Notes 15 false false R16.htm 2126109 - Disclosure - Sale of Puerto Rico Subsidiary Sheet http://www.lantheus.com/role/SaleofPuertoRicoSubsidiary Sale of Puerto Rico Subsidiary Notes 16 false false R17.htm 2129110 - Disclosure - Asset Retirement Obligations Sheet http://www.lantheus.com/role/AssetRetirementObligations Asset Retirement Obligations Notes 17 false false R18.htm 2133111 - Disclosure - Intangibles, Net Sheet http://www.lantheus.com/role/IntangiblesNet Intangibles, Net Notes 18 false false R19.htm 2138112 - Disclosure - Long-Term Debt, Net, and Other Borrowings Sheet http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowings Long-Term Debt, Net, and Other Borrowings Notes 19 false false R20.htm 2141113 - Disclosure - Derivative Instruments Sheet http://www.lantheus.com/role/DerivativeInstruments Derivative Instruments Notes 20 false false R21.htm 2144114 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 21 false false R22.htm 2147115 - Disclosure - Stock-Based Compensation Sheet http://www.lantheus.com/role/StockBasedCompensation Stock-Based Compensation Notes 22 false false R23.htm 2150116 - Disclosure - Leases Sheet http://www.lantheus.com/role/Leases Leases Notes 23 false false R24.htm 2153117 - Disclosure - Net Income Per Common Share Sheet http://www.lantheus.com/role/NetIncomePerCommonShare Net Income Per Common Share Notes 24 false false R25.htm 2156118 - Disclosure - Other Income Sheet http://www.lantheus.com/role/OtherIncome Other Income Notes 25 false false R26.htm 2159119 - Disclosure - Commitments and Contingencies Sheet http://www.lantheus.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 26 false false R27.htm 2161120 - Disclosure - Segment Information Sheet http://www.lantheus.com/role/SegmentInformation Segment Information Notes 27 false false R28.htm 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.lantheus.com/role/SummaryofSignificantAccountingPolicies 28 false false R29.htm 2306301 - Disclosure - Revenue from Contracts with Customers (Tables) Sheet http://www.lantheus.com/role/RevenuefromContractswithCustomersTables Revenue from Contracts with Customers (Tables) Tables http://www.lantheus.com/role/RevenuefromContractswithCustomers 29 false false R30.htm 2309302 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.lantheus.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://www.lantheus.com/role/FairValueofFinancialInstruments 30 false false R31.htm 2315303 - Disclosure - Income Taxes (Tables) Sheet http://www.lantheus.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.lantheus.com/role/IncomeTaxes 31 false false R32.htm 2318304 - Disclosure - Inventory (Tables) Sheet http://www.lantheus.com/role/InventoryTables Inventory (Tables) Tables http://www.lantheus.com/role/Inventory 32 false false R33.htm 2321305 - Disclosure - Property, Plant and Equipment, Net (Tables) Sheet http://www.lantheus.com/role/PropertyPlantandEquipmentNetTables Property, Plant and Equipment, Net (Tables) Tables http://www.lantheus.com/role/PropertyPlantandEquipmentNet 33 false false R34.htm 2324306 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Tables) Sheet http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesTables Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Tables) Tables http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilities 34 false false R35.htm 2327307 - Disclosure - Sale of Puerto Rico Subsidiary (Tables) Sheet http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryTables Sale of Puerto Rico Subsidiary (Tables) Tables http://www.lantheus.com/role/SaleofPuertoRicoSubsidiary 35 false false R36.htm 2330308 - Disclosure - Asset Retirement Obligations (Tables) Sheet http://www.lantheus.com/role/AssetRetirementObligationsTables Asset Retirement Obligations (Tables) Tables http://www.lantheus.com/role/AssetRetirementObligations 36 false false R37.htm 2334309 - Disclosure - Intangibles, Net (Tables) Sheet http://www.lantheus.com/role/IntangiblesNetTables Intangibles, Net (Tables) Tables http://www.lantheus.com/role/IntangiblesNet 37 false false R38.htm 2339310 - Disclosure - Long-Term Debt, Net, and Other Borrowings (Tables) Sheet http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsTables Long-Term Debt, Net, and Other Borrowings (Tables) Tables http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowings 38 false false R39.htm 2342311 - Disclosure - Derivative Instruments (Tables) Sheet http://www.lantheus.com/role/DerivativeInstrumentsTables Derivative Instruments (Tables) Tables http://www.lantheus.com/role/DerivativeInstruments 39 false false R40.htm 2345312 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLoss 40 false false R41.htm 2348313 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.lantheus.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.lantheus.com/role/StockBasedCompensation 41 false false R42.htm 2351314 - Disclosure - Leases (Tables) Sheet http://www.lantheus.com/role/LeasesTables Leases (Tables) Tables http://www.lantheus.com/role/Leases 42 false false R43.htm 2354315 - Disclosure - Net Income Per Common Share (Tables) Sheet http://www.lantheus.com/role/NetIncomePerCommonShareTables Net Income Per Common Share (Tables) Tables http://www.lantheus.com/role/NetIncomePerCommonShare 43 false false R44.htm 2357316 - Disclosure - Other Income (Tables) Sheet http://www.lantheus.com/role/OtherIncomeTables Other Income (Tables) Tables http://www.lantheus.com/role/OtherIncome 44 false false R45.htm 2402401 - Disclosure - Basis of Presentation (Details) Sheet http://www.lantheus.com/role/BasisofPresentationDetails Basis of Presentation (Details) Details http://www.lantheus.com/role/BasisofPresentation 45 false false R46.htm 2407402 - Disclosure - Revenue from Contracts with Customers (Detail) Sheet http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail Revenue from Contracts with Customers (Detail) Details http://www.lantheus.com/role/RevenuefromContractswithCustomersTables 46 false false R47.htm 2410403 - Disclosure - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on A Recurring Basis (Details) Sheet http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on A Recurring Basis (Details) Details 47 false false R48.htm 2411404 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) Sheet http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails Fair Value of Financial Instruments - Narrative (Details) Details 48 false false R49.htm 2412405 - Disclosure - Fair Value of Financial Instruments - Quantitative Information and Assumptions Pertaining To The Fair Value Measurement of The Level 3 Inputs (Details) Sheet http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails Fair Value of Financial Instruments - Quantitative Information and Assumptions Pertaining To The Fair Value Measurement of The Level 3 Inputs (Details) Details 49 false false R50.htm 2413406 - Disclosure - Fair Value of Financial Instruments - Financial Instruments With Significant Level 3 Inputs (Details) Sheet http://www.lantheus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsWithSignificantLevel3InputsDetails Fair Value of Financial Instruments - Financial Instruments With Significant Level 3 Inputs (Details) Details 50 false false R51.htm 2416407 - Disclosure - Income Taxes (Detail) Sheet http://www.lantheus.com/role/IncomeTaxesDetail Income Taxes (Detail) Details http://www.lantheus.com/role/IncomeTaxesTables 51 false false R52.htm 2419408 - Disclosure - Inventory (Details) Sheet http://www.lantheus.com/role/InventoryDetails Inventory (Details) Details http://www.lantheus.com/role/InventoryTables 52 false false R53.htm 2422409 - Disclosure - Property, Plant and Equipment, Net (Detail) Sheet http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail Property, Plant and Equipment, Net (Detail) Details http://www.lantheus.com/role/PropertyPlantandEquipmentNetTables 53 false false R54.htm 2425410 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Details) Sheet http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Details) Details http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesTables 54 false false R55.htm 2428411 - Disclosure - Sale of Puerto Rico Subsidiary (Details) Sheet http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails Sale of Puerto Rico Subsidiary (Details) Details http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryTables 55 false false R56.htm 2431412 - Disclosure - Asset Retirement Obligations - Additional Information (Details) Sheet http://www.lantheus.com/role/AssetRetirementObligationsAdditionalInformationDetails Asset Retirement Obligations - Additional Information (Details) Details 56 false false R57.htm 2432413 - Disclosure - Asset Retirement Obligations - Asset Retirement Obligation (Detail) Sheet http://www.lantheus.com/role/AssetRetirementObligationsAssetRetirementObligationDetail Asset Retirement Obligations - Asset Retirement Obligation (Detail) Details 57 false false R58.htm 2435414 - Disclosure - Intangibles, Net - Schedule of Intangibles, Net (Details) Sheet http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails Intangibles, Net - Schedule of Intangibles, Net (Details) Details 58 false false R59.htm 2436415 - Disclosure - Intangibles, Net - Additional Information (Details) Sheet http://www.lantheus.com/role/IntangiblesNetAdditionalInformationDetails Intangibles, Net - Additional Information (Details) Details 59 false false R60.htm 2437416 - Disclosure - Intangibles, Net - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Details) Sheet http://www.lantheus.com/role/IntangiblesNetScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails Intangibles, Net - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Details) Details 60 false false R61.htm 2440417 - Disclosure - Long-Term Debt, Net, and Other Borrowings (Details) Sheet http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails Long-Term Debt, Net, and Other Borrowings (Details) Details http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsTables 61 false false R62.htm 2443418 - Disclosure - Derivative Instruments (Detail) Sheet http://www.lantheus.com/role/DerivativeInstrumentsDetail Derivative Instruments (Detail) Details http://www.lantheus.com/role/DerivativeInstrumentsTables 62 false false R63.htm 2446419 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Detail) Sheet http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossDetail Accumulated Other Comprehensive Income (Loss) (Detail) Details http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossTables 63 false false R64.htm 2449420 - Disclosure - Stock-Based Compensation (Detail) Sheet http://www.lantheus.com/role/StockBasedCompensationDetail Stock-Based Compensation (Detail) Details http://www.lantheus.com/role/StockBasedCompensationTables 64 false false R65.htm 2452421 - Disclosure - Leases - Operating and Finance Lease Assets and Liabilities (Details) Sheet http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails Leases - Operating and Finance Lease Assets and Liabilities (Details) Details 65 false false R66.htm 2455422 - Disclosure - Net Income Per Common Share (Detail) Sheet http://www.lantheus.com/role/NetIncomePerCommonShareDetail Net Income Per Common Share (Detail) Details http://www.lantheus.com/role/NetIncomePerCommonShareTables 66 false false R67.htm 2458423 - Disclosure - Other Income (Details) Sheet http://www.lantheus.com/role/OtherIncomeDetails Other Income (Details) Details http://www.lantheus.com/role/OtherIncomeTables 67 false false R68.htm 2460424 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.lantheus.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.lantheus.com/role/CommitmentsandContingencies 68 false false R69.htm 2462425 - Disclosure - Segment Information (Details) Sheet http://www.lantheus.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.lantheus.com/role/SegmentInformation 69 false false All Reports Book All Reports lnth-20220331.htm lnth-20220331.xsd lnth-20220331_cal.xml lnth-20220331_def.xml lnth-20220331_lab.xml lnth-20220331_pre.xml lnth10q-033122ex101.htm lnth10q-033122ex102.htm lnth10q-033122ex103.htm lnth10q-033122ex104.htm lnth10q-033122ex311.htm lnth10q-033122ex312.htm lnth10q-033122ex321.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 91 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "lnth-20220331.htm": { "axisCustom": 0, "axisStandard": 24, "contextCount": 197, "dts": { "calculationLink": { "local": [ "lnth-20220331_cal.xml" ] }, "definitionLink": { "local": [ "lnth-20220331_def.xml" ] }, "inline": { "local": [ "lnth-20220331.htm" ] }, "labelLink": { "local": [ "lnth-20220331_lab.xml" ] }, "presentationLink": { "local": [ "lnth-20220331_pre.xml" ] }, "schema": { "local": [ "lnth-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 483, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 12, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 17 }, "keyCustom": 31, "keyStandard": 261, "memberCustom": 31, "memberStandard": 34, "nsprefix": "lnth", "nsuri": "http://www.lantheus.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.lantheus.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105103 - Disclosure - Revenue from Contracts with Customers", "role": "http://www.lantheus.com/role/RevenuefromContractswithCustomers", "shortName": "Revenue from Contracts with Customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108104 - Disclosure - Fair Value of Financial Instruments", "role": "http://www.lantheus.com/role/FairValueofFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114105 - Disclosure - Income Taxes", "role": "http://www.lantheus.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117106 - Disclosure - Inventory", "role": "http://www.lantheus.com/role/Inventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120107 - Disclosure - Property, Plant and Equipment, Net", "role": "http://www.lantheus.com/role/PropertyPlantandEquipmentNet", "shortName": "Property, Plant and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123108 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities", "role": "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilities", "shortName": "Accrued Expenses and Other Liabilities and Other Long-Term Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126109 - Disclosure - Sale of Puerto Rico Subsidiary", "role": "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiary", "shortName": "Sale of Puerto Rico Subsidiary", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetRetirementObligationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129110 - Disclosure - Asset Retirement Obligations", "role": "http://www.lantheus.com/role/AssetRetirementObligations", "shortName": "Asset Retirement Obligations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetRetirementObligationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133111 - Disclosure - Intangibles, Net", "role": "http://www.lantheus.com/role/IntangiblesNet", "shortName": "Intangibles, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2138112 - Disclosure - Long-Term Debt, Net, and Other Borrowings", "role": "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowings", "shortName": "Long-Term Debt, Net, and Other Borrowings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2141113 - Disclosure - Derivative Instruments", "role": "http://www.lantheus.com/role/DerivativeInstruments", "shortName": "Derivative Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2144114 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "role": "http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLoss", "shortName": "Accumulated Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2147115 - Disclosure - Stock-Based Compensation", "role": "http://www.lantheus.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2150116 - Disclosure - Leases", "role": "http://www.lantheus.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2153117 - Disclosure - Net Income Per Common Share", "role": "http://www.lantheus.com/role/NetIncomePerCommonShare", "shortName": "Net Income Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2156118 - Disclosure - Other Income", "role": "http://www.lantheus.com/role/OtherIncome", "shortName": "Other Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2159119 - Disclosure - Commitments and Contingencies", "role": "http://www.lantheus.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2161120 - Disclosure - Segment Information", "role": "http://www.lantheus.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Revenue from Contracts with Customers (Tables)", "role": "http://www.lantheus.com/role/RevenuefromContractswithCustomersTables", "shortName": "Revenue from Contracts with Customers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://www.lantheus.com/role/FairValueofFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315303 - Disclosure - Income Taxes (Tables)", "role": "http://www.lantheus.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318304 - Disclosure - Inventory (Tables)", "role": "http://www.lantheus.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321305 - Disclosure - Property, Plant and Equipment, Net (Tables)", "role": "http://www.lantheus.com/role/PropertyPlantandEquipmentNetTables", "shortName": "Property, Plant and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324306 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Tables)", "role": "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesTables", "shortName": "Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327307 - Disclosure - Sale of Puerto Rico Subsidiary (Tables)", "role": "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryTables", "shortName": "Sale of Puerto Rico Subsidiary (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330308 - Disclosure - Asset Retirement Obligations (Tables)", "role": "http://www.lantheus.com/role/AssetRetirementObligationsTables", "shortName": "Asset Retirement Obligations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2334309 - Disclosure - Intangibles, Net (Tables)", "role": "http://www.lantheus.com/role/IntangiblesNetTables", "shortName": "Intangibles, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2339310 - Disclosure - Long-Term Debt, Net, and Other Borrowings (Tables)", "role": "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsTables", "shortName": "Long-Term Debt, Net, and Other Borrowings (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2342311 - Disclosure - Derivative Instruments (Tables)", "role": "http://www.lantheus.com/role/DerivativeInstrumentsTables", "shortName": "Derivative Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2345312 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "role": "http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2348313 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.lantheus.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "lnth:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2351314 - Disclosure - Leases (Tables)", "role": "http://www.lantheus.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "lnth:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2354315 - Disclosure - Net Income Per Common Share (Tables)", "role": "http://www.lantheus.com/role/NetIncomePerCommonShareTables", "shortName": "Net Income Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2357316 - Disclosure - Other Income (Tables)", "role": "http://www.lantheus.com/role/OtherIncomeTables", "shortName": "Other Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Basis of Presentation (Details)", "role": "http://www.lantheus.com/role/BasisofPresentationDetails", "shortName": "Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "id16b6cdf38ba4cc6ac50c3052a60e908_D20200220-20200220", "decimals": "INF", "lang": "en-US", "name": "lnth:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Revenue from Contracts with Customers (Detail)", "role": "http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail", "shortName": "Revenue from Contracts with Customers (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "ie4dbda4e60d24349880e0478d89d21f9_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on A Recurring Basis (Details)", "role": "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails", "shortName": "Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on A Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - Fair Value of Financial Instruments - Narrative (Details)", "role": "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "shortName": "Fair Value of Financial Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i08febc499776499db08efbd5f3cbd846_D20220101-20220331", "decimals": "INF", "lang": "en-US", "name": "lnth:RoyaltyPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - Fair Value of Financial Instruments - Quantitative Information and Assumptions Pertaining To The Fair Value Measurement of The Level 3 Inputs (Details)", "role": "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails", "shortName": "Fair Value of Financial Instruments - Quantitative Information and Assumptions Pertaining To The Fair Value Measurement of The Level 3 Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "iae88bc1c74974141bd49a3989054e797_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income", "role": "http://www.lantheus.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "ibdfd3a40ac144f0c9ebde2fd68940722_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413406 - Disclosure - Fair Value of Financial Instruments - Financial Instruments With Significant Level 3 Inputs (Details)", "role": "http://www.lantheus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsWithSignificantLevel3InputsDetails", "shortName": "Fair Value of Financial Instruments - Financial Instruments With Significant Level 3 Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "ibdfd3a40ac144f0c9ebde2fd68940722_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416407 - Disclosure - Income Taxes (Detail)", "role": "http://www.lantheus.com/role/IncomeTaxesDetail", "shortName": "Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "id32c4c2bc916441198d0dcd7312abbd7_D20210101-20210331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419408 - Disclosure - Inventory (Details)", "role": "http://www.lantheus.com/role/InventoryDetails", "shortName": "Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422409 - Disclosure - Property, Plant and Equipment, Net (Detail)", "role": "http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail", "shortName": "Property, Plant and Equipment, Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425410 - Disclosure - Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Details)", "role": "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails", "shortName": "Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i9b1a613cefcc4d06b357e8c0cf853212_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnSaleOfBusiness", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428411 - Disclosure - Sale of Puerto Rico Subsidiary (Details)", "role": "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails", "shortName": "Sale of Puerto Rico Subsidiary (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i9b1a613cefcc4d06b357e8c0cf853212_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnSaleOfBusiness", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "lnth:AssetRetirementObligationLiabilitiesExpectedPresentValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431412 - Disclosure - Asset Retirement Obligations - Additional Information (Details)", "role": "http://www.lantheus.com/role/AssetRetirementObligationsAdditionalInformationDetails", "shortName": "Asset Retirement Obligations - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "lnth:AssetRetirementObligationLiabilitiesExpectedPresentValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "ibdfd3a40ac144f0c9ebde2fd68940722_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetRetirementObligationsNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432413 - Disclosure - Asset Retirement Obligations - Asset Retirement Obligation (Detail)", "role": "http://www.lantheus.com/role/AssetRetirementObligationsAssetRetirementObligationDetail", "shortName": "Asset Retirement Obligations - Asset Retirement Obligation (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AssetRetirementObligationAccretionExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435414 - Disclosure - Intangibles, Net - Schedule of Intangibles, Net (Details)", "role": "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails", "shortName": "Intangibles, Net - Schedule of Intangibles, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436415 - Disclosure - Intangibles, Net - Additional Information (Details)", "role": "http://www.lantheus.com/role/IntangiblesNetAdditionalInformationDetails", "shortName": "Intangibles, Net - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "ia3c3a817753b4815a800b4bc5dd3e229_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Changes In Stockholders' Equity (Statement)", "role": "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement", "shortName": "Condensed Consolidated Changes In Stockholders' Equity (Statement)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "ia3c3a817753b4815a800b4bc5dd3e229_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437416 - Disclosure - Intangibles, Net - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Details)", "role": "http://www.lantheus.com/role/IntangiblesNetScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails", "shortName": "Intangibles, Net - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440417 - Disclosure - Long-Term Debt, Net, and Other Borrowings (Details)", "role": "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails", "shortName": "Long-Term Debt, Net, and Other Borrowings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443418 - Disclosure - Derivative Instruments (Detail)", "role": "http://www.lantheus.com/role/DerivativeInstrumentsDetail", "shortName": "Derivative Instruments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AociTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446419 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Detail)", "role": "http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "shortName": "Accumulated Other Comprehensive Income (Loss) (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AociTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449420 - Disclosure - Stock-Based Compensation (Detail)", "role": "http://www.lantheus.com/role/StockBasedCompensationDetail", "shortName": "Stock-Based Compensation (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4500e30b578547b5a221408bea4284f3_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "lnth:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452421 - Disclosure - Leases - Operating and Finance Lease Assets and Liabilities (Details)", "role": "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails", "shortName": "Leases - Operating and Finance Lease Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "lnth:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "if71b113a8f3b4347a4f7697730df987c_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455422 - Disclosure - Net Income Per Common Share (Detail)", "role": "http://www.lantheus.com/role/NetIncomePerCommonShareDetail", "shortName": "Net Income Per Common Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458423 - Disclosure - Other Income (Details)", "role": "http://www.lantheus.com/role/OtherIncomeDetails", "shortName": "Other Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LitigationSettlementAmountAwardedFromOtherParty", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460424 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.lantheus.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i2e6258e860cf40b2888db41af18e1e4e_D20151001-20151031", "decimals": "INF", "lang": "en-US", "name": "us-gaap:LossContingencyPatentsAllegedlyInfringedNumber", "reportCount": 1, "unique": true, "unitRef": "patent", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462425 - Disclosure - Segment Information (Details)", "role": "http://www.lantheus.com/role/SegmentInformationDetails", "shortName": "Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationAmortizationAndAccretionNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Basis of Presentation", "role": "http://www.lantheus.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.lantheus.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lnth-20220331.htm", "contextRef": "i4756e99a5a2f4a3c90779cbbf9d4d789_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 68, "tag": { "country_GB": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED KINGDOM", "terseLabel": "UNITED KINGDOM" } } }, "localname": "GB", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesDetail" ], "xbrltype": "domainItemType" }, "country_SE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SWEDEN", "terseLabel": "SWEDEN" } } }, "localname": "SE", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails", "http://www.lantheus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r569" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails", "http://www.lantheus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lantheus.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "lnth_A1095CommercializationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1095 Commercialization", "label": "1095 Commercialization [Member]", "terseLabel": "1095 commercialization milestone" } } }, "localname": "A1095CommercializationMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "lnth_A1404CommercializationMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1404 Commercialization Milestone", "label": "1404 Commercialization Milestone [Member]", "terseLabel": "1404 Commercialization Milestone" } } }, "localname": "A1404CommercializationMilestoneMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lnth_AccruedFreightCostsCurrent": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for freight and distribution costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Freight Costs Current", "terseLabel": "Freight, distribution and operations" } } }, "localname": "AccruedFreightCostsCurrent", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "lnth_AccruedRebatesDiscountsAndChargebacksCurrent": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for rebates, discounts and chargebacks. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Rebates Discounts And Chargebacks Current", "terseLabel": "Accrued rebates, discounts and chargebacks" } } }, "localname": "AccruedRebatesDiscountsAndChargebacksCurrent", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "lnth_AssetRetirementObligationAccelerationExpense": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Retirement Obligation, Acceleration Expense", "label": "Asset Retirement Obligation, Acceleration Expense", "terseLabel": "ARO acceleration", "verboseLabel": "Accelerated Costs" } } }, "localname": "AssetRetirementObligationAccelerationExpense", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/AssetRetirementObligationsAssetRetirementObligationDetail", "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "lnth_AssetRetirementObligationLiabilitiesExpectedPresentValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of expected present value of asset retirement obligations.", "label": "Asset Retirement Obligation Liabilities Expected Present Value", "terseLabel": "Obligation expected to be incurred" } } }, "localname": "AssetRetirementObligationLiabilitiesExpectedPresentValue", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/AssetRetirementObligationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "lnth_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities Lessee", "label": "Assets And Liabilities Lessee [Table Text Block]", "terseLabel": "Schedule of operating and finance lease assets and liabilities" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "lnth_BusinessCombinationConsiderationTransferredContingentValueRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Contingent Value Right", "label": "Business Combination, Consideration Transferred, Contingent Value Right", "terseLabel": "Business combination common stock under contingent value right (in shares)" } } }, "localname": "BusinessCombinationConsiderationTransferredContingentValueRight", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails" ], "xbrltype": "sharesItemType" }, "lnth_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Shares", "label": "Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Shares", "terseLabel": "Business combination, consideration transferred, equity interests issued (in shares)" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableShares", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails" ], "xbrltype": "sharesItemType" }, "lnth_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesNotReasonablyPossibleValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration Arrangements, Range Of Outcomes Not Reasonably Possible, Value", "label": "Business Combination, Contingent Consideration Arrangements, Range Of Outcomes Not Reasonably Possible, Value", "terseLabel": "Potential payment not reasonably possible" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesNotReasonablyPossibleValue", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "lnth_BusinessCombinationContingentConsiderationAssetMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration asset from business combination.", "label": "Business Combination Contingent Consideration Asset Measurement Input", "terseLabel": "Asset measurement input" } } }, "localname": "BusinessCombinationContingentConsiderationAssetMeasurementInput", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "decimalItemType" }, "lnth_BusinessCombinationContingentLiabilityContingentValueRightConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Liability, Contingent Value Right, Consideration", "label": "Business Combination, Contingent Liability, Contingent Value Right, Consideration", "terseLabel": "Business combination contingent value right of total consideration" } } }, "localname": "BusinessCombinationContingentLiabilityContingentValueRightConsideration", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "lnth_BusinessCombinationContingentLiabilityContingentValueRightPercentageOfNetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Liability, Contingent Value Right, Percentage Of Net Sales", "label": "Business Combination, Contingent Liability, Contingent Value Right, Percentage Of Net Sales", "terseLabel": "Aggregate cash payments percentage" } } }, "localname": "BusinessCombinationContingentLiabilityContingentValueRightPercentageOfNetSales", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "lnth_BusinessCombinationContingentLiabilityContingentValueRightPercentageOfTotalConsideration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Liability, Contingent Value Right, Percentage Of Total Consideration", "label": "Business Combination, Contingent Liability, Contingent Value Right, Percentage Of Total Consideration", "terseLabel": "Percentage of total contingent consideration under CVRs" } } }, "localname": "BusinessCombinationContingentLiabilityContingentValueRightPercentageOfTotalConsideration", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails" ], "xbrltype": "percentItemType" }, "lnth_BusinessCombinationRightToReceiveShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Right To Receive, Share", "label": "Business Combination, Right To Receive, Share", "terseLabel": "Shares to be received from acquisition conversion (in shares)" } } }, "localname": "BusinessCombinationRightToReceiveShare", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails" ], "xbrltype": "sharesItemType" }, "lnth_CashPayments2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Payments 2022 [Member]", "label": "Cash Payments 2022 [Member]", "terseLabel": "Cash Payments 2022" } } }, "localname": "CashPayments2022Member", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lnth_CashPayments2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Payments 2023 [Member]", "label": "Cash Payments 2023 [Member]", "terseLabel": "Cash Payments 2023" } } }, "localname": "CashPayments2023Member", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lnth_ContingentConsiderationNetSalesTargetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration, Net Sales Targets", "label": "Contingent Consideration, Net Sales Targets [Member]", "terseLabel": "Net sales targets - AZEDRA and 1095" } } }, "localname": "ContingentConsiderationNetSalesTargetsMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "lnth_ContingentValueRightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Value Right", "label": "Contingent Value Right [Member]", "terseLabel": "CVRs" } } }, "localname": "ContingentValueRightMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "lnth_CurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Current Liabilities", "label": "Current Liabilities [Member]", "terseLabel": "Current Liabilities" } } }, "localname": "CurrentLiabilitiesMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lnth_CurrentlyMarketedProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currently Marketed Product", "label": "Currently Marketed Product [Member]", "terseLabel": "Currently marketed products" } } }, "localname": "CurrentlyMarketedProductMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetAdditionalInformationDetails", "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "domainItemType" }, "lnth_DefinityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DEFINITY [Member]", "label": "DEFINITY [Member]", "terseLabel": "DEFINITY" } } }, "localname": "DefinityMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/InventoryDetails", "http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail" ], "xbrltype": "domainItemType" }, "lnth_DisposalGroupIncludingDiscontinuedOperationAccruedExpenseAndOtherLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Accrued Expense and Other Liabilities, Current", "label": "Disposal Group, Including Discontinued Operation, Accrued Expense and Other Liabilities, Current", "terseLabel": "Accrued expense and other liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedExpenseAndOtherLiabilitiesCurrent", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "lnth_DisposalGroupIncludingDiscontinuedOperationConsiderationHoldbackAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Holdback Amount", "label": "Disposal Group, Including Discontinued Operation, Consideration, Holdback Amount", "terseLabel": "Disposal group holdback amount" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationHoldbackAmount", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "lnth_EuropeanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "European", "label": "European [Member]", "terseLabel": "European" } } }, "localname": "EuropeanMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "lnth_FinancialAssuranceInFormOfSuretyBond": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of financial assurance given in the form of surety bond.", "label": "Financial Assurance In Form Of Surety Bond", "terseLabel": "Financial assurance in form of surety bond" } } }, "localname": "FinancialAssuranceInFormOfSuretyBond", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/AssetRetirementObligationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "lnth_IPRDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IPR & D", "label": "IPR & D [Member]", "terseLabel": "IPR & D" } } }, "localname": "IPRDMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "lnth_IncrementalCommonSharesAttributableToRestrictedStockAwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to restricted stock awards.", "label": "Incremental Common Shares Attributable To Restricted Stock Awards", "terseLabel": "Effect of dilutive restricted stock (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToRestrictedStockAwards", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/NetIncomePerCommonShareDetail" ], "xbrltype": "sharesItemType" }, "lnth_LeaseLiability": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability", "label": "Lease Liability", "totalLabel": "Total leased liabilities" } } }, "localname": "LeaseLiability", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "lnth_LeaseRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease Right Of Use Assets", "label": "Lease Right Of Use Assets", "totalLabel": "Total leased assets" } } }, "localname": "LeaseRightOfUseAssets", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "lnth_LicenseandRoyaltyRevenuesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License and Royalty Revenues [Member]", "label": "License and Royalty Revenues [Member]", "terseLabel": "License and royalty revenues(2)" } } }, "localname": "LicenseandRoyaltyRevenuesMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail" ], "xbrltype": "domainItemType" }, "lnth_LossContingencyDepositWithCourt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Deposit With Court", "label": "Loss Contingency, Deposit With Court", "terseLabel": "Court deposit" } } }, "localname": "LossContingencyDepositWithCourt", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "lnth_MachineryEquipmentAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Machinery Equipment And Fixtures [Member]", "label": "Machinery Equipment And Fixtures [Member]", "terseLabel": "Machinery, equipment and fixtures" } } }, "localname": "MachineryEquipmentAndFixturesMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "lnth_MeasurementInputProbabilityOfSuccessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Probability Of Success", "label": "Measurement Input, Probability Of Success [Member]", "terseLabel": "Probability of success" } } }, "localname": "MeasurementInputProbabilityOfSuccessMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "lnth_MolecularInsightPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Molecular Insight Pharmaceuticals, Inc.", "label": "Molecular Insight Pharmaceuticals, Inc. [Member]", "terseLabel": "MIP" } } }, "localname": "MolecularInsightPharmaceuticalsIncMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "lnth_MonteCarloSimulationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Monte Carlo Simulation", "label": "Monte Carlo Simulation [Member]", "terseLabel": "Monte Carlo simulation" } } }, "localname": "MonteCarloSimulationMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "lnth_NetSalesTargetsForAzedraMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Sales Targets For Azedra", "label": "Net Sales Targets For Azedra [Member]", "terseLabel": "Net Sales Targets For Azedra" } } }, "localname": "NetSalesTargetsForAzedraMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lnth_NoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesDeferredIncomeTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities, Deferred Income Tax Expense (Benefit)", "label": "Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities, Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred taxes" } } }, "localname": "NoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesDeferredIncomeTaxExpenseBenefit", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "lnth_NoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noncurrent Liabilities", "label": "Noncurrent Liabilities [Member]", "terseLabel": "Noncurrent Liabilities" } } }, "localname": "NoncurrentLiabilitiesMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lnth_NumberOfContingentValueRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Contingent Value Rights", "label": "Number Of Contingent Value Rights", "terseLabel": "Number of CVRs" } } }, "localname": "NumberOfContingentValueRights", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails" ], "xbrltype": "integerItemType" }, "lnth_OperatingExpensesBeforeGainLossOnSaleOfAssets": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Expenses Before Gain Loss On Sale Of Assets", "label": "Operating Expenses Before Gain Loss On Sale Of Assets", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpensesBeforeGainLossOnSaleOfAssets", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "lnth_OtherNonoperatingIncomeExpenseMiscellaneous": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/OtherIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Nonoperating Income (Expense), Miscellaneous", "label": "Other Nonoperating Income (Expense), Miscellaneous", "negatedTerseLabel": "Other" } } }, "localname": "OtherNonoperatingIncomeExpenseMiscellaneous", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/OtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "lnth_OtherPrecisionDiagnosticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Precision Diagnostics", "label": "Other Precision Diagnostics [Member]", "terseLabel": "Other precision diagnostics" } } }, "localname": "OtherPrecisionDiagnosticsMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail" ], "xbrltype": "domainItemType" }, "lnth_OtherRadiopharmaceuticalOncologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Radiopharmaceutical Oncology", "label": "Other Radiopharmaceutical Oncology [Member]", "terseLabel": "Other radiopharmaceutical oncology" } } }, "localname": "OtherRadiopharmaceuticalOncologyMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail" ], "xbrltype": "domainItemType" }, "lnth_PYLARIFYMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PYLARIFY", "label": "PYLARIFY [Member]", "terseLabel": "PYLARIFY" } } }, "localname": "PYLARIFYMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail" ], "xbrltype": "domainItemType" }, "lnth_PrepaymentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepayment Of Debt, Amount", "label": "Prepayment Of Debt, Amount", "terseLabel": "Prepayment of debt" } } }, "localname": "PrepaymentOfDebtAmount", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "lnth_ProgenicsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Progenics", "label": "Progenics [Member]", "terseLabel": "Progenics" } } }, "localname": "ProgenicsMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "lnth_PuertoRicanRadiopharmacyServicingSubsidiaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Puerto Rican Radiopharmacy Servicing Subsidiary", "label": "Puerto Rican Radiopharmacy Servicing Subsidiary [Member]", "terseLabel": "Puerto Rican Radiopharmacy Servicing Subsidiary" } } }, "localname": "PuertoRicanRadiopharmacyServicingSubsidiaryMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "domainItemType" }, "lnth_RadiopharmaceuticalOncologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Radiopharmaceutical Oncology", "label": "Radiopharmaceutical Oncology [Member]", "terseLabel": "Total radiopharmaceutical oncology" } } }, "localname": "RadiopharmaceuticalOncologyMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail" ], "xbrltype": "domainItemType" }, "lnth_RegulatoryMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regulatory Milestone", "label": "Regulatory Milestone [Member]", "terseLabel": "Regulatory milestone" } } }, "localname": "RegulatoryMilestoneMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "lnth_RoyaltiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties", "label": "Royalties [Member]", "terseLabel": "Royalties" } } }, "localname": "RoyaltiesMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "lnth_RoyaltyBackedLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty-Backed Loan", "label": "Royalty-Backed Loan [Member]", "terseLabel": "Royalty-Backed Loan" } } }, "localname": "RoyaltyBackedLoanMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "domainItemType" }, "lnth_RoyaltyPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Percentage", "label": "Royalty Percentage", "terseLabel": "Royalty percentage" } } }, "localname": "RoyaltyPercentage", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "pureItemType" }, "lnth_StockIssuedDuringPeriodSharesOptionsExercisesDuringPeriodandEmployeeStockOwnershipPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Options Exercises During Period and Employee Stock Ownership Plan", "label": "Stock Issued During Period, Shares, Options Exercises During Period and Employee Stock Ownership Plan", "terseLabel": "Stock option exercises and employee stock plan purchases (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOptionsExercisesDuringPeriodandEmployeeStockOwnershipPlan", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "lnth_StockIssuedDuringPeriodValueStockOptionsExercisedandEmployeeStockOwnershipPlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Ownership Plan", "label": "Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Ownership Plan", "terseLabel": "Stock option exercises and employee stock plan purchases" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedandEmployeeStockOwnershipPlan", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "lnth_StrategicPartnershipsAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Strategic Partnerships And Other", "label": "Strategic Partnerships And Other [Member]", "terseLabel": "Strategic partnerships and other revenue" } } }, "localname": "StrategicPartnershipsAndOtherMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail" ], "xbrltype": "domainItemType" }, "lnth_TaxIndemnificationAgreementIncomeExpense": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/OtherIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the tax indemnification income (loss) earned during the period.", "label": "Tax Indemnification Agreement, Income (Expense)", "negatedTerseLabel": "Tax indemnification income, net" } } }, "localname": "TaxIndemnificationAgreementIncomeExpense", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/OtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "lnth_TechneLiteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Techne Lite [Member]", "label": "Techne Lite [Member]", "terseLabel": "TechneLite" } } }, "localname": "TechneLiteMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail" ], "xbrltype": "domainItemType" }, "lnth_TotalPrecisionDiagnosticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Precision Diagnostics", "label": "Total Precision Diagnostics [Member]", "terseLabel": "Total precision diagnostics" } } }, "localname": "TotalPrecisionDiagnosticsMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail" ], "xbrltype": "domainItemType" }, "lnth_TwoThousandandNineteenTermFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand and Nineteen Term Facility [Member]", "label": "Two Thousand and Nineteen Term Facility [Member]", "terseLabel": "2019 Term Loan Facility" } } }, "localname": "TwoThousandandNineteenTermFacilityMember", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "domainItemType" }, "lnth_VestingOfRestrictedStockAwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting of restricted stock awards.", "label": "Vesting Of Restricted Stock Awards", "terseLabel": "Vesting of restricted stock awards and units (in shares)" } } }, "localname": "VestingOfRestrictedStockAwards", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "lnth_VestingOfRestrictedStockAwardsValueNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Vesting of restricted stock awards value.", "label": "Vesting Of Restricted Stock Awards Value, Net", "terseLabel": "Vesting of restricted stock awards and units" } } }, "localname": "VestingOfRestrictedStockAwardsValueNet", "nsuri": "http://www.lantheus.com/20220331", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "srt_MaximumMember": { "auth_ref": [ "r261", "r295", "r333", "r335", "r468", "r469", "r470", "r471", "r472", "r473", "r492", "r531", "r534", "r554", "r555" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails", "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r261", "r295", "r333", "r335", "r468", "r469", "r470", "r471", "r472", "r473", "r492", "r531", "r534", "r554", "r555" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails", "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r171", "r312", "r314", "r494", "r530", "r532" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r171", "r312", "r314", "r494", "r530", "r532" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r261", "r295", "r323", "r333", "r335", "r468", "r469", "r470", "r471", "r472", "r473", "r492", "r531", "r534", "r554", "r555" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails", "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r261", "r295", "r323", "r333", "r335", "r468", "r469", "r470", "r471", "r472", "r473", "r492", "r531", "r534", "r554", "r555" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails", "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r172", "r173", "r312", "r315", "r533", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingenciesDetails", "http://www.lantheus.com/role/IncomeTaxesDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r172", "r173", "r312", "r315", "r533", "r541", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingenciesDetails", "http://www.lantheus.com/role/IncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses and Other Liabilities and Other Long-Term Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable and Other Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other liabilities", "totalLabel": "Total accrued expenses and other liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails", "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r52", "r461" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r19", "r35", "r177", "r178" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r22", "r23", "r55" ], "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r50", "r221" ], "calculation": { "http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r73", "r80", "r81", "r82", "r83", "r389" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Unrealized loss on cash flow hedges" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r38", "r71", "r72", "r73", "r519", "r539", "r540" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r80", "r81", "r440", "r441", "r442", "r443", "r444", "r446" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r70", "r73", "r80", "r81", "r82", "r116", "r117", "r118", "r390", "r535", "r536", "r570" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r69", "r73", "r80", "r81", "r82", "r390", "r441", "r442", "r443", "r444", "r446" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r36" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r116", "r117", "r118", "r342", "r343", "r344", "r415" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Shares withheld to cover taxes" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r336", "r337", "r347", "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash flows from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r104", "r281", "r289", "r290", "r450" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt related costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r104", "r203", "r210" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from diluted net income per common share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/NetIncomePerCommonShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AociTaxAttributableToParent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to accumulated other comprehensive income (loss) attributable to parent.", "label": "AOCI Tax, Attributable to Parent", "terseLabel": "Accumulated other comprehensive loss, tax" } } }, "localname": "AociTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetRetirementObligationAccretionExpense": { "auth_ref": [ "r229", "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability.", "label": "Asset Retirement Obligation, Accretion Expense", "verboseLabel": "Accretion expense" } } }, "localname": "AssetRetirementObligationAccretionExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AssetRetirementObligationsAssetRetirementObligationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetRetirementObligationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asset Retirement Obligation Disclosure [Abstract]", "terseLabel": "Asset Retirement Obligation Disclosure [Abstract]" } } }, "localname": "AssetRetirementObligationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AssetRetirementObligationDisclosureTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an asset retirement obligation and the associated long-lived asset. An asset retirement obligation is a legal obligation associated with the disposal or retirement from service of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.", "label": "Asset Retirement Obligation Disclosure [Text Block]", "terseLabel": "Asset Retirement Obligations" } } }, "localname": "AssetRetirementObligationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AssetRetirementObligations" ], "xbrltype": "textBlockItemType" }, "us-gaap_AssetRetirementObligationRevisionOfEstimate": { "auth_ref": [ "r228", "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the asset retirement obligation from changes in the amount or timing of the estimated cash flows associated with the settlement of the obligation.", "label": "Asset Retirement Obligation, Revision of Estimate", "terseLabel": "Non-cash adjustment" } } }, "localname": "AssetRetirementObligationRevisionOfEstimate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AssetRetirementObligationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetRetirementObligationRollForwardAnalysisRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]", "terseLabel": "Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]" } } }, "localname": "AssetRetirementObligationRollForwardAnalysisRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AssetRetirementObligationsAssetRetirementObligationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AssetRetirementObligationsNoncurrent": { "auth_ref": [ "r230" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncurrent portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.", "label": "Asset Retirement Obligations, Noncurrent", "periodEndLabel": "Asset retirement obligations, ending balance", "periodStartLabel": "Asset retirement obligations, beginning balance", "terseLabel": "Asset retirement obligations" } } }, "localname": "AssetRetirementObligationsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AssetRetirementObligationsAssetRetirementObligationDetail", "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r111", "r157", "r161", "r167", "r185", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r387", "r392", "r431", "r459", "r461", "r500", "r516" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets", "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r20", "r21", "r64", "r111", "r185", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r387", "r392", "r431", "r459", "r461" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets", "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r419" ], "calculation": { "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Non-Current Assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r1", "r2", "r9", "r11", "r14", "r224" ], "calculation": { "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "totalLabel": "Total assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r1", "r2", "r9", "r11", "r14", "r218", "r224" ], "calculation": { "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetail", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r401", "r405" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetail", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Buildings" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r332", "r334" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r332", "r334", "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Share price (in dollars per share)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r103", "r381" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Changes in fair value of contingent assets and liabilities" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r380" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Potential payments, high" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationAsset": { "auth_ref": [ "r376", "r377", "r379" ], "calculation": { "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Asset", "terseLabel": "Contingent receivable" } } }, "localname": "BusinessCombinationContingentConsiderationAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r375", "r377", "r379" ], "calculation": { "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration liabilities" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r375", "r378" ], "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Short-term contingent liability (Note 4)" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Liability measurement input" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r375", "r378" ], "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Long-term contingent liability (Note 4)" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r16", "r115", "r148" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r17", "r48", "r106" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets", "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Money market" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r101", "r106", "r107" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash at end of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]", "terseLabel": "Reconciliation to amounts within the condensed consolidated balance sheets" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r101", "r439" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedge" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r60", "r236", "r505", "r523" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (See Note 19)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r116", "r117", "r415" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails", "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r34", "r297" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r34", "r461" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock ($0.01 par value, 250,000 shares authorized; 68,570 and 67,739 shares issued and outstanding, respectively)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r76", "r78", "r79", "r88", "r509", "r526" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r87", "r95", "r508", "r525" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r92", "r494" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r109", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r275", "r282", "r283", "r285", "r293" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Long-Term Debt, Net, and Other Borrowings" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowings" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r29", "r30", "r31", "r110", "r114", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r271", "r272", "r273", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r287", "r288", "r289", "r290", "r451", "r501", "r503", "r515" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r31", "r286", "r503", "r515" ], "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "totalLabel": "Total principal outstanding" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r258", "r287", "r288", "r449", "r451", "r452" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r57", "r259" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r58", "r110", "r114", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r271", "r272", "r273", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r287", "r288", "r289", "r290", "r451" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r58", "r110", "r114", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r271", "r272", "r273", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r284", "r287", "r288", "r289", "r290", "r298", "r299", "r300", "r301", "r448", "r449", "r451", "r452", "r514" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r271", "r448", "r452" ], "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Unamortized debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r352", "r353" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets, net" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r357" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "terseLabel": "Deferred tax asset, valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "auth_ref": [ "r104" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Depreciation, Amortization and Accretion, Net", "terseLabel": "Depreciation, amortization and accretion" } } }, "localname": "DepreciationAmortizationAndAccretionNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r104", "r219" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r66", "r67", "r68", "r430" ], "calculation": { "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Interest rate swap", "verboseLabel": "Interest rate swaps" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetail", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAverageFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average fixed interest rate related to the group of interest rate derivatives.", "label": "Derivative, Average Fixed Interest Rate", "terseLabel": "Average fixed interest rate" } } }, "localname": "DerivativeAverageFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r68", "r402", "r404", "r407", "r409" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r414", "r418" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/DerivativeInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r399", "r402", "r407" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r395", "r397" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r394", "r396", "r397", "r399", "r400", "r406", "r407", "r410", "r411", "r412", "r414" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r312", "r314", "r315", "r316", "r317", "r318", "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of disaggregation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r217", "r225" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposed of by Sale" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "auth_ref": [ "r1", "r2", "r9", "r224" ], "calculation": { "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "terseLabel": "Accounts receivable, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": { "auth_ref": [ "r1", "r2", "r9", "r218", "r224" ], "calculation": { "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "auth_ref": [ "r1", "r2", "r9", "r224" ], "calculation": { "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Disposal group consideration" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": { "auth_ref": [ "r1", "r2", "r9", "r216", "r224" ], "calculation": { "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent", "terseLabel": "Intangibles, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "auth_ref": [ "r1", "r2", "r9", "r218", "r224" ], "calculation": { "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Inventory, Current", "terseLabel": "Inventory" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "auth_ref": [ "r1", "r2", "r9", "r218", "r224" ], "calculation": { "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": { "auth_ref": [ "r1", "r2", "r9", "r216", "r224" ], "calculation": { "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": { "auth_ref": [ "r1", "r2", "r9", "r216", "r224" ], "calculation": { "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent": { "auth_ref": [ "r2", "r9", "r224" ], "calculation": { "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as defined benefit non-pension postretirement plan obligations attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Postretirement Plan Benefit Obligation, Noncurrent", "terseLabel": "Asset retirement obligations" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": { "auth_ref": [ "r1", "r2", "r9", "r216", "r224" ], "calculation": { "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent", "terseLabel": "Property, plant & equipment, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r15", "r227" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Sale of Puerto Rico Subsidiary" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiary" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r332", "r334" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r89", "r121", "r122", "r123", "r124", "r125", "r129", "r132", "r138", "r139", "r140", "r144", "r145", "r416", "r417", "r510", "r527" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic income per common share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations", "http://www.lantheus.com/role/NetIncomePerCommonShareDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net income per common share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Weighted-average common shares outstanding:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r89", "r121", "r122", "r123", "r124", "r125", "r132", "r138", "r139", "r140", "r144", "r145", "r416", "r417", "r510", "r527" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted income per common share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations", "http://www.lantheus.com/role/NetIncomePerCommonShareDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r141", "r142", "r143", "r146" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income Per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/NetIncomePerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r439" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of foreign exchange rates on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r80", "r81", "r82", "r116", "r117", "r118", "r120", "r126", "r128", "r147", "r186", "r297", "r302", "r342", "r343", "r344", "r360", "r361", "r415", "r440", "r441", "r442", "r443", "r444", "r446", "r535", "r536", "r537", "r570" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment of Debt, Amount", "terseLabel": "Extinguishment of debt" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r419", "r420", "r421", "r429" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair value measurement inputs and valuation techniques" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r273", "r287", "r288", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r420", "r465", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r273", "r324", "r325", "r330", "r331", "r420", "r465" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r273", "r287", "r288", "r324", "r325", "r330", "r331", "r420", "r466" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r273", "r287", "r288", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r420", "r467" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Financial Liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsWithSignificantLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "auth_ref": [ "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "negatedTerseLabel": "Changes in fair value included in net income" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsWithSignificantLevel3InputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r424" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel": "Fair value, end of period", "periodStartLabel": "Fair value, beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsWithSignificantLevel3InputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedTerseLabel": "Changes in fair value included in net income" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsWithSignificantLevel3InputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r424" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Fair value, end of period", "periodStartLabel": "Fair value, beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsWithSignificantLevel3InputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r273", "r287", "r288", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r465", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "auth_ref": [ "r426" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in income for derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3) and still held.", "label": "Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)", "negatedTerseLabel": "Change in fair value of the contingent financial asset and contingent financial liabilities" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsWithSignificantLevel3InputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]", "terseLabel": "Financial Assets" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsWithSignificantLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "auth_ref": [ "r424", "r428" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of financial instruments with significant Level 3 inputs" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Option, Quantitative Disclosures [Line Items]", "terseLabel": "Fair Value, Option, Quantitative Disclosures [Line Items]" } } }, "localname": "FairValueOptionQuantitativeDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueOptionQuantitativeDisclosuresTable": { "auth_ref": [ "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value under fair value option.", "label": "Fair Value Option, Disclosures [Table]", "terseLabel": "Fair Value Option, Disclosures [Table]" } } }, "localname": "FairValueOptionQuantitativeDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r454", "r457" ], "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails_1": { "order": 3.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "verboseLabel": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r454" ], "calculation": { "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "lnth_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance lease, liability, current, statement of financial position [Extensible Enumeration]" } } }, "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r454" ], "calculation": { "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "lnth_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance lease, liability, noncurrent, statement of financial position [Extensible Enumeration]" } } }, "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r453" ], "calculation": { "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "lnth_LeaseRightOfUseAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance lease, right-of-use asset, statement of financial position [Extensible Enumeration]" } } }, "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r180", "r181", "r182", "r183", "r184", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r284", "r296", "r414", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r562", "r563", "r564", "r565", "r566", "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Intangible asset, useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r209" ], "calculation": { "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r211" ], "calculation": { "http://www.lantheus.com/role/IntangiblesNetScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/IntangiblesNetScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r211" ], "calculation": { "http://www.lantheus.com/role/IntangiblesNetScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2027 and thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r211" ], "calculation": { "http://www.lantheus.com/role/IntangiblesNetScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r211" ], "calculation": { "http://www.lantheus.com/role/IntangiblesNetScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r211" ], "calculation": { "http://www.lantheus.com/role/IntangiblesNetScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r204", "r206", "r209", "r213", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetAdditionalInformationDetails", "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r209", "r496" ], "calculation": { "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Cost" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetAdditionalInformationDetails", "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r204", "r208" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetAdditionalInformationDetails", "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r209", "r495" ], "calculation": { "http://www.lantheus.com/role/IntangiblesNetScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails_1": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetScheduleofExpectedFutureAmortizationExpenseRelatedtoIntangibleAssetsDetails", "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)", "terseLabel": "Increase in finite lived assets" } } }, "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r435", "r436", "r437", "r438" ], "calculation": { "http://www.lantheus.com/role/OtherIncomeDetails": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Foreign currency (gains) losses" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/OtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r104" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "Gain on sale of assets", "verboseLabel": "Gain on sale of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r104", "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Gain (Loss) on Disposition of Business", "terseLabel": "Pre-tax book gain on disposal" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r104", "r291", "r292" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Gain on extinguishment of debt", "terseLabel": "Gain on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r291", "r292" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.", "label": "Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost", "negatedTerseLabel": "Gain on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r93" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "lnth_OperatingExpensesBeforeGainLossOnSaleOfAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r199", "r200", "r461", "r499" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r201" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill acquired" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r91", "r111", "r157", "r160", "r163", "r166", "r169", "r185", "r247", "r248", "r249", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r431" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r85", "r157", "r160", "r163", "r166", "r169", "r497", "r506", "r512", "r528" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r332", "r334" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r2", "r3", "r4", "r5", "r6", "r7", "r8", "r10", "r12", "r13", "r14", "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r223", "r235" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r112", "r355", "r356", "r358", "r362", "r364", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r113", "r127", "r128", "r156", "r354", "r363", "r365", "r529" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense", "verboseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations", "http://www.lantheus.com/role/IncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r103" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r103" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r103" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "auth_ref": [ "r103" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.", "label": "Increase (Decrease) in Income Taxes Receivable", "negatedTerseLabel": "Long-term income tax receivable" } } }, "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r103" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "(Decreases) increases in cash from operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r103" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r103" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Other long-term assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Long-term income tax payable and other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r133", "r134", "r135", "r140" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Effect of dilutive stock options (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/NetIncomePerCommonShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r205", "r212" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r212" ], "calculation": { "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 }, "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails_1": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite lived, Cost" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r205", "r212" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets, Period Increase (Decrease)", "negatedTerseLabel": "Decrease in indefinite lived assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangibles, Net" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Total, cost" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r202", "r207" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "totalLabel": "Total, net", "verboseLabel": "Intangibles, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets", "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r84", "r155", "r447", "r450", "r511" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/OtherIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "negatedTerseLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/OtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r413" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "negatedLabel": "Pre-tax deferred losses expected to be reclassified to earnings during the next 12 months" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate swaps" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetail", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]", "terseLabel": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/InventoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r42", "r197" ], "calculation": { "http://www.lantheus.com/role/InventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/InventoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r18", "r62", "r461" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.lantheus.com/role/InventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets", "http://www.lantheus.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r44", "r197" ], "calculation": { "http://www.lantheus.com/role/InventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r43", "r197" ], "calculation": { "http://www.lantheus.com/role/InventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r196" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Provision for excess and obsolete inventory" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r54", "r111", "r162", "r185", "r247", "r248", "r249", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r388", "r392", "r393", "r431", "r459", "r460" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r41", "r111", "r185", "r431", "r461", "r504", "r521" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r56", "r111", "r185", "r247", "r248", "r249", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r388", "r392", "r393", "r431", "r459", "r460", "r461" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets", "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails", "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r419" ], "calculation": { "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-Current Liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails", "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r1", "r2", "r9", "r11", "r14", "r224" ], "calculation": { "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "totalLabel": "Total liabilities held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r1", "r2", "r9", "r11", "r14", "r218", "r224" ], "calculation": { "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licenses" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount awarded from other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded from Other Party", "terseLabel": "Total amount awarded" } } }, "localname": "LitigationSettlementAmountAwardedFromOtherParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingenciesDetails", "http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r31" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-term Debt and Lease Obligation", "terseLabel": "Long-term debt, net and other borrowings", "verboseLabel": "Total long-term debt, net and other borrowings" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets", "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-term Debt and Lease Obligation, Current", "negatedLabel": "Less: current portion" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.", "label": "Long-term Debt and Lease Obligation, Including Current Maturities", "totalLabel": "Total" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt and other borrowings" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r114", "r246", "r277" ], "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r114", "r246", "r277" ], "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r114" ], "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r244", "r245" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of another entity's patents that the entity has allegedly infringed.", "label": "Loss Contingency, Patents Allegedly Infringed, Number", "terseLabel": "Number of patents" } } }, "localname": "LossContingencyPatentsAllegedlyInfringedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r101" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r101" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r101", "r102", "r105" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r14", "r74", "r77", "r82", "r86", "r105", "r111", "r119", "r121", "r122", "r123", "r124", "r127", "r128", "r136", "r157", "r160", "r163", "r166", "r169", "r185", "r247", "r248", "r249", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r417", "r431", "r507", "r524" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.lantheus.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement", "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.lantheus.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r121", "r122", "r123", "r124", "r129", "r130", "r137", "r140", "r157", "r160", "r163", "r166", "r169" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/NetIncomePerCommonShareDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SegmentInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r73", "r83" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r157", "r160", "r163", "r166", "r169" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r454" ], "calculation": { "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "lnth_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating lease, liability, current, statement of financial position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r454" ], "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 }, "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "lnth_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities (Note 16)" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails", "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating lease, liability, noncurrent, statement of financial position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r453" ], "calculation": { "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "lnth_LeaseRightOfUseAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating lease, right-of-use asset, statement of financial position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r22", "r23", "r24", "r55" ], "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r63", "r461" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r385", "r386", "r389" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r71" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Unrealized gain on cash flow hedges, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r75", "r78", "r385", "r386", "r389" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income", "totalLabel": "Total other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement", "http://www.lantheus.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r322", "r350" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other Income" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/OtherIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r59" ], "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "totalLabel": "Total other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails", "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r105" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r94" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.lantheus.com/role/OtherIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other income", "negatedTotalLabel": "Total other income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations", "http://www.lantheus.com/role/OtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSundryLiabilitiesNoncurrent": { "auth_ref": [ "r32", "r502", "r517" ], "calculation": { "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.", "label": "Other Sundry Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherSundryLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r99" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Payments for minimum statutory tax withholding related to net share settlement of equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r97", "r382", "r383", "r384" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r33", "r294" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r33", "r294" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r33", "r461" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r98" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "auth_ref": [ "r96" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Proceeds from Sale of Productive Assets", "terseLabel": "Proceeds from sale of assets, net" } } }, "localname": "ProceedsFromSaleOfProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r98", "r341" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock option exercises" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product revenue, net" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r65", "r222", "r456" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property, plant\u00a0and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r50", "r222" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r227", "r542", "r543", "r544" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Plant and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/PropertyPlantandEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r49", "r220" ], "calculation": { "http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant & equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant & Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r27", "r28", "r222", "r461", "r513", "r522" ], "calculation": { "http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Total property, plant\u00a0and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r27", "r222" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property, plant, and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/PropertyPlantandEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r27", "r220" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/InventoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/InventoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r73", "r83" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedTerseLabel": "Amounts reclassified to earnings" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r100" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Payments on long-term debt and other borrowings" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r351", "r493", "r556" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "lnth_OperatingExpensesBeforeGainLossOnSaleOfAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r26", "r106", "r107", "r498", "r518" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash included in other long-term assets" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r37", "r302", "r345", "r461", "r520", "r538", "r540" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r116", "r117", "r118", "r120", "r126", "r128", "r186", "r342", "r343", "r344", "r360", "r361", "r415", "r535", "r537" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r153", "r154", "r159", "r164", "r165", "r171", "r172", "r175", "r311", "r312", "r494" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Company acquired right to receive certain future milestone", "verboseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations", "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.lantheus.com/role/RevenuefromContractswithCustomersDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r313", "r321" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue from Contracts with Customers" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/RevenuefromContractswithCustomers" ], "xbrltype": "textBlockItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Royalty" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccruedExpensesandOtherLiabilitiesandOtherLongTermLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r73", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of accumulated other comprehensive income (loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/BasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in carrying amount of a liability for asset retirement obligations, for changes such as new obligations, changes in estimates of existing obligations, spending on existing obligations, property dispositions, and foreign currency translation.", "label": "Schedule of Change in Asset Retirement Obligation [Table Text Block]", "terseLabel": "Summary of changes in asset retirement obligations" } } }, "localname": "ScheduleOfChangeInAssetRetirementObligationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AssetRetirementObligationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of income tax expense" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Schedule of derivative instruments" } } }, "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/DerivativeInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r2", "r3", "r4", "r5", "r6", "r7", "r8", "r10", "r12", "r13", "r14", "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Disposal groups including discontinued operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SaleofPuertoRicoSubsidiaryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Summary of net income per common share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/NetIncomePerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r337", "r339", "r346" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense recognized" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r204", "r208", "r495" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetAdditionalInformationDetails", "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r204", "r208" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangibles" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r212", "r214" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangibles" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r25", "r45", "r46", "r47" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of maturities of principal obligations" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of other loss (income)" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/OtherIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r50", "r222" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r338", "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of expected future amortization expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r149", "r151", "r152", "r157", "r158", "r163", "r167", "r168", "r169", "r170", "r171", "r174", "r175", "r176" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "lnth_OperatingExpensesBeforeGainLossOnSaleOfAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r103" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "verboseLabel": "Total stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.lantheus.com/role/StockBasedCompensationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/StockBasedCompensationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Shares withheld to cover taxes (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r108", "r115" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Computer software" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/PropertyPlantandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r61", "r80", "r81", "r82", "r116", "r117", "r118", "r120", "r126", "r128", "r147", "r186", "r297", "r302", "r342", "r343", "r344", "r360", "r361", "r415", "r440", "r441", "r442", "r443", "r444", "r446", "r535", "r536", "r537", "r570" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r116", "r117", "r118", "r147", "r494" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r34", "r39", "r40", "r111", "r179", "r185", "r431", "r461" ], "calculation": { "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets", "http://www.lantheus.com/role/CondensedConsolidatedChangesInStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademarks" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IntangiblesNetScheduleofIntangiblesNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r180", "r181", "r182", "r183", "r184", "r284", "r296", "r414", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r562", "r563", "r564", "r565", "r566", "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsAssetsandLiabilitiesMeasuredatFairValueonARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [ "r51" ], "calculation": { "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails_1": { "order": 4.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "negatedLabel": "Unamortized debt issuance costs" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/LongTermDebtNetandOtherBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowanceLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Valuation Allowance [Line Items]", "terseLabel": "Valuation Allowance [Line Items]" } } }, "localname": "ValuationAllowanceLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationAllowanceTable": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "A listing of an entity's valuation allowances to reduce deferred tax assets to amounts which it is more likely than not will not be realized, including a description of the deferred tax assets for which the valuation allowance has been recorded and the amount of the valuation allowance.", "label": "Valuation Allowance [Table]", "terseLabel": "Valuation Allowance [Table]" } } }, "localname": "ValuationAllowanceTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/IncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Valuation technique calculating present value of future cash flows.", "label": "Valuation Technique, Discounted Cash Flow [Member]", "terseLabel": "Probability adjusted discounted cash flow model" } } }, "localname": "ValuationTechniqueDiscountedCashFlowMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/FairValueofFinancialInstrumentsQuantitativeInformationandAssumptionsPertainingToTheFairValueMeasurementofTheLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r131", "r140" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "verboseLabel": "Diluted weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations", "http://www.lantheus.com/role/NetIncomePerCommonShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r129", "r140" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Basic weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lantheus.com/role/CondensedConsolidatedStatementsofOperations", "http://www.lantheus.com/role/NetIncomePerCommonShareDetail" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r15": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r16": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2510-110228" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392603&loc=d3e7123-110846" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(4)", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "410", "URI": "http://asc.fasb.org/subtopic&trid=2175671" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13201-110859" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r293": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r321": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r322": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r349": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r368": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6411-128476" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r418": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14210-108612" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14217-108612" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r458": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r557": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r558": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r559": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r561": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r562": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r563": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r564": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r565": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r566": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r567": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r568": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r569": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" } }, "version": "2.1" } ZIP 92 0001628280-22-011291-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-22-011291-xbrl.zip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

E$P[)TP[NM@1,I10A'@*)S!NK9+6 M"$2UU H,=_"SS[0WU>52YY8=.ZZS33HQ[ETBKSO6+KF+!UW/3[@YX>-6? M]+N]=/6XJ8?[C&,!^T(%4!3IC@S'H'K M0RU501M-%IO*DY;3Z9,[!DHD@#P&R(\I@VQ@WDD%'BZE',SG[/LI,RO+8X'H MPCFA%+>,!<0\-2:$*$V,-L: YJ))_.Q+Y5@(AYD,1"EBHW:,2ZV!6$$'AI04 M6M)![6ZT6+!G\H*&1H9V*#&&*H:0(YSAH!6.X! +[%,OD1CT(M)KBH(V.L(Q M$# 90-P,^(,>@UD+SBA)L<#16L;G*-]G9B5N^HD^0J4BUP+A("DC 2F'J4+( M>B.#(GR>$H%G7TZG3VX6P<\$&DH3%*->&#"B F-,!',1"3G["YPS*\MC6?VD M3&&"M&"6:R855TH0DI8].26>L+B(])IJD&=DR]8^4YMM79B:KJRF 5W=&I:+%S@AC*#D=;!1>HYC\8&(.T< MF@[8?Y,;"Y_6+ M,[A56$AA->"X:"Z(Q(CQE <-?DR4QOD(B(?=[W]34G>N9)=+;Q"-W(F0JJ,R MK;@DCO.@A4T!]D63W@=FF#H!4NRC84YCL,$"(TEPG(>>*L\B\6[H M!I.[8Z#QK6:T"RS#")P?3+4E+'5$I<'82)2+'DC@-9N+@D1S0^ IE0N2G '4 M"B[UR@.B!H0QH"V,!-(V%/F\6 -+R5FCJP^-M]OAR#37B_'<;M/>:0;7;YI\ M"TX].NY]'#2.#/U>PYEFZD YSO #UADB&9$O"S_TVXT!94(_OYGQ5C"IE^:[ M1K?#")9OU_=WKR^_/G3]/5W_.)P.@G 5E$ .?&!+E%+>,FPB5@$'5E2(P1RC M0I+3A]F3Y+27_D9^-T/G*#=GQXFDMVB_WD_]C\>=>X]YAM'39'5PZDME]88= MSN":=N\!1Q3O/#CV%(ZXN=WPQ1^_W_#@CV_XIG'Q-@_=3C]WH3OX>AR,+R;7 M-[Z^^Q/^N-Z%C+SPA!*="ME3;N&#IXH"VNO)/8K1OUW1[ETU@*4!0V7%( MXON6\;/>'^<-#T,#_OS?2W?/,_D1G&H[O5ZG]9;"F<-?>IVS]!7.[IZ9]O7I MKM/LY&__!8R)8OPCPFQGT;0:S+1I-H[: M;UU(^;SP^KWB/L,3;">'P60P$TUSU@UOKS_\X1O=LZ:Y!.U9O$]QT1]W:9VX MXFO("Z4^?$CQO,'A;PRS@@9,TP/6[/GK)P\/KQ2'WO3\PV-:K6CT_<-H!=\< M>U/<.[\^83C[O. ^N [>*DW3OY?HTKT7'[X*/NM5NIUFPU<*;@ J#H\G)GYX M\,SXU$'Y+:K@XA'?QO"FF*@G4N([<@$/> DOJB?PXM*[_=I6?7VMLE=?K:_O MW>6>&1SMWOJ'_=VM^M;Z7F6UME99_Y\/?ZW6-MNWX":N,L0IN\E^-)CD(FAMN"&1&>HT MDE([:Z/VS$NE'PL#5-HF(<>$XMGKP_K<'WZM46KUTY5%NKXH,3^$P^7>VLU4[@?%PCAZ?5IKK8 M)H>7!U^8NW., P[,OJO6#RX.33U?5 M*]^L?587.VO5RW]X1%)X[@ H"IXQ[&VFJ ?PEAB%!CF* $B 8K\5,"L;U1X M5WF*'./O.TW5+\GQJ(7S*>!NZ=UO:;6@LM,.O\^/3M=Z17'Z$D9@ M*Z!JGL0'SV(ONH(8>PY[?8^7KMF%G%TDAGDXU_KMA7\X9I5O;; M#=?QH5+=^Q[SB'O,PQYEG@DH]4]]<(W!W[C<#6>=O+=4B9V\97KP@(O>V]BX M"#[KY?WYU/L;#;NY+P[@6.VD>E5K[5_6-JL!^Y+"^A0ZN3L%6')P?G)RRG35'=^J.''[9OZJM M?3ZM-=7Y=GVU5]U#%]MU>-NU*OI'411%1#:3.(J, 8$R92C.!),H8)4*?KFE M=__]+RT9_^.^Z;C1%D..?QXS-T-\*.>=L\ECW,(J?-I?W:VO[VX?5';7/^[L MUBL?]W?W]E=K]4I]IP(8O@Y O8)I96>W@OEO_O?*SD:E_M=ZY1:\OX'VJQ_J MZ3#6E-V9HBF[5_II2*V35WK'H?*?:Z&K#,)+E0 ^OY\$AOM8/&]]$.2Z*^P> M?LE:\,SC=%GFS65V&4R>A?9<"O_+05_UZN@?BXR#V159RCW*F DHTXS0S#N* M++'!2,>6WE736D2%XN5*FO,7H;]A$**T[_-AWY^H%W]JWM&$S'N1EMM(<<7O MV_=HFMVY-O GG\YK)^N7AU\^D5IZUN8!K[7^/@:3WZQ]V>>')[7&80( 5^OW M#7RCMK9*JG70$VOPMB=@X.%9!ZUU,/G[^+#>;%7)WZWTO.KG1PR\#5Y'Y7R& MO3 9(XIGVD:3.120UL)RAM70P+.%-O#UW=7:WE9AQJ=EX6\[U).(S3PQ-#,T M^+T;,;RV^#'OM&X,Q,1']J,%D/_^%Q;HC\G_.;7)6'I7Z75*6CQ&BQ^)V41" MH$^CWX=.J]7HIE7HRD8#@!3H6!ORX:N,S\@.,AO2$PW^RL[E.:VO-YF']]/RP566U-5![Y GU7:XMGK/7>A<'9 JVEG;/Z]N M5ME!W:&=+Y^;._7WK8.K(U0[.;TZ/-EGX&B<5C<><1>,H\1+3S(OB,B8Q"I3 MGHJ,2HF$ES9**9?>;0-J_FM]?Z_RU\[VVE9MK:#&$0?YZ6+O9(QP2I+/SX:.8I%K^Z'3;_?RRP\=?S><#Z_@4MYK M+YSEG:_I/G,:QQ\8[MC:;537UB\. MZ^OTD44\N+<_WMG\W(*Q7!V"T:Z2S\V#^N%I[&;;1LZ5W:Z%ISDT>QA_D&X_U?<#?CP>L[P4' M7O12KTYFZ^9B:YA5/]C2,L?!@DD+8_6N,#JFD55"9-@D!!VPS8Q)14.I8#YM M*?<(A)'RC%":63*B=73OIYH^L;K@A' M XINW#8JQ6GYD6DWKHKOOS]!VE\Z59/3;_P0M/%3\^]?'!X8=9_@_O,V52S8JE6O4^#]WN\*]M M& NK=3/K-35PV5A(DE@!F4\4),QC'AF%1*98&FO'=?"I;POH$"EGH?D\7[H M? W (,;_ GS\D8#EG?/!9S)SB1*SQ?D?.^ Q-0\;9P-WJF3]G[+^/8#F>>26 M,Y01ZUG&"$6902)DB/N(@@[6&@!H""OQ(%OJ"8;F$5W^))_(H]CR,T? MX.-.7N^U3MX[ MKKQO-)N)EF;Y!1K\%^)?4PP03)>U"X]F)_^8=[Z"]U*JZJ?P]_I=_F9$1XTX MRKQA-F,RADP39+/4A)H:;(/E@%*JJZ\OI#71P, 8S- 3/;^A**4(P%D.4M0X M,\U*N BNGZHBP<_@!X9NZ?^/W?^?'@L TJTDJ#M?*Z0*K6C-7I2^_O05TC'= M]N4Y)X^"V$4U]@FZKN;!S+D?5EWSQX>;?S<.3HY/#NJ?+M(UU=;&\>$)_%]_ M?WI0/SH'H\_@[_NI)N&=M M%8S^\?'.8ZDFS"#JB9494RDK3UB1:>QDAJA%B*1&RQB#_&NI?B\1Z[B8.)4P M:WX\[K3G.3UTTHQ\#Z5**SG!P6368N,C=8(QLW2.R%QIE"J M]U2N]X!8?TO5^^]_*8+E']U*+S3#66+%2KO@Q>6TZM/LIY>J&%"T%?I;*GB4<]$HY=:.3@Z06.G.YR%Z!+V;HEYBVO_XI-KHP MX$K:C@J,&U-B7_LH ,Q*SG^E:;J]2EYL;_L5'#N8JD8[K8&]92O3V)CYFG+_ MAA.=:MQ,W-L;%(\"3S=O]!IPPT$>:;>?$DI[G0J<4:R#8O*;_3WY MR6DKUZKKO7U:69='I>^1=Y^P]\16-'L1CU&Q(@4?N?>$U0IE>O1.&5[AZFE[ ME9^6/IV@ZTLKPZ WJ!P;CCBL.E&KWZ:[ HL]-;@JDM'?9LIWF;\\) MBOUX9O+!0Q9VXFK#1/V"I\+%P&Y70*6>'S?@EV]Z]P7;&7Y6FW'!>7*,CNO0 M,EYB8@NM,,>.Z\Z:NSI<1Q M9;6TD8=L71U<55GM9!_M?/E$=M+&H:O/)P=DG1Z>[#8.6[7DN%X\7#XT1EH: M5>:0=1FSV&;6=+E?.3%[Y:IK]4/DOM()PVBI> MZ1Z_+*VX%)(Q"\G0)@Q,0BDA3Y"0>Z$='!6VU-LL8 MW3WNI'VPUZ5G>L>F=_]5SLW=\:;!#BX>OLWORT5 [C=RZY4M""Z<9$_@A=)% MQ?EP91K/\&:I!E6W&$DQW!2ITVAP!V\NNRO?+4 R[D2B#_T\-3H=5,5*=KQG M>OWN7*JA7ZK@ 7:8.L^1!@UB/C>UQB_4+SG MJ652?YK#0P9Y&\,2FA.HX/.]$3S.QK7.V"L.V/,*^\R9.DXJ";11J]'K M@1(+3=!*>:>=L%;SLA( =UU6ME(,UK@BP6G-],R@7- ]1?WM'K>#P;O]9AB0 MD2&>=/%N..H/&EX/?M[+ZI7?TDA9&5X;N^X490C.$OE"":BP G:6[.>)GVH>E^?KL7_&&&YU-)EE(0 "I?X3'D?,LP\PHYQ8@(M=6VI M:V=>UX(Z,Y4FO$>H&.= U^:IJ7RA:?*$%!_]M0(,G3URH-LR*7]^"#63,G2= M%LS Y7+"QG S@)%IQHXJ1WGGO'=\?7BHT?9"*(;G0VRTBR*+15)KRGT@\*;? M&61Q&/]Q?=I/3_C^(*]/3/AX>/)W!GQ]9J-=F!/0^38CU[#_-M9?F9^R:%*O M:/FB!DZ$K- 79F/^I-X)?EHQX6?+L M8Y&W\>QHG'KD[5M1ROP#:+.C3G[Y2."M.*G0#U6R?[6S>0#'JQ>U^CHZ MK']NP-B.#[[LGU?7CEO5DR-67=MH'3Q6'H:DC6%1R/*VK+L0>DP) MJ3\I*3&>4Q?'C-4>P_,ETR[>!#R-'?8&+M) @=WX28.O0P]H >?FB>W.TN9)^/R8"\R^WZP?T:@,13)VTFB4\%70+*C, J,X@HP95SE)*G M]?EX929L%%6?)G7J'.C7]6%4::!1-XO0TN#SAU*[CEF[7L_]8-:'\UUJV1=K M6?1 RQ(4G/2.93%( JXTJ%H=9%H@P2*(:!RQ[AE:]A>S5R8=?8\_B'.GS7J/ M!N<;\;$UT&+E$]!XNU,L7/:[@_ XO.>@S> CS8@Z>?&LYF5Z^'D#'@V/K;3A MU3HIXOVUT2W0?=NT7?+Z ?.GLL/IY&[/M+W)?;>2Z@PW_.-;:*YS77XSOS\: M[IY0-Z 1K=\,3R[VB/UQUAG,Y=L\I-7@K^&ZF_) +]VZ;!A51]\N,;;;:?9[ M#R_Y?@;5[3^/\V^J^BAD-@_F-#.Q%_*WIGEN+KM+;^YR/K#]]=C3T+\WT+NK M (!._K@E,_1'(A+C>'9,_J1-TI]F9L92.4: G,1+F%#YXJ MZCCG,GKRCUQZ5R]6:D @/B1[U>YU_WQC'J7W BX>=H]#LWFMX2J_@=XJUN\& M*7+?DBWN+)&!JOC]>\N_!Z$[*_IC_*Y>FKN%Q""_E%]!_M$:I$Y2DQ$>8L:0 M#>"D19-1%X2E6AFG^$\QQ*+D-(PW0C\7>JE^'QW=-%G>*!*2 +UVXV!:!8[ M;;I+=\458X.9A3^TT P+9@AGV'C%N8U.6OO/5B&EC) ET%^NT0+)^_?25FWC MD8S38J_/7MKJLU<\:J??*] 3P*B[0MSNMS+?*0Q,NB$X9.!EP;W0*Q/IVM4! M^<V6PTW65UONEJN=+X1)/43@@M6S_)&R"_3X"&OP[QJ2@A_GQ"_+%W57W2#/R@ M%=UW%."LC+N^^GY[/?60_K!3JZ_7ZGO/&O&$=31?0>A%Z7.I 1<9>3:6HBL8 MCZ%$(IA:-$\2/8 F>52_*N-.CO ,*+!N.T+D00'>^=*OJC<4; MF4I^RHM/R#K\XE">;APP E*N[M8K6RN5C:W::NW#UNHV*-B-G=WJ:GUKI_:( MI?C!AN?O$?F%:.H'Y3<>/"D6_SR7G09E;\?/2X\M&$V)EYXYE&?P$EUZM]4+ MK6',;.476:]-TZ1BBWO'(3SJQ(R?TK?QQPMX\F\[X.S3\5>O_(M$O#<[415]_5_1O69].K.R3E==,N]6*U^KC3A*=UA[T$*NO_Z3=ZE\^2]E*HIR740'-6 MVOA2#=QB"?54-6"ZQY6-9N>\]/;G7 D Q7GI[9=*X!M+4%8TH($A]3J5[VB# MQ\+/IF ML"!_9;?1/2T!]GPKZ$1].JZ(6RG.4Q!G?EM!LQ)B+P1%TV:,'.A5*.>/><<% MG_1Q"8_G7/ORYVK?'V7)_[HQ+;/D1R"NZCI-?FNELE/_:WUWA#GRX\R!+77[ MY'6[PB/-@R\I.A,4W0Y'ICDPTT6OE-).S[F=3D2EXUJ2+*5T"E+*[NC=U3*. MM1 D31&IRH9QO4Y>+OW.N\X%>E)11J861T#E0.=6RG7?Q2#F?GM0JBJD%GY[ MICFH631(M[W=%#;%K/:[15&1(28N ?&\*V<@/U4E(%X8>=9BJ)S+)=W%(.9: MB*;(I]D_Z[1!&[<;G?R64B[1\7PKX$3BT2G@$E!-7V9UN6Z[>!2MPC4 C6, M1'PKCZ:$OW.N?74)?Q=)5@FZD];(2PR\$!3=*8KY;[4'M:KA5B7JG6N]6Q"U M1+V+)*5WLA5%B7H7@J+K%\<-VRBKKLV]NDWIB7JZZ8F3$L[7D)M(D%IZM[>U M65NM[^^N[Y5H:,[%$ZC)T(_$\V%A.W>]60T7=G M>F*CAI37/8"JWZ^!?OLUGL'?=&EFW_IV@O*C53;N%GE^X02(QR;@&99AO)U% M3+MW'/K=RE^=9I'1NSQD@[:;_?8B3ZR0/#-O\7AKM!_RV*R-M=&N](X[?;B' M[RY7PH4+9[UOG;N^_P*W!)[?Q5)3:O>BU JE]"7M7H1:4>)I+52>LFUA1^!F=C+;C0 MLB&_/2'XY[USQA43F\84K':[M\W11#K(3*&BY(RWN9D&Y3_T\QQ$LF)>S@%C MJ/8W\GN,2((KQ=]DA?#9H.GC,96B*&=* ';I0_A/OP$(:.#SW27O<]X>59X; M;)K&J__7+[WB[5?+TUUGZMV^VY2XW_7W.A)'B2W&U*A(+:-,&A:E "^0(A^U MDF[8D;CH&_ZM(W%&KQL2][O9D3%G;Q,GK;9]^FO]&QNM]CZ8/+^$:?NNWD<+/6 MJI)/ES#.JVI](U8OT<5V?;U7W4-7M9/5J]KJ/Y$$RI"4F=?498P@E6E*5(8B MY\I9*QVU2^\PXLN4\P=MC>^V!'^)3%PKO6?(QBBM>ZFA%E1#61\]-0P9AQF+ MR.E@?2#1"Z6!W0DI-!3&I-10LZ:AKNYI*&JXX83++ H=,Z:QR PA+%.,44%B M1(B%I7=:+7.D9DA!C0C9SP3@ZX*0V&98KK1#[[MXGSQO(AY5 MO7.MGT:%H*YG?O=FXFNA-W2Z2K4T*K54^_ .!FG"/?!9D0+E3'N4&:BXYG@ MPC)+.-)8 G"29)DH^JMZZ0>Z85S Z:D>\ZN7Y%$AC5*2)R3)]P$&"E9@07#F M+>+@ F&=60%XPV(K*#82:X*7WBF]3%/I@ID1Y%<55WGU@CLJ %$*[I@$]SY@"-H9)84#SI$F8QB#X$9M,V&5\%'J MB$1*LN;+F,R2X+ZJB,1@FYA[VNKCJ_=A1H4=BED?+/:7GLNH%5'C 8)P0LXGL?1S N M1+1*9@XYDC&+8J8D0YE6S'#JN966#L07__+*QN0"#]=9JL7.EQ]*_*3.'&FD M1,\&ZGD\VZK>Z9GF*%#/SQ+:%ERACFQUIM2EX]"E.P^78Y#AD5+&,[!Y,0.* MV[H=!KJVDW]JIS_5:_F?8:KH6S')Y2[!J&*U=;'9C5J^)KJ?I&IOH>+AL1 M0#HH,)\Q["RH/D8R*P7/%-),1QNC8REC%XMES7\Y_%Q&?697'XP*M93Z8*[T MP8/T%88\44&!OX-%Q@SQF6689RZPZ(,T0@(#%/I 2C)#^F"!-CU^+V>E9]I' M#=L,W9Q CZZU)7K&1]X8K706[]PS7Z:NLU.QY\WFLU2%XTL5[^^FO30 M )]<'9Q7KS[]8XFTRG.14>9XQFS*:7$*9YXA98A$+O+4=HVA98+8#*V-ETDM M,PI.2I&>N$A?WA5IC$TDP:!, MX @LRD(-H: M7WK'Y+(2LU0HH P]S"A^*.5X0G)\ M#U&(2+F,!&6$Z9 01,-A2T^RTC[)> MR%OEIIK);ZJI==JNS"X;M0JJ/H 200AN(F69(U%E#'F4&< 6&7;! /TDQ2F] MC)%EK&?)J2E#$3,*)4H1'K\(WT,1P6A0NL1E.@2<,8M]IARA&0< $3Q1P@65 M&L\M2SY'FVOFM:K'C[:K/(XC1E)K>8'+-C[]_1=&&X]V5TZI?D>G?C\]0%#" M>L&T(IEDX+\Q95UF$;AS7'B%*>(._EAZIRE=QN*7JRH]5R1FO.ALJ=I>G6H; M[0ZD4K6-5+7=1Y;(2!*MRH2,.F/4QDP):C*B)>8>\)T MW*(3!4KX3C\U=AI)GY*G.NWC&>4"K9?^N%%)\QN?_$J_FEEI23/.KC.SYF1^ MIUO)D+!G:3\*6.%.O!7#]L'V"G70*8+;(!AYYSSU OP5WW_18-ECK[@PR&M4 M3N4V\%0=6&H-.*K< 3YR&.8>;C6(W!F@5Y:0<\8B>)C:>I-Q:1"F6COFU:!Z MCIRE -^(S'VICQ94'XW*$RSUT;CUT3VW$-P_377$18@K8]R&3.GH,LXB!H_0 MQ.A]VH>Y+-@<;<-<\&I>LPY>;QJKG)G+U!*@S-Z<5$.5CX,)+U7GR%7GZ0,H M)Q$)6@:12898QB@-F2;69(X(Q22!_Q6(/R'+]-=;J929F[,KPZ-NI5+*\!AE M^/X^$ ;*EP:6RM*@#%@!@SM&1<9],!%K8Q@Q(,-H6:I1U=^;H;CWW*")O!]\ M)5R$O9\]>E@8\(8JVT_2! ;D.?62D6IN4:MN4X>UJP@C@1" M9\P$_2O&>K'C? R;1!FZ( MB!G!3&9,.YUI877FO,.N7EET>V!%=JUC%JUH<;;A46G##)L^"9RYA5(;-.H(P8Y W"6&N>5N"D7!:\ MK+E>"OUXUKE*H1^OT-^#4]Y2[B+U60#PE+%@TBY[Y#*C)(Y!1TZX6WJGT3+3 M\R'S"Y3Y^)VH3\H)KN2AU\A#*NM;Z5@845&8MXSU3&:SR>[-Y.]\F_MR)^ X M--;#S;PD@$[R)F9(49LQ*D2F0+%D'FM)B=5&([+TCN!ECG\Y7;L,[\RN1(]T MCT4IT9.4Z'L8Q#&"?*HRK*FQ*?4O9D93F6D+'DETG'@OB[4F17]YO7CV]O;. M+M+8OI-7790;>U)R=;D"/LYLY-6V_V#.&CW3+-HXW-)7I98:G99ZN 56AT"T MMR(+V+F,">PSJVS(),$B<,M K:3&#%PO4S%+?<++M)89!1ZE4$]!J.]!#X-, M8":XC"A",A8XSY16,=/81LTIH]RE[DN"+F,RJL9S993C!=7)RH2629*1U MRDHY'K\R&'W(&&$Q4U:0C"=?01,<)&9I+R-;!H+.D" OZ%Z< M'^5\C#O78_%7?L>0[E%JI]%IIX,'* /3(*V++.,& \J@2F1&&I,A20/QRCB! M 64P+).6R8\:[<&+D4)]3!B_D*(03J?5:O32DN5@ MXT\24'BKT':I)M9O>R%4:IU>J&#]^PWEX"5^N<34]VEYK4S'@QTNNHVW[4;S MWTN]O!_N*Y);DY%"J;>GHM083] 8#^NQ&!DH$G#_$[*G7=$W3=::_ZX8ZN M^^HW/S/_U]_-0]+\:D_.&K76%M[YLG5UT-JZ@+]A7+LG<#]>^[)Q6ONR3@]/ M]F'\ZZ2VH2ZKG_XA*DA'%8!^3UW&),&98HYFB$7O^/_/WI>] M-V8B5$SMBSU!!&.P#Q,#>,'CB[\X:K4:"XE7BUE^_:UJ"0P2V A:J"5JXAPL MZ%)W=67E4T]F965"Q#2Q/U\6[YA'#W/^Y'FTI/.(8!8,8QIX@SR@+O[07BO MC&%4X[CR.K*V =?A]%[YU!\:)[K7^)ZDVVS<.?/Z2>K]IP&O#5K<7 M\=AECT1-9^+%WKLOBL79IRP'PEH,HM@ET'$9!]X*HYR,-@K2/T&T6^?5G, L MSZLEFE?.$N8D"X 1H],6O ;&*@6T$M)#)R@TT:C K!E)WCTP;C3/&OI*^"_K MA'4[_?YP' M,4D%<<G?:'@_Y =Y(ME>=4/>>4\-YHBA0P)J3CGDX 0Z@#T39F&ID0!5^O M93//J=K/*>DDYM"C:$UZ%HU+R8'!0H XUZ"!6%NE8:WF5%[VZCR=+")42:0! M<3H5:[4.*!\YOE#24F,-1,ZN;72ZOV9?]^=G13DC1H>;?@#.K_;-GGV<8E6A M/S>5M/3X9.VL2CLG]O6(AU(J2($)NBQWY8#4V((H.NP(8Q#;L+91[AC@ES6* M3>CW;/#3X=L[V 3'1[\?;S[6I[M;WY1D 5GG4NIECB@B")@&,6 1MN) M0RJ\0?)!>W*5^7CR)*K])-*8JJ(@'HTPX@"F!D81$1VQ:&%>[JD)=>>V29Y5M9I5#E*NM8[(YB") M&,<%T!'U !:44RN,CC;^V@:732;N W')@5V7539/P?I/09QB0XF#6B,!O$\^ M)6("4-IP@ BA$EF&K57UX6YYI:S]A!),&",D!99%.X!R%FU2[3P@D$(I9!1_ M.E_,15.0Z3QI,V[1-1OQVHF/3;_[]OEC-NR>1>JRJC;LKJGEV.&?56XVE9LL MF4D5) QJ8&&J-NPQ!]I"#A1G1CF#-0DJ\8"JSN,OZ9'[U=;.JG;DLG8^5CLG MMMT,AH9880%,J7QHQ$U@I(LJFG+Y&*T9ER:M:"M8";,.!QSOJ(,0^YG&6+<; M)[IPH.@T["B%9DX0./1,,P,X MCJP_;=X"PV4ZSL:(MP%I*DK^SYI4X!HI] JE4;BSQO;P>-A.@0]1@4)AB\$S M*W?PVY/PBWY\S_AI$I?>^X&./7+;NM=)I2:NB6-K)(V,2]7ATG1-2&T$U2G6 M4+.0HH6M!TH0 2Q!V!(NL0@I/[J03S@:X$*U>?7?&-:(Q*K!DN\*3OS=-WYK=_O]*0ED@ZAR#\VZ#R,:2C?MZ- M9:J'T)\];61.E?X4A.1Z/L_M4B"9$@H%%(0 JF012= MD"K$69T\'PRQIF33H9DUS9B>JR0LX^9,5OTYJ_Y48FF%#2062*528@1$@?(: M A(XU-H8C56(+(73)KTE@K&FJE^1 Z5\-F;K8@FXS+7:3F7 K'>2X.TS4Z(4%< M&A( 1"@ RERDA$%@( @B7DHD*1%K&XJ0)N)5A=Y4ITT+]F5E7,VX6EN:G7'U M27%U,L8Z+HH8F@"D%Q10C@TP+I)N2"'%CA%/N5W;D)PTA:RJ9NKB<;5DY7\, M='SHY:FEVPN-B9M(9GU4@-[3ZV99>>R@Y1O:INU)W3F/(]#H= >)8O?BGSN- M(O;L:Z^,RNX-&MW0&+1\WR>5=;[3]V6ALG(@RZW.4'1TQQ:EYS'^H:R/M'[S M&->U 1EW@_#8SY-NOPQ9?-'S;9W.?[T\+=R@=8D?U[XUEB_\\15M8@^&@[N_ M4I>A1A,GVJ[]3+T=(4V CCM,<.22E!)FX@=')+&,,1$<_H+2^XYGZ0Y->7IN[Y&SHH2OB._Q>_[X6G;B*=(?Q'J[?;/@SZ^-Z M&\=Z=#BX$46A[WZ+:TC$[EA%RP7XQW)1+OKQY=KZI.]?7'YXZ8K^25N?OR@Z M91?++[V\B7SI 9->L/2\T>4Q?'*^CEF)H&-_W/C!8W!=+R]-<)CQ-]DZHN+. MRW =W7GM9[=%;)WRN[_ZL]O^_)JD][:W6*V78HS\T=>CY2]\L[_< MAE%336\Q?D>3?4%&WAUNVKCR^<9N;-?J-[8COKK&GZ;WQ\:N[ME6@Z#F/4H5 M+G;DK_E"9C 5:BZ6Y(:\3Y'(62JN/IN10W.?LPO0@^4_Q_/>?_>=H>_/;5]N MU1R.,[__RO@3J6#<*Z69QH%J8A440EEC@G+4":F^;)7[- @B<+\-F_'<>]WK M'B>K+77A4S%HO1KVXWCXWO:9;0_3.&[V^S[^SRU-//'^A[&O\>CP?._HW_;> MT2'=__2.'AZ]CY]358_/K;WC]-U_B\\'NV3_S3MZY6L\?M_^_&;W;._B?7L7 M']+=K7=GR3>Y=[ #/Q^_/OJ\]6_[\]'AV?Z!A9.^QL]O_OUV>+%-]MY\O/A\ M]/5T;^MU>P]OH]VC]\>'G_:^[7WZ]WCO:#OV_WW8+<9^Q@_P8N]H\V)O\PMQ MAG/H/) $*D %-T!*0P#3VF-I*=5*)"R732F?6VA/QL.,AQ-XZ BVU&)C%>*4 M(J2D@\XZ01#6QCA1XB&ZQ$.4\;#N>'@Q@8<6VR@UC@!G&@)*4^03X1QH:#CE M@D)']-J&PDT&ER;<:66)][*=:WO5[9>[0%^[7==/@G;Y\-J3,<\T^/OA31KZ MM*7M>]\+Z_L?HA RH%8&J.=3!)-QIUWP'B@9891R@H'$7 .DB8=!,TP"6ML0 MJBG1H_EE/K!67WVNG#EE?7X2?9XD2#)%@UMD@"N[+ A@=;SD_8R168K"Q M(0QH1BW@T!)&:)3<: .^2=BCC_KDS*+UU>?*R7S6YR?1YTENKUP@D!(! @LH M%3"'0#NE@39(8NP5@R[EYZ--)*:3!-=-GU> $/W$AUQ[0O3&=WPZ/9@HD7;' M1:?H#WKE^;Z\;_QT#M&1$"*.;MX000;3JL%T>O,X&.A5E!J0!D9R1# '2GD# M'-90!.<$I1$9B&@R*6N_V90WC^M#CK)2/YU23X78&:TM$PQP&E696N6 UO$3 MD119(:B3TD:&Q)N(U%^I5X A+;/+Z+WO^_* 7*)(SG_W[>Y).H&<_49/>*)C M)(*(I5L_!)"!M&(@W9_>0N91>B:N@4#HE'Y+(@\DU5%N$429I%0SBM(6Y$9>,VZAA,!IZ@#E2@)#C0;2*@*3_RCJ=%1IV"2\ MJIWAS(V6/O'K[0@R2OS:O?]V\#W,S&<<;5,9<6IW!JT75[OT8U3M_^4CK/HW MNNBD*AO[G;09NA_2L:]!/T-N99#[X983L!9I%Z46<()<@:(Y:B !P3$2+50= MA(CFJ(!-1*=+<3PJU][BX_ J=$ ]8V2HC']E9%@H,DP==>"IW"?$P(2@(QEC M DA-&$@I58TA03NIUS8H;')15:VM'*;W'+U82;<;$6/Z>I3/4)>ZG7U83[?' M=P6N6W$NCC.C7F(LN@FRH3CS#ESX7C?CZRQ'R0XVI_+'"P8YID@"16T$6,,9 MT#H$P)0W1@;!G(!K&V5Y"ORR]N9N]F MGD$]1*$S:WJD5D]D+Z+(6CE5NA+*CY*P&4ZK@]/M*9*$O DL@AS C- ?7# >!\_1?.4VV"],G)M M@\FFNJ4^?<56Z,HYIU9<^ROG55G[YZW]DV0J8,28TL"%M,=/ @5:. DL\CHP MAR.B^Y),\92G>&FU?P5HUK)E =Y)&:-]?W"Y+YC=34_&H2Z'/D=45(Z@.U/\ M*2Y[$2DA SKPR)H@,\#08(%25N.T,%K$(X)6F- QNYAJJ,254Z&LQ/-4X@D: MQ!$UF"$-A*$24"4H,-@@0*3Q(HJ4<,/6-G!3H$>'C&>7TNKEQ+C<8(O]B_T= M%OU6"FA,6VW.FX<%BS^+DL1^VHBQ&P0Z?>L7 [X>0 M_A9\K^==NK;3[P]UQ_J4^3'OR56"M+M3=$FFVJ.(0A!A$$>Z1 )05B+@M,.* M*FJC>"O;D\MG[IY8]W];]*9<1M6P^H_U!R_<>LQNWO*;F+,A9_:9;&O>];J=[ MT_U^97IF.)P!#M]-<1Z.-/*04H"I()'S8 448AIX+['%*F F^-H&E=/[:_>' MP^P;JK'"5K]/EA6V4H6=X"^>8^:9P !:G*KT: 84X2K2&:@XQ9QK&1=E1A_# M7[(?Z'')E52=BCLOS(8!RU.TARBU9E3\?Q+SJZ=[XS\,?]",*IE[UNF0WOTFF?O?75P?/' M*3YE.>/(()P"N:-YJ:D'RD9X]C3$(4;6$,$B/(NF@G,_.+.LSJ7GBB)SV*?+ M*+(<*#)!\B!VQ"&N 3=" 6H, IJ9 *3SSGD%(1&NS*1): Y]RFZLF4*?+IE> M#GY:$*N+.#LVAO_R'9\+CE2*I8?3)^V\E'$93048,064"0Z4]!H802TR1E)A M2(FEBN0HJ!76YCFQJZS-\]7F"69DL(8!6@4"#5&E%?= 8TQ G+J,L#T_N&,S;[[97FX;A84BZ/_,[_U79NFHG C&V9=/$*]G#@W:R;3/>S,%9Q"9A] %9N@9@W1QW/R;Q$S+)$'$WG;.;<8YNV M$KA&%E"F$)!:6< \DE%6V.A4+B.RU$=']LZL% N.,LGPEN%M8?PWP]L#X6V2 M 7/L&3,82)1.E@6!@(Y+$Z"4$1N#_D!WRG=YT';"](94U=L)]SW?\I2]7(&)O+2&WJW;"<\UVG:D MQO..FKH$D2!/3W?T#(V"&68PVJX@K3F44QI"Y8+ /D )* M" ?2!@6\D$@*314T8FV#RRJ"#7)0?:W5O/*0H:SFBU/S29- 0P^C@%.R+ LH M#!HH!!T0%@HM9?RHHDG 11.J'&Z?@R]F=HL_X%3X2-*W$>='.IF6'8>?BFZ- M13D%QQF)JT/BZ=RDR&@GC8](3,L("6>!"58#&__NE/'*6%>6:H:LXKP252C< M\B6?R#"S8+J78>9)8&8RV;S4VA-& 6;.19A!&D@F"0A82<:8LH[KDO )]&C" M5W>8J2E?_&.@X_O'?UWQ?>//^./R&\>Z][7HE.,T4=O0^I2UY>GA!2=X.6CY MAK:V>QR??9XJ&G:Z@WCWJ-:-V)DB]NQK3[<;)[I79J4?M'P_N8<[+IVI3D/3 M*<\5Z @&C5!T=,<6L7F$@X%/Z9/[ZU<3;G) QMT@//;SLA#JBYYOZT'QW;\\ M+=R@=0F!U[XUGHCPQU>TB3V(8'3G5^HRU/CF4%S_F7H[0L0 '7>88"4$I829 M^,$126Q4;Q$<_H+QVN676KW+-SB)R Q,S^MO0(?X@B]T^U2?]]?^N#D#X_2[ M/NAWC==XIOY0^9?7YBXIE^X[AB^$2H9/W#)\(X6)"TEWE!OI180JWTNM8G=T M;?K2:/72.OR?7PM21-U+4)&T*N5^2LKRYQ]ZX[9)LM#)?-L(K&W\HSL1"X;] MQG^[[83P_>95YL*[5;XNG7]UA5^OKN/7ARO4&@GE^*3G6[%=Q*/&SLW3Z(M_ ML]LQYK>/'3UT17R;W^O?UZ(3UY/N,-[#]>_N[C7P87]54TULLT]%D7Y!I.@6C<,0=>]XW=F.[5K^Q'2'5-?XTO3\V=G7/MAH$ M->\1++#8D;_FM9CAL&S-Q9+\A_<)T[C/&S^[D4-SG[.UV*I8WA/.CPAC>UYI M,F9^_R7U@^:$0+>X.,]WBRL7)][%GUN[!W\?[1U_+O8/WA\?'K2*SP?;;/?" MM7>/M^GNP2:-OU^Y*_>/8EL<^W>P<[J_]>TTN2?WCG;9(7Y=[!U]9;N?MM'^ MIX_D$.]]FW1Q[A[ODL]O#L]VCS;I_L'F^=Z;^/R+]M'AIQT<[W5V>/"1?3YP ML5?OPVXQ=F]^@!=[1YL7>YM?+"2,8RN!3@=,*<(&:$<YY %W.![0T0'/:&_W)$GA\5OE^7 /U5#L&O7X>7I66E9QOP.F9UUO#7 MW5[\M=.PPU[/=^QY8]"+=VN7NU'YU,/35K^\L4\T8D]C\;P:2^<@"6?4OWVR@N#0:\PPW*+XJ#[5L?;U*:V\%(PKKT/ M4Z9E(- BF2IH!J=3M#0#6K, O"5">T-X(#95&H"U#Y7.)R+J8S%E"*@Q!$P9 M75)Z0KP&4BH*J"48*"HYH#1PAGG0'"<(@%6YEK)5]<#3$G7G7Q\[/1_[<.%= MXZLN.HT(.E;W6XW0[IXV6MY]]?UFH^-'(7/Z[#$'*U8;CY^,DB6'UJLHHM=1 M0O]- GH3Y9;^N)D"YMY[V];]?A'B$%YB=$3B,>AF-UA%B#SM[^=<"TPP!E1) M"ZC4 1BJ'' &:TZ\$T'!M0WPP,9$V?1=,GN1?F MD@0-#; I]3VES@!E4GTH1B2$GF@96#HB57\]7P'N]1-^BMFZJ#7W.N@.=+O1 MO=/'_1C_U^/V4)<:@I^4B=W+ULVTJR(P/I^B7=)C2:@G !(?N9>E%&B%81Q> MKR3WJ0RG3[2+J$?#\9)%662TJ!]ARYZQR@%ADITI2C21D9C9X#6@AF"@(241 M&I 6!F%JD%C;D#D88>'4;=F"$5[=@Z+]ZF5G.83\O&+?JA^@E5FB*B>TMZQ. MERM3)JM5K4W[KZ;(JM/!4.@90U":NX=%X% M^E3S\C4963.R+I[\9V1]&F2=V@_7@D(*/>#!24 ]M, 0Q--F#(90$!JG1@I" MEJ@JKVQ=@;6FAD'.)I.SR=PQU*22;#(L9Y/)V606GY!E.IM,8X42R;1TYVM\ M9M&)%[KV6RN^H^_U_^]_)$;B96/[?X?%X+Q&K_IL,LO"+,D$R)V=:V?5 MO6Y;73Z@7S>=;KO@)#?JH4F;KO(U-:92!XT'=,+*PJ(A^ M G@UJJU54L$G3--4*<#WNJ=341(K(Z#-V-=DB.EVR0/?ZL*!G4[Y^94^*0;Q M[S\1VT.'YFB__LO/S M*,H\_ ]8?6/6S3I\H&NMI!'E793*.DN_[*2-=(1_M9$^ KB=?G^8*FXOP\[Y MWF4IEN._O^T>[5[L'_Q[M+NU278OWJ'=X]?%Y^./MPZ/ML]VM M=NM'*9;=\]WC';I_8.GA@2MBW\[WM]X7^Y_>X<.COUJ[GSZ>?W[SNKUWX8K) MG?/#BYWSPZ.OL7^MUA[>(7M;.W3OS0[[O/6YV'VS??;YX.]OAY\^DCW\=]@] MA^<3.^=:>\F$T\ BS@'EV "E40 ",\L--0H9/*K$0E2U6^>K$G)4^XBB^^GY M0P.*ZALO]$A\FPX7J@S#E0.<0B4")$Z(5-A/LF:4\#,#XPQR MSP'D?IL!Y0@20QY()Y2AT4S& MT%-"/2?1.I->6B@8@=%&$Y4@70:SF@XE0)>!="9C>M([R)1SWF$#+!8&4.(MT$1PP U21$I((!85UP#- M*IR!-DNI%EG6,M#.#6@GK7O/C/%!6&"MDH :I8&64@%#K-<$<02]K"'0YA** MN>6*M7P&YP[N+DJ[Z),'R[<^/XQ%W3YG:A%GF:6T#%*J,X+FV;1LLRE+*4MI M">Q;*!@F2'*%!.7!1-O6ZF"51=Y[2UDNB[.T%G$Q'&QW!JU12-\H M8\'6L!?'[6U\A:X;93+8+X7?W[X4_O46<1YLCZ=!>8_]TX[O]5O%R=LX&S(J MSH**T_D-4.2XJ?@R4")5:R66 .EY )09[;D,FE$70;&R\H!Y:V_1JG[+,:NG MT/-_=7LXUM^;NI[UNTK]GCSY3Z@4QG@-&$E5_H+AP$@: (.&8T2\A0Z6-096 M5KM7P9GY'%!(.TN(5Y!!I"DWRABJN,1:< XAAO=WP,P%A;)A5AE$31V*CP:W M=,IQ$)BE@(I(/Y2P C@EF=;"&FW"V@9K*H)6&*=64O]S&%B64I;2\CHV\UI: M\[5TTLG)##1(<@RPY"):\38 :24'%D(I;/Q52C%:2VF-UM)G$!;UK^\/4J&\ M;FCTXL=>85,!J9%;4Y_JGALY/)-2/\RQF3=]%N38'$MV/[R_DFN)>INE5#.B MS8!H^Z^F$[ J@SE#$=!02ETHC0$*202(\I@)$45'Y=H&I]-9%_(^[7*J[+P= ME#_7UY+5[/E!UMO9]'8JY2B%TEJJ _( (H)!1HR"I"11.N D*=^;:.JA*-U MU-I5<#PN+;K,DGRI L_C1!:FC#-SPYDI[R$6D@J%!9"(^P@T1@-II .:"B^I M5P(3<1O0S)R4J8X8LY*ZFV-KLY2RE);<:7C?U>^Z,S 49]Z!"]_KYE5QQE5Q M*MB1>Q>%1 %!+J7]MQHH:"0()@A+J G&\2L=KA$)?P[ACJ5+JG%:#%HMWW:- M03>^:>Q?8Z#/@3[[E 3;;:=1C'\HK_ZE^]ZE MN'#?Z>O4QXQOL^#;ARFO8%RGH/>( &2- -0S U3*HZ^%IW%J$^J(7MM "#Z" M]N?]S;KH\1P]@I=*O.F.AOW!L>\,^N]]63_UH)MU>2ZZ/.DIQ)"C=/H"8.L) MH!838(+GP"A;,E%/E8RZO)J:O I.PF>!.)6%)U:".#F$HC(XFG(H)KL7<2L! M4L@!JCD$2D(( J?40\:\8BJ%4# X'3:]$IBTDKJ>8]RRE+*4GG[=K/R,=5XW M:[)N3KD$><,YEAKF<@0QX\^>UUC]%I)5%BY M-29+*4NI_BOL/!T)>85=@A7V\.8*JP*D&@H-RDJLU%H)I!$6,!UP7&"#99+7 M;X5]!O%-?^FV[EC?;.SJGFTU"&HVDD(N.K!I7&YR-#(O2)2?ZPY-VY@C!04*Z"%(PPR)!1,G)5;\J2K?<.@QH=$\_05QWT;0\F MZV9IH66 Q@*MB =4,@-DM# A?$?*33QFJYM<-ED8CK^Z6%;*U4HSX*W9!:& M#W7#Y_N7L:YR9)83,:=I:&5P>4N%ZXR+,^'B9%+OX! *SD.@,9* *L.!@@0! M8R-8,BZLUBSA8E6Y+%< %&OB/?YERPS>&;RK\-)30ISR. 0NJ9=(!ZH4UX9* M)[TCY#'@G1EOA8QWTIUN?.""(@L01"1">TI3;#4$W@9&3'#,I12!7*$F0QG> M,VQFV*PTB L'3KFC7G.O(NG%2AG+(0PIQ8>6R-^-FQ.)$3* /A6 [MP$4 <1 M0RD3"Q2$ LHT!II#'@?8R'2&!AL1 10)V<2\@K#FC)T9.U<8.V>!3A6(H<': M *.609:V)@1D@7E+:&0OF7+6!3'?W43,2!E#VF "6@L%:/P/2(,5"$C8*$+) M;3H&@IH*5965.H-F!LT,F@DT@T &(:)EPDY"A:9!<"4$@2XH*6P&S;J YL2F M/%-"HRANH B%@%JH@$*6 >6A8<%'>>J4RA^QIF2KL#?UB^W\6OI2<\O<\BL99[2N>6*M6*]8R3^G<7EFQ6=,B2\_-++8]W[6G0N8W;9R528;?F\T>67 MIX4;M%XHM/3IH];QO[,9VK7YCN^.\NYF<$-TXT,L^CN^$:3DF\Q]D M==7TSK,KMQQ?J;< 7G6/C[N=1GD>ZSZ)(._SXD^=RZC7/1U]QBLHH!_Y;TL> MF)+@@IU.^7F<"O=G8GOHT/Q,A*L]W-8.CX=E]:)RC+=\*&PQR&,\QS'>'[1\ M;S2CN\?6+5SS9]!D70KA*2_ZT[ M0]T[;]Q&^A_X^H\IUW!O55G%M..:6*(E$H(10R5B6D)HJ+',.>(Q5F6*!XAP M3CM^([G#T5_'>WB7'A[O?3L\>@<_'[P[V_WTCNZ_V3[?B\_^?+!+=H\.4>S[ MV61RA]TWA^3PHE40&1XT-@F(69.11V<*6S(P MSB#W'$!NE@3!00H@01(J"QPV"$8<0\B1=8V M#Y-H*:HVG0G,I0I ,&@T9T0ZR;+;6!-TF>!S'0E)" M+%"1C0,J P$J: T4Q\1R1@24*"6XIDT,EV8;Y!D4I=[S@T;1L=UCO^@ZU,NW ML5M&[>"7#\O.7J/B%%E*2R6EFN]$Y-FT5+-I):4T2QTJ(BS#%BE'HG6-@@R: M!RN@@UAKSL*7K102%4UM!,H/OZRM$E?4G7)!3;&SF71613J3.3WI/,14*2\P M!EA@"ZCF B@O:32I*968LB"57=M030BG3>JLP;76X(RSRR"E&7#6$6RIQ<8J MQ"E%2$D'G76"(*R-<2+C;'UP=M*X9]P22 */$*L38MVVS*4LI2JK]YRUVYRXD,AI9RB4S@05OEM/ $:TMF-F]+'G3C0/X/ M:S>:OOOA0)^][?92OS8'@UYAAF4&L8/N6]WSG4&V>6>Q>8OI+-2UU:I*_=99:5^8J6><&09A )6C +N M% 24!P54@!8$B27D+F"&:J?4SR (I0S6:G1/2GWT9[YGBWZ\N>ZXAC\^:7?/ M?4JGF=I$/M]IG Q[MJ7[]TO?D1WV#\]%0#0)2-&T.ZJI%U)2)IRP7E#/.,7W MQ[]V9] :A>2-$A)L#7MQW-[&5^BZ4:*"_5+X_>U+X5]O$>?!]G@:E/?8/^WX M7K]5G+R-LR%CXBR8.)V^( J2$28L\%2@R'.0!48S!Z"D7$MH':+I 9[=-!> MWINKB:I/\YPGT?-_=7LXUM^;NI[UNTK]GCS8CX6AU@@)"&,64.(CY9'8 QH- M56@0-9:(J-\KK-VKX(Y\#B@432K*'*,>"TVM5-)8#P-3T&ODG'>+1:$<7U 9 M1$V=>0_&.FTB,A$4C3$JC /*,@_2\38N$9)8P70TBHA'IQ^I,4ZMI/[G.*XL MI2REY?53LH?ZZO):O9\WFS=4:]G70\*JNC/*@ +C)00 U!0 8-@>3( M.&B@PE19=9.0LBZ2;$&:BV?K_+M9:BF5!GW=[1WHLT]) ML-UV&L7XA_+J7[KO70K\]IV^3GW,^#8+OGV8\@IZ"9E%Q@#%M #46@B4(Q;X M2/:AC'_D/MJZ\C&L/V]OUD6-Y^@0O-3A37/ $(&!#X;&94=2I7#$HR93CTG47F-,6DE= MSR%N64I92D^_;E9^ACJOFS59-R<]CH0'S:W30%%H $46 :4,!1 R;3G4*' U M6C>G0W46LFX^@Z##TN,.3%*$,J?:I2;D ,.\VY6EM 126@7_P-+.IIJX!PZZ MFW'D4@]T.^TR['1>Z9-BH-LERS&3+.>]_]]AT2\&_H/O?2^L'QW6>.]M]VNG MO$NY]YJY4&7ED XV!^7_/R0^%-]X:Q=^<4I*3!4#%%H%J,$&2!(_X2 T8@8C MP?G:!FD2)&JT^9K7F.>XQF0I92G5?X6=IR,AK[!+L,(>WEQA)2&&!24 3F4' MJ1 0*$490)12'(@-3*OZK;#/(+SI+]W6'>N;C5W=LZT&0Z689\3BE)46Z53V*MH6"#N@@_$2,86AIFL;7#0I MH16=\:Y">1:\);,P?*@;/M^_"G65([.&;PK &\K5"H-ZK'G MDE+.M0DXA9X:;!B'!CT&O#/CK9#Q3KK3*$X( H]4XK25@$S0BD3BG[$\Z9L7-!V/GN)G9&8P%:*P-0!/I( M/KT'1D,'B%*!> .ME#X%MF(ZG5(S(V=&SHR<#S+6.;8F2.J$A9PR!@VSQ!'J ME%".*$^SL5X7O)S8F8<00X(BN30:"4"1L4!B3(#34D')E%8"KVTP+)L(5970 M?Y&P^8L]_5HZ5'/+W/(G+?.4SBU7K&6>TKGEBK7,4SJW7+&6>4KGEBO6,D_I MW'+%6N8IG5NN6,L\I7/+%6N9IW1NN6(M\Y3.+5>L99[2N>6*M6*]8R3^G<N'2>POC/PO;71V9N-/TWOCXVKHPX5?>U8][X6G=%A!WSS@-2-VURV MMX\]^8/@KX[^X'3TYZ#E&]JF*@2ZS9UYYN-TYT M;]#HAL:@Y?L^CG_'^1*GXT0M'1'5O$YOU!_$.9Q'/]SA$9=X/P MV,^3;K],T?FBEXJ'%-_]R]/"#5J7QY.N?6M\E@3^^(HVL0?#P=U?JFY_4W MH$-\P1>Z?:K/^VM_W)R"F+XU6+QV3^\^O!2FB[B5D2EKU*IVPB\KR MYQ]ZX[9)LM#)?-L(K&W\HSL1"X;]QG]'Y7WZS=$1L9V.O5OEZ]+Y5U?X]>HZ M?GVX0JU2*+K?:KQN=T_[-7J?VY'EMX\=/71%?(??&_7O;-&)RTAW&._A^K__ M:L$?EQXP M<;RP?-[H\A@ZE5R'C"7T'//F\8/'P+I> NLE9[EQ39!U1MF=E^$ZNO/:SVZ+ MT#K&^$&W_?DU!N5\.GN_,?B%;?++/'IJJNDMY]1'D^AICF7_&J?@B)SUO&_L MQG:M?F,[8I9KE"SS*H?SC0.YCQVE'TUOGMN]>3CWIR=W;SF\6_,AQA#C^R3! MOL\;YY&=&%DTR_RL*LMZ'+L%O?'^B4^$,!I1Z=3\]VB>^/YC$JQ7-NDJ2$!: M82<'T82.QK5_3%6#!6=5N>>[WC^MRFVON*#T*/=\ MMQGRHU#!N%=*,XT#U<0J*(2RQ@3EJ!-2E051\&5!%/SK1"EQ#NV44^B?;K^_ M'#E2]E^-[Y[M'ARBW0,7[_'N8O?--MT[V#S_?/3U8N_3[NGA\7:\ MU][1CQPIG^-SWK?WM^SYX7'L]=8[NG_P;_'YS0[9O=@\W3O^?'QX]+ZU]^G? MUF2.E-@__/G-1[IW\7?Q^[FU]97N?_OYV>&0O=K?CS\7>FVWT^=/K ML'L^3E/] 5[L'6U>[&U^@58JK T"VFH!* P6J$ 4L(0028FB6K&U#8J;BN,: M%2]Y((K>.S]41J3E1J3*2S1E1)H7(EU,(A)4A'"( 3*> 1J8 EHK#B!RDFD; M.$\)EE43PNGLH"M?36EQM.Y:C;+&H-OH^:AOMFC[1N>*[Z6_I]]L5/XDPHRAV!9D,?=V._+LK?&KKC MTB9;S_^TRO>2U1)< NY\722;UP2RV7&;E^*(JUE>PZI:P_8^3+%J*X5PE@H@ M$4S%L3 #.F@-O!>(6PW)*,-3F^_U$EGS; MCZ(K'L27;AF U8/4ROA2NS-HO=CL]WV\\:#HE3$0^R:.Q0A0KPEC^RS56_89 M-V?!S6NNQOV#PXO=TR_$!L.?_?%49H8CP?"VTB'L)5 MDA#ID,$&&H4=)VPMJK#$"+^LD6H_*S_-=5LAQ?DY;P:-,NZXC&?N#^[>LW_V M1ESE'IKKPM@/KT4>BW4ENY@AB^^&.K_PS%NDYRD[GJC!P_]44 MEPD4I R20 "B2$&BJ'8":&&@5)<*&M0TDFW'ZU+2_6VU[W>]%/H!:9 M061P-MI#I;^JF]+L^(%O%)WO$6NZO?/LMGHR(K=S.>:?>L7 ;W5/.]G#5-FY MFX.=<:7TN Q<')[N7KS[XI"+0C$*F!2:0TF(UJ4D!# .G5*2<1-$.\U8"1;0$F&"!N')$(;2V@9I$ ML1KI\;-R%GT8=.TW8/0HF^!QBD][>-CO\MJ4BV07'UJZY_]*$GAU30 9F:I# MIMTIAL$(U5(X#*#S$E N.) 46: 9A8PB@:!W:QNLR6MUZA]?4H1>PH M<02H"!08 M)35 E$)A!(]"%6L;B#4QG[9W[K^O]G1.F!6@1\OL-=KRP?=ZWC4&^NR! =3/ MPKZL]HCX7K>3$EKM#/QQ?]!]?YGWZD9"N$$W)@*2L9_DDFRN8;23.H-_?H@EX]5,>/5MBFD0:31C! ,=D2G:/XH"(X4" MA' 7 H-"0[NV$25:(^LG.T?JZAS)*OP4*CQ!.8SR%GK# ?(.IE0Y*E(.)X$Q MUE CJ60(1A7&*U@Z8SEX1SGWGYF;XFD)Q!W)NJY )_EJ2\J7T_H^ '..-J>C M5XQ)<2H:X @Q@%)'@ G2 DV)02E)A45R;4/B?&IHA15W?EGVLN)6IK@39 %! M[REE!) (K2.RH *$0$0I!8&Q$TJO;7"V@L>$ZDL0?KODR?W?DVMB]#'EUQM5 MU9JHIW5K:KV'U=:ZKX6TR'L\*ZJX:4?I0_/^5DU<3Y<"N>XBS_OQ5:U/TP?2 ME0J8> 2!UIRGVK0!2$<$4#9>X=8'AZ,Q*UD3W;)$YLUI/ MT$XIN?(8HV@J0@RH\AIHXU#*;(B88E0YR%*>"7)+8O:\,39OY=QY5*:;Y761 MUXQK7(JA=(IG-*H*C:;/I"OK(@[)B$$Z;7IA98#B%H%H&TL?H)#>PY0M@Q-: MC]QG><=K:5Q76:V?3JTG2 ;VE).4P9 R30&-2@RTU! @A(5Q7F.A4[[DYFTI M#?-6V--MA37&F\#/\ZQWS4A'*9%7(X&,3HAF')H)A]Y-T0L=9Z;C#@.$ XOT M0F"@F"G+!A-DM=6)JOMH]1V@CYP(B35Q@,N>51; M33"07E# F600(42]B6K+2/90+(HW_(C,?01S6%[[IH[,X4=(7T:A!Z#0];PP MWT[WCC:_,,HD8L1$(\9Z0)URP&"'@!1>2FP0XRHD%'K, 8+LF5AIS\0#%3JI&H<^O*[3]PJ*8G/,4Z*!3Q(V0P"#I@' *2H,$I-+4L43*L_)+7,5=C(\# M/3.?1+V(Q:4PWHYDD9VF\^$;X],#.AB%I *8R&CUH&CU*"00<$A!:RE''"=G M19/!1Y?,SCZ+^JKU$\9<9+6>*^L8[X4HKUB(',X$PU)>$Q[-"&2!8$29B.'2 M,9ORFB"4JTV_BCH5UX]QBQJ^J\&LZ M;QM#C&'..% &JH1?"&@I.0B8<4V9P-BGVM=-2*93C6='R$JH]U/&:&3UGK-Z M3Z9)H5XX03'P)FV1$NN 1LG+J:4F''GH!%K;X$V.I^E)':M/SL2*,%L7M68F M>WXP.GIT,LY>V##GUT\@7:4N?(R;Q'1[SO= ?,L7:6#ZW7;A&I?OMH30MD@? M2A38]623?Y7))G=N2S:98:TZ6)O.V\8UP@H'"0*' M#@#)!"X,A?4.0R4 KC M>(K\:&(^'?SQ,+/KWFJT1*Z69PP-E?MA,C0L"!JF3L $Z W1P.*4I45+#(SW M)HXOQ$)R;V$*"E--B1Z=I^6ID&&%SF6+.\_%].]+>>[QXO>2R*(/8<_>R8JX M<1WFP>WX_4J?% /='GGJ7#$8]AY'?9=P"5MH[-%;?7[L.X/^07?3_N^PZ/FX MFKEA4DE_6_!"7KH>L71=3"?[031(+!D%#F(#*(ZKEJ)< >T0DX(I!E59]@^I MQQCK>7>PQBI=.2W-*OVT*CU9R9.[(!$1P!+C /54 &.T EXZK23!GAF:SF.S M1_G?ZK=_'"W7'Z7[N5D-L]GH^,$SVPA<*-\8R^)U%,6'*(G]D-%I M?NBT/44XH$%4<*HC'&$%*$_Y7ZB <7R5Y,(Z*D@JHM>4,-=L6F&]KIYT9+U^ M6KV>S%3,/0V008"DH8!"XH'DB ,OD+)<R5=YJD1$"(- E\-,_,FZT5;;:^+CJZ8_-FZ^,V6U>6 MV]=AXM[AN1UO933B:O,C0X7S9G#M1$<4=*][&M\G;QP_H2/WO3\9"V<_I.I_ M!U$R6U$P>?FM;OF=/KN!-<;(8@TL\CHNOQ8!;0T!4CE)F$7")$Z.FQQ.Y^'+ M^\4KH<9(ROC4)FS[JG*,= M5D:MYQOMD-5Z[FH]P9U5"-Y;K@&D0D4KF$4KF#@-G&".*Q+GG2')"H9TB6(= M5L!;=X-[%/W^4'=L&6MIN\?'W8Z#/&J?%H-7JMM/[-'J^K0?>-0;==(:CT6_IGF_T_6#0 M]NDVB7?X_QT6@_.&/M4]]]S<'K4X5OI^)*.#[H$^^_1#=J^[O0])7'_I:"M% M7$M9^G3J9+:;JD.]Z8@^Y8R#B'L C=(I"[X!AF,6YY\('FDMU,@=PAY5/R=[ M0FJLZ7,[;9HU?:&:/LEOHDP)(PA($R*_L5'=E1<(:,0(E4'0*/4R];1Z3)Q M_9PC2W9,87Q*H1%F"=![AI''M3Z84)>R0J"(+*!Q-6"Q[FE_HVP\."X&'RB (4+N*Z2YN^'E!- M/3 "Z3CUJ%:>.>B#6ML@M"D46@)\6'FWSW8(WI;NFJ@5\4**5+$MW?GJ&[UH M4I3!WXDM-4><*?ETOD<%28ZB% 3>\_U!K[#)$Y2N/\;+LVJXN$@/T$BJ^V%[ M+,OW493[G020Z?_;/X3X_DI^Z<)FQ]W\P[66&1EG0L;#*>)DJ5%2" $@IJF4 M>S0-E2(*$&U)1$6)-5$I2< T+#YLU[PVW*E"_]"J840]N%-&BQJ@Q61*$8\U M=X@#SK@"5!@--(<$2 F58UX%SR):X,=PJ*?"B94/O4D>I6)<>J/QFQL7W_@] M^9;F3)U6U*1<)'5Z%.R]C>_;==-E6&Q[F&1P'6!'H)N-T>I =/K GL D$*4# MD-Q&RB6$ U*%5&P)4^BATTNY@-S1. M2KU[9K%,,\"E<<$13:&VB-( K?+&>1P- MZD+A[W\6.$ KLS $@0Q"1,M #"5Q::!!<"4$@2XH*6RY,,S;$Y<7ANH6AF]3 M)-!1A@2C%@B?RJP8"X&$V@%L#>9<0LN)3R10-*FJZA1/=:JV8-];!MT,NI6# M+H^J%]*95PLYC6S-,$L]?NDVR_2V+\HSTH6W_W+T\(-6I>Z?>U;X_&%/[ZB31S*X>#N MKUP;11M5S_>>'J)PZA.[.137?[9ZEYTYT5\],#VOOP$=8E]?Z/:I/N^O_7'C ME8Z+#K@^?G>]^K'N?8U-?TS*E^._I%E(RJ7VCI$(83YYGN-(C*9UA+INKSQA M]2(JD^^E5K$[NC9]:;1Z:;GX3^$"=-Q%BSX2N2\?@JK301W__\0V_<)N_[:L?33]K;AF=MXQ_=&;3\L-_X[^B<7+\Y@L>= MCEVO?>>C,)SOI+-+\5,)N.5![ ^#^,\X7W.46/(-O&YW3_N-WY+TBL[0N]]K M]&ZWH\EO'SMZZ(KX/K\WZM_9HM,8M+K#> _7OWMLKX$3PC>I^%7WR_7MQVI0 MKJGQ-=KZI.]?7'YX>9E3L>B4G2F_]/(F&J:3=Y-NJO2\T>4QI"JY#AE+J#IV MDHT?/ ;<]1)P)RC"Z)H@ZXRR.R_#=73GM9_=%J%UC/&#;OOS:PS*^73V?F/P M"T?D+_<8U%336^RYT21:D-UR>\F#@[C*^,9N;-?J-[8[J0!4N3#LZIYM-0AJ MWN"ACQVE:Z;X#&RTYD.87&3WJ1)153&(E1HY])#Y52.O_^TO]CX2NHXMVD5) MZE+F%7T<;;:XX*?$+.5BY)-38,P.['5V8'2[3 ?7;WD_N%?YD8HF5M5S<):: M(THA["U?3Q5;FQLMF9=-YM#E[I7N\\#MN_ MNCWTS\&7]^YT[],VV]_Z2G:W/I[O'KV+SWE=[+YYW8[/.ML[^$H^'[P[WS_X MBJ9\>5N;Z/#@&]W?LJ=[!SOG>UOQG3[MG!Y^BN^RM8WVMUQ[;VLGWOO?<.7' M^P O]HXV+_8VOP3L"85" *>(!11#"13!$L# F+3&"$M,VC])R9%9C;*@/=$. M2$:H.KW;@G8A,D(])4)=3" 400)S*3PP&@5 M51 *DP!)@A:)@R'7JQM<-F4 M_-%1?CE-X\,8X?N;L3[I#%I[Z$9)C4;5V7Z4;=-E&?@?4)J;M^WC\\N:$' M.4 YQ\HM*=?+L7+U6#P^3!%!SP."C@H0:,JUK:&,BP=*OW*L($2&.IGCDY\\ M/CD#[OU'9V70-DQR?G9SQC4XW)0I-!6!B9XK8LZ\]W6Z< MZ%Z95W30\OT[XQ+&N==C\_Y5_.+=(9C/+KJ:WQU=G7H[ JM?1?(2NI9#LI]A M2';= I>7.NIZK\2X0;=Q1_CUZRL@^Q&(7:.7^F6X]7U7H04.?^.]_ZI[9?6Q M5Z/%)_XE^)[O6#_R+AWTM/.QP]_N'OIKK\,OU]0B273P N-U]@0O>+LH/G;: MOM^_#.%+W1IMX9T6;\=/5"\>YF%K_W_](C.'+\8B4OZ&7Y6B, MKURJW>6E\A;IVS_3Q_(&Q:#?T$R=^?VCZA2MT MKYCNW[@'E_>_1P\:5P^/I*(,<8Q2CG"7NG*/)_VSNW/W0W:]2X2NL7.LXQ3X M>NUMF^5(CM_NZC'E@W_T[-8'ONUUO_I.8:??[>I*XVU+1]/#^F'))\?OV&SH M.\:Q?&Q\D>;887K+4[?_W\[>](N6?VUL%?IKI]L?I"=O_O6+QUQUO4'S4E7"L!V5;-"(RI5*%)[XWG$Q M2.!=+L8-?7+2CK=/"VQ;GS;+.5?: N4;I]_N_=:WK&?WY&IBK;88C-8;8[-_ M;W@<;V$KR,1ZT\3_:]B/3^WWMWS?]HJRJGLTZO_2_:*_']Y& (QB*^G307SJ M7^VR%NLB#?:+O?.QP7Z\>_IY:R\:VA_9WM;?T5A^=_$Y&=%;[>//QWNM:#Q' M8WXW&M*'\3GOV_Z_[\\_?W(G!E-^>/'7MUT<^W#P#>X>?TQ&_;>]:'SO?_I\ M?(BWX>[1]MGNQ4>Z=_1WV#OZ=K9[^H4HQPQ7'%"*#8@#;X#1S(' &?,6.Q<0 M'7EARG-?F\GMX:,(&"9<>LCGZ=?=+ "JN3JL3( R@4!TA,( M8!Q@13T,1(3)F;0,]&O*IS&\9,:S>"XN([#*U4:/YD__.HMX**TJ+C.[7J,5 MO^G^V+W2>-7N]M/%K7)MC']W/G8O'?OP[>[I[R,FT=+???R#[S1.>OXD+J]E MG%CJ9<^59T/22MV(-_<]'?N1KOB3]*;Z2A'B-V-/BI.XBI9$(:W-O>+XVE@4 MG9&?-6E_>FAYS]3%HM./LZ%T^97+Z>O8K($@>%*?+\87MT MCP_@_ZTW-LL^QN>WR]5^1G=2PW7'1&(DF_ARE^,VV=N1(VO,MN/HG=]_.,;' M;SYVBJO#N*5X-DN,THW?QM3MX_J']<:;S[1!/G5G]8)(SE MS;LG12=U-=XV3GC]M;S<+%](NZ-A?S!ZW]_2D!3]P3AG:2>]8GM,)NVPURLK M'?YH_WLYA$5D0+'C'1^Y5S^QP]0MW0BZZ/WHRK4Y=!EKF)A;XFW]87LTU;N1 M5NF1F-,M4K\'Y7' X]%QP!&9*T\"C@@X0OSV)U(Z/X_>V_:U$;2M(W^%87/^\3Q1%!,[8OG#B*8P?;C.2,Q]N#Q M"U\Q"*F8/S&LVA[ MHS?M0&MM!^K=Y#UY8* EIN%@"&\LXPZN=D L],*N"V0M<]HKQUC,3@*!E>R7 M"PGK#K,+4]?KMDOK3$@ MOW2!S[H/IDDKPR3TQ19X"$T=#SOEIM8$O)9KOVPR&^VQL%4N@G$_P&TEL>L) M9%_8ZT3]U@?N ,,$^#-SV78'%*@6P.!)-[O0.Q.P_/^6(7 "/6S%*>C])W-] M4?JN-DX,GE_?;O;[>91C9/KG[1\33,KOC*XW!" H^TUYR3PS?#*K#3Z&S5*T M^*8YL*">+6'%7 C0;0_D5^X(/#EWT6ZG]N>P P+3%.N":Z^G?4%3ZL!X23=J M)\->?V@[@[$U#)*IH)],NGG?M"#N[4. Z@+J\]=_ XQD@JW'WF'L;=1*!BCU MCC%]P.L7=*%\XJ*YBVX KQ?,".+@<,J[ J^"?HT>^V?HEO*23-2JUY=?"\]? MO+ 8R'C1-RZ>&6-,&&EK$V*XY!C)_6U'6*G\K86/Q0LF_-[WEE^D-_-&X+IG/)04[-[T(J'H]Y,_>J#^ *$Y]5INZ(6"@M M5^K2)'0&O29@=U[7"\4(U/?,4$#58.E4\3[-DOE$;N:)B474AJRT#Z,9X6A>NVJ5U?3MY+G?_@HBC!8+I MYUKNEU<#B!@8J5RGC;SE6ON>CT;5_L]U 1I_Q[(L_$R@AC71YQI3SOG H^": M1(>5"(P%X36694+G;#1/!VI\:+R;B]0H.O5/[M/?MK?;*[3A4)S9NGCU*.0" MOS [NG[\^1SL:$F3Q#@*9)-6B&M%D/8F(4LBD=8X)05[M84W,2;S(1-99RV) M 2S#?G\X O'N< HWBG,Q&:['8'O!MFE"U9*MS=&_U">IK+/<*,&Y$):J2(&L@^;) M)"4*SU!!WN@&.F^!(3/Q50*Q.] (*ZZ<\TQ=Z:I;)$UB<%NTK0T5. ML=?$4V-HY,%Q2W$(-%J+@^1.V0H55T,MK''X-1DL/>4::3!C$)>:(^.X0X)@ MY1VE7H6"6O ":IG"Q(PAKYO7 43I<0;D&GPM*.-K@2^K7OD")\ V N-L-_TQ M>66QY 567 Y+!-W$Y]#$4U S^K'SDHE!['[\ZC03F'&.$B<><2\],EQ8I(GV MRB66L%"OMKJ=.$\+%\L[8OQ2?+RV$POIWT\3# '#.$QV"">V/9!3L319WROVFNBWZ&=/][!YU^F)-_(A 'Q0V:RFE"W]D=JN\ZW9+P;K3&Q[6MD.[V6GV!Z67;M*G=SO;T^9_W8)E M)T<.A7)_-+>7";OV]_Y?VY\^O-NOO3YIIM8P=5LV=ZKVKD;TR. JO2:@A/2* MV6S980<4V$(YF/37Q&#N=U4=_^*JVT7O" N)$<<45 M@1;)(Q 72>KHK"+XU1;'<^#P/YE4"K;H1#!0\V2.O/R#DFTFU V46?JE@9[A M \M?Q!_9-YV;N%:7F"$EG"6(! W(8L65PMI;3QR3FD:GM".+)0D25^V/+Z2A M/T9>_.+K"4$M%_@N7QP1?:2@G4JN#,.6HDB8!BO,$ 2V;T))!1$I)AP[6]2R MVIRGH](OVFZV6F.G]FTHPE B4F*4@B#C^3"$B%R#X7MBF^.MCDZE8Z*':*& O)_%\2 '*[D%\[G4'MG6)+5ZR(-UG MH&83JG+(3$362["Y."?(*,J0D]K):)P(.@#%FTVS6)06&[QY6F<);BH@#ZAY MLD-^A0_T]*CICRX]E+>J"P=V+?8'0!-Y<\V/M^L*/?='\2W<[FY_C8$PIUA"S.9B0U((Y)CV*$;0J+S5P0NYE)3^I0Q6 M&!-8&350!G=F+VJ!HE-!H)>MB.*8T86EF%$X@VFTO1PQU'S>Q[C8W43&;9 M49+;*JVJ?AG4,3*L)IFD:JUF'!9650Z56+I_A:#+!^S*/BP(,+IVV^2R=WJT M[3&U@5:ZH4\N9):]\/O >F9KLY^-Y!R8.XJGSSN8O0L;\"XN0!>$,5%B( O* M@]>:"V>B=5()ZJD?J^^2F!M<@&.TF%JGXGU_YPZ_6']/X_PM;AP?GD$?1/UX MGP++.\*3I8P#!(+RQ6TBR"K+D0M<,Q)\E :$$M]YAQN46Z]Y0W;LKG:=]I!/.4%M[3L( MT'QC#XA]]#F[6$(\B>5N4>:FHSC:"8JENZ=5A,DL,8.%WVG!*Q:R],C#6 M/BR4V-%V5<7)Z\[)K/'QJS-&,Z8X$CH8Q$F*2/,@4;1:84FE9I@NP,4&]H<+'/QED*C ^K):1?+(-QI-@59VP-39*PYSX=3 M30?0O^S#SZHJ+56=8W[$4U"+J7+Q(9>;#ZU\!Z9K@PY#+M*EV*HP?VCRN@"/C5II6,^@4Q;95?3$^@I2L'SQ[LX'4=_Q97O;/Q-) M41[B[.>MNY&A>EE9W*QM9U%71M:/)9.=MB4GI#:R/&]'.X%()WU(3 /]>)\W M;K!G6% K<318KV0G[<*9LM<#]DZQUXLA9P :G'W(0@R4TOZ'HO?;G9 _9 3Z M9]3=9;PO+XT&&SO;M'[X-6)OJ,<<*44B*' 8(QMX FF+J8Y:!$?%JRTJ-S3G M&UK-9U.[T:610>VI$-0B3UY%/HO)Y^UI'?1_*I@#B$+24YJ==Q)IXA0*(G'G M(\A)[UYM:;DA&8:_"X(="T\;"+>1ZVI&51\[L8H R%(S'WVUN4"=ON.I;([7 M]U0VO?=3V?^ )9#C64#OF#D3VXS]-3D/B^N3U&D'Q_4OG_$^M+5_OOWCX/@C MM/GNJ'Y\2.I[G\_WZ>-6"\B;S))WHUW_<;#WZ:BQ%X[K.^_:C9W0WO_R M]FQWY_./QE[C^& //G_)Y/UO:NP=TJ\Z1)8\IT@F L0-OR++4D" 1"EH@Z.E M;/9XL[MT. M?"P]"/TU/$G^")SS[?RKQL0Z8ACBH-4B;D&AT#9RQ&1TA.#D%0NS"VL<-M(F M9Y16W$?JDE/.N) XUC8X,\LYGT:GZ:8XY=)BS//+C?)BB0+AZV&/+L<$\\_= M.,=;TSMH^1!ID6Z%?"\/BY/%U!X(G9W07+<7L M-W?.L<+9^DIS=N_2_%..01G&=[UN.RNS6N#:H-%97C_.U M;X <\*X]3W;W )5V/O#=+^]:!U_@/5\^ &+!^_<^->=0"?JQ"W*ZL7/0:IQG M=3=\R\'%^U_^A?X<_M@__G2T"VTVWH/%#0@'5K;("6J3U*%2A/7(_7H$R45!LO M0_\NF59N[LA,II6D>6+*).X))]*#&>6,59022AWW\MXEY4ZS/PYY@D'LIM', M%,[!ETR(C<.O#+ +)I*C8!2HED)[9+5ER.!$')9><36WGH!QFBC#C$^&>\<= M3+J)2OAD(Y-!/]7$+*G;:G5/"^%1UDDO5&)H)$=EE+SDSB8?^]UASQ>>KO*Y M_IME%&&Q%I79!=Z$Y;Y+979N-K5@*R^A3C:)O%MA]NLZ"Q2%Y=67U["S2\_L M@@3\8^( ((WK<>?J*JY7)>P?:Y'N6K']$2LL+)[INCWN%FZ], 0UZ-=_1GD5 M_\HNV=KK(L:M.X07A/XO2\SYBZUY3Q^PJ/OSFCER[ZS\&/!P0^6$FPLC+%># M[#'\'M<6(AL!R5@=W,C'O,8+O-)^RJP5W]C1!:$Z>>H1VUR@$.9(H3*NXS69 MRLYWW[_]<=#>Y_6=3\W&WD=X_K/8_5(_ M;^Q\AG;>?6O ]_4O%\]1TW]@Y: M]2\?,7S_XR#[$)KX;*9&CX:5]5AY9$2.J(Y,(">Q1-%)%[TT8.+@5UM$XPV, MYT_Z_%21GN=2\*S"PY>#ASBHD$0D3EC% PG.,&@S'S\ :&2,%WA(QGBX5"WA M"@\?$P_Q;(5(1P$.C4)!68,X"#_DG O(*2&#$5JH*%YM:;7!R!.'PV=@NBPN MT/Q$#92_FCYGK2T3,G?/;&LP\5WWGZ"A0G_&4*E*VB]=LI@KKYU5C'B>7#"4 MY_TAG*)3%EM9Z>=/2AZ=S>GG04=,G1!(.N$0%Q$CHYU&VG'IO,UI.'.8K=[0 M:C[ ^_'JW5>,OFI&3\)9*X&U ^,.&YN,#38J9B632:1*\7QBC#ZG>&(97*0. M19XSS/A(D,/8(HZ%E8X+E5QZM24VB+DJF\'Z\/DS4"UG7 .W4BT? TJ*##9S M^N+:E'^O:K__]-0\&U%VIP"Q2I2MJ2AK_#&GLSK,;9 R(1=RC%HT$5DC& HN M">LQ+#K1>8<5E%;]T\)LA2SV--S-%4,DYX08#5:##XH1 M:AWP9&4K/#& G;454J1*4H&1P@"K7&B+#-8!4<%,%$83'NFK+4,WQ*KW[-8( M7]?4R/BU"/)=$%0\F@F4T;;(-O)(D=-?;_CORJCHN0%?[FGS@8M(JCD=OM?'QO^]0"VH>L#>SFW'!_V]X3R1[] M\(=V+O*UG-9WON4$]9%SKRP7*"8I4#Z%B5P4%C$=/+'F7]7)1-E$YG*062MY-J?L7ALD;W.]S=[-?^/K*PAK7M]YNUOUO1%HVG MLL!"HSLHJPJ.*V7D0I&#BR*7DP08&4)&Z=8*[$C#7I% ,,2!;;;ZXWQGX]Y/ MNG+G"I+K=29IDJ6X9?O]9FJ.*E6,'7/CRE7Y$,$8M\>0'OMO<@EFWRS*;X:F M/>QT^X.B8&#/AF;WI%@='X>%I@03F<=U>%:F="SJ=L3#IL]EC0:=V.L?-4]& MZ2^*^1_U8#/7;9]_Q5@2]2<":&-6^I3-C(N17#Q[(0MJGZ[I9FU4?;B0(NVR MBF_.836NJE"4>SYXN_-I>[/VSY*#N>CUC<.WO5Y.;#27L[>\.A'(EZNP;I1I M 6U_=D.^/*/9'?8F=)S+4[_]Z\,_>[N?GF 9PUPVU':*LIWCH]8;EY)N%P'Z MX\)KMG;8ZKJ<]'%/R>M;&]O7S3PMA.Z_BS7.+]TS_CK2?;'4<;E)I!#2LU6L\@=/EU. M;-+MN0*EF5;*X=8\V"JVF=FG?S+,+;@X.,TEDW-#F?R DS=KGR>U<>8;W;CX MKIBW@A+;]ENN7],:MD_R2<9QANE)8NDQ20(UGL9P5#%/X/NS\KWE=,VDD5[<:G\(I#-5KZ68#*#Y HY.AKV3;IZ$ M,CLG$&QC#QJV9[M[V[Q^OLUW/ZY.P\ZD M-6@.RB+(M5PZ&] _C@3>""< "?JPAOW4O,CE6]2]'VD2\4?TPW'UZ,72X&8R MG5(R%D.D!_6F6?0RV>:XJN4MBU%5]+V>]/U6 &WGOM'&7ATW5D??17K/K.#. M"-+^N, @?%E2TK@*XB7:FB+,<3;9"X8I?4VY6!](RT'.DS@BP#*M;58)0C>6 M68)Z\;_#?-O84K2M5K=4_"H ?W$$3NLK!/!>!'NZGVV7DII/NLULJHS!>XJ" M8UDE,V]H +$/1V'8+G9B:@Y*M>B2UR+':%\XZL96X>E1O.S=R(T> O6/C,T) M]@]/NIW;BX:I-U:T_PQIGS5.5T?[8/85CHL1:>9<4(-26\Z;FN3N;=1B?9::V M1;E:9_NE-7PIN]7U:2NKHB+3RZFKHB)549'%)3QNSH9X STOSL1Z(^<_=(XY M<=<<\61=E6?HY>092E9K9Z6VQB7.%!@T5A-+ M:9#.>VI]=49N)4)_7SS^U#G9^AVOYV 9\OQ>:N^_? MM7;WZF+V",?!^[>T-$NV\"PYIR0SB(G!DJ2,(%I.8R%W@-!_WUAN,ZJ>=9ZB"PPH.?SKM M6O*$I9SKQ%A.0\C%WJ5Q/B05!(^A.M'VQ.!P_D2;%#YI('7B,,H5 !' (T- M\@S^CX)$#' H-LS/I[FITJX]8MJU]=#F+T+;[Z3/5UF+EL1M9RTGSF(NF>": M:DV9QAAP'$MO!$N5&OND<'L^/1D%(X4(HQ!V,2$N%46.$(>,")X*Z9/(M>$H MW9!8K'W:HHK1[\SHQDF5P#8UH))QF -+$^.6FFB]3#+82D%[8HP^JZ IF@CF M3B#-<$#<4(6<30S)R"PLJ+7:\8+1 =_7GM&?@0[VU/*3S>M@NZ.3=PM.(]Z' MDW4IK%XPJ\\/JV447 GOE&:)4TF,-5$;;6#PGEM2^1:?%%8OR+_E/2:"L(1B M((#5 -$(=&^%= A)&9<4%RZGDJ3RIW6RQ3#TF-[#BL\O^)PI1Q*1D4A.L;14 M:S.ADL/,&:^M?;4E-XSF M:\_GST E>VINL3)E[.H4L!4:RS^1S/!)0[8"A+:1"@+F%B!UTCQ$+DS"$KY, MG%2JV9."['_F5+,HA>(J:!22 <@.RB)'G4$^2>L#==Q( " M-XCYZ6W?6_'2 M$_*DO51P($Q)QREQVG..6=#$6IF4HY$YQVQ5 N"I@<.8-$0SY"4'N\W: MB RG\,-HZTV,QCO0Y[384&)5SO0J<><+];Z-L^,\MJOMI8)YM%Y0'R2.EO"4 MG U" 9X+1QR8YJ8JW/2TP/Q2@-_AC]V/7X.6)FI&46!>(PYKC;0B K' &9'1 M\Q!PD:-9*77?$2U/U3_W4L$A,<%-"IQJRGC 8"I(L!*T5M:YA"UY>$TO-7_$ M@,YCKUOAPNUP84K).SRKGWY5G%@7/$-@Z2G$=5;RDK4H^J@-)42G(++ UI30 MWYXP,#P#+>^I.?2NVF.]+GOL8WOZGC>07S MP&4PV (-X)PF@C@GHA0!&\P(:'&N!I(X M5<'P2D-[4L@]?]#6!J?!Y+8HT)A/EF&&+*PR(D(HXQB)(+!?;1F^0?"JHF0J M/]PS 0=K>"1:$-#RX9.QQJI()<'6$FJ8$)5:]\3 87;'E6M.4V0)*<,XXL1S M9"V.2#M+ S-*:8I7I-95KKB7Y(I;MH+18[O?7BRR!\D\]<"47,#_3A.M& G& MZF1M4KA2^YX4LL\?3"W.LH#(1I%1@C@'J]U1+9!7E'I&K$I.O=JB>D.H*M"N M H>9PZQ6$DD2DY9Q0XF-0GOF"+?8A6"J^ME/#1QFU3XP FW47"$F)*A](N:# M$U0@XWU026 =7"P.2(F?-@FK.+L7Z.<;%?M\Q%R!B^NTX^M*M2^%Z\\F>]8J M)NC9"+R?K<)1";QU$GB[\R>"H\TA"*#^AN 3XLEPD'71(:.4DTPD:EG6AK'> MT'K%GHX5,-K3R$=806X%N;>(&A @Z@?3)"K7.ALC&>&N3. M)*VSPB^=:^+X[KC: MW%9K 9Q<44JT M61;XA!7PK6ZNGUM'O7B8:^3:HC#;N/SA@C*A9270LGCB5<,JNIW'-NQ< M5.)]#1TK2K$78YU\_TLND#6NS)M]\>7'7CSI]G+E\OR29C?,E"-;7"EK5!SH MAO)#/-<'NHF>'KXX04$\?+,VDEB-(8B(IE^!57!9*+VSS=Z_N6#L3DD"PU[L M[\$+?H=U_?;(7/H]FB>O4VR) O62;\V:SO>9 1^WS__-N/^GN0-NWZ#WCW:?T<^M!^ MET"6X/KV5Z*#L31Z9(D7B'O)D>/.(16]\3(2$BB9K1*7A'-6."$VH=.'V[(Y??ZM;', M&2W]UF627UBRZN9N7.ZVHHXR+:2,P7*1M G,:ALM3!P-2M)75_&$7">(?7=1 M]1CP+,145""V987C$J<*"#KM#ENY9.Q4,-@OIW#4B>E^-3M%1>I<)6_UQ&>K< MI0 ?2OO!0UJEB/>*LO?-O-R%P&:!>?V"T5GQ*?-V+\H0#Y6=8Y&@#!F)"!0 M"VIY_VKVK"CR02F2KA-% AJ#-1YG2#$37K\)KP?%>D1V&1RGZ6Z.6C<6M'%! MO/,-SM!QLS,A^XD>G57V\B4;8RPN8U;@CL[,ZR8/3>'WN'ST1.9="+C7S?XL#O_E+,?+1VR2=+OZS; M%[79X26^V^MU7:X4FC'_;+I#(Z$)7&?SE7QG4#VZ]5)C M92]^J1CV81F6K07#?EZ@F13TV(NI!88QJ#FS]C<0=K.="1N$07 "C&ICA$;Y9;E$?/>T4[#*$ZS)O<@;TC$+#194 M^6&OEV>FK+ ]4IZSFMSN=N+9>!G3L!/Z,[A6ZY_:$_C2CJRBPRSY2]M@HO=. M72F:!H K5V>J@Y>7NMD!C(11Q!^%>M.+J8B0KZ#(N>J2SW M/GL32_2UK<)+TS^*L;1/IN9U6/B![J*#E1,QO42E]V;!K)>6&GS=+HRU"2?, M"0547BHYYA(G7&JT%$USTS5QG@VAD_EM8^=2P803&VFZW<)H+)Q,A6UC!\-> MP+OJ+Z^K057UPDOVT4\Y6&O4*4P<"! MM?MCSE\P/9=)JI<+;.6G&V'0BZMH;ZJ*]E5%^X5^O!O]'B&VDIM2R@S:HR#, MT8M'>+Y9X/G,;G-YC>E-2LB5E_'FU=>N:Y:P36;HG9J]_IK"HNKLT^JL7JK9 M&T*(;S[V0&;+S(\8Z*E7FJ_GG98:(QNU+$4OA8XL.6?K%7NV:)37J7*O"\N@ M.X360_^794*O[UBI?@W7O@@[+V.&LH+T']?[=:O0DE8U#5>RT[.05C/XDS/(;@/F3_\,36G9O?F9PS,KHZ<[)]6H.KG6G7SV^0?F4X'6 MI_8K?B87V7,[H[!HB,_FE '74G!NK%-"Y M_?WVGZW&EW?M@^//;/_\]^;LD8+Z^9]'C9VWI/$%QM/.GS^P?0J_[_W;W&_# M\U\.VHV]<%Q__V>NP?MC]MBR=K"002"73$1<&6R$"B4*I M9'/Y!G'/(+6&]3>>"#Z1&7Q*+B3G7$0B.L"G1"DR(6B4.&7:2$M9SN2\HOH; M%4!5 /502:N$(1J, PQRE1L:G9 )OH/?+77"T J@UA2@V*R51ZA)(%<0V.L. M\5P=UCKO4##&6,L%P3JL(T ]>\?TO$_MPWQHY95NZR72+#_OK'I)$)YD,)$9 MQRV63E&B<4PA) QXA9<%J(M(V'*GH++F5@5&C3^F74[?3NN'7Z--C#J?D/$A M)TC.IY6]9H@:(:55)$4&VA+;8'I510S7*/%/Q;N3=+F"LV"H-%X*[A/6A"JN MK9*",$J]7@WO5CK$7=GV?(9MG67))!&19]0#VQH'1D[D"%B6@I[(J!5NU44& M*\9=0\:-@,_<49QP(%PI:9.75E*IN10T1EL)W37@7C+#O=829S@CR!@!%@"+ M"5D 6<1$U-X8GBSCE=!]]KRK))'!@7P5VG,9F1.8)BQ=JQ2J^7FN^GHU: MH$X[Y;E#++KLT!,4.9$B\L8& LJ9 -NPXNL7P-?<6D\#Y4D:SF6BAC&;A/%! M M/Y<]:=D]EZJ+:]K%9^^!OS9P[\H2!#\30_E,-9WGJ<\\?%CB&-+/*DUG59K. M[GQH(HZ8&9UD-MY T[$V:SKP@QC#!171V>!>;1',-^C*=)TG9+-5>+5.8UOK M6,LK\*J*R[HK5,UZUIEU ?!)(V,I05QY^(3A$XO2!HX-$8*LXYF/"JHJJ%JO M\-$*JE8,5;,>\B U)B$EY ,&K5$F\I*K\V5N2:YR:IX-M*_*P3>U$U/M6MXGBL]'USJB6:(!M$XL/>)&1&02 M)RB1F#31R9+H5X;B*V2B-4_36D%H!:$/ZG.\#816-OM=T7/6O8B#)3B!#IQ@ M$1$7\$/GA+ R<>TX=C$HO.ICGQ5Z5NA9H>=JW: 5>CX$>LYZ/(723A+*D>28 M@^X)/UQ.AJ$(-=+C:&WB%7I6Z%FAYWI[9BOS_<$@=-8)RZ-D0EF-C%=@OC,F MD68"$#4ERP0ABH?5.6'7 $(+Y^VO@YP.$/X-S>];_X$?XRZW;>^PV2G>+1=6 M$"Z^:78"_/:&TDU1X&K1VF349?=AQ"U[TH]OQA]^"\W^2O6EV"IXK'OIM M],+15$!SJ/D)M,Z,^K(!SUZ<7F5;!8\/+,4Y36F-HVY M^C+>)%=>NZY9PC8Y%W=J]OIK"INJLT^KLWJI9F_80;DY21"9K0@^8J"G7A1\ M)_K8=K%78V2C!K+SM!_W&]7[<*96A5T[#,X87G,YU_Q>]Q-)VD MFL&?G$%:S>!/SB"[#9@__;,]Y2'2NQV,N^E\XFWIZ ;Z]^?1[I?/9_4O'W_LMQOM69]; MX[QQ7([K[?G^WB%KO'_7W'W_]D?]/;RG_58<['WX<;#SKKE/#W(!T-F0&6^, M#CH:Y#2AB"="X),'2L9$68-#DH&]VN)X@_!UR@?Z0+L/%4BMT]AN$XE"/<7> M:4=DX$)K#4!E&8Y M]ZE]R-L&L3^H]>P@UOJG]F3NR-O%WO-+KUK+J--*&HF)P9QS[[R3QA*!DV ) M&[\L0,U7K:WP9FF\N5SO\9#53[]&1H*V'".O"."-EPE9"0H1-XY+21VC6+[: M8J(J*?V,F5,;CY7V8,VDP&.DSE/+G.71)B*CLW=GSDI)6 73GL\P+0V"AF02 MBI%@4!)$0#JK"UBZ8)T(2IG5E7VK&'=]&==2K85T,=EHN"#$&)J( @(0/A*M M6255'X9!R:Q4Q8Z+0"U*.!G$8TZJ(SU!6NO@/4TL>5%)U6?.G"SGI,0@0 4W MH/ *BS7CS'(7520B+;W]6DG5^V%:-L.TTGM'293(&TT0QXXA0V-$%J?(,"=$ MJ+".4O4%AK-,Y7ON11^!/5SKZG#7%U\=UH44 'BR3Y#SA+V)+D30]:4V'"M* MET6BJCKL6ACNY4Z&8X ARB"!;0X'$1)9K0+*^?R,"ER"^O%JRVRPM:H.N^KT M^2^>M:,-7A ODS60TU(C(P36*5@-/];1_5_Q]:I%-E5.F!"8$X)+ZZTF\,>#$<$<<7II?WG% MUX_M$"@/3!-/02Q3Y)EGB'/B0%I3BY26Q$3EC-.K2PA>\?7Z\C4+5N+$F ?^ MYA$[2UTR(F^")8XY7=HI4*GB:^$X*)@[,D*TXAAI9PGBGF%DHQ)(LI \CDP! M1:^?*O[L=^S+A+2V\)G=4PW(9Q8B]4(+8*[*/?*B"V ^$/K.IY+%F(ODK$:) M2HFXS,%27 24O%?6$:V)HZ^VN-E0IJKQ6T']P( 2H5HX@3E:/(K$'&Y215/&A+A:4@@2JHJJ!J+<:VUA&OE1%X M'W@UZ^Y.00>KK4-$!HRXX!89K@4B2@FN;* JN[O7S@A\]E[M,NSU+NZVRU[. MJI!C5!9X90U4@2$@1H0C]PC1WFNYL@"$1[43B97!>(K MY*$U3Z-:(6B%H _J<7S1A<0?##QGG8O>&.NL5"AJ!^"I!H:R*PC9Y"6BGEHNJ'",Q0H] M*_2LT'.]_;*5]?Y@$#KK@E4\&,J-1=9YBSA7 =FH&:*:16]2,,JH9V2]%Z[; M7PS%]M.>K7(O0MU.JV MYX]&!8/+(O!T(]_;B[73_*/3K0UZ\/84>_U:LS/HUKJ]6GLT)]O]VHGM%8/(\_)WKWL8.TW?KVW[_PZ;_6:F\V(::G]TV]"_LYK- M%WHP8?G+@N1J,!=E#LE8\T!]MMFII>$ H*L&/8[]0;<3:[83:KWNF6T-SN"- M9^U<%*46AC$_?/'6U.NV:W^<#;H[9YW:AX[?A(9;=I#?UJW9VDFO"9/>!\#+ M'1Z_"Q8CMEK1#X:V!;=T3^#[L\W:WE2GCVQ_<7__SVW@/@6&A=?!<\^39EKI M* BEBE+O'-9?=S+18(()*CZP&=P7L[C_"-+^^:!^__ M;-;W_'GC_3[?/_\&P'YPO-^N_X!WG];/H0_M=PGZC>O;7VGREF'.$4L"P%SK MB*R/!IEHA--&6.W3JRVQ>162 [6V"AHX@1^]>#@$TNOV@.1/@*J^YTPH0,2V M=B7)P'(X ,G+5(-UBLYS8Y22\#, H<3D@DC,NZ"YO(%J/C3>CWAQIA+1E[?J+-?[D3)D!D2,2F\(%JDO.IS:_X_ M$SR"->S$08$K_0PLY7H#Z, _8>@'_%=[G8'P%#B\U@>9VDP@IN';8:?K +W+YYJ=D^&@_PO\6S2>0!VL?<_Z8.VH M&7M91(V0#6 5*"0CX]0]IP!S(8*@;@/0AYJS !IY=# .-]K0K]EP#/@"WP?0 M,$$]R1^][1_54JM[FH=D!_#VC#QP8;J?XS?V2S;H]X?MDSR1($%*("Z$:W>: M<3*^#+UHWS M?=$X_LSK>Q]/ZSO?:/WP:TR)@,5ED!"*(FZDS/G?8%F2=(E9H@33.2G' N@& MLOF\^<_F%&[#W&?*S+!W5OM[_Z_M3Q_>[6<Z;NW(*R7IO3-$E3C]&LR//$H M$L)$@SX014#9C8V\B#AX;(0GY-46P?A&%3#3RVVHPU ":@:C% B7,QZ,B%P[ MYYF(2A,2*NIX7.K@]=.OEEI."2B*1$A0%&ED2%L149)1QF@BE00412)NI(X- M$&?]$] E0**USC:R,I$UB])&;=L?S?:P#;+LI/;Z]*@)@3,5^(0+_%T1@19H+[9;S0[R[\T'4=_QI8V?[!UBN/H'9 M9S009- T Y=')F&,0,(D$J(QQ-*E@.N7S1H01*ES-;J@4I&-6MX HOBWWVV_ M64B]OX%ZLUZ2GRZND=_R.M72L)?]7=F"L,U6/QL.!>6"AKA9VPZA4")M*U/\ M)8=0M@2R$;'$N>59=PXH\-UAO_0IE4IJ5L=/6G$LQR=Z;"'(":N]'HVF^&5* MN1T-Y)?"M.C'Y7HSLG-J)S!3<'MV'XV53YBGX4GNYFVX4(!28)F1*<7(F4W& M\DBB]#XY;90K:P@OX1BJN/ AN/ ;*@]P7P#:8W2 ,[#WUW0SY*DW X M29;];S%H'2-P#RB^4B5N [F)^&XVM9>E/)!ZGZ+MPU!=Z^SO;K_?=*U8D&-% MBHM)\>UY_>-7;0DLE!6(@_ "#21@4(Y)0(0::U6@6FJ=-9 ;:?&2A"<<\^L) M<\JQ6@2JJ-\ (8OS%PN$\E3;&6MG=8#"67AW'=HXYCSPH'>"< _(22E+Q$;/ M"7%$JPI UXEJ/S#0F[6+-F29C:52B$M*D/'<(^HR^@@251*OMO2-"+JD@_\& MO7;D !\KS84,7T2G&[68W:6/LT=0>HC[*]DLR .L9Q:J_6%[K2YTN9T]\06+ M=T-LK6([81X]5K"K4$SPR(C/+YFH7 5@_0[?_@G8=_IF:9G^4 :PPU#(/ MC38BYJ9P--B-!5?S'GW)/4 !S6XHVBH]*)K$L#&A MUKS1D%_; R( MFV=E4M7[+IG6(U RYD:"O\+D,.P-2CZ/TT_($2.8,A@%T,S M0/7P88J;VJ!J#'L%@E_&D'([94D$R>;"I7V\3)Y3$[J(D?L7.S9P1^G]'NU0 M!^#H)B!*4?&V%G^!?GE8\GEN6U;!F% I?/&(=#&4XN/J1JX*9'IIG")Z9G:F?1[UQ;T[L842N M%^TW9!-T]HUMG=JS_JM?+P,#H,+T!%XU]A& 7(2<_38%*>PZ^$AI)5.A%DQ% M"6,A$W%!%F]*'H6[H#MV;?I2.^IE[?#_:8:$@PR44:,4YTPX^!"89EX(H5*@ M7]6KK;U"R #_9(4O\])_?K5;B]9[AB5*Y4T'HRP'8UU;QU4"F42Q%L2+O,\4 MU$A?A6=BV,[Z8 K1"&]MX@;^A&"B-MIA9K *6?U92 1C*?)(Y&_;&9CSGG(3 M@+J9LK#8R- $0^O$4D]HI0 MP"G('4/L2$8=+?7N&9%]*9)RQC^OA(S&6&$IF%G,PQ(IXYU+)O"@M%D8!739 MK)B$!I>YB;<[82INN%[*H;#;^30>'=S0Z'8F@RW>:G[0-[M['@\C[7_#FT.URCUA&:G-#3' MVY]7J^0S5L>4#E0HR05Y%DU,6TC9*#Z4WXVKCCK?\4 [O0 M#8H(:ICBECWIQS?C#[^!5GC2LF=OFIUBHHJ'?KLL&F&EYM)0Y+4L+X_DJ]&; MC+$L8D=),$8O'DG?S4+ZSD2#CZZ)3:KYE9?Q)KGZT>N:Q9N2LCLU>_TUI?7J M.TLVN;KZ\IIUEF\*I:K.WD-G\286=VOV^FN2WVT*;NBL(72I9F](CG-C#FTS M=^N"@V2E ?-(QZ;F].?"W,C:2>W?,F)PL$0J^%LD$U__6Y_JHFU?B/A+2[8D M$:_7$<=%0[S.QGQ=^$.Z0V@]]']9IGK!LD>SUGS5"XVK-E:V5C+P94H"/)/9 MVXD^YJCC\022^P&[IS$9$WNR-C$H7_)T?)[>:OB039S5SL9SX:$*@>X/@9Z- M['ZU-54)Y>)HU5)UAJY:Z5M2S"J(ZQ%>6;WO(=[W[$L3?;K8XY[LME:%AUY( MSFD;M7:>>,6-XH03%W)I&J,-%CPJ]_. M&N_?M7=W/D)?X)GWGVE]K]7>W0O-W;W/].#XS^/99"?[Y_L$VO^QN_@K]'?OH%UO-U+];"Y5J<.86T\P(K"DB&M.D0DI M(H^9\5@HR:EXM44WQ%JEFZZRXU=(=1U2*>T2)<1%@PG75AJLC, B.D*T-8*L M/CM^A52K1JK9O*#2NZ!R%F6%'2 5D0$Y'C!2@7INN2,BF&>+5,]2F?Q[V:C2 M,G+T3L5D7^2\%J&2>=\]Q_GY/)5329?*B,B\,[_&$[I^TF=9KU0U85=-V,_6 M"'GL.L55&_?7QOICZI2LN@A9_YGZYC=.'[W=]"TT4-8/%FZ7N$\81+A-1UF!I M$H'/6#-NK [<,,I$"%>4!*EPY#%QY$=]7%GI?/^T?O[QJY=<"I8H2C1*Q#T& M2"'&(ZYI%$DJ+ZBM@.0G%.Y[,%6J-M:SC;57N'>FSVO>J^%]G7Q<=B-@_:#@ M=O)1>BPBHQST:\>]E3E71Y1,>DJ-LT17>O:ZR<=_YO1L#TH-QLX@QE7.99#^_XXXO'"D=6CR-&L1"4==APS#%@AU,*)\L5#M@H M?T7QJ I''A-'YO3L8!QU) 9$%)CI/$2.M!(*$0>RP1#O-65"#>1DHR M:^MGS=K/24=YB&"B-=T\?[9M5 [LJHTGZ\!>8<3(XTW?1/XLSII7R*QUT^ 6 M.[BC9U1P[HF5W&ME '1(U$$F+I3BK')PKYO2=C;CX/[#X(/_>X1]^]^._6*& MN^VW/^KM#S@7]ZU_^;/=V,ES!)_/M\7!EWVV?_[I6V-OG^6TZO_W_.-7!M9Y M$#8@P01#G&*)K%$<,>^PE$9BKWF9B7&NL!2Z9;6QG&@O\6 Q89X+:QRW"JP& M98SR"O,K$I]7M/9,:.W;5Y4H3A*(B^88!1X\1Y8J@Z*TL/S4)D^SXV !K[%^C'N[.[%]_#^7Q[^]\_6 M 6U]=\==5O_REAZ\AS'M?3AM[.SC_;T/Y[M['V'.ZG!MG^U^^7Q^L.=/]XG& M7XVTQ$5-D)+1(BX<0493C8145&D2L,-L15)")99$#-+;D+BCTDD6!,.9O#"5 M@E?$]KR)37RU1"BNO41))B V%3DR7'B$M<3*!AF4U$N+B>IT1=7&DW7>_7RP M5[6;L;SD(5Y8J1*V3B6NK77>).*TXU*;R$QUJ&+=),_N_*$*R;7&DH#L($D@ M[K1&VHB$7 J&8<>4(6P5P5[/)1:ZPI'5XTBRQ"06 QA,EE,?#>%*T.@9EB&& MZ"H-=OUP9"[8RP:G9 #]4S.B$"?8(">\19AQ%A,7TA.\BF"OYP(D*TKQ5>(! MW:1BG?6RO5QU[[;Q?*.<:1>596JA.\S9+XN\:9*&.'R:LMO6%6EJ5G%3RUYGG(*D2M$'4I1&7!2IP8\U0Y'K&SU"6P"@5+ MB6-.516JN/Z(.ANJJ!67D7J*3,SI$UB.4L21H6SB1\:Q4L2_VC(;K$+4JHUG MWT9A?OU:U.G:6K(6V((MZ4FUSX>M$@9XOHE+3+]UF3!U7R670"S<0\DE;NZA MIAG9I/*N'7KPSO)-1N13Z2S;Y/H^JL7=2V>!B2RP3YJ?=E9/RXV=/K698];[G^+YG M7S"L$6$2; L:'-C>81ST:ZCV]_Y?VY\^O-NOO?[CWT_S^O-MQOY,=[6>Y^Z4 M<8DYZCC33G-!G<6.^^2,MLYXX?GJ]_O_&J/]"]BA.J[C@YW]T_J.Q_OGV^>- MXX\"_O*#+Y^.H+]G]2\'K3I\KK_?%[,[5/5\?NUX^[1Q_ND8VJ6-G6_P]ZAU M\/[=M_KQAQ\'[<\_#MZ_/3TX;BVJ(4:28H9'AVP2.80L:624"XA0'3'C7E/L M7FT9LJ&>8VF>"JZ>*5Q%1X/6*@0:$S=!:DMDDL9385BPEJU^,[V"J_N J[E" M8MJ*9'U ,=&(>.01V2@,2AXG;64@VOA76XIMT.<(5\]2RZQGOJW]87NM;JW? M;.<2M;!83RS7QOH7#*O93KBLS:_Q%*^?[,G:+9@_\ ^KYFT%\W:#\3R.V@#X MCM=/4W7GT[RS.O-:[.*BYQ5E$+Q6F27((1Q[VREN@4 S%,1DN$O"DG MTT_8 M,R2P8=YH%Y2WU0GHI(85@.9= MYAA3;#$WR@(L8F>-(-:$@&T@S&OJJAV^IX"1\Y4P5-#."BR0]S(A[JQ$)@F" M"":&8VLHX;DBT"K2Y:^QQ_S%L[>DB7,;,0M1\9P0$2LAB)2,AX@=OJ**;L7> MZ\;>LSMB- AA),:YX!=H0$8+9*1CR"5/G!.<,*HS>Z_NT/XZLO=S4F$>HAK& M4S@N^IS:J+S=51M/UMN][!;SNM3E>1*J&VA;LIJPGYFPJL)0U<:S4/(>J,+0 M"S.!%]>XMIHSH5(T!(/AZXQ@6L3HJ5(:X MDA8Y21Q*$1-C=,2!J5=;?$VLWL=W_5=P<@^1"412XJ@+,B2>?>71<":9E(HZ MF^053K4*3M8 3N:V$J7S\'\^^A(=1IP;B5QD$@4F/..):Y5#$RH\N;/ZO:;F M=]7&"W1I5 %\#RDFN0$$E8)ZR2Q7G%MMC?3:/F21+D;!0H) '@ D:\5^[5 M%MED%:!4)Z>J.RL"J.ZL"."%W_GLH[@799[:/GB[\VF[.,:>@[RK0.ZK(CVM M8Y)(9Y(4FF/A+7.>!?B?&B5EN*)$:!7IN5:J>9JJAA\PN!$44L3I893KJFQ A/OJ'-,2^]-%N* G8XTWH1/ LK@U6"*MU4^ 6UU]G5'-&+;,Q\BBY9DX& M(0T6,@7J9!6(N*YJV\?![F6[['MX_R\/__MGZX"VOKOCDZ/&SN_'#?JNW=C[ MU(3K>'?G(]O=\WQW[RUOP CV]]Z*.MW_T?A7XZ]4QV Y6'%""8)X,AH9B0," MFJ".8BX"Y@O#COZGAFJW#'XU@3*#HZ0* PUKS1/5TGEX0\ R7''"NZ*Y9T9S MXFO 5GN;+/*&1<0E<\@(!G8&EH1BP[G"^4CX B/C8BNJJ-!828V'E1I*: >F M?L!4$>ZY<9(Q8;'4Q 8)@J2*-UU?#JZ7@33 Q3#BG3J&]EKQ?S^='7P))XYR MV: ?2&/'PYB/@)L/!;0'G/M6[._YL\;YV]/=+Q^!FT-[]\N[U-C^"JL=HG81 M>>4QXMHF9'UBR"8?4XC<1!E6)#>(55$YG2+#BC,=C (!%:3B(B7F2$5U+X3J M=C]^-U\60]>S\?0OQXL_9\ M%*)D6>*6.9-,V#O8_P_*>CQOO/8,I\ MQO7CWX_W]S[RQEZKV:!OH6^'),]C_1V8T4YH0\"8121ZC[C%"IFHLD$='7%, M"'="+6:Y&TP1K4+.HB!:J#KQQVWHLK2B%5-/?,:$Y\Y3PQE6LG MR8A!!2>&(LNH0REA1Z0%XRR(A.&SO J.\/\GR=-79"L][^$\:R#?WX<'[P?O_L MH-T 6Z=16-%@*5/"& J,&V!A;9 UFB&J DE,6D9(MF?D"L1&U"2$:)VUV'/+ MK:9 >29YC3FG1E56] NA.K"B Z;&!R%1#)PCKGE$SH((\=A$3[P43I'%RLHJ MC.AK#D(0NDG%.AM=>]V!G8:W47M5V7JP_]W*K_ MK7)JGDU@';?6TT!YDH9SF:AAS":16973H)RI(F>?!%[OST7.$L.\2!PC+!(% MP 4QKX56* 7-&!68F90!%_-5U U<(6O==T3>#5MR%;!6P+H28&7!2IP8\U0Y M'K&SU"4CDF )F))3544L/Q5@G8E8#LY[)0)'UG('P,HT!!7*&;4!9?\EYUK:]PV:GI%4Z%H#- M3@ L>T/IICAY!'<:G4+V49]G=&0E9#3&"DOSQHLW6"GC'>!YX$%I\W6GT)$) M)NA"6;Z,XN]LL_>O;0UC(PYVX W? ;&_Q^U^/PYF?19AM_,I^F&O!U/]N^TW M^Y\[70>C^IZGN'!FP.5NQ\,S!>SOY>_WH+._M[K^V],$]4N>A7I[_ZSQY5WS MX/V?S?J>/V^\W^?[Y]]^U-\?'.^WZS_@W0#$T(?VN]0X_G"^^_$KTS(J$*LH M'R=!8+E8! NDD-98)4>(U-*5\KG9&<:PG46CTS;*G''!&\5#,$YS27C>2W%> M Y*_JD60E"?9X]L;QE=;[[J]VN"HVX^U!'*XDTOMU)J=/ES,7J9^[;0Y.*KU M 4";"<"T,ZC]%;_'5HW!3;!F_0UX&![MMEK=4UC96L$QM?ZP#2P!=-HO+F'/$#D\ P)]U^,S_]IA=;!:G^=MH,@Z.Q&C3UU$@HX8M'K ,1-!Q<_=,./@0F :#5PB5 OVJ7FT5L)C/ 61M.3/H?WZULZPR MRP&+"'.&G4IX32$:X:U-W, ? (^HC79@4V,5B"1B%FN2C3X9J1V#1SCS+O=5[;L0HD.$ECHR9L5 %8:5:]J0?WXP__#8^4M_L%/-=//3;95K, M3M!9IV>>C_+RB*"-WL1"9)H>N5]'+QZ1^V9![C-J;7F-Z4U.])67\2:Y\MIU MS1*VR;BZ4[/77U/F;D_>T%FNS=/I[/W,+)/R7CHKENO0#9L'-RK*9N[6!=Z< M$CX>R7H7+=).777.(*''^QULOUULY-5 MVB&T'OJ_7$D03W65]T!?B+5\'/FH7WL+PPZU0@.NVYX_JC&R\9)9X':3\[.@ M.>5=N,I;M93F(W]9:)@EQGQBYLYL@KF>ZZ34Y'5:LCJV6<-RW[%VO?L M6-RHN0C67"?[EL#J+=U&MTV-LC0M/+_U'_\I;NY^_W/I_M[KU+DPW,J4)"A.K@,48J<(%XX!19 M[S"*7&CL;*))BU=;9H.M+.G2;:3,8V9DJA"R0LC9L\ Z:6F]XMY%KJS4*@%[ M )M@P6S HD!(7"'DDT;(N1KCS'%!7$Y*DD_]!J>1(P$C;1(17#NGHR_RTE40 M64'DBX?(QU8B^Y'DJG&2S.!DC%RJX"P*EA+$'7%(Y\-%)O)@A7)* M8K:J:+@*)RN^V#<<81O, MI=^6:-O8_. ?HE8DT,)(PA@^_9MU)&$A 681(,&9>]N6M9Q3IRKSR:RL)S.? M"B?9%$YBCTWRU"-.8ZYSK ARE&$D@Q L*"64R(7,154O#TZ633D6I=G%LI5J M_=BPG8.828V5=!'!AG_YUDD^B(2W.W&0_]UM7U]GYF6VA?OC+LE[]R$F/U&( M8L,V.W]W^_W-T:)N=M9M+Y].]$EI2^Y@2^I?9Z*WWHFH8(61A.7.M2P) B4*'L%)9+%,B!#.) X, M-A;@2IBYI9^5(+" (# 'V_^H('"QM[P>",H-YQQ!8CHPE["G1KB(>#0"<2YR M_K]DR%@>"--,$I.;S.HJ+G'B)>/$HCL+)4X\+4Y,!Z:2"HD+BY'U$G#">XO MAGA$E!$4>R*8R54DYYC-7H:>%OB;KXHQ&3OAP5S)LA+,(TW-B[' 21%'"+,Z MY9K-7%F>E#1*,1R2T1"8"=R.W >C#*!F7'3 MH!)REQIRI\.B"C/,B*!(2L<1-]@@&Y1#CD85E3*8*W!S"9T_%:G$W!)S7SWF M/K>;6W*;G@IXIT/-Q"O-B91("\(0E]H"YFJ&K N6<\^]4VENI69+Y"V1MT3> MA?)V2^1]*N2=#M[+Y)E-1B+#&" OCPDY1SDR1 1NC35>YBPE-8]#O@4 WC+J M_SQ1_\4;\+)\\W)UW)G2G%>\,UV3<*(\I%RT@KE7%$;\;:'#[4:L^(+^.\7^ M[::BWNGPFKFX^42=59LC*!7;"5=_W/I5Q*LZ8A$7)5;AK%_TAH, MF<4P5?'G<>STBUO^SQ-2;L3OC]+O41YXR*7>['SK]"* YGD,XY/TVYE>N9RF M]P$E@]_3K<_[V&(?2+1(I4AR0R(PHCY%%#TCSBDL*<]ML/0JO\9P@DZULL", M"_4.BH):[6%!K5@4U"IJ:0V_S4BUDH6B$.)3VZ\<]YJY\F_KK!) ^ ?=D5(4 MG/A>_!$[)[E:<"]ZV\_%@R<^A9\=@3: :(:BX"Y\"C(-8@_KWR^T*DSV:>T7 MMRQ*"8,:V8.AI@$4K%:R+G[LM@$]S@J=\(-^'DFSWX>;YS?M\7$+K'$V[S". M!ESA;%CLN"@+#$\(WQYK&2AI)=H>/) =%C-.S5Y_4/GOB>T-8B_?%)Z?70SF MJD_Y:N5]/[^^*$)6S-FP=/)XH VX_%VTU@DF&5?@"1G!*=$4L5MR BBI_ M3>_*K*Q/U(CAM2E@[?P ;ZUMBMJ:/ZUOOS^M?=YGR1.A.>5F9_U@WTPOMIH;E&NNXQX%!9DACJ$N2?% MIZ^V5GB 8K7RR%T3-HL$L&W[,S<>;W6S^[,HC0ZVOHX4H+U.]]J;/W?;?S5J M&Y]:L/D'13@0]8V_0"E @#=VS[>VOQ_NGG]CLRT4]]J[AY^:N^WUT]V=;[#Y M_ZNYM7:$0>!S&\73O<.:J._D^X8$0L_JG_Y5C(H0KY7F6'AG=8H)!J"82\K1Z48'PUFOP+3GFK@W]1JX<@OP MV]LMQ?9FTC4"R/4GK<*5&J8D5@9Y;BIV, 2%(8LL6G!9>O&XV\OX/B*551RX M9/!Q9_C-/OA=!5S$E&+N]5!27;L M>A&^G!W$W'.BT82;VEZ$&_L<>BEV.+_:1N279Y6N!YNX6OEXTCX9-G,877B( M8"/DRN,X[G5_-/MY):^ZY,RSP?NC 4SLZ"X_I^V ;+2N>MQF'RQGQER8^G#) M%?WWOS0EZNWD9%_LV)K9<8[]7'H2YC:VNJ=OAFC^\#^O[8LQ(:)3C4(GFP0\ M(@Q^]8T83EIQ*^49ZG;RLFVE"W!<'\[-A]B)J3E8J'8PSX&2M=-]YVC0*G D MN =W4DN)K#("21QQ1]B>9^<4Z2'VD4O\OM2QT65#[,>NT M+QV:+G\:R^:,;US6^B[+CSUUO9AK]B#+P?FXY^9DU(#X\\^]G;W&WN'!V=[V MYMGN^6>V>_Z]L;?SO5UOU\3N8:.Y>PZ?;W]O3',^ZFN?6GOM3^VMM;]:M<._ M#NMKX;"^ ^_M[-+=\U9S:P/>:W]JP7NIUIS)+%%1:QR\1%Q2CKA0$AD=+7** M>^*-0MY30]YT9H>C%N>JPBCQ!+AG9,Q' M/0R!Q HIG:6: .2)*F/7'?8L">(MJ",]26"Z=!CPFX.IQ0SG]^+!26M$5.C' M_/^5YJ!?&9V_YGCXB$A3O!UBBKU>/N$#5[O@(?57BPZ*_?Z88S3\^OCWW735 M;^!+_SUI]N!>DRVBX;GL0<&SK1R>A(/\8K6RV;F(C.<[G#8BW*1WW6"*4'V[ MVXNHU3R*K3,T:-@.ZG0'%\-JQ%00?S1A^7RL#IDK>5+CD,'1=8>CH/[X.\57+LY(FW [/[C,,AG-^/ " MG3@^VJ@,AU2IJ )']A>[PQ^?VI[ M >8AA.*ZH,X'C>+Z__2Z!['3]/W*>P^3/VQ/?7D\XY.R_G#9B_MTB^F^8D3] MNQ+&M&?6<,J,Y)(G0PRXU-[+%,$/MTFZV]((UD;+#E9GV+OS^WAP[\=C6P[: MP%.?!]2VO_VLG>Y[EH1P1"%L,KV$V8B,2@R1P")5U'%K,+C,J_0W5(&Q1 Z% M=W"E.H*(9$W]MOK_K5;Z)Z[?#$W;.ZO>F8+BI):!*V^H<3SBJ!G6V'JO,=6, MI%3*SN/+#J^]W[?@>"0"SD9("F3'"XZT,0RI9(G3B2I+ULO/U M- *<3DC/ZFW.)A?+X((1 W'NQ*&#RFK=;[9/6@/;B=V3 M/G@511BW.#;/#*+B@GE%VD.K/S0I![TX-/O%S,"X*T6L?G2>GO]=?*6X\?C' M9Y<>94P)N& BM6TH>*0@28-6IJ-V^_':Y[I8D NCFJ?:GL"O>@7["7P9(C9X UCN=#$YZ<69Z+IX) M?N$R;[594"A<;-A6&LO)^#+N+,]7M5 J^ B4+S,.\N.ZX=:L/QIQ7K9+,<_:A8/P:T+&7N%2:JDMEKEPN&[0TF)="^H'[(3\V5"K+I,^\CQ> M(N+#]MBV+NB7S4(K !AMKJ^66C5^(:9BN]@DS3,)JO\,5[*0DA2%NA\ZQ0S M6;)5 >$:2NUH??\S7B/PJ\]_K=(L>Z1@%P]OESDDO1\PM-$S3!)B;.]R*?(K M:"B@IH6*QX]:5&X?BTTO\KY'@7\5D M)Z.4DWS5G',"_PPG?FSFKK#]U8F$@(FI'PIZEM;B./SJC4\G7$H @)\==+NA M6/D[;E@>&BV;\3XW1@-Y/S*<:R[S.MJ>1&(*6BRYF= M!&D:)+(:G%&LB7#.9+=3WNQV3FGJ;+[9[:G(@BXN%5D^ 14Y,RZ[O;.%HR*3 MVIB+WZXWM[9;C:VUSV)O;>^H?OBE!=]L[K6_T=KY0;X.W._]:9:X&0FEFV)K M9YW7UUKYOK2^ ;^A?[7WMD&JU_*8PU%M[4,3_DOU\_?G^\'"!-)$D-+8(TYD M0!9VILA)(KC"(@)<3!.1@V$R>D^MXHR;D)Q7.$D5:/",@?#-$I%'[/#AEM.-)6Q*UXIAF^2<$;(-C+ 'VB2=D>5X\]\=A*LLB43J?7MH.C\0^ M3"YF^:0SV@1HJ!,(FBF:*9$42)3.<#&]H,8Z833C@L+">L6LP)0+$KT.E@*,QL+RBXYWPF\+7@KWAB)8[.E^<^-6(U(M__<2Z?K=U,KC^)XLRSX1. MS=;$GXW>+W[C040.7,U M?H04@3Q8ACV\7>Y(1= MYE:_>,[R%WM:R6F!O:9M]4NZZ**HA>[)A# VEC^ZG&PE;Z,C@&6@KUW MWZWWJ$C=-[JU\>EHK[T'_ZWSW4,8Y^$'N,XFV]IN-.J'ZV>[>0M^^*DU4Z1N M>Y?O[GQI[\'S[6XWFO6U/7C.35$[]&)K8YW6MO\ZW(5/:SO?4VVV7:7CAE!/ M*:+Y\)RGQ) FG"*.@_#@$5J, VQ66%5+LMSTO9*P7(+>0T'/A128Y=AZPGDF MO487(DU!:L.QHG18S//W+>)+T'M2T)NF+!O.+?&*(X.M1-P3BXP-*O/.N%0) M\R19T>]=8+$LH#??3=WS^:$[W=Y1/I4][G5][,]XHA>/1J]\M)?7(G#N?E:> MX,W./\/I+3'G<3!G-C-,6BHICPI)'0.X5XPBS4U"TNM$P:A0G"MB@:.%U1T= MK<=SF>[0P/-E*^'<[7ZIA$^BA#-=:*(%X-0.$4T5XCHD9%)NTZTP9U%82Q(> M*B&_CF[^B$KXXF-,GYJ=9C]GJ&0*U&U,^ZT>^>7!S=QM_GCB,^.KA)M'@IO9 M/H-8B6@!8)#'D8/-%QI91S$RP5DAJ(I&BI5WJLJ(FM,V8X'")Z4Z/YKW4*KS MDZCSM/? ?=#6*5!BSQWB,5IDO),("V4,\]AIXU;>R:K0=W0>'E6=[Q88&"J? M660O8KL[R!E(8V6X;DYO:H6";^J&\L+"M_.;AQ<#R'/WKP"#2^2=%_+6/\XX M4IPRK3D3"+N[]QPW!Z.DQ^94_G1L-6-.A1TFC!85UKMNF((Z3,_VW78[]HI.6R?]BT9= MH^$4Z8>C+^:ND-UVTX\S<\=?+5(<5RN;Z797A"'D!QL/HTAE[?SRQJ^9GOZ) M;_P:5"^.DW5#)11)AU-E\<=7&2;[YD2;,.X^-$G5*Y(YIQL0W:V2A[5*4>VC M$EIRS)06-DF5P U,3KIX'5C.Y%+>'2R?.7?RR7.%)KO$U-8.SG,I^."CU8$A MJ6EVZPA#CHJ(X%]4)4RD4B+G#UYW(#8NWP%B<4G AM)S.4U\N#PYX7TB@W=M M_=-F?7-[=ZRUN6U!S$V\.B6:QBL7-8E6/GL7Z3Z\+"#@X^Z=E.X/WG;#^WY/F<:Y8 ML'A9K?5QWO5A[>?6V@$X2+6?M?-/S=WSSV(7G*=Z>_=L:V.OO=O>!5WW9&^[ MU9KI,'6^SK?6O("_SVL[N>Q@J[F[?0!.UR8')ZRY!WA3/__>VLK!N&W/ZY_W MB606\Z018'9 W'F,3*04&<6H4XGDBE[3F88DP*Z>)(.%41R#0^6% \0W@@Z3]?K;H3QV%NNU$O:*Y4K4/N\K@W5B M(%+2&H.XC1)$2A#$2*!>@ ?. U[&C-1?LGQ\69;C+UGN1/CC/@FKM\@[>]K\ M,456"2'WRA^3JZ!-7;2$DJ2$YBYQS+"\[='9M:[H M1N_6S=&?.]Q\3V]U%&[>A'&U&CERLIO[\&Y_.:QO?&_N[>RUZNT:V=IN'>WM MY+_K,^'FW<.]HZV==;RU ^\?;OZL;]3PWLY?K1RQV3W_)N#]5OZ[1J],^4J! M6,D#0Y8;BCBC.=PL4B[:HK%6SA W)$%R<5W=U(7+?BA3ODK >Z33-,8T#4FI MI",/W#H9L(/]MO<26^+U;4_32L![,L";/E^3+%$L'$>6"8EXH/#*YD17B25V MTA+#P[(!WIW]T53\;WG\T0\GS58>Z?UHXE<\[-M-,."2V28]0'JF'OHWG5:+9 22ME#MJ<51DGP0@/)J8@ M.,'1**R22CA)SYP(MG0P%DZ5IQT,2S4WE'ADI:2(4ZR0P]XCEI*B)'(25 15 M9E6)]0*I\HN/5&1NWTGFUO6[:7!J>S/-WLMMSD4+$T6$C 03)BGG1EH?M0HD M8BF($(R7#L5BH= 5J5C2!\]$T(@99Q$75B.7B_\[+!/EA'EG 84HKRIY7?N3 M,F+Q E19JX@)CP([Y7FRSK#@!+,LUSMP%*?2H5@X59[).[(R"F84,M8+Q*-- M2!-JD:6>!0!FY9(L5)GI![?N+B,6=W$H.OU!;]21;%@*[Z!WNUIXKW1WXY)G M3"8K=#X)"<[R7-;6*D(=P3K1TJ]8,#":9:40DR3UR:'(2LEBA&SYD26*D(?@7!5;E0JOS00,5#]@H/(Y8MM<+/ MJQA+J?!/I/"S+(;H$F=):X1)@(U$(!QLMW4(8V>"Y%I8S6 C@775\ <7U+ZK MQBQ1Q. 5H\"\BI:4*/!D*#!S/D&\ 'DR2!I-$9=.(2MD1$'AI(VA0E";44" MW7]PO!U*^87@&KO)U;D6L0KP6YN8#?+J^ Z]WFW#)'L]W F M C+,2V2]3L0K\(AD6'EG2-5922,60\\4@H(RPU1!,L5MYIV.*0V2W.LRC\G(@72U,1^/AVU2[NZ6*6 MI3:?8((6VS8L4E!K:6IR+@/<;\W27(*RS#D146(*PV:6)&3!U",J7.!:D!2* M=DU$5LW0:I2#VZ@L3"0>KD \D6)S,G*@=?7NER<4G)K-P4%Q]5\)TNK MWM(;KU9.;?].%7OO50?QIM*]DX\VM=5>CDJ^3UXU$5[O!V.5#0*CR)S*M7L) M.$C6(&D=P'%@F.3>5NR*VKV5<=G>+ UW6?G J.>>.F^(Y)P0HP,./BA&J'4N MJ&+ER7CE2;GRC['R;)\')C5,/%)!P,KCE!LG$XZPEUS[*(S5,:_\;,+ZQ^E65^&,NT+XP161_ MUK=WV=]T[VQWQ\OZX??#O>UO9[L4W):U[ZWZ&OQ[8QWO;A^!P+?:6SOY/G\U M]K:/?H2-[SS\'[@SM/7#'79I?:?>JN?.#=N?>7WG&X9_'^UN?VEL;1^=;^WL MBKWM (KUJ;7U7;/:]F>ZM;8)XSX 9:GA_^]/D]*AG_=J2/7S")?">"&,9%];IC3Q M&&EL4XY=6P33+I".-DEC*:5J1KB6H;[Q6 'BI )T"U%O32G Z-VL (.L )<^ M'S:]..XU^W>J@/S\)8\E665:WZODL5[EF,Z_BK!>%9H]0LECP^[WR]\.EK^N MDL=E8>.RL/'K*FR/FYUSV+\,HR/ M33BKH[W34@2>'^#,?FJZC6]R[_#HK Y.:FWM&ZL=UD[K:Y[NTLVSOY/N[GP[K6][&.M[7#_?.]P]_*M= M6SO"M?8ZW]K^AO<.:Z3V79^- L\__]ZNY9 (W@\I,N=Q1%[Z@'A(%-FH%,*, M:AZ,MXZ:84;*G3OLE26/2]1[8:@WKY.V$O6>&/5JEU&/,R>HU@Q%!SM^KAA' M3B1 /:($84JIF"EKE%;!GBT+ZKWX:D*?>L6_JI70[ ]Z37=RX;?F\[3"BRU+ M(C^:P];JP,9_%%8:K<3'W$RR!*SY ];YC)NFB4J14X:$(Q2!Z8FY((E'-!>Z M#F!QC-$ 6+(J]'4M0D) MIX>1ZG7SZ#74SX(4TYYRQAR-M-O"&BX<00C0;EQ M-!\?;J-T'S\C0^G/1A&/W^ MQV[;-3O%D=7'BQ7)Q:V;8722-3X2/BN1ZW&]$ [W.M^//AD:A4!6) 9>B!/( ML5S#B.>V#9;S@KJO697A>1T(E]&.!53T>;DA\U+TU/P9 SJ/O6ZIX_?W3K*. MBWT6O5366:04!QV7PB 7J4*>\R@=UT2HM +*K"FA;Q=(R5]\Z*-(P2K#'(_M M?!33/)L45CH8\P2$)]X(CV/Y90'', MD2&&H62(MD)Q:T7.?.*TRAY^]%2F/I4HN-PH.,<#NA(%GQ$%IWQ92AW'X&*B MJ(S-@6^%C$D")6Z\RKTC6:[_)'05RWFU3G^J3*CQ0,82SPN(F_>6]A;7F'C@ M*^HLSN,.SS3*%W]RNC5,+.L<5%K1]N.EVCC#4U,B'U3!_H7:QY=I N<6B!U+ MU=]9J"X.@.K=CB]MWMQMGICQ_+FE(*%IRF77&L5N.$!*9>C$Y8*@*<8D>21,!84 M56:8)2CX2VH2O/#.X-\7)1+GSZ)[%8=?S\BB*\'K4<#K9VVR/\SY4='_+]CH M,2,(!^D O@)%+F"*$K5>.^6HM+E4 :Z:AU/IRJ/NQ=7V9Z32E=K^:-I^/J7M M1EE,!#-(<97KQRF-G$P$T:@XEI$K*O'*.YWW4HND[2\_>2YO\D3+NO M,'N]LXD#C1*5'@F5OL[X(&![1&[#@J36%G'G,7* 1HA$:8WTE'NEP $&1X;AIBN!:>12R%+PHV M$CZO8\HR)G)KJMT-+23*GL)E \SE\MM*@']\@&_.>&R6<":-8<@:2A"7%",# MGAH*(3"IO-& _P4/1:EYU8%X_@Z895/A$E,7%5/GZCJ7F/H4F#KM-%/K.8G4 M($F(1YRP!.CJ*9)68P-+J$71VX'R*JSIBP'56[05?DA#3,D7MQVF>?1VF&O- M_G&W;UL;L/;'_C M^EHXVMT^(/4V*.?V7K.^\^6H3N&I-NJY*RROG^Y+#0Y,H#KW%LSY!B0A38U% MS$;#"4V@B':ZY:66,LH0K<"!\&"9]4JKR&#EE 9@UM-=";\"6N8.??^<@')T M*U^:OEOY>N+ZS="TO;.;.UDN04/#J[MM_GZ2IB8UD&2(XMH&QSFL@3,T*(4) M4\Q@IU?>K9WT,MUSV.?PI#=H5/Y[8GNPJ\US"UJ!J\5GN766[9Q5BKYF,52: M'9AS"Y,",EXY/NGY1J:+VH->C+FA=^6/_*-<6H#BMU__>5^\(F__4SEMPAVZ MG6+EFH-^)?YL]@N^:<^&9O>X8<% ^K.*/X$KP\KU<__P?FRU*A;^R]<VWX_P@].8&SRVX%_-U(3'L/U*([9"T86XGP7J"JB\ M3G)&R\6RV !&-/.WWQ1MSYL_XJ@KX\@+F?C5R%#@7S^Q#FS"R>#ZGUS57/(Y M1)*PJ3;+$W\V+MCGQ_8@(M>+]@C9!(-]8UNG]JR_\N=EM0.=FYS ZY[]VUSO+ M7QQ>!@ 'KC39B[$ V2%(#7KP/*.=RBE\$^:Y?])NYXY)@)F5ORS,>>^L0DWQ M(P+.SRVL6G;/%L>LY<>\,!?'8)GC10?X(;(7*)P?_G_NL'?36F*GA$Y>2.YC MR$X>U]Q(@@WX&G*X=\,$W/_)O9NXT=N[V=F[1,2XW+T '9=X9(%HE#1$>*N-<& M=A,V(9_3EI,-/E@)(K1ZW4'86().&TW?N(3Y/?S#E!-.W MQ4=3P 7"T!U)8W8E*Z?=WE&^"NQ2FD5!AG (;FQVAX?P#GYP(7ZVV>F//-P, MY[UXW(M]^-9P$UD%].N!(;CH5^Z[/V+'YMX<#FR+A4<8V:)C&")\:35O>PZC M'V1?V8-##->OM)KMYL4%\Y?=R1D\SBE,!1BN2C8%[<[0!\[X&VP;W+8^C*5_ MTBK\\=3KMBO9C?,->!^^TNQ8[T]@9O.X1B,8S6-10DR][=_A48K.T\64+*L5 MN]YO:/:'5@PF:;P<$VY#:(9*ISLHC/N@.0#'O]A' 2;$@Z:O]!O--!A>J6&S M5+7M(75RK!4G5\$R1PN)P@(>]A_D?_J@Y'..UK%$.Z MM#$*$P@V>8?FU6, Z1B^4ZA -Z]2/X;B,7/(JW!B?HVL#R)2[!3[JY>7_W'# M.5]!FL-)*VZE.P5VX&/8C7X=C_F#;<%CQ*^-& ?O.^%]",5.SK9^!8#ZKSD" MM/5^GQH;L.0,1482XMH%9#TWN600DU@0SC&;CN@LC>JG;JO5/2T,1K%K*IST M'ERD7VC&4&,+91I"Y4CS,P).)M066X?AAF#:M:_\D14F?Y*1Y#]OKL?(V:;S M5T[5:*#C&$01DH8I:]GC?GPS?O$65/ZX9<_>-#O%@Q<_>GMY"PZ7FV%CY!L. M/Q[MXX58Q<.M_(@+,KKQ:)>_6GPT%6$??B;%JI#RVH_Q*KGVLYLNR^@J9?RV ME[WBC'(\,X!-\>[?O"9!7]R0H'^'#/<[?'4NC_&[<=R)Q%/(\Q.?'1 !J_U' M8<>Z)W"-T/_/5*3C 8?55SS]2#&?YV!TYND+Q9P&G&LYTD\D._,EH#^!4,U8 MAT*H1C5G02T6Y?'.[)*[\4.>[\$>/U T0PZY2ZP(9"WWBX._UG]) MW*+01.Z[KVCLMG^VMMJ?#K?6-N'Z[V%^'^X='I#=[4V\M[;[LW[X MU^'N>8WOM?=2[6R"=G?X/E-$9.#)84.1M=(C'HE'UH0( B9]9%Q8'MS*.\&? M-W=KJ!.+ ^Y%1SA.8WUOK5)Y<\ PB.ERJ7&LC=,__N MPJ-^N5BV>EP.4MU2H&7]XPQ:6F*38HPBS3U#W%!XI>&5X2R$J!UG)*V\(U4C M%C^KK/2 'P"9FYT?,()NYE7=&R-?11& 9\#(B[6Y*"!:@M[M0>_K#.AQF[10 MW"-/C4)<6XV,H0DIK8-TVB? /7 1V2*E]R\$Y+TL+W%84&!$W1^%\$L/<>'0 MKUBF$?(-HVXE_MT%_YHS^$>CH5%1A8BB-A_="62P4,@+$ISB)B5B5MY)47I\ MC^[Q?+$44P2&WX02ERC_;#E0+<&:2682XH'Y5QNZX[GG7GVU-FZR^54/@]XUKL=-/>CP/*T M[VD6[Y]>)KL-SJH5F!E8P'_;]O';XM3O.)._'AHJ+L,@C[,1&"_;/WG1WG?" M^GC!)A.P2QMW:QNW-1L9,3H%Y3E%(N;#,QS:V#WHO!P)?E)$Z7FYU7@*1$PL>(#_^" MOS)$? \07)\!0>LT\RP1Y*ACB*=@D?/2(!Z\4993S&GV!-4B]8->"!1\!$_P MV8/$H_262X4T[LB,_1W;^>5R9N_VY"6;]H&A\#(&/C^SL#EC%D)BAF*ED8HY M4ULR@9Q.%KQD[&!MC562KKSC5<4?;!CNI#>+QKR]2R+8,_5 7>!P\U(>"8R/ M R8J0Y9G DNSW;N@C!\/NWB7B3]EXL]C<]Y'#>-+5N=]?)-O,[Y)M)@R0B(B M2<&653&,M%$!,4(EX=Z:2%@N1/1@7E.9^;/(,-[+U4SBS^-3F2$[AW/PYH"9)W $D_ M"Y+"4_ ;#;**XAS8\DA3FL"A% '3J )UX$8*4;(\7WQ(9Y+E689UEG(_D \0 M*KTX:/:&9>N[#L8[K/E7GN4O7&3DGVY_\&NQ,M'S0^S$U!QL72Q;272ZIZ4[ MFB4Z)9-"=!@1FCM="VF0SI53J!8L!1,9MH C#,^K/5EIS!82(V_36+N,E"P* M1$[1G2;OL3PR&0=WX<0GV[31>XUTJ+F.2_E2>0\ D@E^BJT<]W)5]Y\5U^T>50YR9XH[=LP!,01/A_F8O.$BMIC MGV!72 DM>C"0<0\&,M."?*;ET@8,XN]NO[_5R0T=M]*'DSX\3/^7N_K:6M[ M5AQO?=[WT4CFC$.8.8D)?C16](60S;2G?;FZ=;&)JE1L*X[G\_JYU^.:FM'/,M][?S+X6Y[[ZA^^.T, MWF/3NK-[^)[O'GX[WSW\3&"<#"SQZ1;HSM[&Y_/Z1KT)8Z/U;;C^=LB<9%$[ MV.<.=E"<4 2"(Q!/F"+-*$?,!RJH=CX9,]TI5;K@@TJ&$N$X:)Z51@B<).<> M2UBPZ68EP]#QKV6H;$V&CF]J/GME \7?W_[R<(,+,0HK.$OP%16==!X>D0AC M"651K=S0<'&QK-2XCY(?]4;K%YU=6_$ =EF_PO&YMU6>Z-#,?5'R-Y+UXPW8 MR7$W&[?;F=D'( 6%O0B^*X'L;)S"H4>.8KT4[W#BH%G/_5WY]5NDW!W'8W0F> MM<#;H2\X ETZ;/TUWJN>59K]2CO:C!"A,FIQ.6K8=;G+Y<2\9ZJ4SU,&"U T M#BLB2Z%:]+4YAJ?[VX9",5K[8S-#K MO8>"0W0M$$YL<=9'P_]G^)C?\U,N2:N])\;.^MHWNA^]LY@)@V!7F;4;DZ>[P]]CJ6L9_;DW4=^]BPG8.XV;E6=(LVO*_9?-=/ M]X5AVF$7D4VYS(@QF:F+/6),""N3UV#"9^RAY3(YKX)UGHLD3%31@Q"3H'"@ M,4V;[ZO:> &8_0 +E%OE#3MZG8WQT!?+=GWKNQN.D=_<[ Q<[0=?3@]Z11W& M>=EAO.PP?J6#?&^'5US5BVOENKO\#D;>/74G/;P*4WB?3GJ*KE)Q?;>\^W;2 MHV)5<'.KR\ZW7=PSMDN[21NO:2/W^VY]R]$G;MB<^M)C/2D?XCD.94;M7?,. M:=PF;[2?FEMV\KW/[IZ5^C"_J@9W/Z-;%LZ'"RDPR['UA/.$O8E@N&@*4AN. M%:7#8SHP6>06M0VNVB%TO1W _ ML=NN_:P=[K7WVE]@G)_)%NPJIH_DZMNPNSCT/VMK[\]VMS\+V'G L[6:N^?K M9W7XY=[&YAEL>OG>VH=4FRUV&#!QAEJ-!&$YB!@\,M11)#63W"8AG*>P%<95 MS69#\',N9C OKO>5AY_."]MCCS=.?F0 MRP1$L96/'&* [6]_HE)@29I]+""Z^8S@8D5*(+H?$%W1 H$X[A45B% +'I-( M!%EK.6)!$TJ$\,1K\)C,O-RE!?*(EF(S>XF0Y[SE;OA9L?V*3K!"C3@XS#!:MTYJ1N>ACV\5>0<:K3AYC5F+F?A2N:7[77NR9!S"$ M?*V"ZC&FR.2E.JZ$DY@)(;;2BS^:_>+X9'@TFENF=.!*QS#0;LB_/.G',==D MBN92T%<*]HH=T53'YZUVPET>C^+RF$/,R6C-SGC0O\9V<2I[F=D2?X+3$$9? M'Q>W&'YTP8VT!8_F8J8NJ(N57)*KE\6I=79Y&+]^6@&!1][V&Q4;#D_Z@^$Y M\-W(M1&G1)*+02K&/3>.'Q0$ MGI(4W]OB'"$64T8@3#=EL!"!J#&:**,V-5M"SS M4Z_BY0YA<$23*=0'T,0WCS.C;5:38F>L/NDDYQNE6'%GDY]DR[FZ?%R;23)= M,Q.3_WO2[ WY92,"1O&0EQEP:_'8]BYTZA\P TU?^;]H6X GF1TWP8F[_-7U MSH]FK]O)_[2MRC^][B".B'O-#OC%S6'YZI->X2.'V :/8C B1E_)]!@1Z6"P M"2Q6\9UK:(?WY?1=32XL*(XC=F^UDI^[>W+0N(1%F9G8Z5Y@6T;B?AYH_M5P M3G]=[TI.8Y[[_$BP*E?-SD@N,TP4%N'I"7^?QJ-Z/Q[49N<3#&UI?^][(WZMOUS", M4=1V/AW6UUK-K6W8@QS6V#[1/BEN(@HJ1Y2HB,@HFFMV&LH\43&'MJ>8@,8) M)DV,Q"3"P6]R,3%M \R_]""%,T3^2]VLZKF;U9W)^[^_Y>4A6BV3,XG*Z!*X M>,*!U"@G*-92<2O=$Q)2-\$C + '1_SOYH\8IN5PD>BHSR&"?)\'IK1@%DDL M)>(Q"60T;($!K+5^U2NW/4K%ZR!M<.P:(QH6#GED0N>Y?HU MAGL5!%-A9N66(&EFNOU>=9@ZTR_R6M+(1QLQF]]UWVYL]4.=ARL(\W6':[RS[TK.O::H14/>C ; %I MKS<K9?]_N MPF#.AWNN6@31#.6D/_:D9Z)2.G[1/AFGIDV)>SOQCSWP]OK+$ENV> M#1%V:D?7TP]O\;AW.7:_M?NS6,FHDS27*Z,X%$>3C(G689*+L!FN#<4N.L-9 MPI'<(HIS?>QFZ&K\W4R7#V7A.?R;<-++/L=RQG-&))9\O="HP>]R#:7:X9?& MUK876VM?6K7M&H-QD]HYO(8QS)!88.QUNGZ^=]@XJJ_YL_K&.HSUB-%_\Z_7&)*;ZUYOO71X+W_U\"^_;UC=\S)UN'>86UCKU'??G^Z>^[) MWN&7P[V-3;ZU42.UC>^M&MUD]?8FV=K99/_O_/.^2\Q''BA*-&>E*Y>0#3JA MY&SR45&.KO@Y[-_T1_ MPT!.DRBI2I00QXQ+M^7#WG#PL]'K MYNJ)2\"%71;P/Y_BPD87DL+.(6NX0MPPB0R%5XP('S7+QWL*/ %6%1PO2V9H M"7DEY-WAP?]8+,R;B*%,AE!*%)PC"I(I%*2:QQ2<190FBK@(#&F?LU!32A@S M[J3,%:M)55Y1LGHF9%X"8 F RP2 BX5_];@7(I*BUIR.2'XX MRI'*^OG[TZW<@63[2Z-VN,EKVP<8GNET[_![@;S"'B',0<@0L$&C+AT$FGI'?+8"&JP%HK<)]9M9 J>$6)E)-SZ8#+[ M6;$8) _"8%]*ULN6K///^Y@)I42D8$D-0R!C!C8,FB!.!% E"+1/'7G-/N8[4*"H5E]XX*VP9TUU D)N. MZ28B ^8YM2BE;/&T12XRC&($%\@PYQU5*^^,K!KY8!?_T?O=ELI\_VCE$VAS M&:U\?/V>CE8:XKE@/**\B4$\V824%.,B)-!O7M5BMI_U[:.5I6J_ M:CM=QN'FJ\73<;C@L+'4.&2P@SV#D0YIS!T2V+$E?/*_T MX[#D1.NLDLFE,3.91U4L'D0T?2WQMH"M4)Q$SS07TFH2@W5"1!>TM1&749%G MAZ+)@FA;:P>GM6D&8+L.]_O2J*^MG^X=;I[GPFRUG6^B=KA)Z_2;V-T.A[O; M1V>UM I+1DATF..HX6_2VKI"Q>L\\U]!VN=-#%@*P4(%E4*.1$<"HF 3$6E>2)7 M!7(7@VJZ3.&V1V>3EA6BQ[B&I7+66H>UCEQCZB0W45$EJ/'41E$&W!80YJ8# M;MAH)12)R'(*R*0C;,B]EL@++[!2N92> %=>B:K"\V)1+A!/Z(5K\UTB;D^@ MSF7$[?$5?#KB%@3WF%G8JS/8IO.($ZBZT(AE"E224F.-H'%_XN^SK< M7@W_;OKN>.#4JB2BUT)@(@P-KHR#/#_R?+T[DM 6/,9),XF" MXAYQK 5R.%*4/(D*,(HG@W.RPATC;$[SH*7/-6TY9^#L!*V,E<9I9Q0U91F M%RY9YY_W8W1<@S.+-,]'4IX)I(FV*'K%N*8Z26M!LF1):'O^"%MY5'Y;QYU$ M3*Q)1%/!C0%W/1J%59)!**(,+R-L"PAS,VG*T1M#;$!!8H9X*R,5$ M4$S!!N)9%,D790@X)R6E;7E4>[$TNPRPS5>+9RAMN<%7;L3"G4F(&TN0Y=$A M&SWS1C&%-5AI1:M,F 6RTB^>T[86?\16]S@W1(J^T8&['IP]$IGM64MCWCV< MEHS,]$MBE)(\D>@BBY''X!AU'$M;!CV>'V+">63!Z4&.!$)4<%S2W%.XRDL"T-+I\EWB M$T^@S-?&)TH-OHL&S]0 2XY$AA5RQBC$E4W(2HN1J)/@L MC^HNEN:6\8?YJO!T_"$IA[4-8']="(A[:I$F1B*&"541$V92+F9:-?2ZAM8E MO><1E'#SGR__MNWCMVN/Q.]9P)A#_<_WCWJJ^\*.PQ][NEY]+[ ]M:E".@1;W&+4LYCUJC,Y"^ MT#W)C=:+EHFW:Z;XLJO!/VQJ2F,W8^RN.,DJ3=RCF;BMV>QVHZ14E =$9&]Z1C!FIT0.X,WE*Z* DR'#^MZ?TZE M[19_W/#A3542B@%=3-QP!F#26O:X']^,7[P-S?YQRYZ]:78*Y2U^]'8TYM%L MPA!G8DCY?L./WYXVPZ#QQNA5KFC6^%$$:W3CX:=DM0"#J=4Z[,V?*:V69;!D52E>#G:I!BNN_WCRL@\EJ%Q_)*26E_>A MKLFT\;'M8J_"2+4"/@2Y9%Q^,Y&+R=BXZD&'0P,?IMLK]HEO8-UB+W\+=K;- M3F70Z)[ U4-_9I=R%_FYM2E=<*$8Y@%5\L:[7RF,:YZCG/[SV//S$/[02YG] MR7A&I19!-!_40ZJ<]-M,^L=N?U#.\J.+]J^H7652S,N9?^R9AXW^72S[\I^G M;_=LB+DCQH.Z8-RE$_!+K>!'L;01IYBPA=T"X=IY^-O*:$2BUJLBY9B,4XY) MF7(\$6AJUS"\WX)[G>Z>>QC'9UK?]KR^%AKUPR]'^;=PG?.]M2^-Z4!3OE9M MYQL\UX?#^CF,9VV7U,]SH\]U"O<[K6_73NMK]:/ZQJ?<-7NR<2B?Z61P^*6Q M!\^WM5/#>VM'9S!'M+[V"=[[P=7EG!+S(7<)#("9IR M"^Z('*$,:1:I88F"..![M*0EEF@EM<;"80Y_NTBBHICQ)"G'7)>2];(E*[>D MU48YI3$RAE+$8R#(1$F18%'I2!57+LZY)>T<64F/8AY>9/;\W&;R91]WW>+Y M7\R9EC142$ET9#YQQEP^SI)&>HYE!.=BV!*0@)DIRP@LCC&8YEI9%106/J% ML4$\Z(2,E0PYKK14N2ZOXT4=-/%P.O$]0'<)#O]+R%MRR+L+,^H),._U,J.> M#@6GF5'$8N*MBDAJH1%W.B!XQR+JL=+$4VEQR!7.JX+,HN!]B5$E "X6#KQ: M %PL_'L=-2N>#NNF&4Q,4R\H3D@K$Q!G,>1.J1YA' ULV6$O3WDN'(79TCA\ M+[Z@Q<>3/CQN[%5ZL55X _U&\[CL7G.K[C7288V3+GK6:^=X4@H[HD1(TM@R M0OG\$'5VJ?WK3(2RM;6V?KI+]QJUP^^M6B9\KC6:M8U-7F]_:>YN?SC< M6WO/:^WOC:MBWY$(XK0-*&:N.S>1(FLE1YYAK%V,U$MWC]BW$8H&814'1>*> M.1"I1%BD)%IE+,:E9+ULR3K_O&^]5X$DB;!,N3^TU\@XFA#E5$J;F)'4SSGV M_4K+]<">.+9B+^^)R[(]C^G?&Z^3IBG@S'(WTII$>2#$2)$HT::.8VB2US+!!8+VY5W1E:U7J02$:4RSSM:^03:7$8K M'U^_9Z.5@;ID(]+"&L0584AC8U!N)ZL=#3QY#/K-J_**+7S9NV9A57NQ-+N, MP\U7BZ?C<-1SF7NGHIP8"E;:<62C],@F;K3'UF!;Q.&H6"0C_>)YIQ]/>KW8 M&;3.*IE\&C/3^;C7#2?^?O3R!W;B6+)P6[1,2(M]LE;SP)P1R0@A>,)6,H== M&11Y=B2J?[P4%#FKGTT'13XTMC9J;&^[=;B[_:&Q>_B9U[=W^=;&[EG]?!W7 M-^!YX+FVMH]^SH;;_+YQCGL=$B(Q-XM61"%CL$?2&!H5D]92.$9=>PGZ<::0]IY$1EYC)''@EJJILQK1TVGPG>N#CJW,9 M<'M\!9]I%HV#M\J!;ZF50IQI@JSB%(6D!:/.!6,4*#BK,B[*9DW+H]J+I=EE MP&V^6CP=<+-2.!N\0U;D#424 1D?&,I\.!$"AP74^;@^=XN>5>.R7=.CJ>'? M31\[_5CRV7X?8%.6F61!4)45/!>;8R$D@"'+!,V;X#(.\OS(\_52'.3GU@SK M:)/5V^NGN;7T[N'ZS]KA9[A.C>]M[)["\S:WUCS9W?[>V%O[JWT5GXUY[T * M(C(B]YQ3V1GARJ*HJ?:$*R-9SM@B=XRP40.RXCCSFGLN8,O"F%#,\02B!?\7 M2LEZV9)U_GG?:R:5I YA;T&RN%?()9 Q%83E7/E(0NYF*$L^V_-'V,J3\ELZ M[B(X<,28%Q%+'K763F"JB&;18.Q<&6%;1)B;R5*.0H&#;I"U1B N) 7K1QP* MFD@=E5)" #)I4=4/#["5M)<%#K ]@3:7 ;;'U^_I )LV*3EL/0HA,]HL>!Y& M"X:49Y8EX[$A?)A_>\7.O&2T+:QJ+Y9FEP&V^6KQ=(#-&=!5HC$BTFG08BN0 MX<0@1V54,4FG+%EYIWB57A$F+REMCZ:%:_%';'6/8Z@,HF]TX*X'9X]$9EO MSN@W!3T\\UP9B@E+CD<+OJ055E%F@K2:I[(TX@+@S&0!N^WU\_KG?><\I03V M "X:A3@F"CE-/6(TV)0K>>A$KJ"8+4HKSM<1H"A/%F_I^(1$2([B$MC'\F28 M3@'\7ZH9E3[96)916T1(FFE9R;EBU%EDI+6(!Q^1Q1)>86P2B]81+3*9GY<$ MH*73Y;O$)YY F:^-3Y0:?!<-G@Y!*.R=3R$B3<&5X!RV,4Z;B%R@G$;I@J)N MY1V?1_VO4G5?IQDNXP_S5>&9C#I8,2^P0>#_4S#"*2)#*4>66":"<%C)'$6L M&K-(1OC%TWLV__GR;]L^?KOV2/R>!8PYU/]\_ZBGNB_L./RQI^O5!]==2(%9 MCJTGG"?L370ATA2D-APK2F]KW#8[(:;K#=QK;$7[5.9NMLQ+2L0SRB+R'H/' MBIE EMF( G'*RHBI93(GQ%7EPTMWER=G3ZS<__Z7IH2^+9=IL9>IQ.#7A<$S M6PYJM792LF8LL+JM( 8_.*//(=3._GG=G=@6XMR!+2H MU[AE)><'=:)_V<7@'S8UI;&;,797G&25)N[13-S6;':[E\%&'AWB4EG$D[8( M;)U%&)88\X@Y(W'E'=>F:N2<*\8_2)F6HWE&":6O$DKO_B2\,G=+T_IW)U?_?A>#+:MG?0[ R?BHZQL=D) ML3-X0^FJ*&#ZB96>9J7?;L3*QVX;[GQ6Z46?)S]4[(0+4XD_CW-QB:R%E>:@ M7VE>Z&S%%DI;Z:;*_]P!/+@2,AICA:6)6^8-5LIXYY()/"AM"LXX'7/&Z9 S M/H$B8AI%)CVNK32-*;?##[F<^-&*__?E;&\G'#O*9>WP/=L[/&!;6>]W=D'O MOS?R]P #,(P1<.+387VMU=S:_I!JV]]^[KO '76WFQ;2?<20("HQZ Q7E#).>$&!UP\$$Q0JUSX>JL@5(" MYBX!?!\G[G)R(.)68L1QHLAZ%D$"F&&8D^"56'G'5]5O)""#PP"@9-#HQ5AI MPV(W^I78R6!2LSW?&'Z;D6HEJW0A,'EEJX Y_>,(5_P16V>KRP>?FQUXOK/1 ML_QS]G?E#Z(_H;6/G^#U?RJGME^QQ\>]+NP8*^ZLF*%/:^]!-<#$%?_*8ESY M9_?O]U\V/^VN5F ;"0@,1JYU5BT^GX#F%J!M,S5S$E*C@-ZN;^;]YA"%[PK" MBE/M$M-<4?C/:D,8#@9@.'D;K0UW!N$;-L?_P-QVX5W?B[8?U^+P[U(KK]+* M^MJZV*<>/&O+)7(T*O#%J$%:<(=@.2BSF,O(W)W\]62M JOK&":&!\*=\.#> M&95(WBQC>XO5[H,S!:_N>)A:+OT=EUY[01RC#-9!",09$>"0:XDBBY)R 6_8 MW$B9T54] \F_P^A>MUVYX!)6!MV*O[94?[^ :-]MMV/'3WN$ #4C"(J#*=_O-_(4WPX:Q"1 \4X0C;!8-_8UJD]ZZ_\ M>=D$@OV;G,#KGGUD*G_MKMY.&$]VDZ%,:2Y3H:Z8BJ'!#GE_48C%F\("YF_! M<.S"C*4"W@O Y;^:(>$@ V74*,4Y$PY>!*:9%T*H%.B^@IU3WD1F7?B8D;8S MZ/_OGW:ZDE/QYY1*#$'-:IF<253FGF* QPYV0LH)"KJNP!?[!>]7IMW>:PMU M&;B_^D8,)ZW833=8[D\G@Y->G/2NUX>[P>+AMV$\'UI=?_3:@/JP1O;!/0Z6 M:H9@+^,1U]@A)T+N>!^#CQ1+Z_1*)8(M.\Z(U#N)5^KIXKFT.2+@8JM[6BG" M))7^21O&"A?H%Z@?^P.PTH7?>7#0BP?P\NIX0?[;Y^^!H7&Q""X<=. RH0)? M*NR' []X-ISPYMI=P%6P/AKCV%04L2.8J98][L 3&JP483\7!AI])LBJ4O/9C MO$JN_>RFRS*Y2BF_U65_0UE:3+K[#(#CFXW)'\TL6]T3N'KHSQSQW.VQGS4M MXJH'7WD'2'S2N=Q'Z<4ST;[$MFT6&V:PM=F:W3/>/!M1?EU'5[=X_A=S/I44 MR4WAK$[,<<:5Y4E)\.7 9B>CE2_.IV:WN7TU:^?K;'?[2ZM^WFK ZW-PI6B]_4WLM;^W]K;_:DX?7VWM M[.4.X:?U-CS7=FC4-[ZQK9UU>%TC>X>[=&^[U=[;^=ZJM?]*M8GJK>-&GI& M\QL)LHP%Q%U(2"=.$8V4$4YTHC0W#N%50Z^+83^:-I7IC-?H,:@>N]8RO_HL MA^>!KCK+WPJ974>+A>; I>U';I]T2DN8&26>SD,0EUL&H M7! ZGSC9A)RAV9$B7 BNO=*X@"0AY^5(+9&O]-R0)$IW:0$A*5,=2E":%RA- M=K\=@Q)-6F##$#.>(NYI1(;D E.$2*Y"D-B,0 G/'H:6?M(C@Y(L_:3% Z5/ MW9,RXC0_3)J-."E'F>0ZP;8M$L2YX$C'*!$71C&92^5$ MZV1]KN(G394S4_I-BUA6HTS4*Q/UE@7F7T=1UJ>"\]G0'(O.2"IUW@5SQ!E3 MR%!"$=5::JNT$MQGCY-7A7SP<<'RI.C-LHR'PO5;YB9;^7V"R=/3>X9\8;IZ M8XO9.= ^UZ(;K#7[OM7MG_06A\%Y-E+--JCESB:IT>]'\%]K[_ SJ^]\:=3; MGYHU^J59/SSXF7\/JL.G&9Q[AP=P_6_G>SN?X;_O[?J:)WL;ZQ14^WQO8Y-N MK:WGL?ZLG3?2UMHFVWNY(GO@J" G_D/XI:$S_YI:P5U*(?SN6IZ(0;Z6:'9STFH-F[&^E_,CYB?,#+Q9-^,F% M;)WM"Z:LU 0C)PDXXYDP;/]_]MZ\N6TDR0/]*@CMVQ<]$2HU"BA*?M=4MLW4[=FFG!&?Q=.;T(@>-G%(.N+[()W MG3P%"6!HNBBKXK#$N(M<,T2ND4!$AE]RPR_IA%\[O=:W_].&Y?G79/>ZTKL+>S MH^./B=7;;"W87W[9Z"GG8Q/ MKM#B/J&MWLG/T_VE.<4ZY+Z,W8 HKA1&G4%CP^)K1K7'?$EUY*9;N_%VM*2I M6)-2W*04-[ %L'78W]",XDW K,60CQ>XBGI^0H0?AH0EH2!Q&'@8G_:4&X!- M3V/31=W]]?&)FQ?Q>59<:M*)UPN7-BN;>!/@:#%D$>C4E2X5A$MB9=95*U!/@4>7N@<6JFSNS+OOEB[WYO41$M!,%ZXS8)AQ? M=U".AL60]_$]?D7!_(60? /Q9=CJL%\,!R-$]-=\,!C#IEF_50/EJX+R)=%G M*CRI6$J)SZ0$:SA)"!<,_NG[2M.8*1D+@/((D[!7I5H^07SY)2N=7_IE/Q8E M;?P$,%TL.'A?OB9ZGQ$!CX-3M9/8+\^@P:-[X-'18DV(KQ/N>X(2)=R$,.E+ MDD0R)6ZBF8H8HZD$U9*QQ8*09YDR_N(];PM@DQ7%B/>%@MP[( MJ8,,HD^Y_V7&=8,W]\&;Q6B !Q!#/5!]$N&C/TT'8-2*A$B7QXFK/)IJN;7K MQXO%'G?'FZ?SJ#VQ';AIFM.;K&^@JXM-:IUNQM.L:WQ)OYGF]#P)QKCU[W'G MWY<;/V[ ZSY^. M<%L"N3BY;5Q^_I8&7IAX.M^8::]1D3'B2,!))+XU31BG% M:K4@]AHGW MU935.J_6(2^SUY6M^D<&)&(@[FN8]'O;+@4>O;3?N:02C<6RM M#AM;"]CHN51RUY4DBKDB+-(>257(B)0T@,_=- P\Z]GRV"^7\C:>K57P\'M5 M%']57>N="[1Z\OYOIIL]AXEY-R K\:M!K=6AUL=%U$I2RF0:D8BG@%H!C;"> M0!" *Q;2F'DZ0G^\MQU'+\L%MCDJUUSYPK;35\MK&!XH/997Y=U8F/?24Y)7 MOT'K+0365@8TX+\Z\/^R /Z::D$C%0+D:TV89(RD@? (')Z' YWB-#%I?LFV M'ZZJL\/J>.H1"X(?,E?C18[SW!O:4[YS85Z&Q4BJ&#H#'.0Q'4QW4^FHEJXO M5.J%B789]>)81*!]T-!+L/-(RNY8ACR-DR*NS" 'O+[X2XX&ET!;A>IO)ES\ M2G6R^RU08)LFTB=1(- \99*DW/4)I8D* RVCT VV=G7V0Y&QXH-YEG!@!T<# MG+Z">D@W!U+47!BOZK9SV2X9\+)TM7/X>?U9>:R8CEG!TG20#V9&JP9PP MHRQ.1"BY#GR?^3)*?(\"*:H@2?PX#>1R87;8?G,S_1V63/ )>.#S$(?;?% # MK-/C9], &O%^,S*$-5U^"Y+8UXP'1'E1#/9&P$DB9$JXC@/I"==7G&WM>CN+ M'N3_W2,.I[) ZI2U@8AU'J)W'LRZW= MP-VY+ONM&K]H,)B?#93"O9\!V4_YF'>'8_(*E#" ;(3**5)FPX[#@<@ ;H&^ M 9',*-G_*+BB\QJKX,NKG0]\,.RK0>$<'AYN.^]W/NPX63EIRQSRO>=TIX'K M!3SF$A @3,&$"-U4ATF@0,#<./+]K5UW)[B-,HPJ!TH:"*9A-5]Z E1G.5AG?11F^/D2J-IQCF>&H[>PO.)]7A2J..HOPZ:&]):2WM7A^)OBU 7X MT42&/@=4"AE):03&BHX8\V0:@SJ.I'<+*#EF^J^=$8G4=3G(AHKD6B-Q<"2' MN>Q"@*Q>-NK!UQJ'GI [$Y3B>_8+RQ6.SU MY7^4/,,*##C4'R98O7Y-Q=I9U>_OS??VVW=PWS?G)SVXW_['JQ/LP[=_\K.] M_QW'O=+3X\[WD_,]NC 6]NM']Z1W.&Y];6>GQ_)[>[_=:7L';OO\P#TZWJ.G MY_]TC]Y^REK[_V"XYF?K[)NFB12N)\!8 G.=I7%(8A8*XGF1#EFJ0'H'\VW% MF%244BY=:EJTRB0!,U\$H&<&L1MQ/=\A:GHJ3NU8'M!#[/8'SRY4B"B2,=4B M]0+F:9D&5,0R5#0%= X"NAG-J^KR:@3P/^<%*R[Y18&0-%!R))2!F!]@]959 M::A5"UYT'(V=IW!J;2XR@V*EKEX&IJLYZ?,N-Q J"J['"R;/K4I545QB!RS[ MN*ZR"T+HVX&3+HU3X%5WUC U+87L_7(+L(MO9#_'XT0H-N^GLY_F-N\/7QU] MLK^$YW.GG^/ZP4A]F%I(PU@G3"GE12GSW3#Q0&MU@U0(7WLJBHVYZM[)7*W( MO%VN:)-TPB?'GZO#JV^:B20-N4=\U\<0@0>".?)2@@+;3>.(^0P$&OQ]B;WJ M5%)YV!GDH[,.D-NX\H0PJ^5QT 7!!$7*0>UOAFZ0DI8Q4@8\X"O4/7_KX^E[:LII[Q_^_ ;*0N0"MA/F8:?"4 + 8YX8#5G_1][]48X,![A3V86!$8!,CHJV MI0\++PB_8".(#N\C9>6#DKK,3Y8@Y(\R1-'-M*HP=OIDQ.!\A 'WZ3W+']F& M;N-9OURI,!KJ7D*]%C4OX6,@KB([LQ92Y;V>B &G _J0*@Q(P!L2"SLPF:)O@FUF12GOFB<6':5@D_C0 MT3P;@!SICI0U\.Q>%)5/:/IUM3VXANE&SJT&I(5-7Q"PGH'JP!)0^P"-KS!W MAQ]V01)F.K,_GKQ>-0Z^?.P%L&$.ROQH@,=@71+XN=DDN'( 8KV$!:ZU'2"O MN+$_X>BQ/21L:K?KI+"P'FK^>6KDY+ #KVS>:RI=ZS>[S$==B8+-R848#7:< MO>'R[I5P3J/>R%HER]X8Z 8?/'&CW$

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�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